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Abstract 
Diabetes mellitus has been described as a disease involving multiple morbidities including 
physical and psychological conditions. People with diabetes are at greater risk of 
experiencing anxiety and depression than the general population. Recent longitudinal 
studies suggest that the association between depression and diabetes is reciprocal or 
bidirectional. However, relatively little is known about the possibility of anxiety as a risk 
factor for, or a consequence of, diabetes. A slightly increased risk of depression and 
anxiety in people with diabetes in developing countries relative to the developed countries 
has been suggested by previous studies; however, biases and methodological issues in 
these studies may limit the strength of the finding.  
 
The investigations included in this thesis examine the relationships between depression 
and diabetes, and anxiety and diabetes, in a developed and in a developing country. The 
specific objectives were to examine whether: 1)  depression symptoms are independent 
predictors of diabetes mellitus in Australian women; 2) anxiety symptoms are independent 
predictors of diabetes mellitus in Australian women; 3) the presence of diabetes mellitus is 
an independent predictor of depression and anxiety disorders in Australian women; 4) 
symptoms of depression and anxiety are associated with diabetes mellitus in Malaysian 
women; and 5) whether symptoms of depression and anxiety are associated with glycemic 
control in Malaysian women. 
 
The data were taken from two studies; the first was conducted using longitudinal data 
(secondary) from the Mater-University of Queensland Study of Pregnancy (MUSP) study in 
Australia, and the second, using case-control data (primary) from Malaysia. Differences in 
the magnitude and strength of associations found in the Australian and Malaysian samples 
were examined.  
 
MUSP comprised 6753 mothers who met the following three criteria: one or more 
singleton/ multiple birth children discharged alive from the hospital, after the birth, and the 
child was not adopted prior to discharge. The data were collected over 27 years after index 
pregnancy.  In the Malaysian case-control study, a total of 1280 women aged 35 and 
above participated (case: 640, control: 640). The ‘case group’ was comprised of women 
who reported having Type 2 Diabetes Mellitus (T2DM) and the ‘control group’ comprised 
women without T2DM. 
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To test the hypothesis assessing the association between symptoms of depression and 
anxiety and the risk of diabetes, the observed proportion of women who reported a change 
in depression and anxiety symptoms between subsequent phases of the study, at 5-year 
and 14-year follow-up, was estimated. Depression and anxiety disorders were assessed 
via a self-report questionnaire and the CIDI-Auto. Potential confounding factors were 
selected using directed acyclic graphs (DAGs) and priori knowledge. Multivariate 
regression models were used to estimate the risk of relevant outcomes for each 
independent variable, with associations summarized as odds ratios (ORs) and 95% 
confidence intervals (CIs). 
 
Regarding symptoms of depression and anxiety as risk factors for diabetes, the results of 
the adjusted prospective analyses showed that women with persistent depression and 
anxiety symptoms were more likely to report diabetes at the 21-year follow-up. The 
present analyses also indicated that almost one third of the women who reported 
depression symptoms continued to report these at the subsequent follow-up phase. 
Similarly almost half of the women who reported anxiety symptoms continued to report 
these at a subsequent follow-up phase. The cross-sectional analyses using the same 
variables (all measured at 21-years) showed no significant relationships between 
symptoms of depression and anxiety, and diabetes. The results of adjusted analyses 
showed that women with diabetes were at greater risk of reporting lifetime major 
depressive disorder and posttraumatic stress disorder. 
 
The analyses of Malaysian data showed that women with diabetes were more likely to 
report symptoms of depression and anxiety compared with women without diabetes. The 
results of adjusted analyses showed that presence of diabetes, as well as duration of 
diabetes did not increase the odds of depression or anxiety symptoms. With regards to 
glycemic control, depression and anxiety symptoms were not significantly associated with 
poor glycemic control in women with diabetes. 
 
Despite some limitations, the longitudinal study provides insight into the long-term 
bidirectional associations between depression and diabetes, and anxiety and diabetes. If 
the demonstrated longitudinal relationships with the exposures investigated in this study 
are causal, the temporal sequence and strength of these associations provide important 
implications for both prevention and treatment. However, the Malaysian case-control study 
and cross-sectional analyses of MUSP data suggest no relationship. Therefore, additional 
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well-designed studies, preferably longitudinal in nature, are needed to examine this 
relationship especially in developing countries where diabetes prevalence is escalating. 
 
Modest evidence of an association or increased risk of mood disorders as a consequence 
of diabetes was detected in this study. While there are a number of component causes 
associated with the outcomes, the most interesting finding is arguably the fact that both 
represent component causes of each other. 
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Thesis overview 
This PhD study is a quantitative study that uses a range of methods to investigate the 
association between anxiety and diabetes, and depression and diabetes, in women. The 
study methods included a systematic review, meta-analyses, and analyses of longitudinal 
and cross-sectional data. The PhD included data from two studies; the first comprised 
secondary data from the Mater-University of Queensland Study of Pregnancy (MUSP) 
longitudinal study in Australia, a developed country, and the second, case-control data 
(primary) were collected from Malaysia, a developing country, providing a comparison 
about associations between anxiety, depression and diabetes among women in these two 
nations. In both studies, data were comprised of women with and without diabetes and 
aged 35 and older, in Australia or Malaysia. Differences in the magnitude and strength of 
associations in the Australian and Malaysian samples were examined. 
 
The thesis is divided into three main sections (background and methods, results, 
discussion), with the results section divided into two parts, as shown in Figure 1. The first 
section of the thesis covers general background, literature review and introduction 
(methods) to the Australian longitudinal study (MUSP) and a Malaysian case-control study. 
The second section (results) is divided into two parts. Part 1 presents the findings of the 
systematic review and meta-analyses. Part 2 discusses the results from the MUSP 
longitudinal study and the Malaysian case-control study. The final section is a general 
discussion followed by the conclusions that can be drawn from this PhD study.  
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Outline of chapters 
Chapter 1 discusses the general literature regarding diabetes, depression, and anxiety and 
provides the theoretical framework. Chapter 2 describes the methods and disusses the 
connection between theoretical framework and the methodology. The systematic review 
provided findings about the global burden of comorbid depression and anxiety in people 
with diabetes; it addressed a specific research question, and its findings have been 
incorporated into Chapter 3. Four meta-analyses then examined the following 
associations: depression and diabetes, and anxiety and diabetes. Descriptions of the 
meta-analyses and the respective key findings are included in Chapter 4; a random-effects 
model and a novel quality-effects model were used where relevant. Data analyses for the 
longitudinal Australian MUSP study and the case-control Malaysian study are described in 
the respective manuscripts which have been included in the Results section, Chapters 5 to 
10.  
 
Depression and anxiety symptoms were assessed in all the phases of the MUSP study 
using the scale Delusions Symptoms-States Inventory: State of Anxiety and Depression 
(DSSI/sAD). Therefore, the DSSI/sAD was validated and the findings are included in 
Chapter 5. The association between depression symptoms and the risk of diabetes is 
examined in Chapter 6, and the association between anxiety symptoms and the risk of 
diabetes is discussed in Chapter 7. In Chapter 8, the association between diabetes and 
the risk of mood disorders (anxiety and depression) was examined. Relevant published/ 
submitted papers arising from this PhD have been included in the respective chapters.  
 
Chapter 9 reports on the association between mental health (depression and anxiety) and 
diabetes, and Chapter 10, on the relation between mental health status and glycemic 
control in women with T2DM. Published/ submitted/ ‘in press’ papers are included in each 
of these chapters. The final chapter (Chapter 11) includes a general discussion of the 
findings, the causal pathways, strengths and limitations, implications of the findings, and 
general conclusions. 
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CHAPTER 1 
General Background 
 
The prevalence and drug utilization research described in this chapter has been accepted 
for publication to the Australasian Medical Journal in the following form: 
 
1. Hasan, S.S., Clavarino, A.M., Mamun, A.A., Kairuz, T (2015). A comparative drug 
utilization study of the treatment of diabetes in Malaysia and Australia.  Australas 
Med J, In Press. 
 
The accepted, peer-reviewed manuscript in the pre-publication format provided by the 
publishers is attached as Appendix 1A. 
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1.1. Introduction  
The prevalence of diabetes mellitus is increasing worldwide with estimates suggesting that 
382 million (8.3% of adults) people were affected in 2013; by 2035 this number is 
projected to rise to 592 million (IDF, 2013). The predicted increase in patients with 
diabetes is 54%, at an annual growth of 2.2%, which is nearly twice the annual growth of 
the total world adult population (Shaw et al., 2010). According to the World Health 
Organization (WHO), diabetes is the 9th leading cause of death in the world contributing 
1.26 million or 2.2%, of deaths (WHO, 2008). The International Diabetes Federation (IDF) 
estimated that 3.9 million deaths were caused by diabetes in 2010 which represents 6.8% 
of total global mortality (IDF, 2009). In 2010, approximately 1.9 million individuals aged 20 
years and older were diagnosed with diabetes (CDC, 2011). Both the incidence and 
prevalence of diabetes are escalating particularly in developing and newly industrialized 
nations, and also among disadvantaged groups living in developed countries (Shaw et al., 
2010).  
 
About 80% of the total numbers of people with diabetes live in low- and middle-income 
countries with the majority aged between 40 and 59 years (IDF 2013). With more than 138 
million people affected, the Western Pacific has more people with diabetes than any other 
region in the world (IDF 2013). The Western Pacific, which has 39 countries including 
Australia and Malaysia, also includes China, the country with highest prevalence of 
diabetes (9.6%) (IDF 2013). In developing countries, the majority of adults with diabetes 
are between 45 and 64 years old, whereas in developed countries the majority of adults 
with diabetes are 65 years and older (ADA, 2011; King et al., 1998). About 90% of all 
cases of diabetes in both developed and developing countries are type 2 diabetes mellitus 
(T2DM), which is primarily found in adults more than 30 years of age (Shaw et al., 2010). 
Globally, diabetes prevalence is similar in men and women, but after the age of 65 years 
diabetes is more prevalent in women (Wild et al., 2004). In developing countries such as 
China, Brazil, and Egypt, diabetes is more prevalent in women (Hu et al., 2001; Lin et al., 
2008). 
 
Diabetes mellitus has been described as a “complex chronic progressive disease,” which 
is defined as a disease involving multiple morbidities including physical and psychological 
conditions (Sevick et al., 2007). Depression and anxiety are two common co-morbid, 
modifiable mental health conditions associated with diabetes (Kessler et al., 1995; Smith 
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et al., 2013; WHO, 2000). It is reported that people with diabetes are at greater risk of 
reporting anxiety and depression compared to the general population (Anderson et al., 
2001; Bouwman et al., 2010; Egede et al., 2002; Nichols et al., 2007), but this often 
remains unrecognized and thus is often untreated (Pouwer, 2009). A meta-analysis 
demonstrated that 11% of patients with diabetes had comorbid major depressive disorder 
(MDD) and 31% experienced significant depressive symptoms (Anderson et al., 2001). A 
systematic review reported that generalized anxiety disorder (GAD) was present in 14%, 
and elevated symptoms of anxiety in 40%, of patients with diabetes (Grigsby et al., 2002). 
The prevalence of depression and anxiety in women with diabetes was reported to be 
double that of men with diabetes (Ali et al., 2006; Clouse et al., 2003; Engum 2007; 
Grigsby et al., 2002). The association between depressive symptoms and diabetes was 
also stronger among women (Carnethon et al., 2003). 
 
Recent meta-analyses of longitudinal studies suggest that the association between 
depression and diabetes is reciprocal or bidirectional (Mezuk et al., 2008; Rotella & 
Mannucci, 2013; Rotella & Mannucci, 2012). Regarding comorbid anxiety with diabetes, 
results from longitudinal studies are inconsistent (Atlantis et al., 2012; Edwards and 
Mezuk, 2012; Engum 2007). Although there is evidence regarding anxiety disorders and 
increased T2DM burden (Andrews et al., 1998), increased complications of diabetes with 
anxiety (Jonas et., 1997), poor glycemic control (Anderson et a., 2002), and reduced 
quality of life (QoL) (Mendlowicz  and Stein, 2001), there has been little focus on the 
possibility of anxiety as a risk factor for later onset of T2DM. The findings of the only meta-
analysis on this topic suggests that people with diabetes are more likely to have anxiety 
disorders or elevated anxiety symptoms compared with people who do not have diabetes 
(Smith et al., 2013). However, there is no meta-analysis investigating the development of 
diabetes associated with anxiety symptoms and/ or disorders.  
 
The association between mental health conditions and diabetes can be described in terms 
of medications used for the treatment of diabetes and mental health conditions such as 
depression and anxiety. Treatment of diabetes is associated with improved glycemic 
control and reduced complications (Anderson et al., 2002; Lustman et al., 2000). Similarly 
treatment of mental health conditions not only improves the mental health status, but also 
improves glycemic control (Anderson et al., 2002; Lane et al., 1993).  However, significant 
controversy exists over whether or not depression and anxiety in patients with diabetes is 
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associated with poorer glycemic control, with some studies reporting moderate to strong 
associations (Anderson et al., 2002; Eaton et al., 1992; Konen et al., 1996; Lustman et al., 
2000; Mazze et al., 1984; van der Does et al., 1996), while others have found no 
association (Niemcryk et al., 1990; Viinamaki et al., 1995; Wilson et al., 1986).  
 
This PhD study bridges a gap in the literature and examines the bidirectional association 
of depression and anxiety with diabetes, and also discusses possible causal pathways to 
explain these associations. It is important to examine these relationships in people with 
diabetes because co-morbid mental health conditions such as depression and anxiety may 
lead to increased diabetes severity, complications, work disability, increased use of 
medical services and substantially higher health care costs, poor QoL (Khowaja et al., 
2007; Lin et al., 2010; Lin et al., 2009; Mosaku et al., 2008;) and poor glycemic control 
(Lustman et al., 2000).  
 
1.2. Diabetes mellitus in developed and developing countries 
Once a disease of developed countries, diabetes has now spread to every country in the 
world (Hu, 2011). Despite the increasing prevalence in developing nations, there are 
marked differences in prevalence between developed and developing countries. King et al. 
reported a 42% increase, from 51 to 72 million, in developed countries from 1995 to 2025; 
in comparison, the increase in developing countries is predicted to be 170%, from 84 to 
228 million, during the same period (King et al., 1998). Between 2010 and 2030, the 
increase in the number of adults with diabetes in developed and developing countries is 
estimated to be approximately 20% and 69%, respectively (Shaw et al., 2010). In 
developing and developed countries, the majority of people with diabetes are reported to 
be in the age range of 40 to 64 years (King et al., 1998; Shaw et al., 2010).  
 
1.2.1. Prevalence of diabetes in Australia – a developed country 
The estimated resident population of Australia in September, 2013 was about 23.5 million 
(ABS, 2013), and is projected to increase to 48.3 million people by 2061 (ABS, 2013a). 
Approximately two-thirds (67%) of the population was in the working age group (15 – 64 
years) (ABS, 2013b). The National Health Survey (NHS) is a series of regular population 
surveys conducted by the Australian Bureau of Statistics (ABS), and is designed to obtain 
information on a range of health-related issues (ABS, 2013). In 1995, the (second) NHS 
reported that 2.4% of Australians had been diagnosed with diabetes at some time during 
their lives (ABS, 1995). A little over ten years later, an estimated 4.6% of the population in 
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2011-12 (NHS) had been medically diagnosed with diabetes, excluding those with 
gestational diabetes mellitus (ABS, 2011-12). Despite the steady increase, the prevalence 
rate of diabetes in Australia is relatively low compared with North America and the 
Caribbean (10.2%), Middle East and North Africa (9.3%), and South East Asia (7.6%) 
(IDF, 2009).  The prevalence of diabetes in Australia has increased steadily between 1995 
and 2012, as shown in Figure 1.1. 
 
 
Figure 1.1: Source (ABS, 1995; ABS, 2008, ABS, 2011-12) 
 
 
This rise in Australia was largely due to an increase in T2DM, from 1.1% in 1995 to 3.9% 
in 2011-12. The increase in the reporting of T2DM may be partly due to people finding out 
that the type of diabetes they had was T2DM, as the number of people whose type of 
diabetes was unknown decreased from 0.8% in 1995 to 0.1% in 2007-08 (ABS, 2007-8). 
The proportion of people with type 1 diabetes remained relatively stable over this period 
(ABS, 2007-8). Another reason for the increasing prevalence of diabetes prevalence is 
immigrants from high-risk diabetes countries; the age and sex standardized prevalence 
rate of diabetes among the immigrant population (3.0%) was higher than that of the 
Australian-born population (2.1%) (ABS, 2007-8; ABS, 1995).  
 
Males aged 2 years and over accounted for just over five percent (5.1%) of all diabetes in 
2011-12 (ABS, 2011-12), compared with 4.2% of females. The prevalence was highest 
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among those aged 75 to 84 years; this increased from 13% in 2007-08 to 17% in 2011-12) 
(ABS, 2007-8; ABS, 2011-12). Although the prevalence of diabetes is increasing, diabetes 
was not documented as one of the most commonly reported chronic conditions in Australia 
(ABS, 2007-8), which included predominantly cardiovascular related diseases. 
 
1.2.2. Prevalence of diabetes in Malaysia – a developing country 
Malaysia, a newly industrialized country, was among the top 10 countries worldwide for 
diabetes prevalence in 2010 and is predicted to remain in the top 10 until 2030 (Shaw et 
al., 2010). In Malaysia, nearly half the population lives to the age of 70 years and chronic 
diseases are the major cause of death, which is similar to high-income countries (WHO, 
2008). In Malaysia, the National Health and Morbidity Survey (NHMS) is a nationwide 
survey of self-reported data that includes medicine use, dietary habits, various disease 
states, and demographics, and is published every ten years.  The first NHMS was 
conducted in 1986 and was followed by NHMS II in 1996 and NHMS III in 2006. According 
to the NHMS, there was an increase of 80% in the prevalence of diabetes among those 
aged 30 years and older, from 8.3% (1996) (NHMS, 1996), to 14.9% in 2006 (Letchuman 
et al., 2010). The 200% increase in newly diagnosed cases of diabetes between 1996 
(1.8%) (NHMS, 1996), and 2006 (5.4%) (Letchuman et al., 2010), is an indicator of the 
rising epidemic of diabetes in Malaysia. The overall projected prevalence, for the age 
group of 18 years and older, was 11.6% in 2006 (Letchuman et al., 2010); this figure 
reached the projected prevalence much earlier than predicted (Zaini, 2000). The 
prevalence increased dramatically to 22.9% and more than half (12.1%) were newly 
diagnosed (Wan Nazaimoon et al., 2013). 
 
In Malaysia, the majority of people with diabetes are of Indian origin, followed by Malay 
and Chinese, with a high prevalence in people aged between 45 to 75 years of age 
(Letchuman et al., 2010). The prevalence of diabetes in Malaysia over nearly 30 years 
(1986 and 2013) is presented in Figure 1.2. 
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Figure 1.2: Source: NHMS, 1996; Letchuman et al., 2010; Rampal et al., 2010; Wan Nazaimoon et 
al., 2013 
 
 
1.3. Association between diabetes and mental health conditions  
People with diabetes are at higher risk of developing mental health conditions such as 
depression and anxiety (Anderson et al., 2001; Engum, 2007; Lin et al., 2008). Similarly, 
depression and anxiety also increase the risk of diabetes and several studies from 
developed countries suggest that an association between these mental health conditions 
(depression and anxiety) and diabetes is reciprocal or bidirectional in nature (Mezuk et al., 
2008; Rotella & Mannucci, 2013; Rotella & Mannucci, 2012; Smith et al, 2013).  
 
1.4. Association between depression and diabetes 
Depression and diabetes are two serious medical conditions and health concerns that 
afflict millions of people worldwide (IDF, 2013; Mezuk et al., 2008). Multiple meta-analyses 
have suggested an association between depression and diabetes as bidirectional (Mezuk 
et al., 2008; Nouwen et al., 2010; Rotella & Mannucci, 2012; Rotella & Mannucci, 2013). 
The bidirectional association between diabetes and depression was first documented by 
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by lifestyles” (Golden et al., 2008), and Eaton and colleagues were the first to report the 
results of an epidemiological study that confirmed this relationship (Eaton et al., 1996).  
 
The bidirectional relationship between depression and diabetes can be elaborated with the 
help of two hypotheses. One hypothesis suggests that depression is a consequence of 
diabetes and may be a result of the burden of chronic disease or of biochemical changes 
that occur in diabetes (Kinder et al., 2002; Knol et al., 2007). Another hypothesis proposes 
depression as a risk factor for the development of diabetes which may be a consequence 
of a decline in health-maintenance behaviors among depressed persons (Barbour and 
Blumenthal, 2005; Golden et al., 2008; Katon et al., 2004; Kinder et al., 2002) or resulting 
from biochemical changes associated with depression (Bjorntorp, 2001; Knol et al., 2006).  
 
1.4.1. Depression as a risk factor for diabetes 
Previous studies have indicated that the risk of developing diabetes is elevated in persons 
who report high depressive symptoms and/ or clinical depression compared to those with 
fewer symptoms or without a clinical diagnosis (Rotella & Mannucci, 2013; Mezuk et al., 
2008). However, some cohort studies found no effect of depressive symptoms on diabetes 
incidence (Saydah et al., 2003) or no overall association between depression and diabetes 
onset (van den Akker et al., 2004). Eaton et al. also found that major depressive disorder 
was associated with the onset of diabetes, but this was not the case for milder forms of 
depression or other psychiatric disorders (Eaton et al., 1996). In short, after controlling for 
demographic and clinical risk factors, most studies have shown that depression is an 
independent risk factor for the onset of diabetes (Rotella & Mannucci, 2013; Mezuk et al., 
2008).  
 
1.4.1.1. Possible risk mechanisms for the development of diabetes in people with 
depression 
From a biological perspective, various mechanisms of how depression increases the risk 
of developing diabetes have been proposed (Danese et al., 2009; Tsigos et al., 2002; 
Vogelzangs et al., 2007). Detailed discussion on possible risk mechanisms are included in 
this PhD (see appendix 4A and 4C) and results section (see Chapter 6); this chapter 
discusses only two widely studied mechanisms, the hypothalamic–pituitary–adrenal-axis 
(HPA) dysregulation and pro-inflammatory cytokines. 
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1.4.1.1.1. Role of hypothalamic–pituitary–adrenal-axis (HPA) dysregulation 
Depression is associated with physiological abnormalities, including increased activity of 
the HPA-axis and the sympathetic nervous system (Bjorntorp, 2001), resulting in increased 
cortisol release and increased release of the catecholamines (epinephrine and nor-
epinephrine). The dysregulation of HPA axis is the most widely discussed biological 
explanation for the increased risk of diabetes as result of depression. This dysregulation 
can induce insulin resistance and contribute to diabetes risk (Golden, 2007).  
 
Stress can mediate between symptoms of depression and diabetes by over-activating the 
HPA axis; this results in elevated cortisol levels, which stimulates glucose production, 
increases lipolysis and circulating free fatty acids, decreases insulin secretion from beta 
cells and decreases sensitivity to insulin (Bjorntorp, 2001; Ramasubbu, 2002; Weber-
Hamann et al., 2002). It is postulated that a chronically high cortisol level, which is found in 
about 50% of depressed patients, results in obesity, insulin resistance and T2DM 
(Bjorntorp, 2001; Bjorntorp et al., 1999; Maes et al., 1991). Some studies have found 
evidence for this hypothesis (Bjorntorp et al., 1999; Weber-Hamann et al., 2002). A 
chronically elevated cortisol level increases the risk of developing metabolic syndrome, 
which increases the risk for developing diabetes (Bjorntorp, 2001; Knol et al., 2006). 
Metabolic syndrome is characterized by central adiposity or excess accumulation of 
abdominal fat, and insulin resistance, and has been reported in late-onset depression 
(Vogelzangs et al., 2007) and in persistent depression (Lehto et al., 2008). It is considered 
to be an important risk factor for the development of diabetes (Capuron et al., 2008).  
 
Stressful situations have been shown to induce hyperglycemia in euglycemic animals 
(Surwit et al., 1992) and in humans with a genetic predisposition toward developing 
diabetes (Esposito-Del Puente et al., 1994). However, stress only precipitates clinical 
diabetes in persons predisposed to developing diabetes (Wales, 1995). This was 
confirmed by a study where depression scores were found to be associated with both 
diagnosed and undiagnosed diabetes (Holt et al., 2009). 
 
Epinephrine generates responses in glucose and fat metabolism similar to those of cortisol 
(Genuth, 1998), possibly resulting in insulin resistance and diabetes. The credibility of this 
hypothesis is further strengthened by findings from other medical conditions that are 
accompanied by hypercortisolemia such as Cushing’s syndrome, sleeping disorders, work 
stress and schizophrenia (Buckley & Schatzberg, 2005; Lundberg, 2005; Morris & 
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Grossman, 2002; Ryan et al., 2003); the hypothesis appears to be associated with an 
increased level of cortisol, an increased risk of diabetes and insulin resistance (Meisinger 
et al., 2005; Ryan et al., 2003).  
 
1.4.1.1.2. Role of pro-inflammatory cytokines 
The second most widely discussed explanation for the link between depression and 
diabetes involves the inflammatory response or dysregulation of the immune system 
(Howren et al., 2009; Valkanova et al., 2013). Both depression and diabetes are 
associated with increased C-reactive protein, TNF-α and pro-inflammatory cytokines (Au et 
al., 2014; Dentino et al., 1999; Kiecolt-Glaser & Glaser, 2002; Maes et al., 1997; Pradhan 
et al., 2001; Schmidt et al., 1999). However, disagreement between this assumption and 
the proposed hypothesis that cortisol inhibits inflammation and the immune response; 
whereas depression is correlated with both elevated cortisol and increased inflammatory 
markers. This apparent contradiction could be explained with the help of a finding that 
melancholic depressed patients had increased HPA axis activity and no signs of 
inflammation, whereas non-melancholic depressed patients did show signs of 
inflammation and normal HPA axis activity (Kaestner et al., 2005).  
 
There is a growing body of evidence to support an association between inflammation and 
depression (Howren et al., 2009; Valkanova et al., 2013). The elevated levels of pro-
inflammatory cytokines such as interleukin-6 (IL-6) and C-reactive protein (CRP) have 
been implicated in the pathophysiology of T2DM (Doyle et al., 2013; Stuart & Baune, 
2012). Meta-analyses have also suggested an association between elevated level of CRP 
and increased risk of T2DM (Lee et al., 2009; Wang et al., 2013). The association of 
elevated CRP levels and depressive symptoms with a higher incidence of T2DM (Au et al., 
2014), suggests that individual who have both depression and inflammation are at greater 
risk of developing diabetes, and both increased the risk of abdominal obesity, metabolic 
syndrome, and coronary heart disease (Ladwig et al., 2005; Valtonen et al., 2012). 
 
The role of inflammatory mediators in the development of diabetes has been supported by 
at least two population-based studies (Ford, 2002; Schmidt et al., 1999). It is suggested 
that inflammation may be associated with oxidative damage and the release of free 
radicals (Paolisso et al., 1993a) that damage pancreatic β cells (Rabinovitch et al., 1992), 
thus limiting the release of insulin. The inflammatory process may inhibit insulin uptake 
(Paolisso et al., 1993b), a critical process in glucose regulation. Moreover, in cross-
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sectional studies, inflammatory markers, including the cytokines interleukin-1β, and tumor 
necrosis factor-α (Appels et al., 2000) and C-reactive protein (Au et al., 2014; Dotevall et 
al., 2001), were found to be elevated in depressed persons. CRP has been linked to 
insulin resistance via obesity (Nakanishi et al., 2003), adipose tissue which is a main 
source of pro-inflammatory cytokines (Nakanishi et al., 2003), and impairment of 
endothelial permeability (Dehghan et al., 2007).  
 
1.4.2. Depression as a consequence of diabetes 
The presence of diabetes increases the risk for having a diagnosis of depression 
(Anderson et al., 2001; Eaton et al., 1996), and people with diabetes are more likely to 
have deficits in cognitive function (Wandell, 1999). Generally it is perceived that individuals 
experiencing diabetes-related complications and disability experience depression as a 
consequence of their disability (Nouwen et al., 2010; Talbot et al., 1999). Numerous 
prospective studies have investigated the association between diabetes and the risk of 
depression, although the findings are inconsistent (Engum, 2007; Golden et al., 2008; 
Mezuk et al., 2008; Nouwen et al., 2010; Rotella & Mannucci, 2012).  
 
People with diabetes are more likely to suffer from depression and to rate their health 
worse than people without diabetes (Zhang et al., 2005). Diabetes is described as a 
“depressogenic” condition as it increases the risk of developing depression but there is 
only modest evidence to support this hypothesis (Mezuk et al., 2008). The competing risks 
for late-life depression, such as macro-vascular disease, and functional or cognitive 
decline, may mask this relationship (Gallo et al., 1994). However Golden and colleagues 
found that individuals with impaired fasting glucose and those with untreated diabetes had 
a reduced risk of incident depressive symptoms (Golden et al., 2008).  
 
1.4.2.1. Possible risk mechanisms for developing depression in people with diabetes 
Detailed discussion on possible risk mechanisms is included in the meta-analyses (see 
appendix 4B and 4C) and results section (see Chapter 8). When compared with 
depression resulting in diabetes, the association between existing diabetes and the onset 
of depression is weaker and is often conceptualized as having various possible indirect 
mechanisms. Cognition related to diabetes, such as perceived disability and awareness of 
having a chronic illness, may impose higher levels of psychological burden on people with 
diabetes, particularly in individuals with low levels of social support (Knol et al., 2007; 
Talbot & Nouwen, 2000). Biochemical changes associated with diabetes, such as arousal 
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of the nervous system, could account for an increased risk of depression in individuals with 
diabetes compared with those without the condition (Kinder et al., 2002; Knol et al, 2007).  
 
1.5. Association between anxiety and diabetes 
Anxiety is a common, co-morbid, modifiable condition experienced by individuals suffering 
from diabetes (Anderson et al., 2001; Grigsby et al., 2002; Smith et al., 2013). People with 
diabetes are at greater risk of suffering from anxiety than the general population (Grigsby 
et al., 2002; Shaban et al., 2006). Anxiety symptoms appear to be higher among patients 
with T2DM compared with those with T1DM (Hermanns et al., 2005). Among people with 
diabetes, women have significantly higher levels of anxiety than men and the prevalence is 
approximately double (Grigsby et al., 2002). The World Mental Health Survey conducted 
across 17 countries reported that the risk of anxiety disorders was higher among 
individuals with diabetes compared to those without (Lin et al., 2008).  
 
1.5.1. Anxiety as a risk factor for diabetes 
The findings from available longitudinal studies examining the association between anxiety 
and the risk of diabetes are inconsistent (Atlantis et al., 2012; Edwards & Mezuk, 2012; 
Engum, 2007). Anxiety has not been studied closely, unlike depression which is the most 
studied mental health condition associated with diabetes (Smith et al., 2013). There is 
evidence regarding anxiety disorders and increased T2DM burden (Andrews et al., 1998), 
increased complications (Jonas et al., 1997), poor glycemic control (Anderson et al., 
2002), and reduced quality of life (Mendlowicz & Stein, 2001); however, there has been 
little focus on the possibility of anxiety as a risk factor for later onset T2DM. For example, 
there is no meta-analysis investigating the development of diabetes in relation to anxiety 
symptoms. 
 
1.5.1.1. Possible risk mechanisms for the development diabetes in people with anxiety 
Some studies suggest that anxiety and depression have different risk mechanisms, as 
anxiety is characterized by hypocortisolemia and up-regulation of glucocorticoid receptors, 
whereas, depression is generally characterized by hypercortisolemia and a decreased 
number of glucocorticoid receptors (Arborelius et al., 1999; Krystal et al., 2001). 
 
A possible biological explanation for the increased risk of diabetes among people who 
have anxiety may be the chronic or recurrent stress which results in intermittent or 
sustained increase in levels of cortisol and adrenaline in vulnerable individuals (Dinan, 
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2004). Numerous studies have suggested that anxiety is associated with an up-regulation 
or dysregulation of the HPA axis resulting in elevated cortisol levels, which is also seen in 
depression; elevated cortisol can inhibit insulin function in a variety of ways (Chiodini et al., 
2007; Ehlert et al., 2001; Merswolken et al., 2012; Steudte et al., 2011; Young et al., 
2004). Anxiety disorders have been shown to be associated with obesity in various general 
population studies and it is possible for anxiety disorders to lead to weight gain (Gariepy et 
al., 2010). The HPA dysregulation is assumed to contribute to appetite dysregulation 
(Dallman et al., 2005; Torres & Nowson, 2007), increased appetite (Canetti et al., 2002) 
and subsequent weight gain in stressed individuals, and also to stimulate a craving for 
high-sugar and high fat foods (Adam & Epel, 2007; Nowson, 2007; Nieuwenhuizen & 
Rutters, 2008; Torres & Yannakoulia, 2008). In addition, a longitudinal study showed that 
people who developed anxiety or depression at one stage in their life were more likely to 
become obese than those in good mental health (Kivimäki et al., 2009).  
 
The association between anxiety and weight gain may also be explained by factors that 
share a relationship with both anxiety and weight gain. For example obesity and anxiety 
disorders are both partly heritable diseases (Hettema et al., 2001; Walley et al., 2009), and 
may share a common genetic basis (Gariepy et al., 2010). Factors such as negative 
events in childhood and personality traits such as neurocriticism, hypersensitivity to 
criticism and avoidant coping styles (Angst & Vollrath, 1991; Spira et al., 2004; Vink et al., 
2008), can predispose individuals to anxiety and weight gain or obesity. In addition 
environmental endocrine-disrupting chemicals can affect hormonal homeostasis involved 
in weight and emotional regulation (Dallman et al., 2005; Elobeid & Allison, 2008; Torres & 
Nowson, 2007). 
 
Mental health conditions are often comorbid with obesity and some have been found to 
lead to weight gain, such as mood disorders (Atlantis & Baker, 2008; Petry et al., 2008), 
eating disorders (Javaras, 2008; Picot & Lilenfeld, 2003), and personality disorders (Petry 
et al., 2008). Anxiety disorders tend to be co-morbid with depression (Alloy et al., 1990; 
Regier et al., 1990) and an estimated 85% of patients with depression have symptoms of 
anxiety (Beekman et al., 2000; Belzer & Schneier, 2004; Lenze et al., 2000; Mulsant & 
Reynolds, 1996); it is therefore possible that the comorbidity between depression and 
anxiety is the most important factor that increases the risk of developing diabetes.  
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Smoking, physical inactivity, pain and heavy drinking are significantly associated with a 
lifetime diagnosis of anxiety and these factors have also been shown to be associated with 
diabetes (Gerrits et al., 2012; Lin et al, 2008; Skilton et al., 2007; Strine et al., 2008). 
 
1.5.2. Anxiety as a consequence of diabetes 
Diabetes is a significant risk factor for depression and doubles the likelihood of co-morbid 
depression (Grigsby et al., 2002). Although there is evidence regarding anxiety disorders 
and increased diabetes complications (Collins et al., 2009; Jonas et al., 1997), poor 
glycemic control (Anderson et al., 2002), weight gain (Balhara & Sagar, 2011), and 
reduced quality of life (Mendlowicz & Stein, 2001), there has been little focus on the 
possibility of diabetes as a risk factor for the onset of anxiety disorders. Despite the fact 
that literature suggests anxiety is an important comorbid condition associated with 
diabetes, only one review examined the link between diabetes and the risk of developing 
anxiety (Smith et al., 2013). The review suggests that people with diabetes are more likely 
to have anxiety disorders or elevated anxiety symptoms compared with people who do not 
have diabetes (Smith et al., 2013). However, in a longitudinal study, Engum found that 
although elevated baseline anxiety symptoms were associated with an increased risk of 
developing diabetes, diabetes did not predict anxiety (Engum, 2007). 
 
The psychosocial burden of a chronic disease such as diabetes may carry with it a risk of 
developing anxiety symptoms. Various studies have demonstrated that in people with 
diabetes, anxiety is significantly associated with diabetes complications (Collins et al., 
2009; Fisher  et al., 2008; Lloyd et al., 2000; Ludman et al., 2006), increased pain (Gore  
et al., 2005), engaging in unhealthy self-care behaviors (Collins et al., 2009; Lloyd et al., 
2000), greater disability (Ludman et al., 2006), depression (Trento et al., 2011) and an 
increased Body Mass Index (BMI) (Balhara & Sagar 2011). However, many of these 
factors have also been shown to be associated with anxiety and anxiety disorders in the 
absence of diabetes. More studies should explore the association between diabetes and 
the risk of anxiety symptoms and/ or disorders and the role of other factors highlighted 
above.  
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1.6. Study aims and hypotheses 
The hypotheses underpinning this PhD were that a bidirectional relationship exists 
between depression and diabetes, and between anxiety and diabetes. It was also 
hypothesized that similar associations between anxiety, depression and diabetes would be 
found among women in a developed and a developing country. The main aim of this study 
was to examine the bidirectional association between depression and diabetes, and 
anxiety and diabetes in women from both a developed and developing country. Australian 
data from Mater-University of Queensland Study of Pregnancy (MUSP) were used as this 
large birth cohort study provides a unique platform to examine longitudinal effects of 
depression and anxiety (Najman et al., 2005; Ware et al., 2006). By analyzing MUSP data, 
the prevalence of depression and anxiety in women with diabetes was estimated, and the 
bidirectional relationship of mental health conditions and diabetes in women was 
investigated. The same relationships in a developing country (Malaysia) were then also 
investigated using a case-control study. 
 
In order to bridge the gap in the literature, specific objectives of this study were formulated 
and are stated below. It was conducted as two separate studies but which were linked 
through the questionnaires and the analyses.  
 
1.6.1. Specific objectives of the study 
 
1. To calculate the risk-adjusted global prevalence estimates of comorbid 
depression and anxiety in people with diabetes mellitus.  
 
2. To summarize existing literature and synthesize findings on the association 
between depression and diabetes, and anxiety and diabetes in the form of meta-
analyses. 
 
3. To validate the personal disturbance scale (Delusions-Symptoms-States-
Inventory/States of Anxiety and Depression) among women with diabetes using 
the MUSP dataset.  
 
4. To investigate whether change in depression symptoms (exposure) was 
independently associated with the risk of diabetes mellitus, measured at 21-years 
post index pregnancy (outcome) in Australian women. 
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5. To investigate whether change in anxiety symptoms (exposure) was 
independently associated with the risk of diabetes mellitus, measured at 21-years 
post index pregnancy (outcome) in Australian women.  
 
6. To investigate whether the presence of diabetes mellitus (exposure) was 
independently associated with the risk of depressive and anxiety disorders, 
measured at 27-years post index pregnancy (outcome) in Australian women.  
 
7. To investigate whether symptoms of depression and anxiety were associated with 
diabetes mellitus in Malaysian women. 
 
8. To investigate whether depression and anxiety symptoms were associated with 
glycemic control in Malaysian women. 
 
1.6.2. Why Australia and Malaysia?  
There were various reasons for collecting and analyzing data from a developed (Australia) 
and a developing (Malaysia) country in this study. It is suggested that between the years 
2010 and 2030, the increase in the number of adults with diabetes in developing countries 
will be more than double compared to developed countries (Shaw et al., 2010). Malaysia is 
one of the most prominent developing, middle-income countries outside Europe as 
designated by the United Nation (UN) classification (UN, 2007), which excludes Australia, 
Canada, Japan, New Zealand, USA, Singapore, Hong Kong and Taiwan. It is a country in 
the developing world whose population characteristics are comparable to the Australian 
population. To facilitate comparison, the estimated and projected population for Australia 
and Malaysia are summarized in Table 1.1.  
 
Table 1.1: The estimated and projected population of Australia and Malaysia  
Country Estimated Resident 
Population 
Growth 
Rate 
Projected 
Population 
Rank 
2050 
2010 
(million) 
2011 
(million) 
% 2050 (million) 
Australia 22 23 1.4 34 59 
Malaysia 28 29 1.6 43 48 
Source: (ABS, 2011; DSM, 2010) 
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Diabetes contributes substantially to public health issues in a high-income country such as 
Australia (0.24 million annual deaths), and a middle-income country, Malaysia (0.87 million 
annual deaths) (WHO, 2008). Australia was ranked 6th in the worldwide quality of life 
index, whereas Malaysia was the 51st country on the list (EIU, 2005). In terms of the 
human development index (HDI), Australia is categorized under ‘very high’ human 
development compared to ‘high’ for Malaysia (HDI, 2010).  
 
About two-thirds of the population in both Australia and Malaysia are between 15 to 64 
years of age. There were more people over the age of 65 years in Australia compared with 
Malaysia, while Malaysia had a greater number of younger people under 14 years (ABS, 
2011). In Australia, the gender ratio at birth is approximately 100 females per 105 males. 
However, higher male mortality rates at a young age result in the ratio approaching 100 
females per 100 males (ABS, 2011). The gender ratio of the total population for Australia 
was similar to Malaysia in 2011 (99.1 males per 100 females) (ABS, 2011). The age 
distribution of the Australian and Malaysian population respectively, is summarized in 
Table 1.2.  
 
Table 1.2: The age standardized population of Australia and Malaysia  
Country       2010 Media
n Age 
     2015 Median 
Age 
LE 
0-14 15-64 >65 0-14 15-64 >65 
Australia 18.9 67.6 13.5 36.9 18.6 66.1 15.3 39.9 82.1 
Malaysia 30.3 64.9 4.8 26.0 28.2 66.0 5.7 27.5 74.6 
Source: (ABS, 2011; DSM, 2010); LE = Life Expectancy 
 
 
1.6.3. Why is this study important? 
During the process of compiling the literature review for this study, an increasing trend in 
the prevalence of people with diabetes in Malaysia and Australia was identified. A slightly 
increased risk of depression and anxiety in people with diabetes in developing countries 
relative to the developed countries has been suggested by previous studies (Aina and 
Susman, 2006; Bouwman et al., 2010; Collins et al., 2009; Lin et al., 2008); however, 
biases and methodological issues in these studies may limit the strength of the finding.  
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Women’s role in society worldwide has expanded from the traditional carer role, to include 
provider, carer and member of the workforce. Therefore, women’s health is an important 
issue in all countries, including Australia and Malaysia. No longitudinal or case-control 
studies have examined the association between modifiable mental health conditions 
(depression and anxiety) and diabetes in women in Malaysia and the current study 
examined this relationship. This study did not directly compare the data from Australia and 
Malaysia but examined differences in the strength and direction of the relationship 
between modifiable mental health conditions and diabetes in both countries. 
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CHAPTER 2 
Methods 
 
The methods used in Australian and Malaysian arms of the PhD study are described in the 
two sections that comprise this chapter. The chapter covers the major methods used in 
this thesis; further details, relevant to individual papers can be found in those individual 
papers attached in the results section.  
 
2.1. The Mater-University of Queensland Study of Pregnancy (MUSP) 
Data for the Australian arm of the PhD study (the ‘developed country’ arm) were obtained 
from a multidisciplinary study that represents Australia’s largest longitudinal study of 
women’s reproductive life from pre-birth pregnancy, to 27 years post birth, that is MUSP. 
This longitudinal study began in 1978-79 with a number of pilot studies. Full data collection 
commenced in January, 1981. All recruited women gave birth to at least one child at the 
Mater Misericordiae Mothers’ Hospital which is one of the two major obstetric units in 
Brisbane, Australia. The study prospectively collected data across the reproductive life 
course of a large group of 6753 mothers. 
 
2.1.1. Participants 
Pregnant women attending their first clinic visit (at approximately 18 weeks’ gestation) at 
the Mater Hospital were invited to participate in the study which was run over the three 
years between January 1981 and December 1983 (Najman et al., 2005; Ware et al., 
2006). These women were re-interviewed at 3 to 5 days after delivery and their obstetric 
records were collected. Additional interviews were conducted when the children were 6 
months, 5 years, 14 years, 21 years, and 27 years of age.   
 
In this study, the dataset of 6753 mothers met three criteria: one or more singleton/ 
multiple birth children discharged alive from the hospital, after the birth, and the child was 
not adopted prior to discharge. Only data from the mother’s cohort were used in this 
thesis. For completeness, however, methodological details associated with the complete 
sample are reported here.   
 
2.1.2. Phases of the MUSP project 
In the first interview (first clinic visit) data were obtained on the respondent’s demographics 
characteristics, socio-economic status, family structure, and health conditions including 
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mental health, lifestyle and behaviours during pregnancy (Phase I). Data collection was 
undertaken using a 103-item questionnaire administered to mothers between the 3rd and 
5th postpartum day, and four obstetricians extracted some 200 details potentially relevant 
to child development problems such as birth weight and evidence of abnormalities at birth 
(Phase II). The mother’s past medical history is regarded as Phase III of the data 
collection, while details of the birth constituted Phase IV. Subsequently, in Phase V, a 103-
item mailed questionnaire was completed at six months after delivery (Najman et al., 2005; 
Ware et al., 2006). 
 
Phase VI was conducted five years after the birth, at which time mothers completed a 227-
item self-administered questionnaire which included separate sections for the child and for 
themselves. Both mothers and children were then contacted for further information at 14 
years after birth. At Phase VII, mothers were again asked to provide information regarding 
their family as well as themselves. In addition, a 141-item questionnaire was administered 
to the adolescents. For the 21-year follow-up (Phase VIII), comprehensive information was 
reported separately by the young adults and their mothers in relation to health, lifestyle, 
behavior and social factors.  
 
In the Phase IX at 27-year postpartum, comprehensive information was gathered from 
young adults and their mothers in relation to their socio-demographic characterictics, 
financial situation, social history, reproductive health, general health, lifestyle, gambling 
behavior, exercise, sleep quality, relationship, well-being, mental health, food frequency 
and health related quality of life. For all the phases, ethical clearance was obtained from 
the University of Queensland and the Mater Hospital ethics committees. 
 
2.1.3. Exposures and outcomes 
An exposure may represent an actual exposure (e.g. depression or anxiety), a behavior 
(where one works or socializes), or an individual attribute (e.g. age, sex, race) (BES, 
2013). The outcome refers to the disease state, event, behavior, or condition associated 
with health that is under investigation. An outcome in clinical or social research refers to 
the presence or absence of the health-related state or event (e.g. diabetes) (BES, 2013). 
In order to support a causal relationship between exposure and possible outcome, 
measuring intensity and duration of exposure is necessary. The validity of the study also 
depends on the quality of exposure and outcome measurements (BES, 2013). 
Assessment of exposures and outcome status can be performed using standard 
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diagnostic criteria as well as self-report scales. Unlike self-report scales, standard 
diagnostic criteria ensure consistent diagnosis of cases, regardless of where or when they 
were identified and who diagnosed the case. In this study, symptoms of depression, 
anxiety and diabetes were used as both exposures as well as outcomes to measure 
bidirectional associations. 
 
2.1.4. Bidirectional association model 
The bidirectional associations between depression and diabetes as well as anxiety and 
diabetes were examined (Figure 2.1):  
1. Depression and anxiety symptoms as risk factors for diabetes. 
2. Diabetes as a risk factor for depression and anxiety disorders. 
 
2.1.4.1. Depression and anxiety symptoms as risk factors for diabetes 
In this part of this study the association between changes in anxiety and depression 
symptoms and the risk of diabetes were examined for a cohort of women who were 
followed up at intervals over a 21-year period postpartum; it takes into account a range of 
potential confounding factors. Specifically, the association between changes in depression 
and anxiety symptoms measured between 5-year and 14-year follow-up while the risk of 
diabetes was measured at 21-year follow-up. 
 
2.1.4.1.1. Measurement of depression and anxiety symptoms 
Depression was assessed in all phases of the MUSP study using the Delusions 
Symptoms-States Inventory: State of Anxiety and Depression (DSSI/sAD) (Najman et al., 
2005). The exposure was depression and anxiety symptoms measured at 5-years and 14-
years after delivery; symptoms were assessed using the 14-item depression and anxiety 
subscales from the DSSI/sAD (Bedford and Foulds, 1978; Bedford and Deary, 1999; 
Najman et al., 2000). 
 
One of the advantages of using the DSSI instrument is that it covers both depression and 
anxiety. The overall DSSI scale comprises 14 questions covering depression and anxiety. 
The DSSI anxiety subscale consists of seven items constructed to include the primary 
features of anxiety disorder. The seven items each for depression and anxiety, are scored 
using 5-point response options (1 = never, rarely, some of the time, most of the time, or 5 
= all the time), these scores (reverse) are then summed (score range: 10 (all the time) – 50 
(never)); the lower the score, the more depressed or anxious the person. Women are 
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classified as anxious or depressed when they score 4 or more, and as non-anxious or non-
depressed when they score 4 or less out of a maximum 7 score (Bedford and Foulds, 
1978). 
 
The validity of the personal disturbance scale (DSSI/sAD) among women with diabetes 
using Mater-University of Queensland Study of Pregnancy (MUSP) cohort data was 
examined. Exploratory factor analysis and fit indices confirmed the hypothesized two-
factor model of DSSI/sAD. As expected, the scale had poor discriminant validity and good 
convergent validity. DSSI/sAD demonstrated strong relationships with equivalent SF-36 & 
CES-D scales. DSSI/sAD was highly specific with low sensitivity, compared with the DSM 
IV. 
 
2.1.4.1.2. Measurement of diabetes at 21-year follow-up 
During data collection, the presence of diabetes was confirmed with a question to 
participants asking whether a health care professional had informed them that they have 
diabetes. Although pre-partum diabetes and gestational diabetes mellitus were identified 
as pre-pregnancy complications and an adverse pregnancy outcome in MUSP, the 
presence of postpartum diabetes was not determined among the participants in the initial 
phases of MUSP. The question about diabetes was first included in 21-year postpartum 
follow-up and it was retained in the 27-year follow-up questionnaire. In both phases, 
self‐administered questionnaires were used to gather this information. Subsequently, each 
woman was asked, “Have you EVER been told by a doctor that you have diabetes (high 
blood sugars)?” A positive response to this question indicated that the woman had incident 
diabetes at some time during the 21 or 27-years after the index pregnancy.  
 
A limitation in the MUSP study is that self-report diabetes was not confirmed against any 
standard diagnostic criteria. Another limitation is that women who were cared for at Mater 
hospital (MUSP study site) were not screened routinely for gestational diabetes at the time 
of recruitment (Callaway et al., 2007). However, it is beyond the scope of the present 
study, to address these limitations. 
 
2.1.4.1.3. Adjustment for potential confounding 
The conventional approaches of adjusting for potential confounders may introduce 
conditional associations and bias (Shrier et al., 2008). Directed Acyclic Graphs (DAGs) 
have been used in epidemiology to represent causal relations among variables, and they 
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have been used extensively to determine which variables are necessary to control for 
confounders (Vanderweele and Robins, 2007). In DAGs, possible confounders eventually 
resulted in the deletion of all the direct causal pathways between the exposure of interest 
(for example, depression or anxiety) and the outcome (for example, diabetes), and 
between the covariates and the outcome (Pearl, 2000). Potential confounding factors for 
each of the transition models (changes in depression and anxiety symptoms) were 
included from the most recent or relevant previous phase of MUSP; possible confounders 
in the current study were selected using priori knowledge as well as DAGs.  
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Figure 2.1: Bidirectional association models – using Mater-University Study of Pregnany data 
Mental-health conditions (Exposures) 
1. Depression 
2. Anxiety  
 
 
Depression & anxiety (Outcome) 
(Longitudinal association between 
diabetes and depression/anxiety 
disorders at 27-year postpartum) 
 
Diabetes (Outcome)  
(Longitudinal association between 
depression/anxiety and diabetes 
at 21-year postpartum) 
 
Covariates adjusted 
1. Age  
2. BMI 
3. Depression/anxiety 
4. Socio-demographics 
At 21-
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follow-up 
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Diabetes (Exposure)  
1. Self-reported diabetes 
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2.1.4.1.4. Analytical strategy 
To test the hypothesis assessing the association between symptoms of depression and 
anxiety and the risk of diabetes, the observed proportion of women who reported a change 
in depression and anxiety symptoms between subsequent phases of the study, that is the 
5-year and 14-year follow-ups was estimated. In this study, diabetes was the dependent 
variable at 21-years, and a change in depression and anxiety symptoms (i.e. transitions) 
from the previous two phases (at 5 and 14-year follow-ups), was the main predictor. The 
possible transitions that could occur during the period from the 5-year follow-up (FU) 
(origin state) to the 14-year FU (destination state) were classified into four categories, 
based on a cut-off of 4 or more symptoms (Mamun et al., 2009). The details are included 
in the respective manuscripts (Chapter 6 and 7). To assess the robustness of the 
analytical strategy, sensitivity analyses were also performed using the transitions during 
the post-delivery period of 3 to 5 days (origin state) to the 6-month FU (destination state). 
They were classified into the same four categories used in the main analysis.  
 
2.1.4.2. Diabetes as a risk factor for depression and anxiety disorders  
I examined the association between diabetes at the 21-year follow-up and the risk of 
depression and anxiety disorders at the 27-year follow-up, using longitudinal data on 
women collected via the Composite International Diagnostic Interview (CIDI). Previous 
studies investigating the association between diabetes and depression and/ or anxiety are 
not conclusive and have several deficiencies, such as cross-sectional study design (Mezuk 
et al., 2008; Smith et al., 2013). Despite the fact that the literature suggests anxiety is an 
important comorbid condition associated with diabetes, only one review published in 2013 
examined the link between diabetes and the risk of anxiety (Smith et al., 2013).  
 
To examine diabetes as a risk factor for depression and anxiety disorders, a cohort of 
6753 women was used. It was considered important to exclude women who had 
experienced previous cases of anxiety, depression or comorbid depression and anxiety at 
the 21-year follow-up, and thus data from a total of 6472 women were included in the final 
analysis. 
 
2.1.4.2.1. Measurement of exposure – diabetes mellitus at 21-years 
The exposure in the analyses was information regarding self-reported diabetes mellitus in 
21 years after the index pregnancy; data in this phase were collected using a self-
administered questionnaire as described above.  
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2.1.4.2.2. Measurement of outcomes – depressive and anxiety disorders at 27-year 
At the 27-year follow-up, data on mood disorders were extracted from a computerized 
structured interview of depressive and anxiety symptoms using the World Health 
Organization-World Mental Health-Composite International Diagnostic Interview-CAPI 
Modularization Program (WHO WMH-CIDI CAPI: Version: 21.1.3) (WHO, 2004). This 
instrument assesses current and lifetime prevalence of mental health disorders according 
to Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) diagnoses. The CIDI 
summary outcomes (any depressive or anxiety disorder) were calculated as a positive 
diagnosis across a range of DSM IV diagnoses. Three categories were used to define 
duration of (any) depressive or anxiety disorders:  lifetime, 12-month and 30-day periods. 
 
2.1.5. Analyses of data 
The aim of the present investigation was to examine diabetes as a risk factor for, or 
consequence of, depression and anxiety in women. The data were analyzed using the IBM 
Statistical Package for Social Sciences (SPSS) ® version 22 and STATA IC ® version 12, 
with a significance level of ≤ 0.05. Descriptive statistics were initially used to examine the 
percentages, frequencies, means and standard deviations. Cross-tabulation, Chi-Square 
test, and Student t test were used to examine the pattern of prevalence of diabetes, and 
prevalence of symptoms of depression and anxiety in women with diabetes. They were 
also used to compare the characteristics of those women who did and did not provide 
information about diabetes or depressive/anxiety disorders.  
 
In the next step, multiple logistic regression models were developed to test the association 
between symptoms of depression and anxiety and the subsequent development of 
diabetes mellitus, after adjustment for other potential confounding variables. Detailed 
information about the construction of the prediction model for each specific dependent 
variable is given the Methods sections of the relevant manuscripts, which have been 
incorporated into Chapters 6 to 8 of this thesis The following paragraphs provide general 
information about the statistical analyses used in this study and describe how the issue of 
loss to follow-up was addressed using multiple imputations to assess the validity and 
generalizability of the findings of the present study.  
 
2.1.6. Prediction models 
The prediction of diabetes, depression and anxiety incidence primarily employed logistic 
regression and odds ratios (ORs). A direct causal relationship among the variables used in 
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the analyses is not claimed; rather, the aim has been to establish whether symptoms of 
depression and anxiety in postpartum phase tend to be independently associated with 
increased risk of diabetes onset and vice versa. 
 
In most instances, logistic regression was applied when the dependent variable comprised 
a dichotomous outcome, such as the presence or absence of diabetes at 21-year follow-
up. In order to illustrate the model, let Y denote the measurement of a dichotomous 
outcome, presence or absence of diabetes at 21-year or presence or absence of 
depressive and anxiety disorders at 27-year. Then Y = 0 if the woman was not associated 
with diabetes/depression/anxiety and Y = 1 if the woman was associated with 
diabetes/depression/anxiety. Values x1 through xn symbolize additional explanatory 
variables, which may be either dichotomous or continuous. The unified model for a 
dichotomous variable is: 
 
                                   Logit (Y) = b0 + b1x1 + b2x2 + …… bnxn 
 
Logistic regression generates results as an odds ratio (95% confidence interval) for each 
predictor. For instance, all other characteristics being equal, an odds ratio would estimate 
how much more or less likely a man would be to become a diabetic or depressed or 
anxious, compared with a woman (Leyland and Goldstein, 2001). In a rare condition 
(prevalence < 10%), the odds ratio approximates the relative risk, such as the proportion of 
women with diabetes, in this study.  
 
In the present study, the prediction models are based on odds ratios (95% confidence 
intervals) obtained from logistic regression. Simple binomial logistic regression was used 
when the outcome was dichotomous (diabetes: yes/no). When the outcome comprised 
three or more values (glycemic control: normal, mild, moderate, poor), the analyses were 
carried out using multinomial logistic regression (Leyland and Goldstein, 2001).  
 
2.1.7. Multivariate adjusted prediction models 
In order to achieve the most parsimonious model that correctly predicts the category of 
outcome for individual cases, a model should be created that includes all independent 
variables that appear to be associated with the outcome variable (Field, 2005). A stepwise 
regression process was used to enter variables into the model, in the order chosen by the 
investigator or by the logistic regression software after each coefficient is added or 
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deleted. To examine the model diagnostics, likelihood-ratio tests (Cohen, 2003; Dupont, 
2002) were used to find the model by which the outcome variable is best predicted by a 
set of several independent variables.  
 
2.1.8. Investigation of missing data 
Loss to follow-up or attrition over the follow-up phases from the original cohort has been a 
common feature in almost all population-based cohort studies, and was so in MUSP. While 
the cohort began with 6753 mothers and their offspring, at the 21-year follow-up only 54% 
provided information regarding the diagnosis of diabetes mellitus. At 27-year follow-up, the 
number further decreased to 3330 for those who provided information about depressive 
and anxiety disorders. Missing data due to attrition or loss to follow-up and item non-
response inevitably will lead to lower study power and less precise, possibly biased, 
estimates (Criqui, 1979; Miettinen, 1985).  
 
Little and Rubin defined the process for dealing with missing values, or non-response 
(Little and Rubin, 1987); non-response or missingness is of three types. The first one is 
defined as missing completely at random (MCAR) if the missingness is independent of 
both outcome and independent variables. The second one is missing at random (MAR) if, 
condition on the independent variable, the missingness is independent of the outcome 
variable. ‘Missing at random’ means that the probability of the data being missing may 
depend on observed values (Schafer, 1999). Finally, missing not at random (MNAR) is the 
most serious type as the non-response is associated with the outcome (Little and Rubin, 
1987). 
 
In the current study, there are two possible effects associated with MNAR; if loss to follow-
up was greater in those exposed to depression or anxiety measured at 5-year and 14-year 
and the outcome of interest was truly more common among those lost, the findings would 
underestimate the true association. The apparent OR would be less than estimated for the 
complete cohort if the follow-up in the exposed group was only 50% while that in the 
unexposed group was 100%. On the other hand, if those who developed the outcome of 
interest, i.e. development of diabetes, were less likely to drop out of subsequent follow-ups 
than individuals who did not, then the risk would have been overestimated.  
 
Complementary tests were conducted to examine the possible effects of loss to follow-up 
on the validity of the results. These tests were conducted to assess the association 
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between each exposure variable at the early phases (depression and anxiety at 5-year 
and 14-year) of follow-up with losses to the sample at the 21-year follow-up. Analyses 
show that those excluded because of missing data or loss to follow-up were more likely to 
be young when they gave birth (aged between 13 and 19 years), to have one change in 
marital status, to have been consistently poor, to have not completed secondary schooling, 
to have a low BMI, and to be depressed or anxious.  
 
2.1.8.1. Multiple imputations 
Multiple imputations were carried out to adjust for missing data (Sterne et al., 2009). 
Results of the analyses of the complete datasets were combined using Rubin’s rules 
(described above) and performed in Stata IC version 12.0 (Stata Corporation, College 
Station, TX, USA). The relationship between ‘missingness’ (yes vs no) and the predictor 
variables was assessed using logistic regression. In general, it is recommended to impute 
more than the percentage of missing data (Simpson et al., 2007). An imputation model 
was devised using the recommendations of Van Buuren et al. (van Buuren et al., 1999). 
The model included all of the predictor variables excluding the outcome. The data on 
covariates were assumed to be ‘missing at random’.  
 
The imputation model was used to generate sets of imputed values for the missing data 
points thus creating complete datasets. Data were imputed from the posterior predictive 
distribution of the missing data given the observed data. The posterior predictive 
distribution of the data was assumed to be multivariate normal, so that all of the predictor 
variables (categorical and continuous) were assumed to be normally distributed (Simpson 
et al., 2007). The results from the regression modelling of the different datasets were 
combined using the rules given by Rubin to produce a multiple imputation estimate (Rubin, 
1987). Methods used in the Malaysian (developing country) arm of the study are described 
in the following section. 
 
2.2. The Malaysian Case-Control Study 
 
2.2.1. Study design and participants 
For the ‘developing country’ arm of the PhD, I conducted a case-control study in Malaysia 
among women aged 35 or older, with and without known Type 2 Diabetes Mellitus 
(T2DM). The case-control study involved women with diabetes matched to women without 
T2DM in the same age range. A frequency matching technique was used to match 
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participants on ‘cell’ instead of ‘individual’ basis. The frequency matching was conducted 
using two conditions: presence or absence of diabetes and aged 35 years or more. The 
frequency matching was completed in two steps. In the first step, only women aged ≥ 35 
who attended outpatient clinics for the management of T2DM and who had a known 
diagnosis of T2DM were selected (cases). In the second step, cases were matched with 
controls; these were women were aged ≥ 35 years, with no known diagnosis of T2DM. The 
control participants were healthy friends or unrelated family members (no blood relation) of 
women with type 2 diabetes. 
 
Patients belonging to any ethnic group and who had Malaysian citizenship were included 
in this study. Women diagnosed with diabetes before the pregnancy, gestational diabetes 
mellitus that was diagnosed during the pregnancy, and T1DM were excluded from 
analysis.  
 
2.2.2. Development of study questionnaire 
A questionnaire for self-administration in Malaysia consisting of 111 questions was 
developed for this study. The questions covered factors such as: background (9 
questions), medical and pregnancy history (7 questions), lifestyle (11 questions), 
reproductive health (33 questions), mental health (27 questions), sleep quality (9 
questions), quality of life (10 questions) and physical ad clinical measurements (5 
quetions). Of the 111 questions, 86 (78%) questions were used from MUSP questionnaire 
that was administered at 27-year follow-up and were used without any changes to elicit 
information about quality of life, mental health, sleep quality; 20 (18%) questions were 
desgined to explore socio-demographic factors and were MUSP questions that had been 
modified for the Malaysian context; and 5 (4%) were new questions that explored physical 
and clinical parameters.  
 
The English version of the complete questionnaire, designed by the candidate and used 
for primary data collection in Malaysia (March 2012 to January 2013), and can be found at 
the end of this thesis as Appendix 5A. It is important to mention that only questions 
relevant to the PhD study objectives were analyzed and included in the findings; these 
included questions which related to socio-demographics, presence or absence of chronic 
conditions (e.g. diabetes) and mental health.  The specific questionnaire used to identify 
symptoms of depression and anxiety, was validated separately and the findings are 
incorporated in Chapter 5 of this thesis. 
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2.2.3. Validation of the study questionnaire 
 
2.2.3.1. Content validation 
The questionnaire developed for use in Malaysia was written in English as this was the 
language used in the MUSP study questionnaire and was the version subjected to content 
validation. Panellists for content validation were selected according to the Standards for 
Educational and Psychological Testing, which emphasizes the necessity of relevant 
training, experience, and qualifications in selecting content experts to review instruments 
(AERA, 2002). A widely accepted method of measuring content validity developed by 
Lawshe was used to assess how essential each question is (Lawshe, 1975). Ratings for 
each question were entered into a spreadsheet, and the content validity ratio (CVR) was 
calculated for each question based on the formula developed by Lawsche:  
 
CVR = (ne − N / 2) / (N / 2) 
 
Where: ne= number of panellists (jurors) indicating “essential” and N= total number of 
panellists. This formula yields values which range from +1 to -1; positive values indicate 
that at least half the panelists rated the item as essential. The overall mean content 
validation index of the study questionnaire was found to be +0.81.  
 
2.2.3.2. Face validation 
For face validity, questionnaires were then distributed to individuals who were not expert in 
testing instrument design and construction and their feedback and comments were 
incorporated into the final version of questionnaire.  
 
2.2.4. Translation of questionnaire 
Translation of the questionnaire was conceptual as stipulated by the WHO (PTAI, 2012). 
The validated English version of the questionnaire was translated into Bahasa Malaysia 
(the official language of Malaysia) using a forward-back translation process performed by 
two native speakers. The Bahasa Malaysia version was then again translated into English 
by two English language teachers. The reason for translating the questionnaire into 
Bahasa Malaysia was that the majority of Malaysian citizens can speak and understand 
Bahasa Malaysia. Reasons for not translating the questionnaire into Chinese or Tamil 
languages included a scarcity of resources, lack of funding, and trained translators. 
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2.2.5. Feasibility, reliability and piloting of the instruments 
In the final step, the questionnaire (English and Bahasa Malaysia version) was pre-tested 
and piloted on 30 women with and 30 women without T2DM, the target population. The 
feasibility and reliability of the instruments in the questionnaires were investigated. The 
Cronbach alpha values for the main instruments that were incorporated into the 
questionnaire (DSSI, CES-D-10 and SF-12) were found to be more than 0.70 for both the 
English and the Bahasa Malaysia versions which show that items included in the 
questionnaire were internally consistent.   
 
2.2.6. Sampling sites 
There are thirteen states and three federal territories that constitute the total Malaysian 
territory, which is further divided into 2 areas: West and East Malaysia. West Malaysia is 
mainly populated by three ethnic groups namely, Malay, Chinese and Indian. Indigenous 
inhabitants such as Iban, Melanau, and Bedayu are found mainly in East Malaysia, which 
is comprised of the states Sabah and Sarawak. Due to budget and time constraints, 
sampling for this PhD was restricted to West Malaysia. Three Medication Therapy 
Adherence Clinics (MTACs), two hospitals (Hospital Putrajaya and Hospital Tuanku Jaa’far 
Seremban) and one Health Clinic (Health Clinic, Seremban) in West Malaysia were 
selected as primary sampling sites.  
 
Non probability-based design was used to select the sampling sites. Recruitment was 
initially started in Hospital Putrajaya where the majority of the patients were of Malay 
origin. Therefore, to select a sample that included all three ethnic groups, sampling was 
extended to the Seremban region to include patients of Chinese and Indian ethnicity.  
 
2.2.7. Sample size and sampling procedure 
Sample size was calculated based on three factors; prevalence of diabetes in women (p), 
margin of error (2.5%) and 95% confidence interval (Z-value). The prevalence of diabetes 
in Malaysian women in 2012 was extrapolated and estimated as 11.82% (Shaw et al., 
2010); this estimation was made based on the prevalence of diabetes in Malaysian women 
in 2010 and 2030, i.e. 11.6% and 13.8%, respectively (Shaw et al., 2010). Assuming a 
2.5% margin of error, a 95% confidence interval and using the extrapolated prevalence in 
2012, a sample size of 640 was estimated (See Appendix 6A for details). This sample size 
was estimated for women with diabetes (i.e. cases). To match the frequency of cases in 
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same age range, 640 controls were selected. Therefore, a total of 1280 women were 
approached to participate in this case-control study. 
 
To achieve the required sample size, a systematic random sampling technique was 
applied. In this sampling process, every kth was selected where k = N/n. The sampling 
process started with a randomly chosen woman, from 1 to k. The patient list provided by 
clinics at the start of the study had about 1310 women with diabetes. The k was calculated 
as: 
 
N = 1310 students and we want to sample n = 640 patients. 
k = N/n = 1310/640 = 2. 
 
The subsequent sampling of every second patient from the target population on the MTAC 
occurred, and the women were systematically invited to participate. The example of 
sampling process is presented below. 
 
MRN Name Age Sampling 
131 Mrs. XXX 41 - 
156 Miss. YYY 48 Selected 
165 Mrs. KKK 39 - 
182 Miss. GGG 52 Selected 
Note: MRN = Medical Record Number 
 
Those who meet the inclusion criteria then proceeded to complete the questionnaire under 
the guidance of research assistants. The research assistants had been trained and briefed 
by the PhD candidate about the data collection process, with clear instructions not to lead 
the respondents in their answers but to assist when clarification was required. Data 
collection from the three sampling sites started in March 2012 and was completed in 
January 2013. After the data were collected, I merged and analyzed the data as described 
below. 
 
2.2.8. Ethics approval 
The study was conducted according to the principles expressed in the Declaration of 
Helsinki, and was approved by the Ethics Committee at the School of Pharmacy, The 
University of Queensland (Reg. No. 2011/14) and International Medical University 
Research and Ethics Committee (Project ID. No. B01/09-Res (04)2012). The study was 
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also registered with the National Medical Research Registry (NMRR), Ministry of Health 
Malaysia (Research ID: 12444). 
 
2.2.9. Measurement of T2DM 
Data on T2DM were collected through the self-administered questionnaire, where women 
were asked “Have you EVER been told by a doctor that you have diabetes (high blood 
sugars)?” with response options “yes” or “no.” Subjects were categorized as having T2DM 
if they had been told by a physician they had diabetes. The presence of T2DM in the 
selected clinics was identified according to two criteria: A fasting plasma glucose (FPG) 
greater than or equal to 7.0 mmol/l, and random plasma glucose (RPG) greater than or 
equal to 11.1 mmol/l. Women diagnosed with type 1 diabetes were excluded. Information 
was confirmed by accessing patients’ medical records.  
 
2.2.10. Measurement of depression and anxiety  
 
2.2.10.1. Delusions-Symptoms-States Inventory/ States of Anxiety & Depression  
The information about the presence of depression and anxiety symptoms was measured 
using the Delusions-Symptoms-States Inventory/States of Anxiety and Depression 
(DSSI/sAD). The DSSI/sAD contains 14 symptoms; 7 for depression and 7 for anxiety. 
Participants in this study were classified as anxious or depressed when they scored 4 or 
more and as non-anxious or non-depressed when they scored 4 or less, out of a maximum 
score of 7.  
 
2.2.10.2. The Center for Epidemiological Studies Depression (CES-10) 
The information about the presence of depression was also measured using a brief self-
report screening tool, Center for Epidemiological Studies Depression 10 Scale (CES-D 10) 
(Radloff, 1978). It has been shown to have reliability and validity comparable to the 
standard 20-item CES-D instrument and is considered a good instrument for screening 
depression in older adults (Irwin et al., 1999), and patients with T2DM (Swenson et al., 
2008). The CES-D 10 uses a zero-to-three response scale, with total symptom severity 
scores ranging from 0 (no depression) to 30 (severe depression) (Brockington, 1996). 
Participants in this study were categorized as depressed if they scored 11 or more on the 
CES-D 10 scale. The CESD is one of the most commonly used scales in people with 
diabetes and has been validated to use among people with diabetes (Roy et al., 2012). 
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The reliability of the CES-D was investigated and the Cronbach alpha value was found to 
be 0.78. 
 
2.2.11. Measurement of covariates 
The potential confounders and risk factors were identified on the basis of their association 
with outcomes and on the basis of a priori knowledge (Mezuk et al., 2008; Smith et al., 
2013). The covariates measured in this part of the study included: body mass index (BMI) 
(kg/m2), comorbidities or medical conditions other than T2DM, and socio-demographic 
information (age, ethnicity, education, monthly, marital status). Menopausal status was 
identified as pre-menopausal, peri-menopausal or post-menopausal. Menopause-specific 
QoL (MENQOL) was measured using a validated MENQOL instrument (Hasan et al., 
2013). 
 
2.2.12. Analyses of data 
The aim of this part of the investigation was to examine the association between 
depression and diabetes, anxiety and diabetes in Malaysian women. I analyzed the data 
using the IBM Statistical Package for Social Sciences (SPSS) ® version 22 and STATA IC 
® version 12, with a significance level of ≤ 0.05. Descriptive statistics were initially used to 
examine the percentages, frequencies, means and standard deviations. Cross-tabulation, 
Chi-Square test, and Student t test were used to examine the pattern of prevalence of 
diabetes, and prevalence of symptoms of depression and anxiety in women with diabetes.  
 
In the next step, multiple logistic regression models were developed to test the association 
between symptoms of depression and anxiety, and diabetes mellitus, after adjustment for 
other potential confounding variables. Detailed information about the construction of the 
model for each specific dependent variable is given the Methods section of the relevant 
manuscripts and which have been incorporated into the Results section of this thesis 
(Chapters 9 & 10). The following paragraphs provide general information about the 
statistical analyses used in this part of the study.  
 
2.2.13. Association models 
The prediction of diabetes, depression and anxiety incidence primarily employed logistic 
regression and odds ratios (ORs). A direct causal relationship among the variables used in 
the analyses was not claimed; rather, the aim was to establish whether symptoms of 
depression and anxiety tend to be independently associated with diabetes. 
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In this investigation, the models were based on odds ratios (95% confidence intervals) 
obtained from logistic regression. Simple binomial logistic regression was used when the 
outcome was dichotomous (diabetes: yes/no). When the outcome comprised three or 
more values (glycemic control: normal, mild, moderate, poor), the analyses were carried 
out using multinomial logistic regression. The objective of logistic regression was to define 
the most parsimonious model that correctly predicts the category of outcome for individual 
cases. Multiple logistic regressions were then used to further assess the relationship, after 
adjustment for other potential confounding variables. A series of models are presented, 
that were adjusted the potential confounders so that readers can see the effect of factors 
that may have confounded this association.  
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CHAPTER 3 
The global distribution of comorbid depression and anxiety in people with 
diabetes: risk-adjusted estimates  
 
The first objective of this thesis was to calculate the risk-adjusted global prevalence 
estimates of comorbid depression and anxiety in people with diabetes mellitus. The global 
prevalence estimates via risk adjustment were calculated; the methods, results and 
findings were compiled into a manuscript that has been revised and resubmitted for 
publication, and forms the basis for this chapter. The formal citation for the resubmitted 
work: 
 
1. Hasan, S.S., Clavarino, A.M., Mamun, A.A., Doi, S.A.R., Kairuz, T. The global 
distribution of comorbid depression and anxiety in people with diabetes: risk-
adjusted estimates. J Epidemiol [Revised & Resubmitted]. 
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The global distribution of comorbid depression and anxiety in people with 
diabetes mellitus: risk-adjusted estimates 
 
 
Abstract 
 
Background: Previous reports suffer 
from the problem that they simply pooled 
data using aggregate means or standard 
meta-analytic method. The aim of the 
current study was to re-estimate the point 
prevalence of comorbid depression and 
anxiety in people with diabetes.  
 
Methods: The estimates were calculated 
using recently introduced Directly 
Standardized Effect Estimate (DSE) 
method, which gives corrected risk-
adjusted estimates for the population of 
interests. Reported are global and 
regional burden of prevalence, presented 
as risk-adjusted prevalence estimates 
with 95% confidence intervals (CI).  
 
Results: Globally, the burden of 
comorbid depression was higher than the 
burden of anxiety (23.36% vs. 17.58%) 
symptoms and/or disorder in people with 
diabetes. There was a higher burden of 
comorbid depression in people living in 
developing regions (26.32%), in women 
(15.41%) and when assessed by self-
report scales (22.66%). The burden of 
anxiety was higher in developed regions 
in people with T2DM (20.15%) and when 
assessed by self-report scales (20.75%). 
No statistically significant differences 
were seen due to gross heterogeneity 
across countries.  
 
Conclusions: There are wide-ranging 
differences in studies in developed and 
developing regions, regarding the burden 
of comorbid depression and of anxiety 
among people with diabetes and both 
conditions affect approximately a fifth of 
the diabetic population.  
 
Keywords: Prevalence, depression, 
anxiety, diabetes, comorbid 
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INTRODUCTION 
Worldwide estimates of prevalence of 
depression and anxiety among people 
with diabetes seem to vary by diabetes 
type and where the study was conducted, 
including whether countries were 
developed or developing.1-3 These two 
conditions are mental health-related co-
morbidities in people with diabetes,4 and 
their prevalence has been summarised in 
a number of systematic reviews.5-8 A 
meta-analysis published in 2001 reported 
that 11% of patients with diabetes had 
comorbid major depressive disorder 
(MDD) and 31% experienced significant 
depressive symptoms.6 Another meta-
analysis published in 2006, reported that 
the prevalence of clinical depression was 
significantly higher among patients with 
diabetes (17.6%) compared to those 
without diabetes (9.8%).5  
 
Both studies reported that the prevalence 
of depression in women with diabetes 
was double that of men with diabetes; 
they also estimated that the prevalence in 
people with diabetes was nearly twice 
that of people without diabetes.5,6 The 
only meta-analysis on prevalence of 
anxiety was published in 2002 by Grigsby 
et al., who reported that generalized 
anxiety disorder (GAD) was present in 
14% of patients with diabetes; however, 
elevated symptoms of anxiety were found 
in 40% of patients with diabetes who had 
participated in clinical studies.7 
 
These previous reports suffer from the 
problem that they simply pooled data 
using aggregate means or standard 
meta-analytic methods,5-7 which are 
inappropriate given that we are not 
seeking a common underlying estimate 
and therefore this approach could lead to 
biased prevalence estimates. What is 
actually more meaningful is a 
standardized rate and the directly 
standardized rate (DSR) is one of the 
most commonly used methods of 
standardization in epidemiologic studies,9-
11 but its use is limited to rates. Doi and 
colleagues recently introduced a directly 
standardized effect estimate (DSE) which 
can be used to standardize any effect 
size against the size of population at risk.9 
The aim of the current study was to re-
estimate the point prevalence of comorbid 
depression and anxiety in people with 
diabetes using the DSE method which 
gives corrected risk adjusted estimates 
for the population of interests.9 We also 
stratified the estimates by type of region 
(developed vs. developing), type of 
diabetes (T1DM vs. T2DM), type of 
measurement (self-report vs. standard 
criteria), and gender (males vs. females). 
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METHODS 
The databases PubMed, EMBASE, and 
PSYCINFO were systematically searched 
to identify relevant studies published 
between 2000 and 2014. The reason was 
to include more articles. Additional 
articles were sourced from the reference 
lists of relevant review articles and 
original research studies. Keywords 
included original terms and synonyms 
related to diabetes, depression, and 
anxiety, and critical review were 
conducted by the principal investigator. 
The search strategy involved using the 
explode command with a search under 
the MeSH terms, for example 
‘depression/ anxiety’, ‘depressive/anxiety 
disorder’, ‘major depressive disorder’ and 
‘dysthymic disorder’ combined with 
‘diabetes mellitus’ or ‘type 2 diabetes 
mellitus’. This was supplemented with a 
keyword search of the terms ‘depression/ 
anxiety’, ‘depressive/anxiety disorder’, 
and ‘depressive/ anxiety symptoms’ 
combined using Boolean operators with 
‘diabetes’ and ‘diabetes mellitus’. We 
categorised the countries into developed 
and developing using the United Nation 
(UN) classification.12 Developing world 
includes countries outside Europe, 
excluding Australia, Canada, Japan, New 
Zealand, USA, Singapore, Hong Kong 
and Taiwan.  
 
Studies eligible for inclusion in this paper 
were required to assess diabetes mellitus 
type 1 (T1DM) and/ or type 2 (T2DM) in 
an adult population with no limit on age. 
Studies were included only if they had a 
sample size ≥ 30, were published or 
available in English, and if a current 
estimate of proportion with depression or 
anxiety was available either through self-
reports diagnostic criteria. Included 
studies utilized both standard diagnostic 
criteria (SDC) as well as Self-report 
Scales (SRS) to measure these disorders 
and their symptoms. Standard criteria 
comprised structured or semi-structured 
interviews that were based on the 
Diagnostic and Statistical Manual of 
Mental Disorders (DSM). Elevated 
symptoms were assessed using self-
report measures such as the Beck 
Depression Inventory, or the Hospital 
Anxiety and Depression Scale.  
 
Selection criteria were not restricted to 
studies comparing occurrence of 
depression and/ or anxiety disorders or 
elevated symptoms (using a clinically 
significant cut-off) in people with diabetes. 
Because there were many controlled 
studies that reported prevalence of 
depression and anxiety in a non-diabetic 
group, prevalence in the latter studies 
was taken from the diabetic arm only. For 
studies that presented graded 
relationships such as low, medium, or 
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high depressive symptoms, only the 
prevalence for the highest category was 
selected. Studies where the type of 
diabetes, was not specified were included 
as T2DM because the ages of 
populations recruited suggested they 
would be predominantly subjects with 
T2DM.  
 
The quality of the included studies was 
rated independently by the authors using 
criteria that include adequacy of the 
description of groups (type 1 and type 2 
diabetes mellitus, diabetes mellitus, type 
1 and type 2 diabetes mellitus with 
depression/ anxiety, control without 
depression/ anxiety and control with 
depression/ anxiety), control for 
confounding variables, and 
representativeness of sampling. 
 
Statistical analysis 
Each study was examined for information 
regarding events of comorbid depression 
and anxiety in people with diabetes. For 
studies that reported events separately by 
gender (males vs. females), type of 
assessment (self-report scales vs. 
standard diagnostic criteria), and type of 
diabetes (T1DM vs. T2DM), events were 
extracted and burden of depression and 
anxiety within these subgroups were 
calculated.  
 
In addition to comorbid depression and 
anxiety disorders, data on depression and 
anxiety symptoms as well as specific 
anxiety disorders were extracted (GAD, 
panic disorder, phobias, and PTSD).  
 
The country-specific prevalence of 
comorbid depression and anxiety was 
then used to pool the burden of these 
disorders in specific broad populations 
using the DSE approach.9 This process 
involves adjustment for different sizes of 
populations at risk when computing 
summary measures across populations 
with diabetes. The population size at risk 
was the prevalence of diabetes across 
the different countries in the world 
obtained from the International Diabetes 
Federation.13 Sensitivity analysis was also 
conducted by publication years in order to 
explore potential heterogeneity. 
 
This approach is similar to direct 
standardization using the diabetes 
subpopulation size to adjust prevalence 
estimates such that larger populations 
contribute more to the pooled estimate for 
a region than smaller populations.9 Thus 
the DSE is a type of direct 
standardization and can be calculated as: 
  
where the weight is defined as described 
by Doi et al. (2014) and j indexes the sub-
populations and ESj is the subpopulation 
effect estimate of interest (the double 
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arcsine square root transformed 
proportion in this study with results back 
transformed for reporting).9 This weighted 
averaging procedure does not use 
inverse variance weights and thus is not a 
meta-analysis.9 For countries where more 
than one study was available, a single 
estimate was obtained through standard 
meta-analysis thus ensuring that each 
country provided a single estimate. This 
meta-analysis (within country) was 
conducted using an inverse variance 
quasi likelihood based alternative (IVhet) 
to the random effects model, also recently 
introduced by Doi and colleagues.14 Data 
were analysed using STATA 12 
(StataCorp LP, TX, USA), MetaXL 2.0 
(EpiGear International Pty Ltd), and 
Microsoft Excel. Linear regression 
analysis was used to examine trend of 
prevalence between 2000 and 2013.  
 
RESULTS 
The 103 studies selected for review 
generated 103 datasets of which 71 
examined prevalence of depression in 
people with diabetes, and 32 examined 
prevalence of anxiety in people with 
diabetes. Of the 71 studies assessing 
prevalence of depression in people with 
diabetes, 37 studies were from developed 
and 34 from developing countries. 
Similarly, to estimate the prevalence of 
anxiety in people with diabetes, a 
comprehensive review was conducted on 
17 studies from developed and 15 studies 
from developing countries, as shown in 
(see supplementary file). 
 
Burden of depression  
Global: The burden of comorbid 
depression symptoms and/or disorder in 
people with diabetes was 23.36%, and 
was similar to the burden of symptoms 
only at 24.50% and the burden of any 
depressive disorder at 22.27% (Table 1).  
 
Developed: The burden of comorbid 
depression in T1DM and T2DM was 
similar (13.47 vs 17.9%). Subgroups by 
standard diagnostic criteria (21.70%) or 
female gender (12.92%) made up a 
greater burden than self-reports and 
males respectively (Table 1). The 
sensitivity analysis by publication years 
presented a declining trend in the 
prevalence of depression where 
prevalence was lowest in recent years 
(2010 onwards). 
 
Developing: Trends were similar to 
developed nations except that self-reports 
demonstrated exaggerated estimates of 
burden (Table 1). The prevalence was 
higher in recent years (2010 onwards) 
compared to prevalence between 2000 
and 2009. 
 
Burden of anxiety  
Global: The burden of comorbid anxiety 
symptoms or disorder in people with 
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diabetes was lower than that of 
depression (17.58%), the burden of 
symptoms was 20.16% and the burden of 
any anxiety disorder was 7.11% (Table 
1).  
 
Developed: The burden of comorbid 
anxiety in people with T1DM (17.00%) 
was similar to T2DM (20.15%) (Table 1). 
Again, subgroups by female gender and 
self-reports made up a higher burden 
than male gender and standard criteria 
respectively (Table 1). The prevalence 
was highest between 2005 and 2009, and 
almost same in other two groups (2000-
2004 and 2010-2014). 
 
Developing: Again, self-reports were 
associated with a much higher burden of 
anxiety than standard criteria. The 
sensitivity analysis by publication years 
showed an increasing trend in the 
prevalence of anxiety where prevalence 
was highest in years between 2010 and 
2014. 
 
DISCUSSION 
Our findings suggest that about one in 
eight people with diabetes living in 
developed region and one in four people 
with diabetes living in developing region 
are likely to experience depression 
symptoms. We also notice that 
depression and anxiety demonstrate a 
greater burden in females with diabetes 
and by self-reports. The burden of 
depression in people with diabetes 
tended to be lower in developed regions 
compared to developing regions. 
However, the reverse trend was seen for 
anxiety, being higher in developed 
regions than developing regions, in 
people with T2DM. Baxter and colleagues 
also suggested that anxiety was more 
common in general population living in 
high income regions compared to low or 
middle income regions.15 
 
Unlike the previous reviews,5-7 one of the 
strengths of this study is the use of 
standardised prevalence estimates. 
Previous estimates seem to have been 
biased upwards and for instance the 
reported 40% prevalence of comorbid 
anxiety in people with diabetes,7 was 
revised downwards to 20% in this study 
(Table 2). 
 
This study was based on self-report 
scales and thus their validity is of 
paramount importance. This does not 
seem to pose a problem because these 
scales used for screening for depression 
and anxiety have been shown to be 
reliable and valid,16 and are often 
employed in epidemiological surveys 
such as those investigated in this study. 
However the diagnosis of diabetes is also 
important and again it has been shown in 
a meta-analysis that depression 
prevalence varies little across 
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assessments by either blood glucose 
measures, physician diagnosis or patient 
self-report.17  
 
Regarding gender, our findings suggest 
that about one in eight females with 
diabetes living in developed region and 
one in six females with diabetes living in 
developing region are likely to report 
depression. This is consistent with the 
reports from earlier studies.5,6 Similarly 
the gender difference in prevalence 
between females and males has been 
previously reported.7 Even in the general 
population, women are more likely to 
experience mood disorders compared to 
men,18 so this is not unexpected. 
 
The overall burden of any anxiety 
disorder in people with diabetes was 
within the range of 12% to 21% reported 
for the general population.19-21 
Depression was however found to be 
higher (23%) compared to the general 
population (10%).5 Finally prevalence of 
the GAD found in developed regions is 
comparable to the 3–4% observed in 
community studies in the US.22,23 Since 
this burden is within or close to the range 
of estimates reported for the general 
population, there is a possibility that the 
burden can be explained by factors other 
than diabetes per se that share a 
relationship with both diabetes and 
depression or anxiety. For instance 
obesity has been shown to be associated 
with the former condition as well as with 
diabetes.24,25  
 
Co-morbid depression and anxiety 
disorders and elevated symptoms in 
people with diabetes have been shown to 
be associated with increased diabetes 
complications,1 worsened blood glucose 
levels,26,27 and reduced quality of life.28 
This is of particular concern to developing 
regions where resources to address 
depression and anxiety are not 
adequate.29 Indeed it has been reported 
that about 35% to 50% of serious cases 
in developed countries and about 76% to 
85% in less-developed countries received 
no treatment in the 12 months preceding 
the interview.30 
 
There were limited number of studies 
using standard criteria to diagnose 
depression and anxiety disorders. It is 
possible that some estimates and 
confidence intervals may be unstable 
because of the small number of subjects 
used in the calculations, and there is a 
concern about variability in the methods 
used to identify cases of depression and 
anxiety. Various self-report scales were 
used to measure depression and anxiety 
symptoms, and even in studies that 
employed the same scales, different 
threshold scores were used.  
 
 46 
 
We had samples from variety of settings 
including primary, secondary and 
community settings. Patients with 
diabetes recruited from a secondary-care 
setting are likely to differ from those 
selected from primary-care and 
population settings with regard to disease 
stage and severity.31 No statistically 
significant differences were seen due to 
gross heterogeneity across countries. 
Despite these limitations, this review 
presents significant findings regarding 
standardized prevalence of comorbid 
mental health conditions in people with 
diabetes living in different types of 
countries.  
 
The association between depression and 
diabetes, and anxiety and diabetes may 
have deleterious impact on public and 
individual health. Once depression or 
anxiety develops, it can represent a 
barrier to glycaemic control.32 
Unfortunately, both conditions often 
remain unrecognized and thus 
untreated.33 The burden of depression 
found in this study is higher in people with 
diabetes than in general population. 
However the burden of anxiety seems to 
be similar in diabetes as in the general 
population. The burden of comorbid 
depression and anxiety tended to be 
higher in people with diabetes living in 
developing region compared to 
developed region, and in females relative 
to males with diabetes. The above 
findings that people with diabetes are at 
higher risk of having depression and 
anxiety should alert clinicians to screen 
and treat anxiety and depression in 
people with diabetes. 
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Table 1: The standardized prevalence estimates of comorbid depression and anxiety in people with diabetes, by developed and developing countries 
Region 
Variable 
Prevalence of depression (%) Prevalence of anxiety (%) 
 
ES 
95% CI  95% CI 
LCI UCI ES LCI UCI 
Global Symptoms or disorder 23.36 5.03 49.72 17.58 4.22 37.44 
Symptoms 24.50 5.27 51.86 20.16 5.17 41.68 
Any disorder 22.27 3.13 51.98 7.11 1.04 17.87 
Developed T2DM + T1DM 13.58 1.61 32.37 15.46 2.63 36.17 
T2DM 13.47 1.10 36.42 20.15 8.57 35.09 
T1DM 17.90 1.00 51.33 17.00 1.00 42.80 
Self-report 14.53 3.27 30.85 22.26 4.49 48.39 
Standard criteria 21.70 3.20 66.20 11.72 2.60 25.23 
Male 6.55 2.94 24.94 17.50 1.60 42.20 
Female 12.92 1.00 38.68 23.30 14.90 32.90 
Developing T2DM 26.32 1.00 64.93 18.19 2.15 44.90 
Self-report 30.79 9.64 57.51 19.24 2.72 45.71 
Standard criteria 2.20 2.00 52.20 2.50 0.70 5.10 
Male 10.30 0.20 28.80 8.27 1.27 41.16 
Female 17.90 4.70 36.30 15.21 1.20 50.99 
Note: DSE = Directly Standardised Effect Estimate, DM = diabetes mellitus 
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Table 2: Comparison of comorbid depression and anxiety in people with diabetes in percentage, reported by different studies 
Variables Global Burden 
(risk adjustment) 
Burden in 
developed 
regions 
(risk adjustment) 
Burden in 
developing 
regions  
(risk adjustment) 
Gavard et al., 
1993 –  
Burden 
(proportion) 
Anderson et al., 
2001 –  
Burden 
(aggregate 
mean) 
Grigsby et al., 
2002 –  
Burden 
(aggregate 
mean) 
Ali et al., 2006 
– Burden 
(Meta-analysis) 
Depressive symptoms 24.50 14.53 30.79 26.0 31.0 - 17.60 
Any depressive disorder 22.27 21.70 2.20 - -  - 
Anxiety symptoms 20.16 22.26 19.24 - - 39.60 - 
Any anxiety disorder 7.11 11.72 2.50 - - 14.00 - 
GAD 8.76 5.41 12.10 - - 13.50 - 
PTSD 2.30 3.10 1.50 - - 1.20 - 
Any phobia 9.82 13.27 6.37 - - 10.10 - 
Note: GAD = Generalised Anxiety Disorder; PTSD = Post-Traumatic Stress Disorder 
 
 
 
50 
 
CHAPTER 4 
Meta-analyses 
 
The second objective of this thesis was to summarize existing literature and synthesize 
findings on the association between depression and diabetes, and anxiety and diabetes in 
the form of meta-analyses. As part of this chapter, four meta-analyses were completed. 
The major findings of these meta-analyses are presented in this chapter, which also 
includes an overview of statistical methods and a description of a novel approach, namely 
a quality-effects model. The full-text papers are attached at the end of the thesis 
(Appendices 4A to 4D). Three formal citations for the published work are: 
 
Appendix 4A 
1. Hasan, S.S., Clavarino, A.M., Mamun, A.A., Kairuz, T. (2014). Incidence and risk of 
diabetes associated with depressive symptoms: evidence from longitudinal studies. 
Diabetes Metab Syndr, 8(2), 82-7. 
 
Appendix 4B 
2. Hasan, S.S., Clavarino, A.M., Mamun, A.A., Kairuz, T. (2015). Incidence and risk of 
depression associated with diabetes in adults: evidence from longitudinal studies. 
Community Ment Health J, 51(2), 204-10. 
 
Appendix 4C 
3. Hasan, S.S., Clavarino, A.M., Mamun, A.A., Doi, S.A.R., Kairuz, T. (2013). 
Population impact of depression either as a risk factor or consequence of T2DM in 
adults: a meta-analysis of longitudinal studies. Asian J Psychiatr, 6(6), 460-72. 
 
One other manuscript included in this chapter has been revised and submitted for 
publication: 
 
Appendix 4D 
4. Hasan, S.S., Clavarino, A.M., Mamun, A.A., Doi, S.A.R., Kairuz, T. Is anxiety a risk 
factor for the onset of T2DM mellitus in adults? Application of biased-adjusted 
method. J Pharm Policy Pract [Revised & Resubmitted]. 
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4.1. Introduction 
The findings of a recent meta-analysis suggest that people with diabetes are more likely to 
have anxiety disorders or elevated anxiety symptoms compared with people who do not 
have diabetes (Smith et al. 2013). However, there are no meta-analyses investigating 
anxiety symptoms as a risk factor for the development of diabetes. A bidirectional 
relationship between depression and diabetes has been demonstrated (Knol et al., 2006; 
Mezuk et al., 2008; Smith et al., 2013), although the findings of previous meta-analyses 
are far from conclusive because of several deficiencies. For example, absolute risk and 
incidence measures were not computed because most of the longitudinal studies neither 
presented data in a four-fold table form nor supplied adequate information to calculate 
cumulative incidence proportion (CIP) (i.e. raw numbers of incident diabetes by risk 
category). The overall aim of the four reviews was to examine the relationship between 
depression and diabetes and anxiety and diabetes by conducting bias-adjusted (quality 
effects) meta-analyses of longitudinal studies; this was performed in addition to use of the 
conventional random-effects model.  
 
4.2. Methods 
The following electronic databases were searched for each review: MEDLINE (1950 to 
July, 2013); EMBASE (1980 to July, 2013); CINAHL (1982 to July 2013); PsycINFO (1880 
– July 2013). After identifying possible papers, titles and abstracts were screened to select 
relevant studies. The full texts of selected studies were then examined to determine 
whether the studies met the inclusion criteria. To locate additional relevant papers, the list 
of references in identified studies was also examined. When multiple publications from the 
same study population were available, only the most recent publication was included.  
 
4.2.1. Eligibility criteria 
Eligibility criteria were based on study type and population attributes. Regarding study 
type, the following were included: studies that investigated the association, comorbidity 
and/or coexisting prevalence of diabetes and depression or anxiety, and/or depressive or 
anxiety symptoms, in adults with diabetes mellitus.  In the meta-analyses all studies that 
longitudinally examined the relationship between depression and diabetes, and anxiety 
and diabetes, were examined. Studies that focused on efficacy of treatment, comorbidities, 
or included other psychiatric conditions were excluded; studies that only examined 
gestational diabetes mellitus were also excluded.  
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4.2.2. Data abstraction 
Data extracted from the studies included the name of the first author; publication year; 
study design; follow-up time in years; number of subjects in the analysis; gender and age 
of subjects; method of depression and anxiety assessment; method of diabetes 
assessment; binary point estimates and time-to-event (survival) analysis estimates with 
95% CI (adjusted for the largest number of confounders); and number of confounders that 
were adjusted for in the analyses. The method of assessment of diabetes was either 
based on self-report or clinical diagnosis based on blood glucose levels or based on the 
diagnosis of diabetes from administrative data (drug consumption or hospitalization). 
Depression and anxiety were based either on a diagnosis by a psychiatrist (using 
Diagnosis and Statistical Manual (DSM) criteria) or the assessment of depressive or 
anxiety symptoms was by self-administered questionnaire. 
   
4.2.3. Quality assessment 
The studies were carefully weighed against a quality checklist to estimate a quality index 
that served to rank studies in terms of safe-guards against bias. Quality was assessed 
using a study-specific modification of the quality criteria of observational studies published 
by Shamliyan and colleagues (Shamliyan et al., 2010).  The rank of studies by the 
univariate quality score was then used in the bias-adjustment model to discount studies at 
higher risk of bias. This method does not quantify bias and there is no imputation of effect 
sizes in relation to bias parameters.   
 
4.2.4. Statistical analyses 
Four-fold cells (2 X 2 tables; exposure yes/no versus outcome yes/no) were imputed for all 
binary point estimates using the reconstruction method proposed by Pietrantonj 
(Pietrantonj, 2006). Studies using time-to-event estimates (hazard ratios) were presented 
separately, as 2 x 2 table reconstruction was not possible for studies using time-to-event 
estimates. The four-fold cells were used to compute relative risk (RR), risk difference (RD) 
and CIP. Binary point estimates and time-to-event estimates were not combined as done 
by others (Knol et al., 2006; Mezuk et al., 2008). All odds ratios (ORs) were converted to 
Relative Risks (RRs) so that interpretation was uniform.  
 
For studies that presented graded relationships such as low, medium, or high depressive 
or anxiety symptoms, only the estimate for the highest category was selected. 
Heterogeneity was evaluated using the Cochran’s Q heterogeneity test (Q test) and a 
related metric, the I2. A p-value of 0.10 was used as the cut-off point for heterogeneity; 
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therefore a related metric I2 was also reported (I2 = (Q – df) / Q × 100%). Pooled results 
were calculated via the statistical methods mentioned previously.  
 
The first and second meta-analyses (Appendices 4A and 4B) examined depression as a 
risk factor for diabetes, and depression as a consequence of diabetes, using the random-
effects (RE) model, a traditional method used for meta-analysis. However, this estimate is 
known to underestimate the statistical error and be overconfident in results (Doi, 2014). 
The other problem with the RE model is that it introduces other errors (Knol et al., 2006). 
In particular, the methodology in the RE model is flawed because, even in standard meta-
analyses, there is a lack of interpretation of a RE summary (Alkhalaf et al., 2011). Peto 
referred to the use of RE model in meta-analyses as “wrong” because it answers a 
question that is “abstruse and uninteresting” (Peto, 1987). Moreover, use of the RE model 
requires strong assumptions that are unlikely to be valid in practice. It is, nevertheless, 
commonly used when heterogeneity between studies exists (Fleiss & Gross, 1991). 
Therefore, the third meta-analysis to examine the bidirectional relationship between 
depression and diabetes (Appendix 4C), was completed using a bias-adjusted approach 
with the quality-effects model.  
 
In the meta-analysis to examine anxiety as a risk factor for diabetes, the asymmetry of the 
RR was investigated to determine the impact of any excess risk (e.g. anxiety) on diabetes 
incidence, and whether RR for the positive outcome (diabetes) differed substantially from 
the RR for its negative complement, that is, no-diabetes. In addition, the risk difference 
(RD) at two year follow-up was also computed by estimating the events based on the 
yearly incidence rate of the complementary outcome in each study. For studies which had 
a duration of more than two years, the yearly incidence rate (IR) was estimated as IR = - 
[ln (1 – CIt)/t] where CIt is the cumulative incidence proportion of events at the end of the 
study and t is the duration of follow-up (Suissa et al. 2012). The two year cumulative 
incidence was then computed as (2)1 IRe . From a pooled RD, the number needed to be 
exposed for one additional person to be harmed (NNEH) at two years was computed 
(reciprocal of pooled RD). 
 
4.2.5. Sensitivity analyses 
To assess the robustness of the meta-analyses, sensitivity analyses were performed by 
modifying the selection criteria and then examining the effect of the variously modified 
selection criteria on the pooled results. For example selection by self-report versus clinical 
assessment of depression and diabetes was examined, by regional differences (United 
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States versus non-United States), by length of follow-up period, and by number of 
confounders adjusted for in the analyses. The follow-up period was classified into <10 
years and ≥10 years for depression predicting diabetes, and ≤5 years and >5 years for 
diabetes predicting depression. A funnel plot was used to examine the existence of 
publication bias through visual inspection for asymmetry and was considered asymmetrical 
if the intercept of Egger’s regression line deviated from zero with p < 0.10. When the 
funnel plot was found to be asymmetric, additional analyses for publication bias were 
performed using the Duval and Tweedie non-parametric “Trim and Fill” method of 
accounting for missing studies in meta-analysis (Duval & Tweedie, 2000). All imputations 
were done assuming random error only. The meta-analysis was re-run to arrive at a 
pooled estimate that corrects somewhat for publication bias. All analyses were conducted 
using Microsoft Excel and MetaXL software version 2.0 (MetaXL, 2013). 
 
4.3. Key findings 
 
4.3.1. Meta-analysis 1: Depression as a risk factor for diabetes mellitus  
The search yielded 850 unique abstracts from MEDLINE, 180 unique abstracts from 
EMBASE/CINAHL, and 230 from PsycINFO. After removal of duplication and applying the 
eligibility criteria, 96 relevant papers were examined for further consideration. Of these, 80 
studies were excluded for reasons such as failing to remove prevalent cases of diabetes at 
baseline and insufficient data to generate pooled effect sizes. Studies that examined the 
association of antidepressant use and DM were also excluded (Egberts et al., 1997; 
Kivimaki et al., 2010; Knol et al., 2009). A total of 16 articles were then included in the 
review; these provided 16 datasets. 
 
Three studies used the same sample (Arroyo et al., 2004; Pan et al., 2010; Saydah et al., 
2003); however, two of these were retained: the most recent publication by Pan et al. (Pan 
et al., 2010), and Saydah et al. (Saydah et al., 2003) who had used a different risk 
estimate, (Hazards Ratios (HRs)), in the earlier (2003) publication; they were thus different 
analyses. However, for estimating CIP and IR, these studies were not included so as to 
avoid over-inflation of the sample. There were two studies published by Golden et al., in 
2004 (Golden et al., 2004), and 2008 (Golden et al., 2008), where they had used the same 
sample, and only the most recent was retained. Among studies assessing depression 
predicting diabetes, four-fold cells were reconstructed and used to compute CIP from ORs 
(4 studies) or RR (4 studies).  The data presented by Kumari et al. (Kumari et al., 2004) 
was insufficient to compute a four-fold cell and the study was excluded. The reconstructed 
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CIP was then used to compute RR and RD for meta-analysis while original effect sizes 
(HRs) were presented separately. 
 
Nine studies reported their findings in the form of binary point estimates. However, only 
eight studies that presented complete data to formulate four-fold cell were used to 
calculate CIP and RR. Of these eight studies, six studies reported statistically significant 
associations; increasing risk of incident diabetes as a result of depression was present. A 
significant heterogeneity was present, with a pooled RR of 1.67 (95% CI: 1.30 – 2.15) 
(Figure 4.3.1.1) for studies examining depression as a risk factor of diabetes.  
 
 
Figure 4.3.1.1: Random-effects forest plot showing the risk of diabetes for individual studies using 
self-report questionnaires, diagnostic criteria, and all studies combined; studies using 
reconstructed Relative Ratios. Bars and diamonds indicate 95% CIs. RR = Relative Risk 
 
 
For eight studies that presented their findings in the form of hazard ratios, there were four 
studies in which the association was statistically significant and where increasing risk was 
evident. The pooled hazard ratio was 1.45 (95% CI: 1.12 – 1.87) and there was an 
evidence of heterogeneity (Figure 4.3.1.2).  
 
RR
6420
Study 
Mallon et al - Sweden (2005) 
Pan et al - USA (2010) 
Engum et al - Norway (2007) 
Everson-Rose et al - USA (2004) 
Overall 
Q=25.94, p=0.00, I2=73%
Eaton et al - USA (1996) 
Palinkas et al - USA (2004) 
Carnethon et al - USA (2003) 
Stellato et al - USA (2000) 
   RR (95% CI)          % Weight
   0.90  (  0.29,  2.80)      4.10
   1.17  (  1.05,  1.30)     22.93
   1.39  (  1.16,  1.68)     21.18
   1.63  (  1.05,  2.54)     13.79
   1.67  (  1.30,  2.15)    100.00
   2.23  (  0.90,  5.54)      5.82
   2.30  (  1.23,  4.30)      9.67
   2.52  (  1.73,  3.67)     15.61
   2.94  (  1.31,  6.60)      6.91
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Figure 4.3.1.2: Random-effects forest plot showing the risk of diabetes for individual studies using 
self-report questionnaires, diagnostic criteria, and all studies combined; studies using HRs. Bars 
and diamonds indicate 95% CIs. Effect Size (ES) = HR (Hazard Ratios) 
 
 
Studies with <10 years follow-up (RR: 1.98), those adjusted for ≤5 confounders (RR: 2.20), 
and conducted in the US (RR: 1.92) showed significantly higher risk of incident diabetes 
than studies with ≥ 10 years of follow-up (RR: 1.52), adjusted for >5 confounders (RR: 
1.24) and conducted outside the US (RR: 1.37). The funnel plot revealed gross 
asymmetry, as most of the studies reported higher relative risks on one side of the line 
representing the most precise relative risk. The Egger’s test for publication bias also 
suggested asymmetry (intercept 0.449; p = 0.025). Using the Trim and Fill method to 
impute missing studies, three dummy studies were added and the revised estimate was 
1.26 (95% CI: 1.02 – 1.57). 
 
4.3.2. Meta-analysis 2: Depression as a consequence of diabetes 
The aim of the second review was to examine the relationship between diabetes and 
incident depression by conducting a meta-analysis of longitudinal studies using random-
effects models, and extensive review and synthesis of the data. A total of 16 studies were 
included in this review; 11 assessing diabetes and incident depression using binary point 
and five studies using time-to-event estimates. Among the 11 studies assessing diabetes 
predicting depression, four-fold cells were reconstructed and used to compute CIP from 
ORs (10 studies) or RR (1 study).  The reconstructed CIP was then used to compute RR 
and CIP for meta-analysis while original effect sizes (HRs) were used for studies that 
DEP to DM  HR
ES
42
Study 
V den Akker et al - Netherlands (2004) 
Saydah et al - USA (2003) 
Golden et al - USA (2008) 
Carnethon et al - USA (2007) 
Overall 
Q=39.86, p=0.00, I2=82%
Demakakos et al - UK (2010) 
Campayo et al - Spain (2010) 
Chen et al - Taiwan (2013) 
Kawakami et al - Japan (1999) 
    ES (95% CI)          % Weight
   1.04  (  0.84,  1.28)     15.39
   1.11  (  0.79,  1.56)     13.16
   1.21  (  0.87,  1.67)     13.42
   1.41  (  0.91,  2.19)     11.38
   1.45  (  1.12,  1.87)    100.00
   1.62  (  1.15,  2.29)     13.08
   1.65  (  1.02,  2.66)     10.68
   2.02  (  1.80,  2.27)     16.62
   2.31  (  1.03,  5.20)      6.27
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reported time-to-event estimates and presented separately. For details on quantitative 
synthesis, please refer to the original paper attached at the end of the thesis (Appendix 3b) 
 
 
Figure 4.3.2.1: Random-effects forest plot showing the risk of depression for individual studies 
using self-report questionnaires, diagnostic criteria, and all studies combined; studies using 
reconstructed Relative Ratios. Bars and diamonds indicate 95% CIs. RR = Relative Risk 
 
 
The 16 longitudinal studies assessing depression as a consequence of diabetes provided 
16 datasets. Eleven studies that reported their findings using binary point estimates and 
provided sufficient data to formulate four-fold cell were used to reconstruct RR and CIP. In 
six studies the association was not statistically significant but increasing risk of incident 
depression as a result of diabetes was present in most cases. For RR, significant 
heterogeneity was present, with a pooled RR of 1.27 (95% CI: 1.17 – 1.38) (Figure 
4.3.2.1). Only five studies reported time-to-event (survival) estimates but there was 
significant heterogeneity. The five studies generated a pooled HR of 1.23 (95% CI: 1.08 – 
1.40) (Figure 4.3.2.2). 
 
RR
321
Study 
Bisschop et al - 2004 
Palinkas et al - 2004 
Kim et al - 2006 
Maraldi et al - 2007 
Engum et al - 2007 
de Jonge et al - 2006 
Knol et al - 2009 
Overall 
Q=18.65, p=0.04, I2=46%
Pan et al - 2010 
O' Connor et al - 2009 
Kivimaki et al - 2010 
Luijendijk et al - 2008 
    RR (95% CI)          % Weight
   0.69  (  0.39,  1.23)      1.90
   0.76  (  0.44,  1.30)      2.16
   0.99  (  0.41,  2.36)      0.86
   1.16  (  0.96,  1.39)     12.17
   1.23  (  0.79,  1.94)      2.98
   1.24  (  0.90,  1.72)      5.29
   1.27  (  1.24,  1.30)     31.49
   1.27  (  1.17,  1.38)    100.00
   1.29  (  1.18,  1.40)     23.91
   1.31  (  1.07,  1.62)     10.49
   1.84  (  1.40,  2.42)      7.06
   2.01  (  1.09,  3.71)      1.69
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 Figure 4.3.2.2: Random-effects forest plot showing the risk of depression for individual studies 
using self-report questionnaires, diagnostic criteria, and all studies combined; studies using 
hazards ratios. Bars and diamonds indicate 95% CIs. ES = Effect Size (hazards ratio) 
 
 
In the sensitivity analysis, non-US studies (RR: 1.33, 95% CI: 1.09 – 1.64), studies that 
adjusted for less than 5 confounders (RR: 1.22, 95% CI: 1.05 – 1.43), and studies ≤ 5 
years of follow-up (RR: 1.54, 95% CI: 1.16 – 2.04)  produced a significantly higher relative 
risk than studies conducted in the US (RR: 1.24, 95% CI: 1.13 – 1.37), studies that 
adjusted for 5 or more confounders (RR: 1.22, 95% CI: 1.05 – 1.43), and studies with more 
than 5 years of follow-up (RR: 1.25, 95% CI: 1.17 – 1.33). The funnel plot was reasonably 
asymmetrical and Egger’s test for publication bias also suggested asymmetry (intercept = 
0.243, p= 0.001) for studies using binary point estimates.  However ‘Trim and Fill’ method 
used to impute missing studies did not result in additional dummy studies. 
 
For studies using time-to-event, the funnel plot revealed gross asymmetry, as most of the 
studies reported higher relative risks on one side of the line representing the most precise 
relative risk. The Egger’s test for publication bias also suggested asymmetry. The Trim 
and Fill method resulted in two dummy studies being added and the revised estimate was 
1.14 (95% CI: 1.00–1.30). 
 
4.3.3. Meta-analysis 3: Bidirectional association between depression and diabetes  
The third meta-analysis examined the bidirectional association between diabetes and 
depression using a bias-adjusted approach with quality-effects model. A total of 29 articles 
were included in this review; 15 assessing depression and incident diabetes and 14 
ES
21
Study 
Brown et al - 2006 
Polsky et al - 2005 
Overall 
Q=12.58, p=0.01, I2=68%
Aarts et al - 2009 
Chen et al - 2013 
Golden et al - 2008 
    ES (95% CI)          % Weight
   1.04  (  0.94,  1.15)     26.94
   1.17  (  0.98,  1.41)     19.79
   1.23  (  1.08,  1.40)    100.00
   1.26  (  1.12,  1.42)     25.37
   1.43  (  1.16,  1.77)     17.46
   1.52  (  1.09,  2.12)     10.43
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examining diabetes and incident depression (Figure 4.3.3.1). Of these 29 studies, four 
studies examined both depression predicting diabetes and diabetes predicting depression 
and were retained for analysis: (Palinkas et al. (Palinkas et al., 2004), Engum (Engum, 
2007), Golden et al. (Golden et al., 2008), Pan et al. (Pan et al., 2010)).  
 
Among studies assessing depression predicting diabetes, four-fold cells were 
reconstructed and used to compute CIP from ORs (4 studies) or RR (4 studies).  Similarly 
CIP was reconstructed from 9 studies examining diabetes predicting depression. The 
reconstructed CIP was then used to compute RR for meta-analysis while original effect 
sizes (HRs) were used for studies that reported time-to-event estimates and presented 
separately. 
 
4.3.3.1. Depression as a risk factor for diabetes mellitus 
Nine studies reported their findings in the form of binary point estimates. However, only 
eight studies presented complete data to formulate four-fold cells and were used to 
reconstruct CIP and RR. Of these eight studies, only two studies reported statistically 
insignificant associations; however, increasing risk of incident diabetes as a result of 
depression was present. For both RR, significant heterogeneity was present, with a pooled 
RR of 1.41 (95% CI: 1.13 – 1.76) (Figure 4.3.3.1). For six studies that presented their 
findings in the form of hazard ratios, there were four studies in which the association was 
not statistically significant but increasing risk was evident. However, there was no 
evidence of heterogeneity and the pooled hazard ratio was 1.24 (95% CI: 1.05 – 1.47).  
 
Studies with <10 years follow-up time had a significantly higher relative risk (RR: 2.05) 
than studies with ≥10 years (RR: 1.34) of follow-up time. Studies conducted in the US 
were almost similar to studies conducted outside the US (RR: 1.32). However, studies 
where the outcome was adjusted for ≤ 5 confounders showed almost double the risk 
compared to studies where more than five confounders were adjusted in analysis. The 
funnel plot to detect publication bias revealed gross asymmetry, as most of the studies 
reported higher relative risks on one side of the line representing the most precise relative 
risk. The Egger’s test for publication bias also suggested asymmetry (intercept 0.449; p = 
0.025). Using the Trim and Fill method to impute missing studies, three dummy studies 
were added and the revised QE estimate was 1.26 (95% CI: 1.02 – 1.57).  
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Figure 4.3.3.1: Quality-effects forest plot showing the risk of diabetes (top) and risk of depression 
for individual studies using self-report questionnaires, diagnostic criteria, and all studies combined; 
studies using reconstructed RR. Bars and diamonds indicate 95% CIs. DM = Diabetes Mellitus; 
DEP = Depression 
 
 
4.3.3.2. Depression as a consequence of diabetes mellitus 
Fourteen studies examined depression as a consequence of diabetes. Nine of them 
reported their findings using binary point estimates and provided sufficient data to 
formulate four-fold cells were used to reconstruct CIP, RR and RD. There were six studies 
in which the association was not statistically significant but increasing risk of incident 
depression as a result of diabetes was present in most cases. The pooled RR was 1.23 
(95% CI: 1.15 – 1.31) (Figure 4.3.3.1). Five studies reported time-to-event (survival) 
estimates, and generated a pooled HR of 1.22 (95% CI: 1.05 – 1.42). 
 
61 
 
Studies with ≤5 years following time (RR: 1.40), non-US studies (RR: 1.36) and studies 
that used standard criteria (RR: 1.24) produced significantly higher relative risk than 
studies with >5 years of follow-up time (RR: 1.18), US studies (RR: 1.17) and studies that 
used self-report scales (RR: 1.20). Only non-US studies suggested diabetes as a 
significant predictor of depression. However, studies where more than 5 confounders were 
adjusted in analysis were almost similar to studies where the outcome was adjusted for 
less than or equal to 5 confounders. The funnel plot was reasonably symmetrical and 
Egger’s regression concurred (intercept = 0.655, p= 0.107). 
 
4.3.4. Meta-analysis 4: Anxiety as a risk factor for diabetes 
The aim of this final review was to examine the relationship between anxiety and incident 
diabetes by conducting a meta-analysis of longitudinal studies using bias-adjustment as 
described by Doi (Doi et al., 2010). It has also been reported that the RR for a positive 
outcome (diabetes) may differ substantially from the RR for its negative complement (no 
diabetes) (Furuya-Kanamori & Doi, 2014) and thus the outcome with higher baseline risk is 
the correct outcome to report.  
 
The risk of diabetes in exposed/unexposed groups in this study represents the smaller 
baseline risk and therefore its complement (no-diabetes) was reported as well. The 
reasoning behind this is that small baseline risks are associated with exaggerated RRs as 
a mathematical anomaly with ratios made from small numbers. In addition, RRs are 
reported rather than the ORs because this magnification occurs at both ends of the risk 
spectrum for the OR while it only arises at the lower end of the risk spectrum for the RR 
(Furuya-Kanamori & Doi, 2014). The risk difference (RD), and the number needed to be 
exposed for one additional person to be harmed (NNEH) at two years follow-up, were also 
computed from studies that followed subjects for 2 years or more. 
 
Only four longitudinal studies were available for this review; these provided four 
longitudinal datasets assessing anxiety and incident diabetes. All four studies reported 
their findings in the form of odds ratios, and only two studies reported statistically 
significant associations.  
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Figure 4.3.4.1: Quality-effects forest plot showing the risk of diabetes for individual studies using 
self-report questionnaires, diagnostic criteria, and all studies combined; studies using 
reconstructed RR, top (anxiety to diabetes) and below (anxiety to no diabetes). Bars and diamonds 
indicate 95% CIs.  
 
 
The pooled QE estimate for diabetes after exposure to anxiety was a RR of 1.65. The RR 
for the negative complement, no-diabetes, was 0.987. Both analyses resulted in 
statistically significant results; however, the magnitude of the effect seems exaggerated 
when the risk of diabetes was directly computed (RR 1.65, 95% CI: 1.15 – 2.36) versus its 
negative complement (no-diabetes) (RR 0.987, 95% CI 0.978 – 0.995) (Figure 4.3.4.1). 
The pooled RD at 2 years was 0.031 (95% CI: - 0.007 – 0.054) (Figure 4.3.4.2). The 
NNEH was 33 (95% CI 19 to 143) at 2 years post exposure. The Egger’s test for 
publication bias did not suggest asymmetry (intercept 0.379; p = 0.280). Using the Trim 
and Fill method to impute missing studies, one imputed study was added and this revised 
the effect size down to 1.52 (95% CI: 1.07 – 2.14). 
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Figure 4.3.4.2: Quality-effects forest plot showing the risk of diabetes for individual studies using 
self-report questionnaires, diagnostic criteria, and all studies combined with outcome at 2 yrs; 
studies using RD. Bars and diamonds indicate 95% CIs.  
 
 
4.4. Discussion of the findings of the meta-analyses 
The first meta-analysis conducted documented higher cumulative incidence of diabetes in 
depressed than in non-depressed subjects. Of 15 studies included in the first review, eight 
studies were from Northern America, five from Europe and two from East Asia. A study 
conducted in Taiwan in East Asia (Chen et al., 2013) documented the highest CIPs 
whereas a study from Norway in Europe (Engum, 2007) recorded the lowest CIPs for 
diabetes in both the depressed and non-depressed groups. The first meta-analysis found a 
significant association between depression and incident diabetes and of the 16 studies 
assessing this association, 10 suggested increased risk. In our quantitative analysis using 
the random-effects model, there was a 1.67 fold increase in risk or 1.45 fold increase in 
hazard for diabetes in adults with depressive symptoms. Similar results were reported in 
previous meta-analyses, although binary point estimates had not been separated from 
HRs for estimating pooled effect sizes (Knol et al., 2006; Mezuk et al., 2008).  
 
In the second meta-analysis, patients with diabetes showed greater cumulative incidence 
of depression compared to non-diabetes patients. Of the 16 studies of diabetes predicting 
incident depression, only eight studies suggested increased risk. In the quantitative 
analysis using random-effects model, a 1.27-fold increase in risk for depression in adults 
with diabetes was demonstrated. These relative estimates are similar to previously 
reported figures that were calculated without segregating binary point and time-to-event 
estimates by Mezuk et al. (1.15-fold) and Nouwan et al. (1.24-fold) (Mezuk et al. 2008; 
Nouwen et al. 2010). However, Routelle and Mannucci presented their findings as 
y
RD
0.10
Study 
Edwards & Mezuk et al - 2012 
Atlantis et al - 2012 
Overall 
Q=22.27, p=0.00, I2=87%
Engum et al - 2007 
Hasan et al - 2013 
   RD (95% CI)              % Weight
  -0.002  ( -0.060,  0.056)     11.428
   0.009  ( -0.001,  0.019)     37.653
   0.031  (  0.007,  0.054)    100.000
   0.041  (  0.029,  0.053)     41.345
   0.109  (  0.042,  0.177)      9.575
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adjusted hazard ratios (Routelle & Mannucci, 2012) and found a higher incidence of 
depression in diabetes subjects, with adjusted risk of 1.25-fold.  
 
Given that the first and second meta-analyses did not consider sources of potential bias, it 
was prudent to re-visit the analyses using strict bias assessments and bias adjusted 
models. In the third meta-analysis, therefore, the effect sizes were re-estimated for the 
bidirectional association between depression and diabetes using the quality-effects model. 
This re-analysis revealed that the associations were weakened and the confidence 
interval, too, was shifted in the direction of the null. Nevertheless, results remained 
statistically significant. Therefore this suggests that the depression – diabetes association 
may be explained partly through sources of bias. Indeed, the residual effect seen may be 
due to residual confounding. 
 
In the fourth and final meta-analysis examining anxiety as a risk for diabetes, a significant 
relationship between anxiety and incident diabetes was found in quantitative analysis, with 
a 65% increase in the risk of diabetes in adults with anxiety. This is higher than the 25% 
increase in odds reported previously by Smith et al. for the converse outcome of anxiety in 
diabetes (Smith et al. 2013). However, analysis of the negative complement outcome (no-
diabetes) revealed a low relative risk of diabetes mellitus with anxiety when compared to 
reports that use the outcome of incident diabetes. Specifically, the RR estimate for ‘no-
onset of diabetes’ was 0.987. This suggests only a 1.3% increase in the risk of new 
diabetes onset if patients who are unexposed to anxiety were to be exposed; this differs 
substantially from the magnitude of effect when risk of diabetes was the outcome. 
 
It therefore seems that by selecting the RR as the effect size as well as the outcome with 
the higher baseline risk (in this case no-diabetes), artificial magnification of the effect size 
was avoided. In absolute terms however, the differences between the two groups 
(exposed and unexposed to anxiety) were not affected by the outcome chosen (diabetes 
or no-diabetes) and were statistically significant. The risk difference was 3% at two years 
follow-up and thus one more patient is harmed by the onset of diabetes for every 33 
patients exposed to anxiety over a two year period when compared with the unexposed 
group. Again, we cannot be certain that this association is causal though care was taken to 
address sources of bias.  
 
One major limitation that may affect the findings of these meta-analyses is that all 
longitudinal studies were from developed countries; not a single longitudinal study from 
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developing regions was available at the time of this PhD study. Additional limitations of the 
meta-analyses are discussed in detail in each of the attached article at the end of the 
thesis (Appendices 4A to 4D) 
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CHAPTER 5 
The validity of Personal Disturbance Scale (DSSI/sAD) in people with 
diabetes 
 
The third objective of this thesis was to validate the personal disturbance scale (Delusions-
Symptoms-States-Inventory/States of Anxiety and Depression) among women with 
diabetes using the MUSP dataset. This was necessary because DSSI/sAD used in this 
PhD study had not yet been validated among people with diabetes. 
 
The validation process described in this chapter has been published. The formal citation 
for the published work: 
 
1. Hasan, S.S., Clavarino, A.M., Mamun, A.A., Dingle, K., Kairuz, T. (2015). The 
validity of personality disturbance scale (DSSI/sAD) in people with diabetes 
mellitus, using longitudinal data. Pers Individ Dif, 72, 182-8. 
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DSSIDespite being used since 1976, Delusions-Symptoms-States-Inventory/states of Anxiety and Depression
(DSSI/sAD) has not yet been validated for use among people with diabetes. The aim of this study was to
examine the validity of the personal disturbance scale (DSSI/sAD) among women with diabetes using
Mater-University of Queensland Study of Pregnancy (MUSP) cohort data. The DSSI subscales were
compared against DSM-IV disorders, the Mental Component Score of the Short Form 36 (SF-36 MCS),
and Center for Epidemiologic Studies Depression Scale (CES-D). Factor analyses, odds ratios, receiver
operating characteristic (ROC) analyses and diagnostic efﬁciency tests were used to report ﬁndings.
Exploratory factor analysis and ﬁt indices conﬁrmed the hypothesized two-factor model of DSSI/sAD.
We found signiﬁcant variations in the DSSI/sAD domain scores that could be explained by CES-D
(DSSI-Anxiety: 55%, DSSI-Depression: 46%) and SF-36 MCS (DSSI-Anxiety: 66%, DSSI-Depression: 56%).
The DSSI subscales predicted DSM-IV diagnosed depression and anxiety disorders. The ROC analyses
show that although the DSSI symptoms and DSM-IV disorders were measured concurrently the estimates
of concordance remained only moderate. The ﬁndings demonstrate that the DSSI/sAD items have similar
relationships to one another in both the diabetes and non-diabetes data sets which therefore suggest that
they have similar interpretations.
 2014 Elsevier Ltd. All rights reserved.1. Introduction
Anxiety and depression are two common, co-morbid, modiﬁable
conditions associatedwith diabetes (Anderson, Freedland, Clouse, &
Lustman, 2001; Grigsby, Anderson, Freedland, Clouse, & Lustman,
2002). Diabetes haswell documented, detrimental effects on health,
and studies have shown signiﬁcant negative associations between
Health-related Quality of Life (HRQoL) and its prognosis
(Landman, van Hateren, Kleefstra, Groenier, Gans, & Bilo, 2010 ;
Rubin& Peyrot, 1999). Depression and anxiety in peoplewith diabe-
tes are linked to at least two unfavorable outcomes: poor metabolic
control (Anderson et al., 2002; Lustman, Anderson, Freedland, de
Groot, & Carney, 2000) and decreased HRQoL (Ali, Stone, Skinner,
Roberston, Davies, & Khunti, 2010; Kohen, Burgess, Catalán, &
Lant, 1998). The strength of the association between thesesymptoms and HRQoL is stronger for females, people with low edu-
cational attainment, disrupted marital status, and low levels of
social support (Khuwaja, Lalani, Dhanani, Azam, Raﬁque, & White,
2010). Anxiety and depression are more common among women
suffering from diabetes, the target population of our study
(Anderson et al., 2001; Grigsby et al., 2002).
According to a recent review of screening tools that are used for
measuring depression and anxiety symptoms in people with type 1
and 2 diabetes, the Delusions-Symptoms-States-Inventory/States of
Anxiety and Depression (DSSI/sAD), a tool developed in 1976, was
not included as it has not been validated for use among people with
diabetes (Bedford, Foulds, & Shefﬁeld, 1976; Roy, Lloyd, Pouwer,
Holt, & Sartorius, 2012). Although not developed or validated for
use in the diabetes population, the DSSI/sAD has been extensively
used to examine symptoms of anxiety and depression (Bedford,
Watson, Henry, Crawford, & Deary, 2011; Mamun, Clavarino,
Najman, Williams, O’Callaghan, & Bor, 2009; Najman, Andersen,
Bor, O’Callaghan, & Williams, 2000; Saiepour, Najman, Clavarino,
Baker, Ware, & Williams, 2013). Similar to the Hospital Anxiety and
Depression Scale (HADS), the DSSI/sAD assesses both depression
S.S. Hasan et al. / Personality and Individual Differences 72 (2015) 182–188 183andanxiety (Bedford&Foulds, 1978;Zigmond&Snaith, 1983).Unlike
HADS, some items included in DSSI/sAD could be confounded with
the symptoms of diabetes or poorly controlled diabetes
(International diabetes federation (IDF): clinical guidelines task
force, 2005), such as sleeplessness (Meisinger,Heier, & Loewel, 2005).
This is the ﬁrst study to validate the DSSI/sAD in Australia, to
determine whether the DSSI/sAD could be used to identify depres-
sion and anxiety symptoms in women with diabetes using a large
prospective cohort (Mater-University of Queensland Study of Preg-
nancy). To date, no study has directly compared the correspon-
dence of the DSSI anxiety and depression subscales with any
DSM-IV depressive and anxiety diagnoses. As the Center for Epide-
miologic Studies Depression Scale (CESD) and 36-item short form
scale (SF-36) are the most commonly used scales in people with
diabetes (Roy et al., 2012) we assessed the validity of the DSSI/
sAD subscales, and their association with CES-D and SF-36.2. Materials and methods
2.1. Participants
To validate the DSSI/sAD instrument, we examined a sample of
women who were part of the Mater-University of Queensland
Study of Pregnancy (MUSP), a multidisciplinary study that repre-
sents Australia’s largest longitudinal study among women with
data collected over 30 years since 1981. Pregnant women attend-
ing their ﬁrst antenatal clinic visit (FCV = at approximately
18 weeks’ gestation) at a major tertiary hospital (Mater Misericor-
diae Hospital) in South Brisbane were invited to participate in the
study, data were collected over three years between January 1981
and December 1983 (Najman, Bor, O’Callaghan, William, Aird, &
Shuttlewood, 2005). Originally 7861 women were enrolled (8556
pregnancies) of whom 6753 constitute the MUSP mothers’ cohort.
To be enrolled in the cohort women had to have delivered at least
one live baby who neither died nor was adopted before leaving
hospital, and had to have complete data from an initial ﬁrst clinic
visit (FCV) and a birth interview. Information regarding diabetes
mellitus was collected with self-reported items. Women were
asked ‘‘Have you EVER been told by a doctor that you have diabetes
mellitus (high blood sugars)?’’ (Callaway, Lawlor, O’Callaghan,
Williams, Najman, & McIntyre, 2007).
2.2. DSSI/sAD instrument
Depression and anxiety symptoms of women in the original
MUSP study were assessed at seven time points over 27 years,
using the 14-item DSSI/sAD instrument (Bedford & Foulds, 1978).
The DSSI/sAD has been validated in previous studies using factor
analysis (Bedford, Henry, & Crawford, 2005; Henry, Crawford,
Bedford, Crombie, & Taylor, 2002). Recent studies using Mokken
scale analysis suggested a uni-dimensional scale using seven of
the 14 items (Bedford et al., 2011) and a stable structure over time
(Saiepour et al., 2013). In the present study, the seven items were
summed, each with 5-point response options (all the time, most of
the time, some of the time, rarely, or never); the higher the score,
the more depressive or anxious the person. Participants were clas-
siﬁed as anxious or depressed when they scored 4 or more, and as
non-anxious or non-depressed when they scored less than 4 out of
a maximum score of 7.
2.3. Validation procedure
For our study, we utilized a four-part methodology to cover
both views of validity (traditional and contemporary) (Zumbo,
2005). This methodology consisted of: (a) Exploratory Factor Analysis (EFA), and
 (b) Partial Conﬁrmatory Factor Analysis (PCFA); both analyses
were conducted on MUSP 21-year dataset using IBM SPSS
version 22 (Gignac, 2009).
 (c) Concurrent (concordance with CES-D and SF-36 MCS)
validity, and
 (d) Concordance with DSM-IV disorders using receiver operat-
ing characteristic (ROC) analyses and diagnostic efﬁciency tests;
the latter were conducted on MUSP 27-year dataset with STATA
IC version 12.
2.3.1. Exploratory and Conﬁrmatory Factor Analyses
Exploratory factor analysis (EFA) is a widely utilized and
broadly applied statistical technique in the social sciences
(Costello & Osborne, 2005). EFA is a variable reduction technique
which identiﬁes the number of latent constructs and the underly-
ing factor structure of a set of variables, that cannot be measured
directly (Child, 1990).
The analysis may be referred to as a partial conﬁrmatory factor
analysis (PCFA) when the number of factors is expected to be
known but the speciﬁc pattern of salient and nonsalient loadings
may not be (Bollen, 1989). A PCFA may be considered to lie
between conventional exploratory factor analysis (EFA) and conﬁr-
matory factor analysis (CFA) on the spectrum of evaluating the
plausibility of a model (Gignac, 2009). We performed the factor
analysis in two steps. In the ﬁrst step we performed EFA of
maximum likelihood estimation (MLE) unrestricted factor analysis,
followed by a second step of restricted/PCFA analysis as estimated
via MLE.
2.3.2. Concordance with SF-36 and CES-D, using MUSP 21-year dataset
We examined the degree to which symptoms measured by SF-
36 and CES-D were associated with symptoms on the DSSI/sAD
domains on MUSP 21-year dataset using the SF-36, a generic qual-
ity of life instrument, to examine both physical and mental health
(Ware, Snow, Kosinki, & Gandek, 1993). A mental health sub-scale
of SF-36 has been utilized in a number of studies of diabetes and
depression (Roy et al., 2012). Note that unlike the DSSI/sAD
domains, where high scores indicate a high number of anxiety or
depressive symptoms, higher SF-36 component scores represent
better quality of life. All questions were scored on a scale from 0
to 100, with 100 representing the highest level of functioning pos-
sible (Ware et al., 1993).
The CES-D was selected because it is the second most widely
used instrument to measure depression symptoms among people
with diabetes, after the Beck Depression Inventory (BDI) (Roy
et al., 2012). In patients with T2DM, the CES-D is used more com-
monly than BDI (Roy et al., 2012). Overall scores range from 0 (no
symptoms) to 60 (Radloff, 1977). Higher scores on the CES-D indi-
cate a greater number of depression symptoms. Similarly, higher
scores on the DSSI/sAD indicate a higher number of symptoms.
2.3.3. Concordance with DSM-IV disorders, using MUSP 27-year
dataset
Although the DSSI/sAD has been in use for more than two dec-
ades, to date no study has directly compared the association of the
DSSI anxiety and depression subscales with DSM-IV depressive
and anxiety diagnoses. For this comparison, we used DSSI depres-
sion and anxiety symptoms measured at MUSP 27-year follow-up
study. At the 27-year follow-up, psychiatric disorders were
extracted from a validated, computerized structured interview of
psychiatric symptoms, theWorld Health Organization-World Men-
tal Health-Composite International Diagnostic Interview-CAPI
Modularization Program (WHO WMH-CIDI CAPI: Version: 21.1.3)
(Andrews& Peters, 1998;WorldHealthOrganization (WHO), 2004).
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disorder) which were calculated as a positive diagnosis across a
range of DSM IV diagnoses. The term ‘any depressive or anxiety
disorder’ indicates the presence of at least one disorder. We esti-
mated the risk of having a DSM-IV lifetime, and 12-month disorder
for each DSSI subscale.
2.4. Statistical analysis
The data were analyzed using the Statistical Package for Social
Sciences (SPSS) version 22 and STATA IC version 12, with a
signiﬁcance level of 6 0.05. Results are presented for women with
and without diabetes. Descriptive statistics were used to calculate
percentage frequencies, means and standard deviations. Since the
DSSI/sAD had not been previously validated in a sample of women
with diabetes, we conducted an Exploratory Factor Analysis (EFA)
(Bentler & Yuan, 1996; Costello & Osborne, 2005) to examine the
underlying components or domains of DSSI/sAD. In order to
achieve a favorable ratio (>10:1) of respondents over instruments
items, a minimum of 200 participants was required to conduct fac-
tor analysis (Bentler & Yuan, 1996). The corrected item-total score
correlations were also examined. Reliability of DSSI/sAD items and
domains were assessed using Cronbach’s alpha and intra-class cor-
relation coefﬁcients.
DSSI/sAD constructs were identiﬁed and conﬁrmed using a SEM
approach to PCFA (Gignac, 2009; Keller, Ware, Bentler, Aaronson,
Alonso, Apolone, 1998). We performed the partial CFA model esti-
mation using the maximum likelihood estimation (MLE) (Gignac,
2009; Gignac, Bates, & Jang, 2007). MLE extraction method was
preferred because it allows for the computation of a wide range
of indices of the goodness of ﬁt of the model and testing of statis-
tical signiﬁcance of factor loadings (Fabrigar, Wegener, MacCallum,
and Strahan, 1999.
Regarding various formal statistical ﬁt indices, this study
adapted both absolute as well as incremental ﬁt indices. Absolute
ﬁt indices were derived from the ﬁt of the observed and implied
covariance matrices (Hu & Bentler, 1995). Concerning various
absolute ﬁt indices, our study evaluated model ﬁt by using the
model chi-square test, RMSEA (the root mean square error of
approximation), and the SRMR (the standardized root mean square
residual). The goodness of ﬁt of the model to the MUSP 21-year
data was evaluated for both diabetes and non-diabetes groups
using chi-square. Since the sample sizes for both diabetes and
non-diabetes groups were large, chi-square values were expected
to be insigniﬁcant (indicating lack of ﬁt) (Yu & Yu, 2007). Model
ﬁt was therefore deﬁned as Normed Fit Index (NFI), Comparative
Fit Index (CFI) and Tucker–Lewis Index (TLI) greater than 0.90
(Hu & Bentler, 1995). Incremental (comparative) ﬁt indices
measure goodness-of-ﬁt that compare the current model to a spec-
iﬁed ‘‘null’’ (independence) model to determine the degree of
improvement over the null model (Hu & Bentler, 1995).
The current concordance of the DSSI subscales was assessed
against lifetime and 12-month DSM-IV depressive and anxiety dis-
orders. This was assessed by ROC analyses, reported using area
under the curve (AUC) and 95% Conﬁdence Interval (95% CI). We
have calculatedAUC to obtain a global summary statistic of diagnos-
tic accuracy and to capture the trade-off between sensitivity and
speciﬁcity over a continuous range. The AUC ranges from 0.5 (ran-
dom chance or no predictive ability) to 1 (perfect discrimination
or accuracy) (Doi, 2013). The sensitivity, speciﬁcity, and positive
predictive value (PPV) for each subscale and major depression or
anxiety were also calculated. Univariate logistic regressions with
odds ratios (OR) and 95% CIswere used to estimate the risk of having
a DSM-IV lifetime, and 12-month disorder for each DSSI subscale.
To validate the DSSI/sAD depression and anxiety domains
against the SF-36 MCS and CES-D scores, linear regression wasused, while logistic regression analysis determined the degree to
which the presence or absence of diabetes was associated with
depression and anxiety symptoms on the DSSI/sAD domains. Age,
education, body mass index (BMI), and marital status were also
included as covariates to control for their potential effects on both
mental health and diabetes (Hasan, Clavarino, Mamun, Doi, &
Kairuz, 2013). These variables were included as covariates in all
linear and logistic regression analyses used in this study. Finally
to examine the correlation between the instruments (DSSI, CES-
D, and SF-36 MCS), Pearson correlation test was applied.3. Results
About 8% of women who participated at the 21-year and 27-
year follow up studies reported ‘‘ever’’ having been diagnosed with
diabetes. The mean ages of womenwith and without diabetes were
similar. As expected, women with diabetes had higher mean BMI
compared to women without diabetes (30.82 versus 27.37 kg/m2,
p < 0.05) (Table 1). The majority of women were married or living
with a partner and had completed (at least) secondary high
schooling.3.1. Exploratory Factor Analysis
The Kaiser–Meyer–Olkin (KMO) test of sampling adequacy was
applied prior to factor extraction, which resulted in an overall
index of 0.95, suggesting that the sample was adequate for factor
analysis. The EFA revealed a bi-factorial model explaining 53.4%
of the variation, where 9 items loaded onto the ﬁrst factor and 5
items onto the second factor. The second factor explained only
5.2% of the variation. The items loaded highly on their factors (all
factor loadings exceed 0.30) indicating good convergent validity,
with the presence of cross-loadings of items and 50% of shared
variance between the two factors indicating poor discriminant
validity of DSSI/sAD. Similar results were obtained for both data
sets (diabetes and non-diabetes), as shown in Table 2. There was
good consistency between items, the Cronbach’s alpha for the full
scale (measured at 21-year) was 0.93 respectively. The alphas of
DSSI/sAD depression and anxiety domains were almost compara-
ble for women with and without diabetes, and both were within
an acceptable range.3.2. Conﬁrmatory Factor Analysis
As indicated in Table 3, the model chi-square values indicate
poor ﬁt to the data (diabetes = 18.518; non diabetes = 1163.172).
Owing to the large sample size of the present study (diabe-
tes = 315; non diabetes = 2845), other indices for evaluating model
ﬁt are discussed.
An examination of the ﬁt indices for our MUSP data (21 year fol-
low-up) with DSSI/sAD, such as RMSEA which is a measure of
model ﬁt, showed that the two latent variables model was consid-
ered adequate (RMSEA = 0.077). Moreover, the SRMR values of the
models range between 0.033 and 0.035 for diabetes and non-dia-
betes groups (cut-off < 0.10). In summary, regarding the absolute
ﬁt indices, the data ﬁt the model well.
Concerning the incremental ﬁt indices, the NFI (the normed ﬁt
index) deﬁnes the null model as a model in which all of the
correlations or covariances are zero; the benchmark, however, is
> 0.90. In our study, the NFI equals 0.93 (for both diabetes and
non-diabetes groups), the CFI (comparative ﬁt index) equals 0.95
(for diabetes and non-diabetes groups), and the TLI (Tucker–Lewis
Index) equals 0.93 (for both diabetes and non-diabetes groups); all
exceed the benchmark (> 0.90).
Table 1
Descriptive statistics of women with and without diabetes.
Items Diabetes n = 315 No diabetes n = 2845 p-value
Age, mean (range) 47.26 (36.5463.82) 46.48 ± 5.00 0.006
BMI, mean (range) 30.87 (18.3066.10) 27.37 ± 5.96 0.001
Overall Mean DSSI score, mean ± SD 19.27 ± 6.84 18.71 ± 8.14 0.001
CESD score, mean ± SD 11.19 ± 10.69 9.02 ± 9.11 0.001
SF-36 MCS, mean ± SD 48.10 ± 10.86 49.76 ± 9.81 0.005
Independent t-test and Chi-square test were applied to obtain p-values.
21-Year follow-up dataset was used.
Table 2
Summary of exploratory factor analysis and corrected item total score correlations of the DSSI/sAD administered to diabetes and non-diabetes patients.
Items Diabetes No diabetes
n = 315 n = 2845
Anxiety Depression Anxiety Depression
1. I have breathless or had a pounding heart (Q3) 0.80 – 0.59 –
2. I have been so worked up that I couldn’t sit still (Q4) 0.78 – 0.72 –
3. For no good reason I have had feelings of panic (Q7) 0.71 – 0.50 –
4. I have worried about everything (Q1) 0.69 – 0.62 –
5. I have had a pain or tense feeling in my neck or head (Q9) 0.65 – 0.39 –
6. I have been so anxious that I couldn’t make up my mind about the simplest thing (Q13) 0.64 – 0.53 –
7. I have been so miserable that I have had difﬁculty sleeping (Q2) 0.62 – 0.74 –
8. I have been depressed without knowing why (Q5) 0.61 – 0.48 –
9. Worrying has kept me awake at night (Q11) 0.52 – 0.72 –
10. I have been so depressed that I have thought of doing away with myself (Q14) – 0.88 – 0.93
11. The future seems hopeless (Q10) – 0.86 – 0.69
12. I have gone to bed not caring if I ever woke up (Q6) – 0.82 – 0.88
13. I have lost interest in just about everything (Q12) – 0.70 – 0.57
14. I have been so low in spirit that I have sat up for ages doing absolutely nothing (Q8) 0.41 0.46 0.40 0.42
Cronbach’s alpha 0.91 0.90 0.86 0.88
Percent of variance (%) 53.41 5.16 44.55 5.14
⁄Items were listed in a descending order of magnitude of factor coefﬁcients by factor for diabetes sample. The sequence of the items in the DSSI measure was put in the form
of numbers in parentheses.
21-Year follow-up dataset was used.
Table 3
Fit index summary of partial conﬁrmatory factor analysis model, by diabetes and no diabetes groups.
Fit index Diabetes N = 315 No diabetes N = 2845 Benchmark
Absolute ﬁt indexes
Chi-square 180.52 1163.17
Degrees of freedom 64 64
p-value of Chi-square test 0.000 0.000 < 0.05
RMSEA 0.07 0.07 < 0.08
SRMR 0.03 0.03 < 0.100
Incremental ﬁt indexes
NFI 0.93 0.94 > 0.90
CFI 0.95 0.94 > 0.90
TLI 0.93 0.92 > 0.90
RMSEA = root Mean Square Error of Approximation; SRMR = Standardized Root Mean Residual; NFI = Normed Fit Index; CFI = Comparative Fit Index; TLI = Tucker–Lewis
Index.
21-Year follow-up dataset was used.
Model solution via maximum likelihood estimation (MLE).
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The correlation matrix also showed that there were strong cor-
relations between the scale items. The correlation between the
anxiety and depression subscales was 0.819 (p = 0.001), while
between the subscales and the full DSSI/sAD scale it was 0.96
(p < 0.001) and 0.95 (p < 0.001) respectively. All the items corre-
lated signiﬁcantly with the domain speciﬁc and full DSSI/sAD scale,
CES-D and SF-36 MCS (p < 0.001).
Table 4 displays the results of the linear regression analysis of
the validation instruments, including covariates, on DSSI/sADdepression and anxiety domains. Our results indicated that better
QoL on the SF-36 MCS sub-scale was signiﬁcantly related to lower
mean scores on DSSI-Anxiety and DSSI-Depression subscales.
When the SF-36 MCS increased by one unit, the DSSI/sAD anxiety
and domain score decreased by 0.443 units (p = 0.001) among par-
ticipants with diabetes, while it decreased by 0.396 (p = 0.001)
units in participants without diabetes. In both groups performance
on the SF-36 MCS accounted for similar percentages of the variance
in the DSSI/sAD anxiety domain scores (46% versus 40%).
Our results also showed that higher mean scores on DSSI-Anxi-
ety and DSSI-Depressionwere signiﬁcantly related to a highermean
Table 4
Results of linear regression analyses with the DSSI/sAD domains as the dependent variables, CESD and SF-36 MCS scores as independent variables, and covariates.
Outcome Factors Diabetes (n = 315) No diabetes (n = 2845)
Parameter
coefﬁcients
p-value 95% CI Variance R2 Parameter
coefﬁcients
p-value 95% CI Variance R2
DSSI – Anxiety CESD 0.52 0.001 0.46, 0.57 0.554 0.47 0.001 0.45, 0.49 0.484
Age a 0.11 0.040 0.21,0.01 0.03 0.037 0.07,0.01
BMI b 0.10 0.010 0.03, 0.18 0.01 0.834 0.03, 0.02
Education c 0.38 0.593 1.79, 1.03 0.701 0.003 1.16,0.24
Marital status d 0.23 0.733 1.07, 1.53 0.08 0.695 0.31, 0.46
SF-36 MCS 0.44 0.001 0.50,0.38 0.459 0.40 0.001 0.41,0.38 0.403
Age a 0.07 0.239 0.19, 0.05 0.04 0.018 0.08,0.01
BMI b 0.18 0.001 0.09, 0.27 0.03 0.035 0.01, 0.06
Education c 0.71 0.387 2.31, 0.90 1.31 0.001 1.82,0.81
Marital status d 0.44 0.573 1.08, 1.95 0.34 0.107 0.75, 0.07
DSSI - Depression CESD 0.54 0.001 0.49, 0.58 0.658 0.52 0.001 0.50, 0.53 0.586
Age a 0.02 0.701 0.10, 0.07 0.01 0.570 0.04, 0.02
BMI b 0.05 0.175 0.02, 0.11 0.01 0.534 0.02, 0.03
Education c 0.22 0.712 0.97, 1.42 0.27 0.171 0.67, 0.12
Marital status d 0.95 0.088 2.05, 0.14 0.39 0.020 0.71,0.06
SF-36 MCS 0.48 0.001 0.53,0.42 0.558 0.41 0.001 0.43,0.40 0.482
Age a 0.03 0.591 0.08, 0.13 0.02 0.153 0.06, 0.01
BMI b 0.12 0.003 0.04, 0.20 0.05 0.001 0.02, 0.07
Education c 0.20 0.779 1.601, 1.20 1.03 0.001 1.48,0.57
Marital status d 0.55 0.415 1.87, 0.78 0.96 0.001 1.33,0.59
Overall DSSI CESD 0.53 0.001 0.48, 0.58 0.659 0.50 0.001 0.48, 0.51 0.576
SF-36 MCS 0.46 0.001 0.51, 0.41 0.555 0.40 0.001 0.42,0.39
CI = Conﬁdence interval; MCS = Mental Component Score; CESD = Center for Epidemiologic Studies Depression Scale.
21-Year follow-up dataset was used.
a Age measured as continuous variables in years.
b BMI in kg/m2.
c Education was measured as 1 = Incomplete High schooling; 2 = Completed High schooling or higher.
d Married/living together = 1; not presently married, i.e., divorced, single, widowed, separated = 0.
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the score for the DSSI/sAD depression domain decreased by 0.535
(p = 0.001) in a sample of participants with diabetes, and it
decreased by similar amount (0.516 units) in participants without
diabetes. The association between CES-D and DSSI/sAD domains
remained signiﬁcant after adjusting for covariates. As reported in
Table 4, similar results were obtained when the full DSSI/sAD scale
was validated against the CES-D and SF-36 MCS scales.
3.4. Concordance with DSM-IV disorders
The DSSI subscales were good predictors of an absence of DSM-
IV mood disorders, evidenced by the high negative predictive value
(NPV) and speciﬁcity values (Table 5). The scale identiﬁed more
than half of the participants with current anxiety disorders (sensi-
tivity 52.8%). Women with diabetes had high odds of major depres-
sive disorder (ORs ranged from 4.93 to 13.50) or anxiety disorder
(ORs ranged from 4.65 to 8.10) compared with those without DSSI
symptoms. The ROC analyses show that although the DSSI symp-
toms and DSM-IV disorders (both measured at 27-year after the
initial interview) were measured concurrently the estimates of
concordance remained only low to moderate (AUC ranged from
0.63–0.89). Our ROC analyses show that 12-month DSM disorders
had moderate estimates (Depression = 0.78, Anxiety = 0.77)
compared to lifetime disorders (Depression = 0.64, Anxiety = 0.63).
Differences between DSM-based depressive and anxiety scales
were signiﬁcant. Conﬁdence intervals of the DSSI subscales and
DSM-IV depressive and anxiety disorders overlapped, indicating a
lack of systematic differentiation between the diagnoses.
4. Discussion
The ﬁndings support the construct validity and conﬁrmed the
psychometric properties of DSSI/sAD for use among women withdiabetes. The results provide evidence supporting the reliability
of the DSSI/sAD for use among similar subjects. The full DSSI/sAD
scale had high internal consistency (0.932), suggesting that the
14 items included in the instrument are reliable. The Cronbach’s
alphas were more than 0.80 for both groups with and without dia-
betes. The good consistency and reliability found here are similar
to the ﬁndings of previous studies (Bedford, Foulds, and Shefﬁeld,
1976; Bedford & Foulds, 1978).
An interesting ﬁnding of the present study is the conﬁrmation of
bi-factorial model of the DSSI/sAD; this is similar to reports for
HADS (Bjelland, Dahl, Haug, & Neckelmann, 2002; Herrmann,
1997). With few exceptions, the coefﬁcients were 0.40 or higher
for each itemwith its hypothesized factor (demonstrating good con-
vergent validity), but some items were cross-loaded and were
highly correlated (demonstrating poor discriminant validity). Con-
cerning the various ﬁt indices of the current model, the data closely
ﬁt the hypothetical model. As expected, chi-square was signiﬁcant,
indicating lack of ﬁt. However, the chi-square alone is not an appro-
priate indicator of ﬁt in large data sets (Keller et al., 1998).The other
absolute and incremental ﬁt indices such as RMSEA and CFI sug-
gested that this hypothesized two-factor CFA model of DSSI/sAD
provided an excellent description of the pattern of relationships in
both data sets, diabetes and non-diabetes. For example, the CFI
values indicated that the model explained about 95% of the varia-
tion and covariation among observations in both diabetes and
non-diabetes data sets. In the case of RMSEA, which is an absolute
measure of model ﬁt, showed that the two latent variables model
was considered adequate (RMSEA = 0.077). This is comparable to
what has been reported for CES-D (RMSEA = 0.069) (Zumbo,
2005). The data ﬁt the model well regarding the ﬁt indices for both
data sets (diabetes and non-diabetes).
We examined the extent to which the DSSI subscales are asso-
ciated with DSM-IV diagnoses of major depression and anxiety.
The DSSI was highly speciﬁc with low sensitivity, compared to
Table 5
Sensitivity, speciﬁcity and concordance of DSM-IV depressive and anxiety disorders by DSSI subscales (women with diabetes only).
DSM-IV Affective disorders a DSSI-Depression (measured at 27-year FU)
Cases DSM-IV cases Congruent (DSM-IV & DSSI)b Se c(%) Sp d(%) PPV e(%) NPV f(%) OR (95% CI) AUC (95% CI)
Lifetime disorder 32 74 18 64.30 73.30 25.01 93.70 4.93 (2.14–11.35) 0.64 (0.59–0.73)
12 month disorder 28 21 8 28.60 93.60 38.10 90.40 5.82 (2.15–15.71) 0.78 (0.67–0.88)
DSM-IV Anxiety disorders g DSSI-Anxiety (measured at 27-year FU)
Lifetime disorder 40 134 30 83.30 48.20 23.10 93.90 4.65 (1.85–11.68) 0.63 (0.56–0.71)
12 month disorder 36 76 26 72.20 75.60 35.60 93.60 8.10 (3.63–17.97) 0.77 (0.67–0.88)
Univariate analysis to obtain ORs; Se = sensitivity; Sp = speciﬁcity. 27-Year follow-up dataset was used.
a Major Depressive Disorder and/or dysthymia disorders.
b Empirical or DSM-oriented scales.
c The proportion of people with DSM-IV recent depression or anxiety who were cases on the relevant DSSI scale.
d The proportion of people with a negative DSM-IV recent depression or anxiety who had a negative screening test.
e Positive predictive value the proportion of cases on the DSSI scale that subsequently met the DSM-IV criteria for recent depression or anxiety.
f Negative predictive value the proportion of cases that were negative on the DSSI scale and subsequently did not met the DSM-IV criteria for recent depression or anxiety.
g Generalised Anxiety Disorder, PTSD, panic and/or phobic disorders.
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who had co-morbid depression, was too small (< 10%). However,
the number of participants who screened negative using the DSSI
(i.e. they had diabetes without depression) permits us to conclude
that these patients would also screen negative using the DSM IV.
Our ROC analyses show that 12-month DSM disorders had moder-
ate estimates compared to lifetime disorders. This may be a result
of a close time frame as the DSSI reports symptoms experienced in
recent weeks.
The validity of the DSSI/sAD domains was also demonstrated
through strong relationships with the equivalent SF-36 MCS scale.
Our results indicated that better SF-36 MCS scores were signiﬁ-
cantly related to lower anxiety and depression symptoms of the
DSSI/sAD. Correlation analysis showed a signiﬁcant negative corre-
lation between DSSI/sAD domains and the SF-36 MCS scale; thus,
as anxiety or depression symptoms decreased, as measured by
DSSI/sAD scale, the SF-36 MCS scores increased, indicating good
mental health, endorsing the validity of our assessment. The
assessment of depression and anxiety symptoms in people with
diabetes is important as both conditions have been linked to the
onset of diabetes and vice versa (Grigsby et al., 2002; Hasan
et al., 2013). All three instruments (DSSI/sAD, CES-D, and SF-36
MCS) predicted the likelihood of diabetes, with differences in the
sizes of the effect estimates.4.1. Limitations
The results cannot be generalized to other women and they may
differ for men. The data were collected from antenatal clinics, and
women who frequently attended these outpatient clinics were
more likely to be sampled than those who attended less frequently,
and therefore were presumed to have fewer symptoms of anxiety
and/or depression, which may have introduced selection bias.
There may have been participant recall bias which would be a sys-
tematic error which may have affected accuracy of self-reported
information and there was no objective conﬁrmation of self-
reported diabetes mellitus. It is likely that some women in this
cohort had undiagnosed diabetes mellitus; this may be differential
because women who have been diagnosed with depression or anx-
iety may go on to receive more health screening. Regarding sample
size, it has been suggested that meaningful qualitative conclusions
can be drawn from ROC/AUC experiments performed with a total
of about 100 observations where a minimum of 50 cases may be
required in each of the two groups (Doi, 2013). However in some
groups we did not have a minimum of 50 observations. Despite
the limitations, our investigation of the validity of the depression
and anxiety domains of the DSSI/sAD found them to be valid mea-sures to examine depression and anxiety symptoms in women
with diabetes.5. Conclusions
This is the ﬁrst study to examine the validity of the DSSI/sAD
symptoms with DSM-IV depressive and anxiety disorders in
women with diabetes. These results also demonstrate that the
DSSI/sAD items have similar relationships to one another in both
diabetes and non-diabetes groups and therefore suggests that they
have similar interpretations. Based on the partial CFA results, this
study concluded that the items listed in the scale could generate
the hypothesized two-factor CFA model of DSSI/sAD. As expected,
the scale had poor discriminant validity and good convergent
validity. The scale appears to be reliable based on good internal
consistency and signiﬁcant correlations with other validated
instruments. The analyses presented here may be considered as a
step towards better understanding of the factor structure of the
DSSI/sAD.Conﬂict of interest
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CHAPTER 6  
Psychological health and the risk of diabetes mellitus in Australian women: A 
21-year prospective study 
 
The fourth objective of this thesis was to investigate whether change in depression 
symptoms was independently associated with a risk of diabetes mellitus; this was, 
measured at 21-years post index pregnancy in Australian women. This was necessary 
because changes in depression symptoms and the risk of diabetes have not been studied 
formally, particularly when symptoms can be recurrent or limited to one episode. 
 
The analyses described in this chapter have been published. The research investigated 
depression symptoms as a risk factor for diabetes and the findings suggest that there is an 
elevated risk associated with persistent symptoms only. The formal citation for the 
published work: 
 
1. Hasan, S.S., Clavarino, A.M., Dingle, K., Mamun, A.A., Kairuz, T. (2014). 
Psychological health and the risk of diabetes mellitus in Australian women: A 21-
year prospective study. J Womens Health, 23(11), 912-9. 
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Abstract
Background: Symptoms of depression can be recurrent or limited to one episode. This study discusses the
prospective association between psychological health, measured as change in depression symptoms, and the risk
of diabetes mellitus in Australian women.
Methods: Data obtained from the Mater-University of Queensland Study of Pregnancy. Depression was measured
using the Delusions-Symptoms: States Inventory. To examine possible transitions over time, depression was
grouped into four categories and assessed at different phases over the 21-year period. Multiple logistic regression
models and sensitivity analysis to assess the robustness of our analytical strategy were performed.
Results: Three hundred and one women reported diabetes 21 years after the index pregnancy. Almost one-third
of the women who reported depression symptoms continued to report these at a subsequent follow-up (FU)
phase. About 1 in 20 women who had not reported depression symptoms at the 5-year FU did so at the
subsequent 14-year FU. In prospective analyses, we did not find a significant association between diabetes and
negative change (not depressed to depressed, at subsequent phase); however, for women with positive history of
symptoms of depression and women with persistent symptoms, there was a 1.97-fold (95% confidence interval
[CI]: 1.14–3.40) to 2.23-fold (95% CI: 1.09–4.57) greater risk of diabetes.
Conclusions: Our study suggests that an increased risk of diabetes is significantly associated with persistent
depression symptoms. It highlights the importance of recognizing depression symptoms in terms of women’s
psychological wellbeing and thus provides a basis for targeting those most at risk.
Introduction
D iabetes mellitus may be described as a chronic pro-gressive disorder, and is often coupled with multiple mor-
bidities that include physical as well as psychological disorders.1
Obesity and lack of physical exercise are well-known, modifi-
able risk factors of diabetes,2 while depression is a common,
comorbid, and modifiable condition3,4 and is the most widely
studied psychological condition associated with diabetes.5–7 The
prevalence of depression in people with diabetes is considerably
higher than the normal population and ranges between 10% and
30%.5,8,9 People with diabetes are at higher risk of developing
depression,3,5 and vice versa.6,7 Symptoms of depression are
recurrent, chronic, or limited to one episode; therefore depres-
sion often remains unrecognized and thus, untreated.10
Diabetes is a leading cause of mortality worldwide and re-
sulted in 1.0 million (1.9%) deaths in 2000, which increased to
1.4 million (2.6%) deaths in 2011.11 Depressive disorder is a
major contributor to the burden of disease.12 In Australia, both
diabetes and depression contribute significantly to the burden
of disease, with depression the leading contributor among
women.13 Stressful events are a well-documented cause of
depression and women usually experience more potentially
stressful life events (for example, pregnancy),14 particularly
prior to the onset of diabetes. Women with diabetes and co-
morbid depression reported experiencing greater disease bur-
den and restrictions in their social interactions as well as more
physical complaints,15 poor diabetes self-care, and poor gly-
cemic control.16 However Rotella et al. suggested that clinical
features have a much greater impact on attainment of thera-
peutic goals than psychopathology.17
Several longitudinal studies from developed countries sug-
gest that the association between depression and diabetes is
reciprocal or bidirectional.3,18,19 The bidirectional association
Schools of 1Pharmacy and 3Population Health, The University of Queensland, Queensland, Australia.
2Queensland University of Technology, Queensland, Australia.
4School of Pharmacy, James Cook University, Queensland, Australia.
JOURNAL OF WOMEN’S HEALTH
Volume 23, Number 11, 2014
ª Mary Ann Liebert, Inc.
DOI: 10.1089/jwh.2014.4832
912
between diabetes and depression was first documented by
Golden et al., who described the relationship as ‘‘modest’’ and
‘‘partially explained by lifestyles,’’19 and Eaton and colleagues
were the first to report the results of an epidemiological study
that confirmed the relationship between depression and diabetes
in 1996.20 Multiple meta-analyses have suggested an associa-
tion between depression and diabetes as bidirectional.6,7,21,22
However, among psychiatric disorders or symptoms, not only
depression or anxiety are independently associatedwith diabetes
onset, impulse control disorders such as eating disorders are also
important.23
A consistent association between diabetes and psychiatric
disorders is commonly found in the literature;3,6,7 however,
change in depression symptoms (positive, negative, persistent
symptoms) and the risk of developing diabetes have not been
studied formally, particularly when symptoms of depression
can be recurrent or limited to one episode. Therefore. this study
examines the relationship between psychological health, mea-
sured as change in depression symptoms and the risk of dia-
betes for a large cohort of women who were followed up at
intervals over a 21-year period postpartum, and takes into ac-
count a range of potential confounding factors. We performed
sensitivity analysis to assess the robustness of our analytical
strategy. Finally, we also examined the cross-sectional asso-
ciation between depression and diabetes.
Materials and Methods
Participants
We examined the association between depression symp-
toms and subsequent reporting of diabetes mellitus 21 years
postpartum in a sample of women who were part of an
Australian pregnancy and birth cohort. The Mater-University
of Queensland Study of Pregnancy (MUSP) is a multidisci-
plinary study that represents Australia’s largest longitudinal
study spanning a large part of a woman’s reproductive life
from pre-birth for 21 years postpartum. The longitudinal
study began in 1978–1979 with a number of pilot studies, and
full data collection commenced in January, 1981. Women
recruited into the study gave birth at the Mater Misericordiae
Mothers’ Hospital, which is one of two major obstetric units
in Brisbane, Australia.24,25 The original study was approved
by the Human Subjects Research Ethics Committee of the
University of Queensland and was conducted according to
the Declaration of Helsinki.
Data were collected prospectively across the reproductive
life course of a large group of women. Originally 7861 women
were enrolled (8556 pregnancies), and of these women, 6753
constitute the ‘‘MUSP mothers’’ cohort. Women enrolled in
the cohort had to deliver at least one live babywho neither died
nor was adopted before leaving the hospital and have (initial)
data from the first clinic visit (FCV), at approximately 18
weeks’ gestation, and shortly after the birth. These women
were reinterviewed 3 to 5 days after delivery, and data from
their medical records were also collected. Additional inter-
views and follow-ups were conducted when the children were
6 months, 5 years, 14 years, and 21 years of age. At the start of
the MUSP study, women who were cared for at this hospital
were not screened routinely for gestational diabetes mellitus.
Women who had been diagnosed with diabetes mellitus before
the index pregnancy or who developed gestational diabetes
mellitus, or type 1 diabetesmellitus, that was diagnosed during
the index pregnancy (n= 46), were excluded from analysis.
After excluding women who did not provide any information
regarding the presence of diabetes mellitus at the 21-year
follow-up, 3663 women provided information regarding their
own physical health and diabetes mellitus.
Measurement of diabetes mellitus
The outcome in our analyses was information regarding
self-reported diabetes mellitus in the 21 years after the index
pregnancy; data were collected using a self-administered
questionnaire. Women were asked, ‘‘Have you EVER been
told by a doctor that you have diabetes mellitus (high blood
sugar)?’’ Women with preexisting or gestational diabetes
mellitus at the time of the index pregnancy were excluded
from this study, and a positive response to this question in-
dicated that the woman had incident diabetes mellitus some
time during the 21 years after the index pregnancy.26
Measurement of depression symptoms
The exposure was depression symptoms measured at 5
years and 14 years after delivery; symptoms were assessed
using the seven-item depression subscale from the Delusion
Symptoms States Inventory: State of Anxiety and Depression
(DSSI/sAD).27 This measure was developed to detect the
signs and symptoms of psychopathology that limit a person’s
capacity to function and maintain relationships. The measure
has high internal validity,27,28 correlates well, and shares
items with other measures of depression and anxiety, such as
the Edinburgh Postnatal Depression Scale and the Hospital
Anxiety and Depression Scale.29 In MUSP, the Cronbach’s
alphas for the scale (DSSI/sAD) ranged from 0.79 to 0.88,
measured at 14-year follow-up.30 In the present study, the
seven items, each with 5-point response options (never,
rarely, some of the time, most of the time, or all the time),
were summed [score range: 10 (all the time) to 50 (never)];
the lower the score, the more depressed the person. Women
who reported four or more symptoms were considered to be
depressed.27
Defining changes in depression symptoms:
psychological health
We examined psychological health by estimating the ob-
served proportion of women who reported a change in de-
pression symptoms between subsequent phases of the study.
In the present study, diabetes was the dependent variable at
21 years, and changes in depression symptoms (i.e., transi-
tions) from the previous two phases (at 5- and 14-year follow-
ups), was the main predictor. Potential confounding factors
for each of the transition models (changes in depression
symptoms) were included from the most recent or relevant
previous phase. MUSP is a prospective study with unequal
time intervals between data collection phases, andmost of the
variables are time dependent; therefore, the number of wo-
men making transitions (that is, experiencing changes in
depression symptoms) for exposure at each of the unequal
time intervals was estimated in the following manner:30
possible transitions that could occur during the period from
the 5-year follow-up (FU) (origin state) to the 14-year FU
(destination state) were classified into four categories, based
on 1 standard deviation above the mean cutoff. The
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categories are (1) no depression, (2) women reporting de-
pression at 5-year but not at 14-year FU (positive history of
depression), (3) women reporting depression at 14-year FU
but not at 5-year FU (negative change), and (4) women with
persistent depression symptoms.
Given the length of time between the follow-ups, it is
likely that some women may have experienced more than
one episode of depression during that time. Two phases—
post-delivery (3–5 days after delivery) and 6-month follow-
up—were not included, as pregnancy or intervals after
delivery may be sensitive periods with regard to depres-
sion symptoms and could confound the associations under
investigation.
Sensitivity analysis
There were two phases that were not included in the main
analysis: post-delivery (3–5 days after delivery) and 6-month
follow-up. However, we used these phases to assess the ro-
bustness of our analytical strategy: the sensitivity analysis
was performed using the same possible transitions during 3–5
days FU (origin state) to the 6-month FU (destination state).
They were classified into the same four categories used in the
main analysis.
Adjustment for potential confounding
The potential confounders and risk factors were identified
on the basis of their association with outcomes and on the basis
of a priori knowledge.6,7 We determined six variables neces-
sary to control for confounding: age, marital status to 5-year
FU, family annual incomes to 5-year FU, education, use of
psychotropic drugs and body mass index (BMI). Age at first
clinic visit, both as a categorical and continuous variable, was
included. At each phase during the study, the woman was
asked her current marital status; that is, whether she was
married, living together, separated/ divorced, or single. A
change in marital status to 5 years post-delivery was included,
and this measure was categorized into nil partner change, one
change, or two plus changes. In the data collection stages of the
study, namely at 5, 14, and 21 years, women were asked to
select, from a 7-point scale, the (Australian) dollar range that
best represented their total family annual income. In the cur-
rent study, changes in family annual income to 5 years FU
were categorized into consistent poverty, mid income, and
high income. Maternal education at the first antenatal visit was
recorded as one of three categories: did not complete sec-
ondary schooling, completed secondary schooling, and com-
pleted further or higher education. The information about
psychotropic drugs was categorized as yes and no.
Participants’ height and weight at first antenatal visit and
an estimate of prepregnancy weight were obtained at the start
of the study, from either obstetric records or questionnaires.
Participants’ estimates of prepregnancy weight and measured
weight on the first antenatal visit correlated highly (Pearson’s
correlation coefficient, 0.95).22 In the present study, BMI was
categorized into normal, 10% low, and 10% high.
Statistical analysis
The data were analyzed using the Statistical Package
for Social Sciences (SPSS) version 20 and Stata IC ver-
sion 12 (StataCorp LP), with a significance level of £ 0.05.
Descriptive statistics were used to calculate percentages, fre-
quencies, means, and standard deviations. The Student t-test
and chi-squared tests were used to compare the characteristics
of those women who did and did not provide information about
diabetes at 21-year evaluation, or who were lost to follow-up
and therefore excluded from the analysis. Multiple logistic
regression models were then used to further assess the associ-
ation between the characteristics, depression symptoms, and
diabetes, measured at FCV (at the start of the study), with those
lost to follow-up or with incomplete data.
Logistic regression was used to assess the relationship
between depression symptoms and self-reported diabetes
mellitus. Multiple logistic regression was then used to further
assess the relationship between depression symptoms and
subsequent self-report of diabetes mellitus, after adjustment
for other potential confounding variables. The same method
was used for longitudinal and cross-sectional data.
We present a series of models that were adjusted for the
potential confounders so that readers can see the effect of
factors that we considered might confound this association.
Multiple imputations were carried out to adjust for missing
data.31 Combining the results of the analyses of the complete
datasets using Rubin’s rules was performed in Stata IC ver-
sion 12.0. The relationship between ‘‘missingness’’ (yes
versus no) and the predictor variables was assessed using
logistic regression.
Investigation of missing data
The distribution of missingness of study covariates by
outcome (diabetes at 21-year follow-up is shown in Table 1.
Of the 6753 women who were eligible for this study, 3663
women (54.2%) completed the 21-year follow-up and pro-
vided information regarding the diagnosis of diabetes mel-
litus (excluding type 1 and gestational diabetes). The same
subset (3663) was used to impute for the missing values on
study covariates. The proportion of missing data ranged from
0% to 20% for all variables. For the main predictor, ‘‘changes
in depression symptoms,’’ 22% of data were missing, and
therefore, data were imputed for all covariates except age,
where the amount of missing data was zero. It is generally
recommended to impute more than the percentage of missing
data,32 and therefore we imputed missing data based on the
percentage of missing data on covariates. An imputation
model was devised using the recommendations of Van
Buuren et al.33 The model included all the predictor variables
excluding the outcome i.e. presence or absence of diabetes
(yes/no). The data on covariates were assumed to be ‘‘miss-
ing at random,’’ which means that the probability of the data
being missing may depend on observed values.34
For each of the completed datasets, a logistic regression
was performed (inclusion of all predictor variables without
outcome), from which the estimate of interest and its esti-
mated variance were obtained. The results from the logistic
regression modelling of the different datasets were combined
using the rules proposed by Rubin to produce a multiple
imputation estimate.35 The estimate obtained for multiple
imputations is simply the average of the different estimates.
Results
A total of 301 (8.2%) of the participating women reported
diabetes at 21-year FU. The proportion of women with four or
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more symptoms was 13.69% at post-delivery (3–5 days after
delivery) and 13.35% at the 14-year FU. In our descriptive
analysis, of the women with persistent depression symptoms,
almost 17% reported diabetes compared with about 8% of
women persistently not depressed. About 13% and 8% of
women with positive and negative change, respectively, re-
ported diabetes at 21-year follow-up (Fig. 1).
The proportion of women reporting transitions or changes
(depression symptoms) between consecutive phases (5-year
and 14-year FU) is presented in Table 2. About one-third
(33.2%) of the women who reported depression symptoms (at
5-year FU) continued to report these at the subsequent 14-year
FU phase. About 1 in 20 women (5.7%) who had not reported
depression symptoms at the 5-year FU did so at the subsequent
14-year FU. However, transitions can only inform us of the
proportion of women changing from one state to another,
whereas multivariate analysis can provide further insight into
the independent developmental processes associated with
these transitions.30 Results from multivariate analyses for
women with imputed data on all variables are presented in
Table 3, using four models. The first of these models, all of
which used longitudinal data, presents unadjusted estimates,
while age was included in Model 2. In Model 3, socio-
demographic characteristics were included in the analysis, and
finally, in the fourth model (4) the estimates were further ad-
justed for use of psychotrophic drugs and BMI. In the unad-
justed Model 1, women with persistent symptoms (depression
symptoms at both 5-year and 14-year FUs) had a 2.45-fold
greater risk of diabetes (95% confidence interval [95%
CI]: 1.23–4.92). The effect size of negative change (from no
Table 1. Comparison Between Lost to Follow-Up and Information Collected for Diabetes
at 21-Year Follow-Up by Sociodemographic and Clinical Factors
Factors Number
Women who
provided diabetes
data at 21-year
FU (n = 3686)
Women who
were missing
at 21-year FU
(n = 3067)
Adjusted
OR (95% CI)a
Chi-squared
p-value
Mothers’ age at entry to study (years) - 25.49– 5.02 24.43 – 5.27 - -
Changes in depression symptoms
Persistently not depressed 3554 2710 (67.1) 844 (20.9) 1.00 > 0.05
No depression to depression 233 165 (4.1) 68 (1.7) 0.81 (0.57–1.14)
Depression to no depression 161 119 (2.9) 42 (1.1) 1.08 (0.69–1.69)
Persistent depression symptoms 85 59 (1.5) 26 (0.6) 0.66 (0.38–1.14)
Age groups
13–19 1146 482 (13.1) 664 (21.6) 1.00
20–34 5307 3036 (82.4) 2271 (74.1) 1.17 (0.90–1.52)
‡ 35 300 168 (4.6) 132 (4.3) 1.05 (0.66–1.68) > 0.05
Changes in marital status to 5-year FU
Nil partner change 3859 2695 (73.1) 1164 (37.9) 1.00
One change 480 292 (7.9) 188 (6.1) 0.98 (0.72–1.33)
Two plus 389 240 (6.5) 149 (4.9) 1.06 (0.76–1.47) > 0.05
Changes in family annual income
Consistent poverty 225 131 (3.6) 94 (3.1) 1.00
Mid income 3424 2385 (64.7) 1039 (33.9) 1.30 (0.87–1.93)
High income 476 369 (10.0) 107 (3.5) 1.60 (1.01–2.57) 0.001
Education level
Incomplete secondary education 1215 572 (15.5) 643 (21.0) 1.00
Complete secondary education 4294 2354 (63.9) 1940 (63.2) 1.23 (0.98–1.54)
Post-secondary education 1190 734 (19.9) 456 (14.9) 1.69 (1.27–2.26)* 0.001
Body mass index
Normal 5004 2843 (77.1) 2161 (70.5) 1.00
Low 10% 629 303 (8.2) 326 (10.6) 1.08 (0.81–1.44)
High 10% 599 322 (8.7) 277 (9.0) 0.96 (0.66–1.40) > 0.05
aAdjusted for all other variables in table.
bPredictive variable equals ‘‘diabetes at 21-year FU’’ not missing (coded as ‘‘0’’) vs missing (coded as ‘‘1’’).
CI, confidence interval; FU, follow-up; OR, odds ratio.
FIG. 1. Proportions of women reporting diabetes, by
change in depression symptoms.
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depression to depression) is comparable to a positive change
(from depression to no depression); however, only positive
change was significantly associated with diabetes (odds ratio
[OR] 1.91; 95% CI: 1.12–3.25).
In Model 2, experiencing depression symptoms at both the
5-year FU and 14-year FU was significantly associated with
diabetes at the 21-year FU (2.49;95% CI: 1.24–4.98), as well
as positive change (1.95; 95% CI: 1.15–3.32) (Table 3).
Models 3 and 4 were included to further adjust for the pos-
sible effects of sociodemographics, psychotropic drugs, and
BMI, and the associations identified remained consistent and
robust for persistent depression. In the fully adjusted model
(Model 4), women with positive change had a 1.97-fold risk
(95% CI: 1.14–3.40), while those with persistent symptoms
had a 2.23-fold risk (95% CI: 1.09–4.57) of subsequent dia-
betes at the 21-year FU.
In cross-sectional analysis, the unadjusted and age-
adjusted models produced significant associations between
depression symptoms and diabetes (both measured at 21-year
follow-up study) (Table 4). In the multivariate model, the
association became insignificant. It is interesting to note that
after multiple imputations, we observed that effect sizes were
reduced, but there was increased precision suggested by
narrow confidence intervals.
Sensitivity analysis
In order to examine the robustness of our findings and to
ensure that our findings are not spurious, we conducted a
sensitivity analysis using the same analytical strategy but
with depression symptoms measured at different time points.
Similar to the findings of our main analysis, women with
persistent depression symptoms (6.33; 95% CI: 2.50–16.00)
and women with positive change (1.82; 95% CI: 1.01–3.31)
were significantly associated with diabetes.
Discussion
This study examines the prospective association between
psychological health, measured as change in depression
symptoms, and the reporting of diabetes mellitus in Australian
women and found that almost one-third who reported de-
pression symptoms at 5-year FU continued to report these at
the subsequent 14-year FU phase. About 1 in 20 women who
had not reported depression symptoms at 5-year FU did so at
Table 2. Proportion (Percent) of Women Who
Experienced Change in Depression
Symptoms Between Phases
Symptom reported
at each phase Symptom at subsequent phase (%)
Post-delivery 6-month FU
No depression Depression n
No depression 97.0 3.0 3415
Depression 83.1 16.9 118
6-month FU 5-year FU
No depression Depression n
No depression 94.8 5.2 3064
Depression 78.9 21.1 109
5-year FU 14-year FU
No depression Depression n
No depression 94.3 5.7 2875
Depression 66.8 33.2 178
14-year FU 21-year FU
No depression Depression n
No depression 91.4 8.6 3090
Depression 62.8 37.2 250
Table 3. Unadjusted and Adjusted Odds Ratios (95% CI) of Reporting Diabetes at 21-Year
Follow-Up, by Changes in Depression Symptoms (Longitudinal Analysis)
Items No diabetes (referent) Diabetes mellitus
Persistently not depressed (referent) 1.00 1.00
Model 1 (unadjusted) n= 3663
No depression changes to depression 1.00 1.13 (0.84–1.51)
Depression changes to no depression 1.00 1.91 (1.12–3.25)*
Persistent depression symptoms 1.00 2.45 (1.23–4.92)*
Model 2a (age adjusted) n= 3663
No depression changes to depression 1.00 1.13 (0.85–1.51)
Depression changes to no depression 1.00 1.95 (1.15–3.32)*
Persistent depression symptoms 1.00 2.49 (1.24–4.98)*
Model 3b (adjusted) n= 3663
No depression changes to depression 1.00 1.11 (0.83–1.48)
Depression changes to no depression 1.00 1.91 (1.11–3.29)*
Persistent depression symptoms 1.00 2.41 (1.20–4.85)*
Model 4c (adjusted) n= 3663
No depression changes to depression 1.00 1.12 (0.83–1.50)
Depression changes to no depression 1.00 1.97 (1.14–3.40)*
Persistent depression symptoms 1.00 2.23 (1.09–4.57)*
ORs obtained using imputed data.
aAdjusted for age.
bAdjusted for Model 2 plus marital status to 5-year FU, changes to family annual incomes to 5-year FU, and maternal education.
cFurther adjusted for psychotropic drugs and body mass index.
*Statistically significant.
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the subsequent 14-year FU. Perhaps surprisingly, this study
also found that a positive change in depression symptoms
(depression to no depression) was significantly associated with
diabetes at 21-year FU. Women who had persistent symptoms
of depression at both 5-year FU and 14-year FU were signif-
icantly associated with diabetes at 21-year FU. A greater risk
of diabetes in people with depression symptoms has been re-
ported previously.3,6,7 However, it is important to note that we
did not observe a significant association between depression
symptoms and diabetes in our cross-sectional analysis.
Our results indicated that psychological health, as measured
by change in depression symptoms, was significantly associ-
ated with the reporting of diabetes, exerting effects indepen-
dent of previously established risk factors for diabetes such as
age, socioeconomic status, education, or obesity. These factors
did not mediate the association between depression and dia-
betes; a negative change in their depression symptoms (no
depression to depression symptoms) was not significantly as-
sociated with the adverse outcome (diabetes).
Conversely, women who experienced a positive change—
that is, from having depression symptoms to having no
symptoms—had a substantial impact on diabetes. This par-
ticular finding suggests that not only current but also previous
episodes of depression are important determinant of diabetes
onset. This finding is consistent with the previous study by
Brown et al.36 They examined an association between history
of depression and incident diabetes and found individuals with
newly diagnosed diabetes were 30%more likely to have had a
previous history of depression compared with people without
diabetes.36 We replicated the same results in our sensitivity
analysis, endorsing the accuracy of our main analysis.
The possible risk mechanisms linking depression with an
increased risk for diabetes are described elsewhere.6,7 Based
on small relative and absolute effect sizes, Hasan et al. sug-
gested that the causal direction (not association) between
these two conditions may share common causes or risk fac-
tors.6 Prior to this, Mezuk suggested exploring the common
cause or risk factor.37 One of the possible explanations for the
increased risk of diabetes when symptoms of depression are
present is chronic or recurrent stress. This would result in
intermittent or sustained increased levels of cortisol and
adrenaline in biologically vulnerable individuals.38 Campayo
et al. suggested that a metabolic syndrome in depressed pa-
tients may be the mediating mechanism with chronic stress as
a potential mediator.39 This hypothesis is further strength-
ened by the fact that antidepressant use is not associated with
a lower risk of developing diabetes;40 treating depression
without addressing underlying stress does not remove or in-
fluence the risk of developing medical conditions subsequent
to depression.37 Moreover, controversy exists about the use
of antidepressants and diabetes, with some antidepressants
linked to worsening glucose control, others linked to im-
proved control, and yet more showing mixed results.41
Stress can mediate between symptoms of depression and
diabetes by over-activating the hypothalamus-pituitary-adrenal
(HPA) axis; this results in elevated cortisol levels that can inhibit
insulin function in a variety of ways.42,43 The HPA dysregula-
tion is assumed to contribute to appetite dysregulation,44,45 or
increased appetite,46 and subsequent weight gain in stressed
individuals, and it also stimulates a craving for high glycemic
and high lipid foods.45–49 Over a long period of time, this could
predispose people to developing conditions such as diabetes
mellitus.
Limitations of the study
There are some methodology-related limitations that may
affect the generalizability of our findings. The sample was
restricted to women who had at least one child, and therefore,
the results cannot be generalized to other women, and it is
possible that the associations identified may differ for men.
Two-thirds of the original cohort provided information on de-
pression throughout the study period, but in the regression
analysis, complete data on all relevant variables was only
available for just over half of these respondents. Information
was derived from either medical records or self-reported,
possibly leading to information bias and misclassification of
depression symptoms, mental health status, and/or clinical
conditions. One of the concerns with self-report measures is
that it does not provide the exact timing of the onset of a
medical condition.5 It seems unlikely, however, that self-report
is a major bias, as previous research has reported relatively
good agreement between self-report and interviews regarding
chronic somatic diseases such as diabetes.50,51 The results
suggest that with multiple follow-ups extending over a 21-year
period, the relationship between depression and diabetes is
strong; that is, persistent depression may lead to diabetes. Since
depressive symptoms and major depression has been linked to
the development of diabetes,19,20 the possibility of comorbid
anxiety and depression symptoms increasing the risk of de-
veloping diabetes should not be ruled out.
In our study a positive response for the outcome at the 21-
year follow-up represents ‘‘incident diabetes mellitus;’’
however, it is possible that women developed diabetes during
an earlier period (for example, between the 5-year and 14-
year follow-ups); similarly, a woman could have developed
gestational diabetes during a subsequent pregnancy and be
included in the group of women who reported diabetes in the
21 years after the index pregnancy. These factors could lead
to a higher prevalence andmisclassification of the outcome as
Table 4. Unadjusted and Adjusted Odds Ratios
(95% CI) of Reporting Diabetes and Depression
Symptoms at 21-Year Follow-Up
(Cross-Sectional Analysis)
Items
No diabetes
(referent)
Diabetes
mellitus
Not depressed (referent) 1.00 1.00
Model 1 (unadjusted) n = 3663
Depression symptoms 1.00 1.44 (1.03–2.02)*
Model 2a (age-adjusted) n = 3663
Depression symptoms 1.00 1.48 (1.05–2.07)*
Model 3b (adjusted) n = 3663
Depression symptoms 1.00 1.34 (0.94–1.89)
Model 4c (adjusted) n = 3663
Depression symptoms 1.00 1.28 (0.90–1.82)
ORs obtained using imputed data.
aAdjusted for age.
bAdjusted for 2 plus marital status at 21-year FU, family income
at 21-yr, maternal education.
cFurther adjusted for body mass index at 21-year FU.
*Statistically significant.
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well as potential bias. Therefore, we used the term associa-
tion instead of prediction to reduce bias and also to signify a
statistical relationship rather than causality.
Conclusions
Our study suggests that persistent symptoms of depression
and womenwith a positive history of depression are associated
with an elevated risk of diabetes. Despite some limitations, this
study provides insight into the long-term association between
changes in depression symptoms and diabetes across the re-
productive life of women and provides an interesting finding
that warrants further study. It also highlights that women who
are depressed in their early ages (20s–30s) possibly have an
increased risk of diabetes later in life, whether or not the de-
pression persists. These women would be worth targeting for
nutrition and other lifestyle modifications, as well as education
about symptoms of diabetes.
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CHAPTER 7 
Anxiety symptoms and the risk of diabetes mellitus in Australian women: 
evidence from 21-year follow-up 
 
The fifth objective of this thesis was to investigate whether anxiety symptoms were 
independently associated with the risk of diabetes mellitus which was measured at 21-year 
post index pregnancy in Australian women. This study was undertaken because changes 
in anxiety symptoms and the risk of diabetes have not been studied formally, particularly 
when symptoms can be recurrent or limited to one episode. 
 
The research described in this chapter investigated anxiety as risk factor for diabetes. 
Persistent anxiety symptoms, similar to depression, are significant risk factors for the onset 
of diabetes. The formal citation for the revised and resubmitted work: 
 
1. Hasan, S.S., Clavarino, A.M., Mamun, A.A., Kairuz, T. Anxiety symptoms and the 
risk of diabetes mellitus in Australian women: evidence from 21-year follow-up. 
Public Health J [Revised & Resubmitted]. 
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Anxiety symptoms and the risk of diabetes mellitus in Australian women: evidence 
from 21-year follow-up 
 
Abstract 
Objectives: This study aimed to explore 
the association between transitions in 
anxiety symptoms and the risk of 
diabetes in women, using longitudinal 
data.  
 
Study design: This longitudinal study 
measured diabetes, and transitions in 
anxiety symptoms, using validated 
instrument. 
 
Methods: Data obtained by the Mater-
University of Queensland Study of 
Pregnancy were analysed. Anxiety was 
measured using the Delusion Symptoms 
States Inventory (DSSI). To examine 
possible transitions over different time 
periods, anxiety was grouped into four 
categories and assessed at different 
phases over a 21-year period.  
 
Results: Three hundred and one women 
reported diabetes at 21-year after the 
index pregnancy. Almost half of the 
women who reported anxiety symptoms 
continued to report these at a subsequent 
Follow-up (FU) phase. About 1 in 10 
women who had not reported anxiety 
symptoms at 5-year FU did so at the 
subsequent 14-year FU. In prospective 
analyses, we did not find significant 
association of diabetes with negative 
transition (no anxiety to anxiety at 
subsequent phase) or with positive 
history of anxiety symptom, but 
increasing risk was evident. Women with 
persistent symptoms had a 1.85-fold 
greater risk of diabetes (95% CI: 1.18 – 
2.90). The cross-sectional analysis did 
not produce significant results.  
 
Conclusions: Despite some limitations, 
this study provides insight into the long-
term association between events of 
anxiety and the risk of diabetes across 
the reproductive life of women. However, 
the evidence is not strong enough to 
support a direct effect of anxiety in 
causing diabetes. 
 
Keywords: prospective, anxiety, diabetes, 
Australia, women 
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Introduction 
Diabetes mellitus (DM) may be described 
as a “complex chronic disease,” and is 
defined as a disease involving multiple 
morbidities including physical as well as 
mental health conditions.1,2 Anxiety is a 
common, co-morbid, modifiable condition 
associated with people of DM.3-6 The 
prevalence of anxiety in people with DM 
is considerably higher than in general 
population.4,7 Because of the difficulties 
associated with recognizing and properly 
diagnosing anxiety, epidemiological 
prevalence rates may underestimate the 
true number of people experiencing 
anxiety.8  
 
A systematic review by Grigsby et al. 
reported that elevated symptoms of 
anxiety were present in 40% of patients 
with DM.4 Anxiety symptoms appear to be 
higher among patients with type 2 
diabetes mellitus (T2DM) and women 
compared with those with type 1 diabetes 
mellitus (T1DM) and men.4,9 A recent 
meta-analysis (2013) found that DM is 
associated with an increased likelihood of 
having anxiety disorders and elevated 
anxiety symptoms. However, from the 
cross-sectional data used in the review, 
one cannot deduce the strength and/ or 
direction of association between DM and 
anxiety.10 There are numerous other risks 
factors reported in previous studies which 
are associated with new-onset diabetes. 
As expected, body mass index (BMI), 
lifestyle factors (particularly physical 
inactivity), and family history of diabetes 
(two or more close relatives) significantly 
associated with new-onset diabetes, 
where some studies indicating that BMI 
and physical activity could be the major 
mediating factors.11-12 
 
A limited number of longitudinal studies 
from developed countries have examined 
the association between anxiety and the 
risk of DM, but reported inconsistent 
results.3,13,14 It is evident from the 
literature that there has been less focus 
on anxiety compared to depression in 
patients with DM,10 although Engum 
(2007) attempted to examine the direction 
of causality and association, and 
concluded that anxiety was a significant 
independent risk factor for the onset of 
T2DM.3 This prospective study examines 
the relationship between anxiety 
symptoms and the risk of DM for a large 
cohort of women who were followed up at 
intervals over a 21-year period, and takes 
into account a range of potential 
confounding factors. We performed 
sensitivity analysis to assess the 
robustness of our analytical strategy. 
Finally we also examined the cross-
sectional association between anxiety 
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and DM, both measured at 21-year 
follow-up. 
 
Methods 
 
Participants 
We examined the association between 
transitions in anxiety symptoms and 
subsequent reporting of DM at 21 years 
follow-up in a sample of women who were 
part of an Australian pregnancy and birth 
cohort. The Mater-University of 
Queensland Study of Pregnancy (MUSP) 
is a multidisciplinary study that represents 
Australia’s largest longitudinal study of 
women’s reproductive life-course from 
pre-birth for 21 years postpartum. The 
longitudinal study began in 1978-79 with 
a number of pilot studies and full data 
collection commenced in January, 1981. 
The recruited women gave birth at the 
Mater Misericordiae Mothers’ Hospital 
which is one of two major obstetric units 
in Brisbane, Australia.15,16  
 
The study prospectively collected data 
across the reproductive life course of a 
large group of 6753 women. To be 
enrolled in cohort women had to deliver at 
least one live baby who neither died nor 
was adopted before leaving hospital and 
have complete data from initial (first clinic 
visit (FCV) at approximately 18 weeks’ 
gestation) and birth interview. These 
women were re-interviewed 3 to 5 days 
after delivery and data from their medical 
records were collected. Additional 
interviews were conducted when the 
children were 6 months, 5 years, 14 
years, and 21 years of age.  
 
The outcome in our analyses was 
information regarding self-reported DM in 
the 21 years after the index pregnancy; 
data were collected using a self-
administered questionnaire. Women were 
asked “Have you EVER been told by a 
doctor that you have DM (high blood 
sugars)?” Because women with DM at the 
time of the index pregnancy (pre-existing 
or gestational) were excluded from this 
study, a positive response to this question 
indicated that the woman had incident 
DM some time during the 21 years after 
the index pregnancy.17 Women with DM 
before the index pregnancy and 
gestational DM or T1DM, that was 
diagnosed during the index pregnancy (n 
= 46), were excluded from analysis.  
 
Measurement of exposure – anxiety 
symptoms  
The exposure was transitions in anxiety 
symptoms measured at 5-years and 14-
years after delivery; symptoms were 
assessed using the seven-item anxiety 
subscale from the Delusion Symptoms 
States Inventory: State of Anxiety and 
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Depression (DSSI/sAD).18 This measure 
had been developed to detect signs and 
symptoms of psychopathology that limit a 
person’s capacity to function and 
maintain relationships.18 The measure 
has been validated recently for use 
among people with and without DM.19 
The instrument correlates well, and 
shares items with other measures of 
depression and anxiety, such as the 
Edinburgh Postnatal Depression Scale 
(EPDS), and the Hospital Anxiety and 
Depression Scale.20 In the present study, 
the seven items, each with 5-point 
response options (never, rarely, some of 
the time, most of the time, or all the time), 
were summed (score range: 10 (all the 
time) – 50 (never)); the lower the score, 
the more anxious the person. Anxiety 
symptoms were also categorized into 
number of symptoms (≥ 4 symptoms) and 
quartile based groups.18  
 
Defining transitions in anxiety 
symptoms 
We estimated the observed proportion of 
women who reported a transition in 
anxiety symptoms between subsequent 
phases of the study. In the present study, 
DM was the dependent variable at 21-
years, and transitions in anxiety 
symptoms (i.e. transitions) from the 
previous two phases (at 5 and 14-year 
follow-ups), was the main predictor. 
Potential confounding factors for each of 
the transition models (transitions in 
anxiety symptoms) were included from 
the most recent or relevant previous 
phase. Since MUSP is a prospective 
study with unequal time intervals between 
data collection phases and most of the 
variables are time dependent,21 the 
number of women making transitions 
(that is, experiencing transitions in anxiety 
symptoms) for exposure at each of the 
unequal time intervals was estimated in 
the following manner:21 possible 
transitions that could occur during the 
period from the 5-year follow-up (FU) 
(origin state) to the 14-year FU 
(destination state) were classified into 
four categories, based on a cut-off of 4 or 
more symptoms: (1) no anxiety, (2) 
women reporting anxiety at 5-year but not 
at 14-year FU (positive transition or 
positive history of symptoms), (3) women 
reporting anxiety at 14-year FU but not at 
5-year FU (negative transition or current 
symptoms), and (4) women with 
persistent anxiety symptoms. The 
continuous anxiety scale (10 – 50) was 
also categorised based on quartile 
ranges: (1) no anxiety symptoms, (2) mild 
anxiety symptoms, (3) moderate anxiety 
symptoms, and (4) severe anxiety 
symptoms. 
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Two phases, post-delivery (3-5 days after 
delivery) and 6-month follow-up were not 
included, as pregnancy or intervals after 
delivery may be sensitive periods with 
regards to anxiety symptoms, and could 
confound the associations under 
investigation. However these two phases 
were used to assess the robustness of 
our analytical strategy: the sensitivity 
analysis was performed using the same 
possible transitions during 3 to 5 days FU 
(origin state) to the 6-month FU 
(destination state). They were classified 
into the same four categories used in the 
main analysis.  
 
Adjustment for potential confounding 
Directed Acyclic Graphs (DAGs) have 
been used in epidemiological studies to 
represent causal relations among 
variables, and they have been used 
extensively to determine which variables 
are necessary to condition on for 
controlling for confounders.22,23 In this 
study, we used a six-step process using 
an unbiased estimates approach to adjust 
for potential confounding.24 Using the 
DAGs framework, we determined six 
variables necessary to condition on for 
controlling for confounders: maternal age, 
changes to marital status to 5-year FU, 
changes to family annual incomes to 5-
year FU, maternal education, pre-
pregnancy Body Mass Index (BMI), and 
depression symptoms. Maternal age at 
first clinic visit was included. At each 
phase, each woman was asked her 
current marital status, that is, whether she 
was married, living together, separated/ 
divorced, or single; a change in marital 
status to 5-years post-delivery was 
included. This measure was categorised 
into nil partner change, one change, or 
two plus changes. Follow-up stage of the 
study, namely 5, 14 and 21 year, women 
were asked to select, from a 7-point 
scale, the (Australian) dollar range that 
best represented their total annual family 
income. In the current study, changes in 
family annual income to 5-years FU were 
categorised into: consistent poverty, mid 
income, and high income. Maternal 
education at the first antenatal visit was 
recorded as one of three categories: did 
not complete secondary schooling, 
completed secondary schooling and 
completed further or higher education.  
 
Participants’ height and weight at first 
antenatal visit and an estimate of pre-
pregnancy weight were obtained at the 
start of the study, either from obstetric 
records or questionnaires. In the present 
study, maternal body mass index (BMI) 
was derived from self-report of pre-
pregnancy weight and height at the first 
visit and was categorized into normal, 
10% low, and 10% high. Depression 
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symptoms at 5-year FU were measured 
by DSSI-Depression scale. 
 
Statistical analysis 
The data were analysed using the 
Statistical Package for Social Sciences 
(SPSS)® version 20 and STATA IC® 
version 12, with a significance level of ≤ 
0.05. Descriptive statistics were used to 
calculate percentages, frequencies, 
means and standard deviations. The 
Student t test and chi-squared tests were 
used to compare the characteristics of 
those women who did and did not provide 
information about DM at 21-year 
evaluation, or who were lost to follow-up 
and, therefore, excluded from the 
analysis. Multiple logistic regression 
models were used to assess the 
relationship between anxiety symptoms 
and subsequent reporting of DM, after 
adjustment for potential confounding 
variables and for those who lost to follow-
up. The cross-sectional association 
between anxiety symptoms and DM was 
also examined using 21-year follow-up 
data. We present a series of models that 
were adjusted for these potential 
confounders so that readers can see the 
effect of factors that we considered might 
confound this association.  
 
 
 
 
Investigation of missing data 
The distribution of study covariates for 
women who did and did not provide DM 
data at 21-year follow-up is shown in 
Table 1. Of the 6753 women who were 
eligible for this study, 3663 women 
(54.2%) completed the 21-year follow-up 
questionnaire and provided information 
regarding the diagnosis of DM. Multiple 
imputations were carried out to adjust for 
missing data.25 The same subset (3663) 
was used to impute for the missing values 
on study covariates. An imputation model 
was devised using the recommendations 
of Van Buuren et al.26 The model 
included all of the predictor variables 
excluding the outcome i.e. presence or 
absence of DM. The data on covariates 
were assumed to be ‘missing at 
random’.27 
 
We imputed the missing data based on 
the percentage of missing data on 
covariates.28 The proportion of missing 
data ranged from 0% to 20% for all 
variables. For the main predictor, ‘anxiety 
symptoms’, 17% of data were missing. 
For the purpose of this paper, therefore, 
data were imputed for all covariates 
except age, where the amount of missing 
data was zero. For each of the completed 
datasets, a logistic regression was 
performed (inclusion of all predictor 
variables without outcome), from which 
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the estimate of interest and its estimated 
variance was obtained. The results from 
the logistic regression modelling of the 
different datasets were combined using 
the rules given by Rubin to produce a 
multiple imputation estimate.29 This was 
performed in Stata IC version 12.0 (Stata 
Corporation, College Station, TX, USA). 
The estimate obtained for multiple 
imputations is simply the average of the 
different estimates. The relationship 
between ‘missingness’ (yes vs no) and 
the predictor variables was assessed 
using logistic regression. The results 
using both multiple imputations and 
complete case analysis are presented in 
this paper. 
 
Our analyses show that those excluded 
because of missing data or loss to follow-
up were more likely to be young when 
they gave birth (aged between 13 and 19 
years), to have one change in marital 
status, to have been consistently poor, to 
have not completed secondary schooling, 
to have a low BMI, and to be depressed. 
Those who completed the questionnaire 
regarding self-reported diabetes mellitus 
at 21 years post delivery were slightly 
older, more likely to be young when they 
gave birth (aged between 13 and 19 
years), more likely to have changes in 
marital status, more likely to belong to a 
high income household, better educated, 
and less likely to be overweight or obese 
compared to those who completed the 
questionnaire. 
 
Results 
A total of 301 (8.22%) of the participating 
women reported DM at 21-year FU. The 
proportion of women reporting transitions 
in mental health status (anxiety 
symptoms) between consecutive phases 
(5-year and 14-year FU) is presented in 
Table 2. Almost half of the women who 
reported anxiety symptoms continued to 
report these at the subsequent FU phase. 
About 1 in 10 women who had not 
reported anxiety symptoms at the 5-year 
FU did so at the subsequent 14-year FU.  
 
About 15% of women with persistent 
anxiety symptoms reported DM at 21-
year FU. However, transitions can only 
inform us of the proportion of women 
changing from one state to another, 
whereas multivariate analysis can provide 
further insight into the independent 
developmental processes associated with 
these transitions.21 Results from 
multivariate analyses for women with 
complete case and imputed data on all 
variables are presented in Table 3, using 
four models. In the unadjusted Model 1, 
women with persistent symptoms (anxiety 
symptoms at both 5-year and 14-year 
follow-ups) had a 2.29-fold greater risk of 
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DM (95% CI: 1.54 – 3.40). After multiple 
imputations, the effect size (OR) was 
reduced by 0.16, but with increased 
precision i.e. narrow confidence interval 
(OR 2.13, 95% CI: 1.46 – 3.13). The OR 
of positive transition (women with positive 
history of symptoms of anxiety) is smaller 
compared to a negative transition (no 
anxiety to anxiety). However with imputed 
data, the effect size of positive history is 
comparable to a negative transition 
(difference = 0.01). 
 
In Model 2a, experiencing anxiety 
symptoms was significantly associated 
with DM at the 21-year FU, for either 
negative transition (1.61, 95% CI: 1.04 – 
2.49) or persistent anxiety (2.18, 95% CI: 
1.39 – 3.43). However, with imputed data, 
the negative transition became 
insignificant, while persistent anxiety 
remained a significant predictor of DM 
(Table 3). In the fully adjusted model 
(model 4c), women with negative 
transition had a 1.83-fold risk (95% CI: 
1.17 – 2.87), while those with persistent 
symptoms had a 2.30-fold risk (95% CI: 
1.38 – 3.84) of subsequent DM at the 21 
year FU. Again with imputed data, 
persistent anxiety remained a significant 
predictor of DM with increased precision 
(1.85, 95% CI: 1.18 – 2.90). 
 
In the case of quartile-based categories 
(derived from a continuous anxiety scale), 
only severe anxiety symptoms were a 
strong predictor of subsequent DM at 21-
year FU (Table 4). The associations 
remained consistent and robust after 
adjustment for potential confounders. In 
the fully adjusted model, women 
experiencing severe anxiety symptoms 
had a 2.23-fold (95% CI: 1.45 – 3.42) 
greater risk of subsequent DM, while mild 
to moderate forms of anxiety did not 
increase the odds of subsequent DM in 
this study. We noticed wider confidence 
intervals and higher sample variability for 
complete case analysis compared to data 
generated by multiple imputations. 
Sensitivity analysis using the same 
analytical strategy but with depression 
symptoms measured at different time 
points resulted in similar findings where, 
women with persistent depression 
symptoms (2.27, 95% CI: 1.29 – 4.01) 
were significantly associated with the risk 
of DM. 
 
In cross-sectional analysis, the 
unadjusted and age-adjusted models 
produced significant associations 
between anxiety symptoms and DM (both 
measured at 21-yr follow-up study). In the 
multivariate model, although the 
association became insignificant, an 
increasing trend is evident. 
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Discussion 
This study examined the associations 
between transitions in anxiety symptoms 
and the risk of DM in a sample of women 
who provided information about DM at 21 
year FU, and found that almost half of the 
women who reported anxiety symptoms 5 
years after giving birth continued to report 
these at the subsequent 14-year FU 
phase. About 1 in 10 women who had not 
reported anxiety symptoms at 5-year FU 
did so at the subsequent 14-year FU. The 
odds of developing DM were higher 
among those who had persistent 
symptoms of anxiety at both 5-year FU 
and 14-year FU. This finding is in 
agreement with a previous study, where 
individuals reporting symptoms of anxiety 
at baseline had increased risk of onset of 
T2DM.3  
A possible biological explanation for the 
increased risk of DM among women who 
have symptoms of anxiety may be 
associated with chronic or recurrent 
stress resulting in intermittent or 
sustained increased levels of cortisol and 
adrenaline in vulnerable individuals.30 
Numerous studies have suggested that 
anxiety are associated with an up-
regulation or dysregulation of the 
Hypothalamo-Pituitary-Adrenal (HPA) 
axis resulting in elevated cortisol levels, 
which is also seen in depression, and that 
can inhibit insulin function in a variety of 
ways.31-34 Obesity has been shown to be 
associated with anxiety disorders in 
various general population studies.35 The 
HPA dysregulation is assumed to not only 
contribute to appetite dys-regulation,36-37 
or increase appetite,38 and subsequent 
weight gain in stressed individuals, but 
stimulate a craving for high glycaemic 
and high lipid foods.36,39-41 Kivimaki et al 
(2009) in a longitudinal study showed that 
people who developed anxiety or 
depression at one stage in their life were 
more likely to become obese than those 
in good mental health.42 
Anxiety disorders are not only associated 
with DM but tend to be co-morbid with 
depression.43 It is possible that the 
comorbidity between depression and 
anxiety is the most important factor. Since 
comorbid anxiety and depression is 
common; an estimated 85% of patients 
with depression have symptoms of 
anxiety,44-46 the possibility of comorbid 
anxiety and depression symptoms 
increasing the risk of developing DM 
should not be ruled out. However, some 
studies suggest that anxiety and 
depression have different risk 
mechanisms, anxiety is characterised by 
hypocortisolaemia and up-regulation of 
glucocorticoid receptors; whereas, 
depression is generally characterised by 
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hypercortisolaemia and decreased 
numbers of glucocorticoid receptors.47,48 
In the present study, anxiety and 
depression as possible risk factors for DM 
could not be investigated separately.  
There are a number of methodology-
related limitations associated with this 
study that may affect the generalizability 
of our findings. In this study, information 
was derived from either medical records 
or self-reports and like other large 
population-based studies, information 
about exposure, outcome, and potential 
confounders was based on self-report 
and questionnaires, possibly leading to 
information bias and misclassification of 
mental health status. It seems unlikely; 
however, that this is a major bias, as 
previous research has reported relatively 
good agreement between self-report and 
in-person interviews with regard to 
chronic somatic diseases such as DM.49-
51 A positive response for the outcome at 
the 21-year follow-up represents "incident 
DM" but it is possible for a woman to 
develop DM in between the 5 and 14-year 
follow-ups. Similarly, it is also possible 
that women can develop gestational DM 
in a subsequent pregnancy and were 
included in the group of women who 
reported DM in the 21 years after the 
index pregnancy.  
 
In conclusion, only persistent anxiety 
symptoms are associated with a modest 
increase in the risk of DM. However, the 
evidence is not strong enough to support 
a direct effect of anxiety in causing DM. 
Despite some limitations, this study 
highlights that women who are anxious in 
their early ages (20s-30s) possibly have 
an increased risk of DM later in life, 
whether or not the anxiety persists. The 
present study provides insight into the 
long-term association between events of 
anxiety and the risk of DM across the 
reproductive life of women and provides 
an interesting finding that warrants further 
study.  
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Table 1: Comparison between lost to follow-up and information collected for diabetes at 21-year follow-up by study variables 
Factors Number Diabetes at 21-year Adjusted Odds Ratio 
(OR: 95% CI)b 
 
 Women who provided 
diabetes data at 21 yr 
(N=3663) 
Women who were 
missing at 21 yr  
(N=3044) 
Mothers’ age at entry (yrs) 6753 25.49 ± 5.02 24.43 ± 5.27 0.98 (0.96 – 1.00) 
Transitions in anxiety     
Persistently not anxious 2994 2292 (76.5) 702 (23.5) 1.0 
‘No anxiety’ to anxiety 421 303 (72.0) 118 (28.0) 1.36 (1.01 – 1.85)* 
Anxiety to ‘no anxiety’ 333 246 (73.9) 87 (26.1) 1.02 (0.72 – 1.45) 
Persistent anxiety symptoms 314 230 (73.2) 84 (26.7) 0.95 (0.66 – 1.37) 
Changes marital status to 5-yr     
Nil partner change 3859 2695 (69.8) 1164 (30.2) 1.00 
One change 480 292 (60.8) 188 (39.2) 1.09 (0.78 – 1.54) 
Two plus 389 240 (61.7) 149 (38.3) 1.17 (0.83 – 1.66) 
Changes in annual income     
Consistent poverty 225 131 (58.2) 94 (41.8) 1.00 
Mid-income 3424 2385 (69.7) 1039 (30.3) 0.78 (0.51 – 1.20) 
High-income 476 369 (77.5) 107 (22.5) 0.83 (0.50 – 1.38) 
Maternal education     
Incomplete secondary education 1215 572 (47.1) 643 (52.9) 1.00 
Complete secondary education 4294 2354 (54.8) 1940 (45.2) 0.92 (0.71 – 1.19) 
Post secondary education 1190 734 (61.7) 456 (38.3) 1.06 (0.77 – 1.45) 
Pre-pregnancy BMI     
Normal 5004 2843 (56.8) 2161 (43.2) 1.00 
Low 10% 629 303 (48.2) 326 (51.8) 1.08 (0.79 – 1.48) 
High 10% 599 322 (53.8) 277 (46.2) 0.96 (0.70 – 1.32) 
Depression at 5-year     
No 4501 3092 (68.7) 1409 (31.3) 1.00 
Yes 323 192 (59.4) 131 (40.6) 0.97 (0.65 – 1.44) 
a =Adjusted for all other variables in table; BMI = Body Mass Index 
b Predictive variable equals ‘diabetes at 21‐year’ not missing (coded as ‘0’) vs missing (coded as ‘1’). 
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Table 2: Proportion (%) of women who experienced transition in anxiety symptoms between phases  
Symptom reported at each phase  
Symptom at subsequent phase (%) 
Post-delivery  6-month FU  
 No anxiety Anxiety n 
No anxiety 92.3 7.7 5499 
Anxiety  67.0 33.0 724 
6-month FU  5-year FU  
 No anxiety Anxiety n 
No anxiety 87.0 13.0 4219 
Anxiety  52.9 47.1 440 
5-year FU  14-year FU  
 No anxiety Anxiety n 
No anxiety 87.6 12.4 3415 
Anxiety  51.5 48.5 647 
14-year FU  21-year FU  
 No anxiety Anxiety n 
No anxiety 84.0 16.0 2782 
Anxiety  46.8 53.2 600 
FU = Follow-up 
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Table 3: Unadjusted and adjusted odds ratios (95% CI) of reporting diabetes at 21-year follow-up, by transitions in 
anxiety symptoms (longitudinal analysis) 
Items Diabetes at 21-year FU 
No Yes 
(complete case 
analysis) 
No Yes 
(imputed data) 
Persistently not anxious (Referent) 1.00 1.00 1.00 1.00 
Model 1 (unadjusted)  n = 3051  n = 3663 
No anxiety to anxiety 1.00 1.34 (0.88 – 2.05) 1.00 1.14 (0.80 – 1.61) 
Anxiety to no anxiety 1.00 1.22 (0.76 – 1.96)  1.00 1.15 (0.73 – 1.80) 
Persistent anxiety symptoms 1.00 2.29 (1.54 – 3.40)* 1.00 2.13 (1.46 – 3.13)* 
 Model 2a (adjusted)  n = 2462  n = 3663 
No anxiety to anxiety 1.00 1.61 (1.04 – 2.49)* 1.00 1.11 (0.76 – 1.58) 
Anxiety to no anxiety 1.00 1.20 (0.70 – 2.04) 1.00 1.15 (0.73 – 1.81) 
Persistent anxiety symptoms 1.00 2.18 (1.39 – 3.43)* 1.00 2.09 (1.41 – 3.08)* 
 Model 3b (adjusted)  n = 2431  n = 3663 
No anxiety to anxiety 1.00 1.84 (1.18 – 2.88)* 1.00 1.18 (0.83 – 1.69) 
Anxiety to no anxiety 1.00 1.32 (0.77 – 2.27) 1.00 1.17 (0.74 – 1.85) 
Persistent anxiety symptoms 1.00 2.46 (1.54 – 3.92)* 1.00 2.15 (1.45 – 3.20)* 
 Model 4c (adjusted)  n = 2431  n = 3663 
No anxiety to anxiety 1.00 1.83 (1.17 – 2.87)* 1.00 1.18 (0.83 – 1.68) 
Anxiety to no anxiety 1.00 1.26 (0.71 – 2.23) 1.00 1.05 (0.65 – 1.71) 
Persistent anxiety symptoms 1.00 2.31 (1.39 – 3.86)* 1.00 1.85 (1.18 – 2.90)* 
a =adjusted for maternal age, marital status to 5‐year FU, changes to family annual incomes to 5‐year FU, maternal education. 
b = adjusted for 2a plus pre‐pregnancy body mass index. 
c = further adjusted for depression symptoms 5‐year FU. 
* = p<0.05 
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Table 4: Unadjusted and adjusted odds ratios (95% CI) of reporting diabetes at 21-year follow-up, by quartile-based 
categories of anxiety symptoms  
Items Diabetes at 21-year 
No 
(Referent) 
Yes 
(complete case 
analysis) 
No 
(Referent) 
Yes  
(imputed data) 
Quartile-based categories   
No anxiety symptoms (Referent) 1.00  1.00 1.00 
Mild symptoms     
Model 1 (unadjusted) 1.00 0.73 (0.46 – 1.18) 1.00 0.92 (0.63 – 1.34) 
Model 2a (adjusted) 1.00 0.69 (0.40 – 1.19) 1.00 0.92 (0.63 – 1.34) 
Model 3b (adjusted) 1.00 0.75 (0.42 – 1.32) 1.00 0.90 (0.61 – 1.31) 
Model 4c (adjusted) 1.00 0.74 (0.42 – 1.32) 1.00 0.90 (0.61 – 1.31) 
Moderate symptoms     
Model 1 (unadjusted) 1.00 0.99 (0.69 – 1.42) 1.00 1.09 (0.78 – 1.53) 
Model 2a (adjusted) 1.00 1.12 (0.75 – 1.66) 1.00 1.09 (0.77 – 1.53) 
Model 3b (adjusted) 1.00 1.19 (0.79 – 1.81) 1.00 1.06 (0.75 – 1.50) 
Model 4c (adjusted) 1.00 1.20 (0.79 – 1.81) 1.00 1.06 (0.75 – 1.49) 
Severe symptoms     
Model 1 (unadjusted) 1.00 1.76 (1.24 – 2.50)* 1.00 1.82 (1.29 – 2.57)* 
Model 2a (adjusted) 1.00 1.88 (1.27 – 2.80)* 1.00 1.81 (1.27 – 2.58)* 
Model 3b (adjusted) 1.00 2.18 (1.44 – 3.31)* 1.00 1.83 (1.28 – 2.62)* 
Model 4c (adjusted) 1.00 2.23 (1.45 – 3.42)* 1.00 1.70 (1.17 – 2.47)* 
a =adjusted for maternal age, marital status to 5‐year FU, changes to family annual incomes to 5‐year FU, maternal education. 
b = adjusted for 2a plus pre‐pregnancy body mass index. 
c = further adjusted for depression symptoms 5‐year FU. 
* = p<0.05; only imputed data was used. 
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CHAPTER 8 
Diabetes mellitus and the risk of depressive and anxiety disorders in 
Australian women: a longitudinal study 
 
The sixth objective of thesis was to investigate whether the presence of diabetes mellitus 
was independently associated with the risk of depressive and anxiety disorders; this was, 
measured at 27-year post index pregnancy in Australian women. Previous reports have 
several deficiencies, such as cross-sectional study design and most of the studies focused 
on symptoms measured by self-reported scales instead of DSM-based disorders. 
 
The research described in this chapter investigated diabetes as risk factor for depressive 
and anxiety disorders. The formal citation for the accepted work: 
 
1. Hasan, S.S., Clavarino, A.M., Dingle, K., Mamun, A.A., Kairuz, T. (2015). Diabetes 
mellitus and the risk of depressive and anxiety disorders in Australian women: a 
longitudinal study. J Womens Health, In Press. 
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Diabetes mellitus and the risk of depressive and anxiety disorders in Australian 
women: a longitudinal study 
 
Abstract 
Background: Longitudinal studies 
examining the risk of depressive and 
anxiety disorders associated with 
diabetes are limited. This study examined 
the association between diabetes and the 
risk of depressive and anxiety disorders 
in Australian women using longitudinal 
data. 
 
Methods: Data were from a sample of 
women who were part of an Australian 
pregnancy and birth cohort study. Data 
comprised self-reported diabetes mellitus 
and the subsequent reporting of 
depressive and anxiety disorders. Mood 
disorders were assessed according to the 
Diagnostic and Statistical Manual of 
Mental Disorders (DSM)-IV obtained from 
participants using Composite 
International Diagnostic Interview (CIDI)-
Auto (WHO WMH-CIDI CAPI: Version: 
21.1.3). Multiple regression models with 
adjustment for important covariates were 
used. 
 
Results: Women with diabetes had a 
higher lifetime prevalence of any 
depressive and/or anxiety disorder than 
women without diabetes. About 3 in 10 
women with diabetes experienced a 
lifetime event of any depressive disorder, 
while 1 in 2 women with diabetes 
experienced a lifetime event of any 
anxiety disorder. In prospective analyses, 
diabetes was only significantly associated 
with a 30-day episode of any anxiety 
disorder (1.53, 95% CI: 1.09–2.15). In the 
case of lifetime disorders, diabetes was 
significantly associated with any 
depressive disorder (OR 1.37, 95% CI: 
1.03–1.84), major depressive disorder 
(OR 1.36, 95% CI: 1.01–1.85), and 
posttraumatic stress disorder (OR 1.42, 
95% CI: 1.01–2.02). 
 
Conclusions: The findings suggest that 
the presence of diabetes is a significant 
risk factor for women experiencing 
current anxiety disorders. However, in the 
case of depression, the association with 
diabetes only held for women who had 
experienced past episodes, there was no 
association with current depression. This 
suggests that the evidence is not strong 
enough to support a direct effect of 
diabetes as a cause of mood disorders. 
 
Keywords: Prospective, diabetes, 
depressive, anxiety, disorder, women 
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Introduction 
People with diabetes are at higher risk of 
developing depression and anxiety1,2 and 
women are almost 50 percent more likely 
to experience a mood disorder than men 
over their lifetime.3 Previous studies have 
demonstrated that a significant number of 
patients with diabetes have comorbid 
Major Depressive Disorder (MDD), 
Generalized Anxiety Disorder (GAD) or  
experience depressive and anxiety 
symptoms.1,4 Globally, MDD is projected 
to be one of the three leading contributors 
to the burden of disease by 2030.5 In 
industrialized countries, MDD occurs 
twice as frequently in women,6 and the 
prevalence is significantly higher in 
women than in men with diabetes.7 
  
Studies among people with Type 1 
(T1DM) and Type 2 (T2DM) diabetes 
mellitus have shown a similar increase in 
the risk for developing depressive and 
anxiety disorders or symptoms;1,8,9 In the 
majority of cases the initial onset of mood 
disorders seems to precede the diagnosis 
of T2DM while in T1DM, these disorders 
typically follow its diagnosis.10,11 Although 
both types of diabetes have dissimilar 
etiologies and progression of the disease, 
depression was found to increase the 
severity of complications, with a similar 
effect on both T1DM and T2DM.12 
 
Regarding anxiety disorders and 
diabetes, there is evidence of increased 
complications,13 poor glycemic control,14 
weight gain,15 and reduced quality of 
life;16 however, there has been little focus 
on the possibility of diabetes as a risk 
factor for the onset of anxiety disorders. 
Unlike studies of depression, only a few 
longitudinal studies have examined the 
association between diabetes and the risk 
of anxiety symptoms or disorders.10,17-21  
 
Most of the available studies have several 
methodology-related deficiencies, such 
as cross-sectional study design and use 
of self-reported scales instead of DSM-
based diagnoses.8,22 Despite the fact that 
literature suggests that anxiety is an 
important comorbid condition associated 
with diabetes, only one review published 
in 2013 examined the link between 
diabetes and the risk of developing 
anxiety.8 
 
The current study bridges the gaps in the 
literature about depression, anxiety and 
diabetes. The aim is to examine the 
prospective association between diabetes 
and the risk of developing depressive and 
anxiety disorders, diagnosed using DSM-
based criteria. The study focuses on 
women because both depression and 
anxiety are reported to be higher in 
women than men.1,3,23 
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Methods 
Participants 
We examined the association between 
diabetes mellitus, identified at 21-year 
follow-up, and the subsequent reporting 
of depressive and anxiety disorders, 
measured six years later at 27-year 
follow-up. The sample of women was part 
of an Australian pregnancy and birth 
cohort, the Mater-University of 
Queensland Study of Pregnancy (MUSP). 
This is a multidisciplinary study that 
represents Australia’s largest longitudinal 
study of women’s reproductive life-course 
from pre-birth for 27 years postpartum. 
The longitudinal study began in 1978-79 
with a number of pilot studies and full 
data collection commenced in January, 
1981. The recruited women gave birth at 
the Mater Misericordiae Mothers’ Hospital 
which is one of two major obstetric units 
in Brisbane, Australia.24,25 
 
The original study was approved by the 
Human Subjects Research Ethics 
Committees of the Mater Hospital and the 
University of Queensland. MUSP data 
were collected prospectively across the 
reproductive life course of a large group 
of women; originally 7861 women were 
enrolled in the study (8556 pregnancies), 
and 6753 of these women constitute the 
MUSP mothers’ cohort. To be enrolled in 
the cohort study, women had to deliver at 
least one live baby who neither died nor 
was adopted before leaving hospital, and 
had to have complete data from an initial 
interview (first clinic visit (FCV) at 
approximately 18 weeks’ gestation) and 
an interview conducted shortly after the 
birth. These women were re-interviewed 
3 to 5 days after delivery and data from 
their medical records were collected. 
Additional interviews were conducted 6 
months, 5 years, 14 years, 21 years, and 
27 years after the index pregnancy. Table 
1 presents the average age of the cohort 
at various stages, and the key outcome 
and exposure variables. 
 
The exposure in our analyses was 
information regarding self-reported 
diabetes mellitus in the 21 years after the 
index pregnancy; data were collected 
using a self-administered questionnaire. 
Women were asked “Have you EVER 
been told by a doctor that you have 
diabetes mellitus (high blood sugars)?”  
Only 32 women had reported diabetes at 
the time of the index pregnancy, and a 
positive response to this question 
indicated that the woman had developed 
incident diabetes mellitus at some stage 
during the 21-year after the index 
pregnancy.26 
 
A total of 3486 women provided 
information regarding diabetes mellitus at 
 106 
 
21-year follow-up. These women were 
followed prospectively, and 283 
responded positively to the question 
about diabetes, of whom 32 had 
previously been diagnosed with T1DM or 
gestational diabetes. The remaining 251 
did not specify the type of diabetes, 
although their age at the time the 
diabetes was reported, suggested they 
would be predominantly participants with 
T2DM. 
 
Measurement of depressive and anxiety 
disorders 
At the 27-year follow-up, data on 
disorders were extracted from a 
computerized structured interview of 
depressive and anxiety symptoms using 
the Composite International Diagnostic 
Interview (CIDI). This instrument 
assesses current and lifetime prevalence 
of mental health disorders according to 
the Diagnostic and Statistical Manual of 
Mental Disorders (DSM-IV) diagnoses. 
The CIDI was administered via the World 
Health Organization-World Mental Health-
Composite International Diagnostic 
Interview-CAPI Modularization Program 
(WHO WMH-CIDI CAPI: Version: 
21.1.3).27 Diagnostic concordance 
between the interviewer-administered 
CIDI and clinical checklists are 
satisfactory for depressive disorders, 
anxiety and phobic disorders.28 The CIDI 
has been reported to have acceptable 
validity when compared with clinicians’ 
diagnoses, with overall agreement similar 
to comparisons between the paper-and-
pencil CIDI and clinician diagnoses.28 
 
The CIDI summary outcomes (any 
depressive or anxiety disorder) were 
calculated as a positive diagnosis across 
a range of DSM IV diagnoses. The term 
‘any depressive or anxiety disorder’ 
indicates the presence of at least one 
disorder. For specific disorders, we 
focused on MDD, GAD, panic disorder, 
specific phobias (e.g. social phobia), and 
post-traumatic stress disorder (PTSD). 
Other disorders were excluded because 
we did not have enough numbers in each 
category to produce reliable results. We 
included three categories to define onset 
of (any) depressive or anxiety disorders:  
lifetime, 12-month and 30-day periods. 
Lifetime disorders were included to 
estimate the prevalence of lifetime 
disorders in women with and without 
diabetes and to examine the association 
between lifetime disorders and diabetes 
irrespective of the onset of each 
condition. 
 
Depressive and anxiety symptoms, 
measured using the Delusions-
Symptoms-States-Inventory /states of 
Anxiety and Depression (DSSI/sAD) at 
 107 
 
the 21-year follow-up, were used to 
identify cases of preexisting symptoms of 
anxiety and depression. Women who had 
symptoms of anxiety (n = 212), 
depression (n = 13), or comorbid 
depression and anxiety (n = 56) at the 21-
year follow-up were excluded from 
analysis, and thus a total of 6472 women 
were included in the analysis. 
 
Adjustment for covariates 
The covariates were identified on the 
basis of their association with outcomes 
and on the basis of a priori knowledge.8,22 
The seven most frequently used 
covariates were selected, to adjust the 
associations in question;8,22 these were: 
age, education level, marital status, 
income level, body mass index (BMI), 
alcohol consumption and smoking. The 
age of women at the 21-year follow-up 
was included as a continuous variable. 
Marital status, that is, whether she was 
married, living together, separated/ 
divorced, or single, was determined. 
Regarding income, women were asked to 
select, from a 7-point scale, the 
(Australian) dollar range that best 
represented their total annual family 
income. In the current study, family 
annual income at the 21-year follow-up 
was categorized into either low 
(<$10,440), or normal/ average income. 
Education was recorded as one of three 
categories: did not complete secondary 
schooling, completed secondary 
schooling and completed further or higher 
education. Smoking at the 21-year follow-
up was categorized based on the number 
of cigarettes smoked per day: none, 1–19 
cigarettes, and 20 or more cigarettes. 
Alcohol consumption at 21-year follow-up 
was categorized as abstainer, light 
drinker (less than half a drink per day), 
moderate drinker (half to less than one 
drink per day), or heavy drinker (average 
of 4 or more drinks per day). 
 
During the interview at the 21-year follow-
up, women were invited to attend a 
clinical assessment and to have height (n 
= 1907), and weight (n = 1907) 
measured. Height was measured using a 
portable stadiometer, which is accurate to 
1 mm. Weight was determined with the 
average of 2 measurements, with the 
woman lightly clothed; the scale was 
accurate to 0.2 kg. Callaway et al. 
reported a high correlation between 
measured height and weight and self-
reported height and weight at the 21-year 
follow-up (Pearson’s correlation 
coefficient, 0.98) and did not find 
evidence of any systematic bias.26 
 
Statistical analysis 
The data were analyzed using the 
Statistical Package for Social Sciences 
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(SPSS) ® version 20 and STATA IC® 
version 12, with a significance level of ≤ 
0.05. Descriptive statistics were used to 
present demographic data. The Student t 
test and chi-squared tests were used to 
compare the characteristics of those 
women who did and did not provide 
information about diabetes at the 21-year 
evaluation, or who were lost to follow-up 
and, therefore, excluded from the 
analysis. Multiple logistic regression 
analysis was then used to assess the 
association between characteristics, 
diabetes and mood (depressive and 
anxiety) disorders, with those lost to 
follow-up or with incomplete data.  
 
Logistic regression was used to assess 
the relationship between diabetes and 
mood disorders (depression and anxiety). 
Multiple logistic regression models were 
then used after adjustment for other 
covariates. We present a series of 
models that were adjusted for these 
covariates so that readers can see the 
effect of factors that might change the 
strength of this association. Multiple 
imputations were carried out to adjust for 
missing data.29 The results of the 
analyses of the complete datasets were 
combined using Rubin’s rules, and were 
performed using Stata IC version 12.0 
(Stata Corporation, College Station, TX, 
USA). The relationship between 
‘missingness’ (yes/no) and the predictor 
variables, was assessed using logistic 
regression. 
 
Investigation of missing data 
First we investigated the distribution of 
missingness of study covariates by 
outcomes (depressive and anxiety 
disorders). Of the 6472 women who were 
eligible for this study, 2791 women 
(43.1%) completed the 27-year follow-up 
questionnaire and provided information 
regarding the classification of DSM-based 
depressive and anxiety disorders. The 
overall dataset (6472) was used to impute 
for the missing values on study covariates 
(excluding our outcomes). For the 
purpose of this paper, therefore, data 
were imputed for all covariates and the 
main predictor, excluding the outcomes 
i.e. depressive and anxiety disorders. 
 
We imputed the missing data based on 
the percentage of missing data on 
covariates.30 An imputation model was 
devised using the recommendations of 
Van Buuren et al.31 The data on 
covariates were assumed to be ‘missing 
at random’ which means that the 
probability of the data being missing may 
depend on observed values.32 
 
Data were imputed from the posterior 
predictive distribution of the missing data 
 109 
 
given the observed data.30 For each of 
the completed datasets, a logistic 
regression was performed (inclusion of all 
predictor variables without outcome), 
from which the estimate of interest and its 
estimated variance were obtained. The 
results from the logistic regression 
modelling of the different datasets were 
combined using the rules proposed by 
Rubin; to produce a multiple imputation 
estimate.33 The estimate obtained for 
multiple imputations is simply the average 
of the different estimates.  
 
Results 
Prevalence of depressive disorders 
Almost a quarter of the women who 
participated in the 27-year follow-up 
(24.4%; 681/2791) had a lifetime 
prevalence of any depressive disorder 
whereas the prevalence of 12-month and 
30-day duration of any depressive 
disorder was much lower, at 8% (219) 
and 3% (87), respectively (Figure 1). A 
large proportion of women with diabetes 
(31%; 71/227) had a lifetime prevalence 
of any depressive disorder compared to 
24% (611/2564) for women without 
diabetes, although the difference was not 
significant. Similarly, there was a higher 
proportion of women with diabetes who 
reported a period of duration of any 
depressive disorder of 12-month (9.2% 
vs. 7.7%) and 30-day (4.4% vs. 3.0%), 
compared to women without diabetes 
(Table 2). 
 
Prevalence of anxiety disorders 
Regarding any anxiety disorder, almost 
half of the women who participated at the 
27-year follow-up (50.7%) had lifetime 
prevalence, whereas the proportion of 12-
month and 30-day duration of any anxiety 
disorder was much lower, at 24% and 
15% respectively (Figure 1). Just over 
half of the women with diabetes (54%) 
had a lifetime prevalence of any anxiety 
disorder compared to women without 
diabetes (50%). When comparing women 
with diabetes and those without, women 
with diabetes had a higher prevalence of 
12-month (27.9% vs. 23.8%) and 30-day 
(20.8% vs. 14.1%) duration of any anxiety 
disorder (Table 2). Regarding specific 
disorders, most women with diabetes 
were found to have MDD, GAD, panic 
disorder, specific phobias and PTSD, as 
shown in Table 3.  
 
Association between diabetes mellitus 
and lifetime disorders 
In the unadjusted model, with complete 
case analysis, the proportion of women 
with diabetes at the 21-year follow-up 
was significantly associated with any 
lifetime depressive disorders (1.45, 95% 
CI: 1.08–1.95) (Table 4). After multiple 
imputations, the effect size (OR) was 
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reduced, but had increased precision i.e. 
narrow confidence interval (OR 1.37, 95% 
CI: 1.03–1.83). In the multivariate model, 
after controlling the effect on any lifetime 
depressive disorder for study covariates, 
diabetes remained significantly 
associated with a lifetime depressive 
disorder (OR 1.37, 95% CI: 1.03–1.84). In 
the case of MDD, diabetes was 
significantly associated only with lifetime 
MDD (OR 1.36, 95% CI: 1.01–1.85) 
(Table 5). In the case of specific anxiety 
disorders, diabetes was significantly 
associated only with lifetime PTSD (OR 
1.42, 95% CI: 1.01–2.02) (Table 6). 
Diabetes mellitus and the risk of current 
disorders 
In case of depressive disorders, we did 
not find diabetes increasing the risk of 12-
month and 30-day period of duration of 
any disorder in both, univariate and 
multivariate analyses. Similarly, in both 
univariate and multivariate analyses, we 
did not find that diabetes increased the 
risk of 12-month period of duration of any 
anxiety disorder (Table 4). 
However, in the adjusted model, with 
complete case analysis, women with 
diabetes had a 2.43-fold greater risk of 
any 30-day period of duration of any 
anxiety disorder (95% CI: 1.59–2.25). 
After multiple imputations, the effect size 
(OR) was reduced, but with increased 
precision i.e. a narrow confidence interval 
(OR 1.54, 95% CI: 1.10–2.15). In the 
multivariate model, diabetes remained a 
significant predictor of 30-day period of 
duration of any anxiety disorder (OR 1.53, 
95% CI: 1.09–2.15). 
Discussion 
This study examined the association 
between diabetes and the risk of 
depressive and anxiety disorders in 
Australian women. Based on our 
analyses, a chronic condition (diabetes) 
at a baseline of 21 years post index 
pregnancy was significantly associated 
with current anxiety only during follow-up 
6 years later, where ‘current anxiety’ was 
a 30-day period of duration of any anxiety 
disorder. Regarding depressive disorders, 
diabetes was significantly associated only 
with lifetime depressive disorders as the 
association only held for past, not current, 
depression. This finding is more 
consistent with depression leading to 
diabetes, and not with diabetes 
increasing the risk of depression. 
However, diabetes may be affected by 
other factors (for example, weight gain or 
obesity) which may increase the risk of 
developing depression and anxiety.34,35 
The findings should be used cautiously as 
establishing a causal sequence is not 
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straight forward in the case of depressive 
or anxiety disorders respectively. 
Generally mood disorders (anxiety and 
depression) begin at a young age, well 
before the onset of diabetes, particularly 
T2DM.36 The second issue in establishing 
a causal sequence is that anxiety and 
depression are chronic or recurrent in 
nature,1,23 so having a recent disorder 
tends to mean that the respondent has a 
history of such disorder. 
 
Unlike most previous studies,8,22 this 
study used standard DSM-based criteria 
of mood disorders to capture lifetime, 12-
month and 30-day period of duration of 
depressive and anxiety disorders to 
examine their association with diabetes. 
In this study, we found that a higher 
proportion of women with diabetes had 
higher lifetime, 12-month and 30-day 
period of duration of any depressive and 
anxiety disorder compared to women 
without diabetes. Women with diabetes 
had a higher proportion of MDD, GAD, 
panic disorder, specific phobias and 
PTSD compared to women without 
diabetes.  
 
Our finding that diabetes was significantly 
associated with lifetime depressive 
disorder and particularly lifetime MDD, 
are in concordance with previous 
studies.1,10 This association with lifetime 
MDD may be due to the fact that in most 
instances the development of MDD 
precedes the diagnosis of diabetes by 
many years.10 MDD, the most serious 
form of (unipolar) depressive disorders, is 
the most prevalent of the DSM mood 
disorders, among adults aged 18 years 
old and older,37 with a lifetime prevalence 
of 16.6%.38 It has been suggested that 
anxiety disorders are far more common in 
persons with MDD than vice versa, and 
pure MDD (MDD without a history of 
anxiety) is relatively rare.39,40 The main 
anxiety disorders associated with chronic 
conditions are GAD and panic 
disorder.41,42 However, unlike the case of 
MDD, we did not find significant 
associations between these disorders 
(GAD and panic) and diabetes. 
 
Various explanations for an association 
between diabetes and mood disorders, 
particularly depression and anxiety, have 
been documented.10,13,14,57 Most studies 
reported alterations in the activity of the 
Hypothalamus-Pituitary-Adrenal (HPA) 
axis, such as increases in cortisol 
production, as an underlying mechanism 
of increased mental disorders in people 
with diabetes.8,10,22,43-45 Individuals 
experiencing diabetes-related 
complications and disability may 
experience depression and/ or anxiety as 
a consequence of the disability. 8,10,22,43,46 
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Perceived disability and awareness of 
having a chronic illness may impose 
higher levels of psychological burden on 
people with diabetes, particularly in 
individuals with low levels of social 
support.46 
 
A possible biological explanation for the 
increased risk of mood disorders 
(depression and anxiety) among people 
with diabetes could be obesity; it is 
strongly associated with diabetes,47 and 
is also associated with depressive and 
anxiety disorders.48,49 Roberts et al., 
using prospective data on older people, 
found evidence that obesity at baseline 
was associated with being depressed at 
follow-up 5 years later.49 This finding is 
not limited to older people although 
females who have been obese since 
adolescence are also at greater risk of 
developing MDD and anxiety disorder 
compared to obese males.50 In our 
sample, the only anxiety disorder 
significantly associated with diabetes was 
lifetime PTSD. Although there is strong 
evidence that PTSD increases the risk of 
diabetes.51,52 The reverse is not clear 
despite the finding by Scott et al. that 
PTSD was more strongly associated with 
obesity compared with other anxiety 
subtypes or disorders.53 
 
In our sample of women, these disorders 
may be due to alterations in hormone 
levels because they seemed to increase 
at times of changing hormone levels, 
such as menopause.54 There is some 
evidence suggesting that managing or 
replacing female hormones during 
menopause may improve depression,54,55 
as well as glycemic control.56 
Management of depression and anxiety in 
patients with diabetes may be beneficial 
for various reasons. Appropriate 
recommendations may improve self-care 
behaviour and compliance with lifestyle 
modifications (dietary and physical) and 
adherence to prescribed medications.57,58 
This is important because mood disorders 
are associated with worse outcomes for 
patients with diabetes.59,60 These 
disorders may have high recurrence rate 
and remain for longer duration if not 
properly managed.10,61 
 
Limitations of the study 
The strengths of this study include a 
large, population-based, mothers’ cohort 
and the use of standard DSM-based 
classification of depressive and anxiety 
disorders. There are some methodology-
related limitations that may affect the 
generalizability of our findings, such as 
the restriction to women who had at least 
one child. Therefore the results cannot be 
generalized to other women, and it is 
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possible that the associations identified 
may differ for men. We had limited data 
on some specific depressive and anxiety 
disorders limiting our ability to explore 
their association with diabetes. Another 
limitation is the use of self-reported 
diabetes. It is possible that women may 
have incorrectly reported the presence or 
absence of diabetes. However, self-report 
diabetes is considered to be a reliable 
measure of the presence of diabetes,62 
although not as accurate as direct 
glucose measurement. In the United 
States and Taiwan, a self-report of 
diabetes yielded high agreement when 
compared with medical records data and 
physical examination and HbA1c.63,64 
Finally, for the analysis of different types 
of diabetes and risk of mood disorders, 
we had limited information about the 
specific type of diabetes. However, 
distinguishing between T1DM and T2DM 
in large epidemiological studies may not 
be possible since the exact timing of 
diabetes onset and diagnosis may not be 
fully reliable.65 
Implications 
Although the strength of diabetes as a 
cause or risk factor for developing 
depressive or anxiety disorders is not 
strong, the present prospective study 
suggests that diabetes may represent 
one of the causes; other major causes 
such as diabetic complications for 
diabetes predicting mood disorders may 
be required to create a sufficient cause. 
The findings of the present study suggest 
that healthcare professionals, as well as 
people at risk, should be aware that there 
is an evidence of diabetes as a 
component cause (albeit weak) of mood 
disorders. 
The findings of this study offer important 
implications for treatment and suggest 
that health care professionals managing 
people with diabetes should consider the 
possible link between diabetes and mood 
disorders. The treatment of one condition 
to limit the onset of another is critical in 
reducing the burden of disease. 
Conclusions 
Despite some limitations, this study 
suggests that the presence of diabetes 
significantly increases the risk of current 
anxiety disorders only. In case of lifetime 
disorders, diabetes was significantly 
associated with MDD and PTSD. This 
study provides evidence of mood 
disorders experienced by women with 
diabetes which warrants further study. 
Evidence is not strong enough to support 
a direct effect of diabetes in causing 
depressive and anxiety disorders; 
however, the study highlights the 
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importance of recognizing and managing 
depressive and anxiety disorders in terms 
of women’s psychological wellbeing and, 
thus, provides a basis for targeting those 
most at risk. 
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Table 1: Content of measurements 
Stage Average age in 
years 
Selected variables measured 
First clinic visit 
(1981-83) 
25.01 Socio-demographics (e.g. marital status), lifestyle factors (e.g. 
smoking), mental health (e.g. DSSI-depression, DSSI-anxiety), 
physical health (e.g. weight), clinical factors (e.g. pre-existing 
diabetes, hypertension) 
3-5 days after birth 
(1981-84) 
25.42 Socio-demographics (e.g. employment during pregnancy), lifestyle 
factors (e.g. smoking), mental health (e.g. DSSI-depression, 
DSSI-anxiety), physical health (e.g. problems during labor, 
obstetrical data) 
6 months follow-up 
(1981-1984) 
26.10 Socio-demographics (e.g. changes in marital status), lifestyle 
factors (e.g. breastfeeding duration), mental health (e.g. post-natal 
DSSI-depression, DSSI-anxiety), physical health (e.g. child 
development) 
5 years follow-up 
(1986-88) 
31.32 Socio-demographics (e.g. children in household), lifestyle factors 
(e.g. patterns of child care), mental health (e.g. DSSI-depression, 
DSSI-anxiety, life events, CBCI), physical health (e.g. health 
problem inventory) 
14 years follow-up 
(1995-97) 
39.72 Socio-demographics (e.g. family income), lifestyle factors (e.g. 
food frequency, physical activity), mental health (e.g. DSSI-
depression, DSSI-anxiety, CBCI, violence in marital status), 
physical health (e.g. health problem inventory) 
21 years follow-up 
(2001-04) 
46.56 Socio-demographics (e.g. number of children), lifestyle factors 
(e.g. food frequency, physical activity), mental health (e.g. DSSI-
depression, DSSI-anxiety, medical service use, CES-D), physical 
health (e.g. weight, waist and hip circumference) clinical factors 
(e.g. diabetes, BP, respiratory function). 
27 years follow-up 
(2008-2011) 
53.26 Socio-demographics (e.g. marital status), lifestyle factors (e.g. 
smoking), mental health (e.g. DSSI-depression, DSSI-anxiety, 
CIDI), physical health (e.g. weight, waist and hip circumference) 
clinical factors (e.g. diabetes, BP). 
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Table 2: Proportion of any depressive and anxiety disorder, by main predictor, diabetes 
mellitus (n = 2791) 
DSM disorders No Diabetes 
n (%) 
Diabetes 
n (%) 
Total 
n 
p-value 
Any Depressive disorder  
No lifetime depressive disorder 1953 (69.97) 156 (5.59) 2109 0.012 
Lifetime depressive disorder(s) 611 (21.89) 71 (2.54) 682  
No 12-month depressive disorder 2366 (84.77) 206 (7.38) 2572 0.412 
12-month depressive disorder(s) 198 (7.10) 21 (0.75) 219  
No 30-day depressive disorder 2487 (89.11) 217 (7.77) 2704 0.244 
30-day depressive disorder(s) 77 (2.76) 10 (0.36) 87  
Any Anxiety disorders  
No lifetime anxiety disorder 1269 (45.56) 103 (3.70) 1372 0.247 
Lifetime anxiety disorders 1290 (46.32) 123 (4.42) 1413  
No 12-month anxiety disorder 1951 (70.10) 163 (5.85) 2114 0.165 
12-month anxiety disorder(s) 608 (21.83) 63 (2.26) 671  
No 30-day anxiety disorder 2199 (78.96) 179 (6.43) 2378 0.006 
30-day anxiety disorder(s) 360 (12.93) 47 (1.69) 407  
Note: For descriptive statistics original data without imputation was used 
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Table 3: Proportion of specific depressive and anxiety disorders, by main predictor, 
diabetes (n = 2791) 
Disorders No Diabetes 
n (%) 
Diabetes 
n (%) 
Total 
n 
p-value 
Major depression disorder     
No lifetime MDD 546 (19.6) 65 (2.3) 611 0.010 
Lifetime MDD 2018 (72.3) 162 (5.8) 2180  
No 12-month MDD 177 (6.3) 19 (0.7) 196 0.407 
12-month MDD 2387 (85.5) 208 (7.5) 2595  
No 30-day MDD 67 (2.4) 9 (0.3) 76 0.230 
30-day MDD 2497 (89.5) 218 (7.8) 2715  
Generalized anxiety disorder     
No lifetime GAD 224 (8.0) 25 (0.9) 249 0.241 
Lifetime GAD 2339 (83.9) 201 (7.2) 2540  
No 12-month GAD 81 (2.9) 9 (0.3) 90 0.503 
12-month GAD 2482 (88.9) 217 (7.8) 2699  
No 30-day GAD 36 (1.3) 5 (0.2) 41 0.333 
30-day GAD 2527 (90.5) 221 (7.9) 2748  
Panic disorder     
No lifetime panic disorder 863 (30.9) 84 (3.0) 947 0.307 
Lifetime panic disorder 1701 (60.9) 143 (5.1) 1844  
No 12-month panic disorder 239 (8.6) 22 (0.8) 261 0.854 
12-month panic disorder 2325 (83.3) 205 (7.3) 2530  
No 30-day panic disorder 65 (2.3) 6 (0.2) 71 0.921 
30-day panic disorder 2499 (89.5) 221 (7.9) 2720  
Specific phobias     
No lifetime specific phobias 350 (12.5) 41 (1.5) 391 0.066 
Lifetime specific phobias 2214 (79.3) 186 (6.7) 2400  
No 12-month specific phobias 255 (9.1) 30 (1.1) 285 0.119 
12-month specific phobias 2309 (82.7) 197 (7.1) 2506  
No 30-day specific phobias 176 (6.3) 24 (0.9) 200 0.038 
30-day specific phobias 2388 (85.6) 203 (7.3) 2591  
Posttraumatic stress disorder     
No lifetime PTSD 351 (12.6) 44 (1.6) 395 0.017 
Lifetime PTSD 2209 (79.1) 182 (6.5) 2391  
No 12-month PTSD 148 (5.3) 14 (0.5) 162 0.799 
12-month PTSD 2412 (86.4) 212 (7.6) 2624  
No 30-day PTSD 82 (2.9) 8 (0.3) 90 0.784 
30-day PTSD 2478 (88.8) 218 (7.8) 2696  
Note: For descriptive statistics original data without imputation was used. MDD= major depressive disorder; GAD = generalized anxiety disorder; 
PTSD = posttraumatic stress disorder 
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Table 4: Unadjusted and adjusted odds ratios (95% CI) of reporting any DSM mood disorder by main predictor, diabetes  
Disorders Complete case analysis Imputed data 
No 
(Referent) 
Diabetes 
Unadjusted  
OR (95% CI) 
 
Diabetes 
Adjusted  
OR (95% CI) 
 
No 
(Referent) 
Diabetes 
Unadjusted  
OR (95% CI) 
 
Diabetes 
Adjusted  
OR (95% CI) 
 
Any Depressive disorder   
No lifetime depressive disorder 1.00 1.00 1.00 1.00 1.00 1.00 
Lifetime depressive disorder(s) 1.00 1.45 (1.08 – 1.95)* 1.34 (0.89 – 2.01) 1.00 1.37 (1.03 – 1.83)* 1.37 (1.03 – 1.84)* 
No 12-month depressive disorder 1.00 1.00 1.00 1.00 1.00 1.00 
12-month depressive disorder(s) 1.00 1.22 (0.76 – 1.95) 1.00 (0.50 – 1.98) 1.00 1.17 (0.72 – 1.88) 1.16 (0.72 – 1.89) 
No 30-day depressive disorder 1.00 1.00 1.00 1.00 1.00 1.00 
30-day depressive disorder(s) 1.00 1.49 (0.76 – 2.92) 1.02 (0.35 – 2.97) 1.00 1.42 (0.72 – 2.79) 1.45 (0.73 – 2.88) 
Any Anxiety disorder   
No lifetime anxiety disorder 1.00 1.00 1.00 1.00 1.00 1.00 
Lifetime anxiety disorder(s) 1.00 1.17 (0.89 – 1.54) 1.29 (0.88 – 1.87) 1.00 1.15 (0.88 – 1.51) 1.15 (0.87 – 1.52) 
No 12-month anxiety disorder 1.00 1.00 1.00 1.00 1.00 1.00 
12-month anxiety disorder(s) 1.00 1.24 (0.92 – 1.68) 1.62 (1.09 – 2.40)* 1.00 1.22 (0.91 – 1.65) 1.22 (0.90 – 1.64) 
No 30-day anxiety disorder 1.00 1.00 1.00 1.00 1.00 1.00 
30-day anxiety disorder(s) 1.00 1.60 (1.14 – 2.25)* 2.43 (1.59 – 3.73)* 1.00 1.54 (1.10 – 2.15)* 1.53 (1.09 – 2.15)* 
OR = odds ratio; models adjusted for age, education, income, marital status, body mass index, alcohol consumption, smoking
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Table 5: Unadjusted and adjusted odds ratios (95% CI) of reporting MDD, by main 
predictor, diabetes  
Disorders No 
(Referent) 
Diabetes 
Unadjusted 
OR (95% CI) 
Diabetes 
Adjusted 
OR (95% CI) 
No lifetime MDD 1.00 1.00 1.00 
Lifetime MDD 1.00 1.37 (1.01– 1.85)* 1.36 (1.01 – 1.85)* 
No 12-month MDD 1.00 1.00 1.00 
12-month MDD 1.00 1.14 (0.70 – 1.87) 1.13 (0.69 – 1.86) 
No 30-day MDD 1.00 1.00 1.00 
30-day MDD 1.00 1.44 (0.67 – 3.13) 1.46 (0.67 – 3.20) 
Note: ORs were obtained using imputed data; MDD = Major depressive disorders; models adjusted for age, education, income, 
marital status, body mass index, alcohol consumption, smoking 
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Table 6: Unadjusted and adjusted odds ratios (95% CI) of reporting anxiety disorders by 
main predictor, diabetes  
Disorders No 
(Referent) 
Diabetes 
Unadjusted 
OR (95% CI) 
Diabetes 
Adjusted 
OR (95% CI) 
Generalized anxiety disorder  
No lifetime GAD 1.00 1.00 1.00 
Lifetime GAD 1.00 1.22 (0.78 – 1.88) 1.19 (0.76 – 1.85) 
No 12-month GAD 1.00 1.00 1.00 
12-month GAD 1.00 1.17 (0.55 – 2.50) 1.10 (0.51 – 2.36) 
No 30-day GAD 1.00 1.00 1.00 
30-day GAD 1.00 1.46 (0.53 – 4.03) 1.38 (0.50 – 3.84) 
Panic disorder    
No lifetime panic disorder 1.00 1.00 1.00 
Lifetime panic disorder 1.00 1.13 (0.85 – 1.51) 1.15 (0.86 – 1.53) 
No 12-month panic disorder 1.00 1.00 1.00 
12-month panic disorder 1.00 1.02 (0.63 – 1.64) 1.03 (0.64 – 1.65) 
No 30-day panic disorder 1.00 1.00 1.00 
30-day panic disorder 1.00 1.06 (0.46 – 2.43) 1.04 (0.45 – 2.39) 
Specific phobias    
No lifetime specific phobias 1.00 1.00 1.00 
Lifetime specific phobias 1.00 1.32 (0.92 – 1.91) 1.31 (0.91 – 1.89) 
No 12-month specific phobias 1.00 1.00 1.00 
12-month specific phobias 1.00 1.33 (0.87 – 2.02) 1.32 (0.87 – 2.02) 
No 30-day specific phobias 1.00 1.00 1.00 
30-day specific phobias 1.00 1.53 (0.96 – 2.43) 1.51 (0.95 – 2.42) 
Posttraumatic stress disorder    
No lifetime PTSD 1.00 1.00 1.00 
Lifetime PTSD 1.00 1.42 (1.01 – 2.00)* 1.42 (1.01 – 2.02)* 
No 12-month PTSD 1.00 1.00 1.00 
12-month PTSD 1.00 1.01 (0.56 – 1.80) 1.01 (0.56 – 1.80) 
No 30-days PTSD 1.00 1.00 1.00 
30-days PTSD 1.00 1.06 (0.50 – 2.22) 1.04 (0.49 – 2.20) 
Note: ORs were obtained using imputed data; MDD = Major depressive disorders; models adjusted for age, education, income, 
marital status, body mass index, alcohol consumption, smoking 
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 Figure 1: Proportions of women reported any depressive and anxiety disorders 
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RESULTS 
PART 2 
THE MALAYSIAN CASE-CONTROL STUDY 
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CHAPTER 9 
Psychological health and menopause-specific quality of life of Malaysian 
women with type 2 diabetes  
 
The seventh objective of this thesis was to investigate whether symptoms of depression 
and anxiety were associated with diabetes mellitus in Malaysian women. This study was 
undertaken to investigate this potential association because limited data was available 
about psychological problems in people with diabetes. The work described in this chapter 
has been revised for publication in the following form: 
 
1. Hasan, S.S., Thiruchelvam, K., Ahmed, S.I., Clavarino, A.M., Mamun, A.A., Kairuz, 
T. Psychological health and menopause-specific quality of life of Malaysian women 
with type 2 diabetes. Asian J Psychiatr [Revised & Resubmitted]. 
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Psychological health and menopause-specific quality of life of Malaysian women 
with type 2 diabetes 
 
Abstract 
 
Anxiety and depression are more 
common among females and those 
experiencing diabetes and menopause. 
Menopausal symptoms experienced by 
women can vary tremendously from 
population to population; therefore, there 
is a need to investigate these symptoms 
and associated risk factors in different 
communities. This study investigated the 
differences in psychological health and 
menopause-specific quality of life 
(MENQOL) between women with and 
without diabetes type 2 (T2DM) in 
Malaysia. Women with T2DM (n=320) 
were matched by age range to controls 
without T2DM (n=320). Data were 
collected from March 2012 to January 
2013. Two instruments were used to 
identify depression and anxiety 
symptoms: Center for Epidemiological 
Studies Depression Scale-10 and the 
Delusions Symptoms States Inventory. 
Women with diabetes had higher 
depressive (11.8% versus 8.4%) and 
anxiety (8.4% versus 6.6%) symptoms 
compared to women without diabetes. In 
both groups, the most common 
menopausal symptom was aches 
(muscles and joints). Women without 
diabetes had significantly higher scores 
for the sexual domain compared to 
women with diabetes (4.20 versus 3.21, p 
= 0.001). The odds that a 
postmenopausal woman with diabetes 
was depressed or anxious on the DSSI 
scale increased significantly when the 
MENQOL score on the physical, 
vasomotor, and psychosocial domains 
increased by one unit. Both diabetes and 
psychological problems have negative 
impact on MENQOL. Our findings support 
the view of screening postmenopausal 
women with diabetes for depressive and 
anxiety, to improve overall quality of life. 
 
Keywords: Diabetes, type 2, depression, 
anxiety, women 
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1. Introduction 
The world prevalence of diabetes is 
increasing rapidly; diabetes affected 382 
million people worldwide in 2013 and the 
number is projected to rise to 592 million 
by 2035 (IDF, 2013). The prevalence is 
expected to shift to the South East Asia 
Region by 2025, with an estimated 
prevalence of 13.5% and affecting 145 
million people (IDF, 2013; IDF, 2003). In 
Malaysia, a middle-income, developing 
country located in the South East Asia 
Region, the prevalence of diabetes has 
doubled over the past decade (Hasan et 
al., 2013; Zanariah et al., 2010). The 
National Health and Morbidity Survey I 
(NHMS-I) conducted in 1986, reported a 
6.3% prevalence of diabetes among 
adults aged ≥35 years; however, the 
prevalence rose to 8.3% in 1996 and 
15.2% in 2011 (Institute for Public Health, 
2011; Zanariah et al., 2010). WHO 
estimates a total of 2.48 million people 
with diabetes in Malaysia by 2030 
(Zanariah et al., 2010). In other 
developing countries such as China, 
Brazil and Egypt, diabetes is more 
prevalent among women, regardless of 
age (Hu et al., 2001; Wild et al., 2004). 
The prevalence of diabetes worldwide is 
similar among men and women although 
it is more prevalent in women after the 
age of 65 years (Wild et al., 2004). 
Diabetes mellitus is one of the chronic, 
inherited or acquired diseases where 
patients experience a number of co-
morbidities including physical and 
psychological problems (aHasan et al., 
2013). Depression and anxiety are two 
common, co-morbid, modifiable 
psychological conditions associated with 
diabetes (bHasan et al., 2013; Smith et 
al., 2013), and recent meta-analyses 
have found significant and positive 
associations for diabetes with both 
depression (bHasan et al., 2013), and 
anxiety (Smith et al., 2013) although, 
Brown et al. found no association (Brown 
et al., 2006). Co-morbid conditions of 
diabetes with depression and/or anxiety 
intensify the burden of diabetes 
symptoms (Katon, 1982; Konen et al., 
1996), increase complications 
(Kaholokula et al., 2003), increase 
glycaemic levels (Gary et al., 2000), 
increase non adherence to medications 
(Lin et al., 2004), and reduce quality of life 
(Lloyd et al., 2000). Despite the high 
prevalence of diabetes in the general 
population in Malaysia (Institute for Public 
Health, 2011; Zanariah et al., 2010), only 
a few cohort or case-control studies are 
available on this topic. These studies 
support the hypotheses that people with 
diabetes are more likely to have 
depression or anxiety symptoms than 
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people who do not have diabetes (Kaur et 
al., 2013; Subramaniam et al., 2009). 
Some authors have also suggested that 
depression and anxiety symptoms are 
significantly higher in postmenopausal 
women compared to premenopausal 
women (Saqsoz et al., 2001). 
 
Type 2 diabetes mellitus is one of the 
most common chronic diseases in women 
after menopause (Monterrosa-Castro et 
al., 2013). However, whether menopausal 
status independently influences or 
increases diabetes risk remains 
controversial (Kim, 2012; Monterrosa-
Castro et al., 2013; Szmuilowicz et al., 
2009). There is a higher prevalence of 
diabetes among women with a history of 
menstrual irregularity (Roumain et al., 
1998), particularly in those with long and 
highly irregular menstrual cycles 
(Solomon et al., 2001). The increase in 
abdominal fat caused by depletion of 
ovarian function (Meyer et al., 2011), may 
cause disturbances in insulin sensitivity 
and glucose metabolism in 
postmenopausal women (Szmuilowicz et 
al., 2009). The changes in hormonal 
levels during the menopausal transition 
and after menopause can trigger 
fluctuations in blood glucose levels 
(Otsuki et al., 2007). The changes in 
hormonal levels may also result in weight 
gain (Simkin-Silverman et al., 2000), 
sleep (Australian Menopause Society, 
2013), and sexual problems (Dennerstein 
et al., 2003). 
 
Women can experience a number of 
menopausal symptoms as part of a 
normal physiological process that often 
occurs in women at an average age of 50 
years (Burger et al., 2002). These 
symptoms are often attributable to 
reduced hormone levels and include 
vasomotor, psychological, 
musculoskeletal or physical and 
urogenital or sexual symptoms (Ogbera 
et al., 2011). These symptoms can affect 
the quality of life as measured by 
Menopause Specific Quality of Life 
(MENQOL) in postmenopausal women 
(Williams et al., 2009). Women with 
diabetes generally appeared to have 
worse quality of life and mental well-being 
compared to men with diabetes; explicitly, 
more diabetes-related worries and less 
ability to cope (Unden et al., 2008). This 
suggests that diabetes combined with 
menopausal symptoms may significantly 
reduce quality of life. 
 
Anxiety and depression are more 
common among females and those 
experiencing diabetes and menopause; 
hence women are the target population in 
our study (Collins et al., 2009; Grigsby et 
al., 2002; Khuwaja & Kadir, 2010). 
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Menopausal symptoms experienced by 
women can vary tremendously from 
individual to individual, and population to 
population (Gold et al., 2000; World 
Health Organization, 1990; World Health 
Organization, 1996); therefore, there is a 
need to investigate these symptoms and 
associated risk factors in different 
communities. The primary objective of 
this study was to determine the pattern of 
menopausal symptomatology in 
Malaysian women with and without type 2 
diabetes. The specific aims of this study 
include the following: to determine the 
association between symptoms of 
depression and anxiety and type 2 
diabetes, and MENQOL domains and 
type 2 diabetes using case-control data; 
and to compare the symptomatology of 
menopause in postmenopausal women 
with and without type 2 diabetes. 
 
2. Methods 
2.1. Study design and population  
This study involved women with diabetes 
matched to women without type 2 
diabetes in the same age range. A 
frequency matching technique was used 
to match participants on cell instead of 
individual basis. The frequency matching 
was conducted using two conditions: 
presence or absence of diabetes and 
aged 35 years or more. The frequency 
matching was completed in two steps. In 
the first step, only women aged 35 and 
older who attended outpatient clinics for 
the management of T2DM and who had a 
known diagnosis of T2DM were selected 
(cases). In the second step, cases were 
matched with controls; these were 
women were aged 35 years and older, 
with no known diagnosis of T2DM. The 
control participants were healthy friends 
or unrelated family members (no blood 
relation) of women with type 2 diabetes. 
Three Medication Therapy Adherence 
Clinics (MTACs), two hospital-based 
(Hospital Putrajaya and Hospital Tuanku 
Jaa’far Seremban) and one Health Clinic 
(Health Clinic, Seremban) in West 
Malaysia were selected as primary 
sampling sites. Non probability-based 
design was used to select the sampling 
sites. Recruitment was initially started in 
Hospital Putrajaya where the majority of 
the patients were of Malay origin. 
Therefore, to select a sample that 
included all three ethnic groups, sampling 
was extended to the Seremban region to 
include patients of Chinese and Indian 
ethnicity. Data were collected from March 
2012 to January 2013. 
Every second woman with diabetes on 
the respective patients’ lists at the clinic 
sites was systematically invited to 
participate; verbal or written consent was 
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obtained from participants who met the 
inclusion criteria. Out of 415 women with 
diabetes invited to participate in the 
study, 320 (77%) accepted and 
participated. Out of 390 women without 
diabetes who were invited to participate, 
320 (82%) accepted and participated. 
Face-to-face interviews were conducted 
at the outpatient clinics, using study 
questionnaires. 
 
2.2. Assessment of Type 2 diabetes 
Data on type 2 diabetes were collected 
through a self-administered 
questionnaire, where women were asked 
“Have you EVER been told by a doctor 
that you have diabetes (high blood 
sugars)?” with response options “yes” or 
“no.” Participants were categorized as 
having type 2 diabetes if they had been 
told by a physician they had diabetes. 
Information was further confirmed by 
accessing patients’ medical records. The 
presence of type 2 diabetes is identified 
in the hospital according to two criteria: A 
fasting plasma glucose (FPG) greater 
than or equal to 7.0 mmol/l, and random 
plasma glucose (RPG) greater than or 
equal to 11.1 mmol/l. Participants were 
not recruited if data on their blood 
glucose levels were missing, and women 
diagnosed with type 1 diabetes were 
excluded. The 320 women with diabetes 
were categorized based on the duration 
of type 2 diabetes: 0–5 years, 6–10 
years, and >10 years. 
 
2.3. Measurement of depression and 
anxiety symptoms 
The information about the presence of 
depression and anxiety symptoms was 
measured by Delusion Symptoms States 
Inventory: State of Anxiety and 
Depression (DSSI/sAD). The DSSI is a 
14-item measure developed for use with 
community samples and was validated 
against clinical samples with diagnosed 
mental illness (Bedford & Folds, 1977; 
Foulds & Bedford; Morey, 1985). The 
DSSI correlates well, and shares items 
with, other established symptoms scales 
such as the Edinburgh Postnatal 
Depression Scale (EPDS) and the 
Hospital Anxiety/Depression Scale 
(HADS) (Bedford & Deary, 1999; Najman 
et al., 2000). The DSSI/sAD was 
validated in people with diabetes (Hasan 
et al., 2015). The DSSI contains 14 
symptoms; 7 for depression and 7 for 
anxiety. Participants in this study were 
classified as anxious or depressed when 
they scored 4 or more.  
 
2.4. Menopausal status 
Menopausal status was identified as pre-
menopausal (no irregular periods in the 
previous 12 months, peri-menopausal 
(irregular periods less than 12 months), or 
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post-menopausal (cessation of menses 
for 12 months or longer; included both 
natural as well as surgical). There were 
very few women with peri-menopausal 
status; therefore we did not include them 
in the analysis and focused on pre and 
post-menopausal women only. 
 
2.5. Measurement of menopause specific 
quality of life (MENQOL) 
Since MENQOL is validated only in the 
postmenopausal population, MENQOL 
assessment was restricted to 
postmenopausal women only. The 
MENQOL is a validated instrument used 
to measure quality of life and is able to 
capture not only the existence of frequent 
menopausal symptoms, but also the 
extent to which the symptom(s) is/are 
bothersome (Hilditch et al., 1996; Van 
Dole et al., 2012). MENQOL was 
developed using data from 
postmenopausal women, aged between 
47 to 62 years who had not been on 
hormone replacement therapy Hilditch et 
al., 1996; Van Dole et al., 2012). We used 
29 questions in this study (3 questions on 
vasomotor aspects, 7 questions on 
psychosocial aspects, 16 questions on 
physical aspects and 3 questions on 
sexual aspects).  
 
According to the scoring system of the 
original version of MENQOL, each 
question should be scored by 8 points 
using a Likert scale from 2 to 8, or ‘not at 
all bothered’ to ‘extremely bothered’. 
Thus, higher scores represent poorer 
quality of life. For analyses, we scored 
the items ranging from 1 to 8 in the 
following manner: (1) The participant 
responded ‘NO’, she did not experience 
the problem; (2) the participant 
experienced the problem and rated it as 
‘0’ on the bothered scale; (3) The 
participant experienced the problem and 
rated it as ‘1’ on the bothered scale; (4) 
rated as ‘2’; (5) rated as ‘3’; (6) rated as 
‘4’; (7) rated as ‘5’; (8) rated as ‘6’. Each 
domain score ranges from 1 to 8 Hilditch 
et al., 1996; Van Dole et al., 2012). The 
total scores for vasomotor aspects 
ranged from 3 to 24; psychosocial 
aspects from 7 to 56; physical aspects 
from 16 to 128; and sexual aspects from 
3 to 24. The total MENQOL score for 
each participant ranged from 29 (the 
lowest level) to 232 (the highest level) 
points. The MENQOL instrument has 
been validated for measuring quality of 
life in postmenopausal women with 
diabetes (cHasan et al., 2013). 
 
This study was approved by the Ethics 
Committee at the School of Pharmacy, 
The University of Queensland (Reg. No. 
2011/14) and by the International Medical 
University Research and Ethics 
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Committee (Project ID No: B01/09-Res 
(04) 2012). The study was registered with 
the National Medical Research Registry 
(NMRR), Ministry of Health, Malaysia. 
 
2.6. Statistical analysis 
The data were analyzed using the 
Statistical Package for Social Sciences 
(SPSS)® version 20 and STATA IC® 
version 12, with a significance level of ≤ 
0.05. Descriptive statistics were used to 
calculate percentages frequencies, 
means and standard deviations. The 
relationships between variables for 
categorical data were performed using 
the X2 (Chi-Sq). Fisher’s Exact test was 
applied in cases where the sample size 
was small and on occasions where we 
had less than 5 readings per cell for Chi-
Square. Comparisons between groups 
with normal distribution were performed 
using the Student’s t-test. To verify the 
existence of a correlation between the 
mean scores or other values of 
instruments, Pearson’s correlation test 
was used. Logistic regression was used 
to investigate the relationship between: 
psychological conditions (depression and 
anxiety symptoms) and diabetes, and 
menopausal symptoms and diabetes. The 
potential confounders and risk factors 
were identified on the basis of their 
association with outcomes and on the 
basis of a priori knowledge (bHasan et al., 
2013; Kaur et al., 2013; Smith et al., 
2013). Multiple logistic regressions were 
then used to assess the relationship, after 
adjustment for other potential 
confounding variables. We present a 
series of models that were adjusted for 
these potential confounders so that 
readers can see the effect of factors that 
we consider might confound this 
association. The overall extent to which a 
given model fits the data was measured 
by a Goodness-of-Fit test. Maximum 
Likelihood method was applied because it 
minimises bias and maximises precision 
of estimates. We did not include any 
interaction terms in the model. 
 
The final multivariate model included 
seven covariates, selected using priori 
knowledge. Height (m) and weight (kg) 
measurements were obtained from 
participants’ medical records and used to 
calculate body mass index (BMI) (kg/m2). 
BMI 30 or greater was used as the cut-off 
point to categorize participants as obese 
and non-obese. The information on 
comorbidities or medical conditions other 
than type 2 diabetes was collected from 
medical records. Socio-demographic 
information were collected from patients 
and included age, ethnicity (Malay, 
Chinese, Indians and others), education 
(no formal education, primary education, 
secondary education and graduation or 
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post-graduation), monthly income in 
Ringgit Malaysia (1 RM = 3.2 $ US). In 
this study, the woman was asked about 
her current marital status, that is, whether 
she was single, married, divorced, or 
widowed. 
 
3. Results 
A total of 640 women (320 people with 
diabetes and 320 people without 
diabetes) were interviewed, and the 
socio-demographic characteristics of 
those with diabetes and those without 
diabetes are summarised in Table 1. The 
median age at diagnosis of diabetes was 
50 years (Range: 27 – 70); patients with 
diabetes were slightly older than those 
without diabetes, with a mean difference 
in age of 9.3 ± 1.05. In the diabetes 
group, most of the participants were of 
Indian origin (37%), no income (54%), 
and had at least one comorbid condition. 
The diabetes group had lower education 
and income levels than the group without 
diabetes (p<0.05). None of the 
participants smoked and only a few (<5) 
were consuming alcohol at the time of 
study. 
 
Of the total number of participants, 378 
women (with diabetes = 258, control = 
120) had attained menopausal status, 
while 262 women (with diabetes = 62, 
control = 200) had not attained 
menopausal status. Both women with and 
without diabetes experienced their first 
period around the same age (mean age: 
13.25 versus 13.10, p = 0.680). Similarly 
they attained menopause around the 
same age (mean age: 49.35 versus 
48.87, p = 0.426). Women with diabetes 
had a higher number of pregnancies 
(mean: 4.15 versus 3.64, p = 0.001), 
percentage of gestational diabetes and 
hypertension (13.4% versus 8.1%, p = 
0.03) and miscarriages (22% versus 
15%), compared to women without 
diabetes. 
 
3.1. Anxiety, depression and type 2 
diabetes 
Women with diabetes had slightly higher 
depressive (11.8% versus 8.4%) and 
anxiety symptoms (8.4% versus 6.6%) 
compared to women without diabetes. 
Postmenopausal women in the diabetes 
group and premenopausal women in the 
control group had slightly higher 
proportions of depressive and anxiety 
symptoms compared to their 
counterparts. 
 
In the diabetes group, most of the 
depressed and anxious participants were 
aged 45 – 54 years (27.0% and 27.5% 
respectively), married (49% and 50%), 
had completed secondary education 
(35% and 30%), and received a monthly 
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income of 7000 Ringgit Malaysia or more 
(24% and 23%). Anxiety was more 
commonly reported by Chinese women 
(30%), while depression was more 
frequently found among Indians (19%). In 
the non-diabetes group, most of the 
depressed and anxious participants were 
older, of Indian origin, had attained only 
primary education, and belonged to the 
lower socio-economic group. Women with 
0 to 5 years’ duration of diabetes had the 
highest percentages of depression and 
anxiety symptoms compared to those 
with 6 or more years of diabetes. 
 
In the multivariate logistic regression 
model, the association between 
depressive symptoms and diabetes was 
not statistically significant, both in 
postmenopausal (OR 0.39, 95% CI: 0.13 
– 1.17) as well as in premenopausal 
women (OR 0.27, 95% CI: 0.10 – 1.33), 
as shown in Table 2. Similarly, in the 
case of anxiety, we did not find significant 
association between anxiety symptoms 
and diabetes, both in postmenopausal 
(OR 0.46, 95% CI: 0.12 – 1.71) and 
premenopausal women (OR 0.91, 95% 
CI: 0.10 – 8.62).  
 
3.2. MENQOL domains and type 2 
diabetes 
Since MENQOL is only validated in the 
postmenopausal population, MENQOL 
assessment was restricted to 
postmenopausal women only (case = 
258, control = 120). A comparison of the 
pattern of occurrence of menopausal 
symptoms in postmenopausal women 
with and without the diabetes is 
presented in Table 3. In both groups, the 
most common menopausal symptom was 
aches of muscles and joints (> 70%) 
while symptoms originating from sexual 
aspects were the least self-reported. In 
terms of pattern of occurrence of specific 
menopausal symptoms in 
postmenopausal women, women with 
diabetes reported significantly higher 
percentages compared to women without 
diabetes for the following symptoms: 
nights sweats (32.9% versus 21.7%, p = 
0.025), decrease in physical strength 
(72.1% versus 56.7%, p = 0.003), 
decrease in stamina (73.3% versus 
53.3%, p = 0.001), lack of energy (73.6% 
versus 54.2%, p = 0.001), and frequent 
urination (51.9% versus 27.5%, p = 
0.001).  
 
Women with diabetes had insignificantly 
higher scores for vasomotor (6.17 versus 
5.75, p = 0.357) and physical (37.01 
versus 36.75, p = 0.884) domains 
compared to women without diabetes. 
However in terms of total MENQOL 
score, women without diabetes had an 
insignificantly higher score (59.85 versus 
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58.36, p = 0.566). Interestingly women 
without diabetes also had significantly 
higher score for the sexual domain 
compared to women with diabetes (4.20 
versus 3.21, p = 0.001).  
 
The odds that a postmenopausal woman 
did not have diabetes, significantly 
increased when the MENQOL score on 
the sexual domain decreased by one unit 
(OR 0.69, 95% CI: 0.57–0.84). The 
results for other domains were statistically 
insignificant. Table 4 shows the results of 
the logistic regression analysis examining 
the relationship between the presence or 
absence of diabetes and each of the four 
MENQOL domains. 
 
3.3. Depression, anxiety and MENQOL 
domains  
The odds that a postmenopausal woman 
with diabetes was depressed on the DSSI 
scale increased 1.13 times when the 
MENQOL score on the vasomotor 
domain increased by one unit (95% CI: 
1.04–1.22), the odds ratio increased 1.14 
times when the MENQOL score on the 
psychosocial domain increased by one 
unit (95% CI: 1.07–1.21), and the odds 
ratio increased 1.08 times when the 
MENQOL score on the physical domain 
increased by one unit (95% CI: 1.04–
1.11). Similar results were obtained for 
anxiety symptoms and MENQOL 
domains. Similarly, the odds that a 
postmenopausal woman without diabetes 
was depressed or anxious on the DSSI 
scale increased significantly when the 
MENQOL score on the physical, 
vasomotor, and psychosocial domains 
increased by one unit. Table 5 shows the 
results of the logistic regression analysis 
examining the relationship between 
symptoms of depressive and anxiety and 
each of the four MENQOL domains. 
 
4. Discussion 
This study investigated the psychological 
health and menopause-specific quality of 
life among pre and postmenopausal 
women with and without diabetes in 
Malaysia. In this study, most of the 
patients with diabetes were of Indian 
origin (36.6%), followed by Chinese 
(30.9%) and Malay (30.6%); these 
demographics are similar to those of 
NHMS III (Zanariah et al., 2010). Women 
with diabetes were slightly older than 
women who did not have diabetes, 
suggesting that the age range differs 
between the two groups. The sharpest 
increase in the prevalence of diabetes 
occurred after the age of 55 years.  
Women in the 55 to 64 year age group 
had the highest proportion of diabetes. In 
our study, about 40% of those with type 2 
diabetes had experienced menopause 
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compared to only 18% of those without 
diabetes, suggesting that an earlier onset 
of diabetes results in an earlier age of 
menopause. This is consistent with 
reports that revealed an early 
menopausal age for women with diabetes 
compared to women without diabetes 
(Malacara et al., 1997; Monterrosa-Castro 
et al., 2013).  
 
As described earlier, women experience 
a variety of symptoms during or after 
menopause (Ogbera et al., 2011). 
Consistent with previous reports 
(Australian Menopause Society, 2013; 
Ogbera et al., 2011), the most common 
complaint reported by participants in both 
groups was aches in muscles and joints. 
Our findings are also similar to those of 
Ogbera et al., who found that half the 
women in both groups reported poor 
memory (Ogbera et al., 2011). In terms of 
MENQOL domains, symptoms originating 
from the sexual aspects were the least 
self-reported and the least reported 
symptom was that of facial hair, which 
occurred in 2.4% of the participants. This 
is in agreement with a study among 
menopausal Arabic women in Sydney (Lu 
et al., 2007), where the presence of facial 
hair was the least reported menopausal 
symptom.  
 
Of the physical, psychosocial and sexual 
symptoms, our findings show that night 
sweats, decreased physical strength, 
decreased stamina, lack of energy, and 
frequent urination were the predominant 
menopausal symptoms reported by our 
participants with diabetes. The MENQOL 
instrument used for screening 
menopausal symptoms contained some 
symptoms that could be confounded with 
symptoms of diabetes or poor controlled 
diabetes (Hilditch et al., 1996; Van Dole 
et al., 2012). However, we demonstrated 
the validity of MENQOL domains in a 
sample of women with diabetes in a 
previous study and concluded that 
MENQOL can be administered to a 
population with diabetes (cHasan et al., 
2013). 
 
Although women with diabetes reported 
higher percentages of depression (11.8% 
versus 8.4%) and anxiety symptoms 
(8.4% versus 6.6%) compared to women 
without diabetes, the differences were 
statistically insignificant. Similarly, anxiety 
(31.8% versus 33.3%) and depression 
symptoms (20.9% versus 20.8%) as 
measured by the psychosocial domain of 
MENQOL were also similar for both 
groups, suggesting that attainment of 
menopausal status did not increase or 
decrease the psychological burden in 
participating women. A recent study in 
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Malaysia (2013) found a relatively higher 
prevalence of depression and anxiety 
symptoms among people with diabetes 
(Kaur et al., 2013). This may be a result 
of differences in the screening instrument, 
the age groups (less than 35 and more 
than 75 years), and the inclusion of male 
participants. Consistent with the findings 
of previous studies, we found that 
depression was more prevalent among 
women of Indian ethnicity (19%), while 
anxiety was more prevalent among the 
Chinese ethnicity (30%) (Dunlop et al., 
2003; Fisher et al., 2004). Ben-Haroush 
et al., hypothesized that minority groups, 
are more likely to experience 
socioeconomic constraints, poor 
education and perceived discrimination 
that may result in higher prevalence of 
psychological and chronic conditions 
(Ben-Haroush et al., 2004); this applies 
particularly to Indians in our study,.  
 
Women with duration of 0 to 5 years of 
diabetes had the highest percentages of 
depression and anxiety symptoms 
compared to those with 6 or more years 
of diabetes. Our findings are in 
agreement with previous studies 
conducted in Malaysia (2013) and 
Bahrain (2008) (Almawi et al., 2008; Kaur 
et al., 2013). This may be attributed to 
inadequate or inefficient coping skills for 
managing diabetes shortly after 
diagnosis.  
 
Co-morbid conditions of diabetes and 
anxiety disorders are linked to increased 
diabetes burden (Andrews et al., 1998), 
increased complications (Jonas et al., 
1997), poor glycaemic control (Anderson 
et al., 2002), and reduced quality of life 
(Mendlowicz & Stein, 2001). However, 
there has been little focus on the 
association of diabetes with anxiety. A 
recent meta-analysis found significant 
and positive associations for diabetes 
with both anxiety disorders and elevated 
anxiety symptoms (Smith et al., 2013). 
However, a limited number of longitudinal 
studies from developed countries 
reported inconsistent results about the 
association between anxiety and diabetes 
(Smith et al., 2013). Anxiety is an episodic 
disorder and participants may have not 
had anxiety attacks during the time of the 
studies. We also noted significant positive 
correlation between anxiety and 
depression suggesting that as the 
depression symptoms increased, anxiety 
symptoms correspondingly increased. It 
is well established that depression and 
anxiety go hand in hand and they are 
usually diagnosed together (Center for 
Disease Control and Prevention, 2008). 
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Regarding depression as a cause of 
diabetes, previous studies reached 
different conclusions (aHasan et al., 
2013); Saydah et al. found no evidence to 
support an etiological relationship 
between depression and diabetes 
(Saydah et al., 2003), and a retrospective 
Scandinavian study published in 2004 
also reported no overall relationship (van 
den Akker et al., 2004). However, a 
recent meta-analysis (2013) documented 
that symptoms of depression are 
associated with diabetes (aHasan et al., 
2013).  
 
4.1. Limitations 
There are a number of limitations 
associated with this study that may affect 
the generalizability of our findings. This 
study used self-report scales to assess 
menopausal, depressive and anxiety 
symptoms; although diagnosis of these 
conditions by a trained health care 
professional according to standard criteria 
would be preferable, this was not 
possible. Participant recall bias may be a 
systematic error due to lack of 
completeness of memory of past events 
or experiences, and may have affected 
the accuracy of self-reported information. 
Although we applied systematic sampling, 
participants who frequently attended the 
outpatient clinics were more likely to be 
sampled than those who attended less 
frequently; we presume that they had 
better overall health status due to their 
regular attendance. This may have 
introduced selection bias. Finally, the 
control group is slightly younger than the 
group of cases and there also seem to be 
differences in ethnicity and income 
level. These differences in cases and 
controls could well explain differences in 
depressive and anxiety symptoms. 
 
5. Conclusions 
Despite some limitations this study has 
both clinical and research implications. 
From the clinical perspective, the results 
indicate that symptoms of depression and 
anxiety are more prevalent among 
women with diabetes than women without 
diabetes. Both diabetes and 
psychological issues have negative 
impact on MENQOL. Except for some 
aspects, the menopausal 
symptomatology in Malaysian women 
with type 2 diabetes is comparable to 
symptomology among women without 
type 2 diabetes. The finding that 
symptoms of depression and anxiety are 
more prevalent among women with newly 
diagnosed diabetes warrants clinical 
attention because they are associated 
with an increased risk of developing 
major forms of depression and/or anxiety. 
In order to achieve desired therapeutic 
and non-therapeutic outcomes, 
 140 
 
healthcare professionals should screen 
postmenopausal women with diabetes for 
depressive and anxiety symptoms.  
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Table 1: Socio-demographic characteristics of women, by diabetes and menopausal status 
Variables No type 2 diabetes 
N = 320 
N (%) 
Type 2 Diabetes 
N = 320 
N (%) 
Pre-
menopause 
Post-
menopause 
Total 
N 
Pre-
menopause 
Post-
menopause 
Total 
N 
Age       
35 – 44  91 (90.0) 10 (10.0) 101 32 (91.4) 3 (8.6) 35 
45 – 54  104 (67.0) 51 (33.0) 155 28 (39.4) 43 (60.6) 71 
55 – 64  4 (9.1) 40 (90.9) 44 0 (0.0) 127 (100.0) 127 
> 65 1 (5.0) 19 (95.0) 20 2 (2.3) 84 (97.7) 86 
Marital Status       
Single – Not married 10 (90.9) 1 (9.1) 11 1 (100.0) 0 (0.0) 1 
Married 174 (63.0) 102 (37.0) 276 61 (21.2) 226 (78.8) 287 
Divorced 11 (73.3) 4 (26.7) 15 0 (0.0) 4 (100.0) 4 
Widowed 5 (27.8) 13 (72.2) 18 0 (0.0) 28 (100.0) 28 
Ethnicity       
Malay 49 (73.1) 18 (26.9) 67 23 (23.5) 75 (76.5) 98 
Chinese 95 (59.4) 65 (40.6) 160 15 (15.1) 84 (84.9) 99 
Indian 51 (61.5) 32 (38.5) 83 22 (18.8) 95 (81.2) 117 
Others 5 (50.0) 5 (50.0) 10 2 (33.3) 4 (66.7) 6 
Education level       
No educ. 1 (12.5) 7 (87.5) 8 1 (2.4) 40 (97.6) 41 
Primary educ. 20 (55.6) 16 (44.4) 36 29 (18.2) 130 (81.8) 159 
Secondary educ. 100 (59.5) 68 (40.5) 168 25 (25.0) 75 (75.0) 100 
Bachelors or higher 79 (73.1) 29 (26.9) 108 7 (35.0) 13 (65.0) 20 
Monthly income       
No income 30 (49.2) 31 (50.8) 61 15 (8.6) 159 (91.4) 174 
< 3500 35 (66.0) 18 (34.0) 53 20 (23.8) 64 (76.2) 84 
3500 – 6999  54 (62.8) 32 (37.2) 86 12 (36.4) 21 (63.6) 33 
≥ 7000 81 (67.5) 39 (32.5) 120 15 (51.7) 14 (48.3) 29 
Co morbidities       
No 170 (69.1) 76 (30.9) 246 0 (0.0) 0 (0.0) 0 
Yes 30 (40.5) 44 (59.5) 74 62 (19.4) 258 (80.6) 320 
Obesity       
Non obese 182 (61.1) 116 (38.9) 298 53 (17.9) 243 (82.1) 296 
Obese 18 (81.8) 4 (18.2) 22 8 (34.8) 15 (65.2) 23 
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Table 2: Unadjusted and adjusted odds ratios (95% CI) of depression and anxiety symptoms according to diabetes 
and menopausal status 
Variables  Postmenopausal women (N = 378) Premenopausal women (N = 252) 
No Diabetes 
 (Referent) 
Diabetes No Diabetes 
 (Referent) 
Diabetes 
Depression symptoms   
Unadjusted  1.0 0.42 (0.21 – 0.83) 1.0 0.71 (0.26 – 1.96) 
Age Adjusted  1.0 0.55 (0.26 – 1.15) 1.0 0.71 (0.26 – 1.98) 
Fully Adjusted  1.0 0.39 (0.13 – 1.17) 1.0 0.27 (0.10 – 1.33) 
Anxiety symptoms   
Unadjusted  1.0 0.47 (0.21 – 1.04) 1.0 0.74 (0.24 – 2.29) 
Age Adjusted  1.0 0.54 (0.23 – 1.25) 1.0 0.75 (0.24 – 2.32) 
Fully Adjusted  1.0 0.46 (0.12 – 1.71) 1.0 0.91 (0.10 – 8.62) 
Note: Full logistic model adjusted for age, ethnicity, marital status, education level, monthly income, comorbidities, and obesity. 
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Table 3: Comparison of the pattern of occurrence of menopausal symptoms in post-menopausal women with and 
without diabetes, given as n (%) 
Domains Total 
N = 378 
No diabetes 
N = 120 
Diabetes 
N = 258 
p-value 
Vasomotor      
1. Hot flushes or flashes 86 42 (35.0) 44 (17.1) 0.001 
2. Night sweats 111 26 (21.7) 85 (32.9) 0.025 
3. Sweating 165 54 (45.0) 111 (43.0) 0.718 
Psychosocial      
4. Being dissatisfied with personal life 26 17 (14.2) 9 (3.5) 0.001 
5. Feeling anxious or nervous 122 40 (33.3) 82 (31.8) 0.764 
6. Experiencing poor memory 199 63 (52.5) 136 (52.7) 0.969 
7. Accomplishing less than I used to 82 37 (30.8) 45 (17.4) 0.003 
8. Feeling depressed, down or blue 79 25 (20.8) 54 (20.9) 0.983 
9. Being impatient with other people 134 60 (50.0) 74 (28.7) 0.001 
10. Feelings of wanting to be alone 70 26 (21.7) 44 (17.1) 0.283 
Physical      
11. Flatulence (wind) of gas pains 149 49 (40.8) 100 (38.8) 0.701 
12. Aches in muscles and joints 278 85 (70.8) 193 (74.8) 0.415 
13. Feeling tired or worn out 254 81 (67.5) 173 (67.1) 0.932 
14. Difficulty sleeping 164 50 (41.7) 114 (44.2) 0.645 
15. Aches in back of head or neck 146 65 (54.2) 81 (31.4) 0.001 
16. Decrease in physical strength 254 68 (56.7) 186 (72.1) 0.003 
17. Decrease in stamina 253 64 (53.3) 189 (73.3) 0.001 
18. Feeling a lack of energy 255 65 (54.2) 190 (73.6) 0.001 
19. Drying skin 167 52 (43.3) 115 (44.6) 0.821 
20.  Weight gain 92 44 (36.7) 48 (18.6) 0.001 
21. Increased facial hair 9 8 (6.7) 1 (0.4) 0.001 
22. Changes in appearance, texture or tone skin 67 40 (33.3) 27 (10.5) 0.001 
23. Feeling bloated 56 32 (26.7) 24 (9.3) 0.001 
24. Low backache 148 43 (35.8) 105 (40.7) 0.367 
25. Frequent urination 167 33 (27.5) 134 (51.9) 0.001 
26. Involuntary urination when laughing or coughing 77 27 (22.5) 50 (19.4) 0.483 
Sexual      
27. Changes in sexual desire 36 27 (22.5) 9 (3.5) 0.001 
28. Vaginal dryness during intercourse 39 29 (24.2) 10 (3.9) 0.001 
29. Avoiding intimacy 26 18 (15.0) 8 (3.1) 0.001 
Note: p-value obtained by Chi-Sq test 
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Table 4: Results of logistic regression analyses with diabetes as the dependent variable and the MENQOL domains as 
the independent variables (N = 378) 
Domains No Diabetes 
N = 120 
(Referent) 
Diabetes 
N = 258 
p-value 
Vasomotor    
Mean (SD) 5.75 (0.33) 6.17 (0.27) p = 0.357 
Unadjusted  1.0 1.03 (0.97 – 1.08)  
Age Adjusted  1.0 1.06 (0.99 – 1.12)  
Fully Adjusted  1.0 1.07 (0.97 – 1.18)  
Psychosocial    
Mean (SD) 13.15 (0.66) 11.96 (0.37) p = 0.096 
Unadjusted  1.0 0.97 (0.94 – 1.01)  
Age Adjusted  1.0 0.98 (0.94 – 1.01)  
Fully Adjusted  1.0 0.95 (0.91 – 1.00)  
Physical    
Mean (SD) 36.75 (1.67) 37.01 (0.93) p = 0.884 
Unadjusted  1.0 1.00 (0.99 – 1.02)  
Age Adjusted  1.0 1.00 (0.99 – 1.02)  
Fully Adjusted  1.0 0.99 (0.97 – 1.01)  
Sexual    
Mean (SD) 4.20 (0.20) 3.21 (0.08) p = 0.001 
Unadjusted  1.0 0.68 (0.58 – 0.81)*  
Age Adjusted  1.0 0.68 (0.58 – 0.80)*  
Fully Adjusted  1.0 0.69 (0.57 – 0.84)*  
Total MENQOL score    
Mean (SD) 59.85 (2.48) 58.36 (1.38) p = 0.566 
Unadjusted  1.0 1.00 (0.99 – 1.01)  
Age Adjusted  1.0 0.99 (0.99 – 1.01)  
Fully Adjusted  1.0 0.99 (0.98 – 1.01)  
Note: Means were compared using t test. Full logistic model adjusted for age, ethnicity, marital status, comorbidities, and obesity. 
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Table 5: Results of logistic regression analyses with depression and anxiety symptoms as the dependent variables 
and the MENQOL domains as the independent variables, by diabetes (N = 378) 
Dependent Domains Odds Ratio p-value 95% CI 
Women with diabetes (n = 258)  
Depression a Vasomotor 1.13 0.004 1.04 – 1.22 
 Psychosocial 1.14 0.001 1.07 – 1.21 
 Physical 1.08 0.001 1.04 – 1.11 
Anxiety b Vasomotor 1.18 0.001 1.07 – 1.29 
 Psychosocial 1.14 0.001 1.07 – 1.22 
 Physical 1.09 0.001 1.05 – 1.13 
Women without diabetes (n = 120)  
Depression a Vasomotor 1.22 0.002 1.08 – 1.39 
 Psychosocial 1.19 0.001 1.10 – 1.30 
 Physical 1.06 0.001 1.03 – 1.10 
 Vaginal/Sexual 0.98 0.884 0.78 – 1.24 
Anxiety b Vasomotor 1.23 0.006 1.06 – 1.42 
 Psychosocial 1.21 0.001 1.10 – 1.34 
 Physical 1.06 0.289 1.03 – 1.10 
 Vaginal/Sexual 1.01 0.931 0.79 – 1.29 
a = depression was measured with DSSI: depressed = 1; not depressed = 0; b = anxiety was measured with DSSI: anxious = 1; not anxious = 0; 
Logistic model adjusted for age and marital status 
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CHAPTER 10 
Relation between mental health-related variables and glycemic control in 
Malaysian women with type 2 diabetes mellitus 
 
The eighth and final objective of this thesis was to investigate whether depression and 
anxiety symptoms were associated with the poor glycemic control in Malaysian women. 
This study was undertaken as good quality data on this association was lacking in 
Malaysia, yet T2DM is a major public health problem in Malaysia. 
 
The work described in this chapter investigated the association between symptoms of 
depression and anxiety and poor glycemic control and has been published in the following 
form: 
 
1. Hasan, S.S., Thiruchelvam, K., Ahmed, S.I., Clavarino, A.M., Mamun, A.A., Kairuz, 
T. (2015). Relation between mental health-related variables and glycemic control in 
Malaysian women with type 2 diabetes mellitus. Int J Diabetes Dev Ctries, DOI: 
10.1007/s13410-014-0250-7. 
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Abstract The primary objective of this study was to examine
the association between depression, anxiety symptoms, and
glycemic control in Malaysian women with type 2 diabetes
mellitus (T2DM). Another objective was to examine the as-
sociation between glycemic control and mental status, mea-
sured by mental composite score (MCS). This study was
conducted on 611 randomly sampled Malaysian women with
T2DM who were treated as outpatients at medication therapy
adherence clinics (MTAC). The Delusions-Symptoms-States
Inventory: State of Anxiety and Depression (DSSI/SAD) and
Center for Epidemiologic Studies Depression Scale 10 (CES-
D 10) were used. Five most recent readings of hemoglobin
A1c (HbA1c), fasting, and random glucose levels were re-
corded. Regression analysis was used to correlate glycemic
control with depression, anxiety symptoms, and MCS, while
considering potential confounders. For depression symptoms,
an increase of one category was associated with a small
average HbA1c increase of 0.10 % (95 % CI −0.38, 0.68),
whereas for anxiety symptoms, there was a small decrease in
average HbA1c of 0.44 % (95 % CI −1.17, 0.28); both were
not significant. Very poorly controlled HbA1c was not signif-
icantly associated with symptoms of depression (OR 1.43,
95 % CI 0.45–4.55) or anxiety (OR 0.47, 95 % CI 0.15–
1.49). MCS was found to have a strong inverse correlation
with HbA1c. That is, women who reported poor MCS had a
significantly higher, and therefore very poorly controlled,
HbA1c (OR 1.70, 95 % CI 1.01–2.88). The presence of
depression and anxiety symptoms was not significantly asso-
ciated with glycemic control in women with T2DM,
supporting the hypothesis that argues against the existence
of a link between depression, anxiety, and glycemic control.
Keywords Mental health . Depression . Anxiety . Type 2
diabetesmellitus .Women .Malaysian
Introduction
People with diabetes mellitus (DM) experience a number of
complications during the course of the disease, including
psychological problems. Depression and anxiety are the two
most common comorbid conditions associated with DM [1].
Comorbid depression or anxiety together with DM may result
in poor metabolic control, higher complication rates, poorer
quality of life (QoL), increased management costs, disability,
and mortality rates [2–4]. It has been estimated that depressive
disorders are higher among women with or without diabetes
than among men; globally, depressive disorders in women
were the fourth leading cause of disease burden and the
seventh leading cause in men [2–4]. Studies from developed
countries reported higher prevalence of depression in women
compared to men [3, 5]. Although not many studies have been
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conducted in developing countries, a higher prevalence of
depression and anxiety symptoms among women has been
reported [6, 7]. Women with DM also exhibit poorer diabetes
self-care, glycemic control, and QoL than men with DM,
which are further exacerbated by depression [8].
Glycemic control is one of the top priorities in the man-
agement of people with DM in order to reduce the macro- and
micro-vascular complications [9]. Depression has been found
to affect glycemic control as well as macro-vascular and
micro-vascular complications [9–11], and there is substantial
evidence that comorbid depression among individuals with
DM is associated with poor DM outcomes such as poor
glycemic control [9, 12].
Significant controversy exists over whether or not depres-
sion and anxiety in patients with DM is associated with poorer
glycemic control, with some studies reporting moderate to
strong associations [10, 13–15] between depression symp-
toms and hemoglobin A1c (HbA1c), while others have found
no association [16–18]. Recent studies suggest that anxiety
disorders may also be associated with less favorable glycemic
control among adults with DM [19–21]. However, glycemic
control as a risk factor was associated only with higher anxiety
scores [22]. Prevalence of moderate to severe depression was
found to be significantly associated with poor glycemic con-
trol in men but not in women [19, 23], and cross-sectional
studies have found a significant positive correlation between
depression symptoms and HbA1c in patients with type 1
diabetes but no significant correlation in patients with type 2
diabetes mellitus (T2DM) [24, 25]. The evidence gives rise to
the hypothesis that depression and anxiety affect glycemic
control in men and those with type 1 DM but not women
and patients with T2DM. In order to test this hypothesis in a
developing country, we conducted a study to examine the
association between depression, anxiety symptoms, and gly-
cemic control in Malaysian women with T2DM.
Methods
Study design and participants
Six hundred and eleven Malaysian women with a known
diagnosis of T2DM for at least 1 year, who were treated as
outpatients at medication therapy adherence clinics (MTAC)
at PutraJaya Hospital in PutraJaya, and Tuanku Jaa’far Hos-
pital and Seremban Health Clinic in Negeri Sembilan, were
invited to participate in this study. Face-to-face interviews
were conducted at the outpatient clinics, using self-
administered questionnaires. The study was conducted ac-
cording to the principles expressed in the Declaration of
Helsinki and was approved by the School of Pharmacy Ethics
Committee at The University of Queensland, Australia (Ref.
No. 2011/14), and the International Medical University
Research and Ethics Committee (Project ID No: B01/09-Res
(04) 2012).
Women were categorized as having T2DM if they were
attending MTAC for the management of T2DM. Every sec-
ond woman with diabetes on the respective patients’ list at the
clinic sites was invited to participate; verbal or written consent
was obtained from participants who met the inclusion criteria.
The data were collected on women aged 35 and above. Infor-
mation was confirmed by accessing patients’medical records.
The presence of T2DM was identified according to two
criteria: A fasting plasma glucose (FPG) greater than or equal
to 7.0 mmol/l and random plasma glucose (RPG) greater than
or equal to 11.1 mmol/l. Women diagnosed with T1DM were
excluded.
Measurement of depression and anxiety symptoms
Center for Epidemiologic Studies Depression Scale 10 (CES-
D 10), a brief self-report screening tool for depressive symp-
toms derived from the validated 20-item CES-D 20 [26], was
used to assess depression symptoms. It has been shown to
have reliability and validity comparable to the standard 20-
item CES-D instrument and is considered a good instrument
for screening depression in patients with T2DM [27]. The
CES-D 10 uses a zero-to-three response scale, with total
symptom severity scores ranging from 0 (no depression) to
30 (severe depression) [28]. Participants in this study were
categorized as depressed if they scored 11 or more; this is a
commonly used cutoff point for CES-D [26].
The anxiety symptoms were assessed using the Delusions-
Symptoms-States Inventory: State of Anxiety and Depression
(DSSI/SAD). It contains 14 symptoms, 7 for depression and 7
for anxiety. The DSSI was developed for use with community
samples and has been validated against clinical samples with
diagnosed mental illness [29–31], and was also found to
correlate well, and shares items with, other established symp-
toms scales such as the Edinburgh Postnatal Depression Scale
(EPDS) and the Hospital Anxiety/Depression Scale (HADS)
[32]. Participants in this study were classified as anxious when
they reported four or more symptoms.
DSSI/SAD is an instrument used to evaluate anxiety and
depression symptoms but has not yet been validated for use
among people with diabetes [29]. Therefore, we validated the
DSSI instrument. Internal consistencywas 0.86 for the anxiety
and 0.90 for depression subscales, and 0.93 for the full scale of
DSSI/SAD. Principal component analysis revealed a bi-
factorial model. Correlation analysis showed a significant
negative correlation between DSSI-Anxiety and the mental
composite score (MCS) scale of Short Form 12 of the Medical
Outcomes Study (SF-12; r=−0.404, p=0.001); thus, as anxi-
ety symptoms decreased (DSSI), the MCS increased, indicat-
ing lower mental health-related limitations. We found signif-
icant variations in the DSSI/SAD domain scores that could be
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explained by CES-D (DSSI-Anxiety 55 %, DSSI-Depression
46 %) and SF-36 MCS (DSSI-Anxiety 66 %, DSSI-
Depression 56 %) suggesting that the DSSI/SAD can be used
for measuring depression and anxiety symptoms in people
with diabetes.
Mental health status by mental composite score (MCS)
We also measured overall mental health functioning using
MCS of the SF-12. SF-12 is a multipurpose survey instrument
comprising 12 questions, developed as a legitimate alternative
to the SF-36. The two summary scales, MCS and the Physical
Component Summary (PCS), provide an insight into mental
and physical health as well as disability level [33]. MCS
examining the impact of health on mental health function
was calculated using the method described by Ware et al.
[34]. The MCS ranged from 0 to 100; “0” implies poor mental
health and “100” implies goodmental health. Themedian split
method was used to categorize participants where scores less
than the median indicate poor MCS.
Assessment of glycemic control
Five most recent blood glucose readings were collected from
patients’ medical records. Mean and median values were
calculated and used for all comparisons. The monitoring of
hemoglobin A1c (HbA1c) is considered the gold standard for
glycemic control. The general HbA1c target in people with
T2DM is ≤7 %, and adjustment to diabetes treatment should
be considered when HbA1c is above this level [35], although
other guidelines suggest 6.5 % or less as the treatment goal,
which is closer to the normal healthy value [36]. The HbA1c,
fasting blood glucose (FBG), and random blood glucose
(RBG) values were used as both continuous and categorical
outcomes. We used >7 % HbA1c value as the cutoff point to
define poor glycemic control. The HbA1c was also catego-
rized based on quartile values: good controlled, moderately
controlled, poorly controlled, and very poorly controlled
HbA1c.
For fasting and random blood glucose, we used the Na-
tional Health and Medical Research Council (NHMRC) clas-
sification for people with T2DM, namely normal, moderate,
and high levels [37]. A fasting value between 4 and 6 mmol/l
was normal, between 6.1 and 6.9 mmol/l was moderate, and
anything above 7 mmol/l was high [37]. For non-fasting or
random blood glucose, a normal value was between 4 and
7.7 mmol/l, between 7.8 and 10.9 mmol/l was moderate, and
anything above 11 mmol/l was high [37].
Assessment of covariates
Potential confounders and risk factors were identified on the
basis of their association with outcomes and a priori
knowledge [11, 23, 38]. Socio-demographic information in-
cluded age, ethnicity, education, occupation, monthly income,
alcohol consumption, and cigarette smoking (non-smokers,
past smokers, and current smokers). These were collected
from participants. Clinical and physical parameters such as
comorbidities or medical conditions other than T2DM and
height (m) and weight (kg) measurements were obtained from
participants’medical records. Body mass index (BMI, kg/m2)
was then calculated to categorize participants based on the
WHO criteria [39]. For physical health, the Short Form 12 of
the Medical Outcomes Study (SF-12) was used, with lower
scores indicating poor physical health. The PCS scores were
calculated using the scores of the questions, ranging from 0 to
100, with lower scores indicating greater physical limitation
[33]. The median split method was used to categorize partic-
ipants where scores less than median indicate poor PCS. The
self-reported information on level of physical activity (not at
all, one to two times a week, three or more times a week), and
sleep problems (Nil, acute and chronic), were collected from
participants.
Statistical analysis
The data were analyzed using the Statistical Package for
the Social Sciences (SPSS)® version 20 and Stata IC®
version 12, with a significance level of ≤0.05. Descrip-
tive statistics were used to calculate percentages, fre-
quencies, means, and standard deviations. The relation-
ship between variables for categorical data was per-
formed using the χ2 (Chi-Sq). Fisher exact test was
applied in cases where sample size was small. Similarly,
on occasions where we had less than five readings per
cell for Chi-Sq, likelihood ratio test was applied. Com-
parisons between groups with normal distribution were
performed using the Student’s t test. Pearson’s correla-
tion test was used to verify the existence of a correla-
tion between instruments’ mean scores or other values.
Therefore, a series of multiple linear, logistic, and
multinomial regression models (see footnotes of Ta-
bles 3, 4, 5, and 6) was used to determine the associ-
ation of mean blood glucose levels with depression and
anxiety symptoms assessed as continuous and categori-
cal outcomes. The effects were adjusted for demograph-
ic, lifestyle, and clinical factors [11, 23, 38]. For logis-
tic regression, we used the median split method to
categorize the variables into binary groups. These binary
groups include number of pregnancies, age at last preg-
nancy, and PCS. For potential confounding, the unad-
justed associations of depression and anxiety symptoms
with glycemic control were compared with the adjusted
associations, with confounding confirmed when the un-
adjusted effect size and adjusted effect size estimates
differed.
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Results
Socio-demographic characteristics and glycemic control
The median ages of the 611 participating women at the time of
this study and at diabetes diagnosis were 58 and 48 years,
respectively. The majority were aged between 45 and 64 years
(67 %), were married (82 %), were of Malay ethnicity (38 %),
had completed only primary education (76.3 %), and were
earning less than 3500 Ringgit Malaysia monthly (1 RM=3.1
US$). Regarding HbA1c levels, there were higher levels
among younger women aged 35 to 44 (8.14±1.47) and 45
to 54 years (8.37±1.98) than older women (7.43±1.51).
Women of Indian ethnicity had higher levels of HbA1c
(8.73±1.98) compared to other ethnic groups. The median
values of HbA1c, FBG, and RBG were 7.77 % (N=611),
7.65 mmol/l (N=352), and 9.80 mmol/l (N=314),
respectively.
Anxiety and depression symptoms and glycemic control
Depression (8.7 %) and anxiety (9.0 %) symptoms were not
commonly reported by participants in this study. Women with
anxiety had slightly higher FBG (8.54 versus 8.34) and RBG
(11.10 versus 9.87) levels compared to women without anx-
iety symptoms. Unlike women with anxiety, women with
depression symptoms had slightly higher HbA1c (8.24 versus
8.10) compared to women with no depression (Table 1). Cor-
relation analysis shows a weak correlation between HbA1c
and anxiety (inverse) and HbA1c and depression (positive)
symptoms.
The univariate analysis shows that for an increase of one
category of depression symptoms, there were small increases
in HbA1c (0.15 %, 95 % CI −0.38–0.68), FBG (0.33 mmol/l,
95 % CI −0.77–1.42), and RBG (1.02 mmol/l, 95 % CI
−0.20–2.25). The effect estimates were reduced after adjust-
ments for the effect of confounders (Table 2). In case of
anxiety symptoms, HbA1c decreased by a small amount.
Very poorly controlled HbA1c was not significantly asso-
ciated with increased odds of depression (OR 1.43, 95 % CI
0.45–4.55) and anxiety (OR 0.47, 95 % CI 0.15–1.49) symp-
toms; similarly, neither weremoderately and poorly controlled
HbA1c (Table 3). The high FBG range was not significantly
associated with increased odds of anxiety (3.38, 95 % CI
0.67–17.11) and depression (1.47, 95 % CI 0.41–5.26) symp-
toms (Table 4). Similarly, the expected risk remaining in the
high RBG range was higher for women with anxiety and
depression symptoms, but this was not significant (Table 5).
Mental health function and glycemic control
Almost half of the participating women were found to have
poormental health functional status, as measured byMCS. On
average, women with poor MCS had higher HbA1c, FBG,
and RBG compared to women with good MCS (Table 1).
Correlation analysis shows a strong inverse correlation be-
tween HbA1c and MCS.
A 1-unit score increase in the MCS was associated with
0.47 % (0.17, 0.77), 0.70 mmol/l (0.10, −1.31), and
0.11 mmol/l (−0.58, 0.79) HbA1c, FBG, and RBG levels,
respectively. We found very little confounding of MCS, since
there was little difference between the univariate analysis
coefficients and the adjusted coefficients (Table 2). Poor
MCS were significantly associated with very poorly con-
trolled HbA1c (OR 1.93, 95 % CI 1.22–3.03) and remained
significant after adjustments for confounders (OR 1.70, 95 %
CI 1.01–2.88); however, neither moderately nor poorly con-
trolled HbA1c was observed compared to women with normal
level (Table 3).
Discussion
This was the first study to investigate the association between
depression, anxiety symptoms, and glycemic control among
Malaysian women with T2DM. We did not find strong asso-
ciations between depression and glycemic control or between
anxiety and glycemic control. However, women with comor-
bid depression and anxiety symptoms had higher mean blood
glucose values compared to those without depression and/or
anxiety symptoms. In our study, fewer than 10 % of women
with T2DM exhibited depression and anxiety symptoms. In
contrast, almost half of the women reported poor mental
functional status, as measured by MCS, indicating the oppo-
site trend. Almost two thirds of the women (65.6 %) had
HbA1c values greater than 7 % and more than a quarter of
them were above 9 % indicating poor glycemic control. This
reflects the trend reported by the American Diabetes Associ-
ation (ADA)which suggest that only one of every two patients
with diabetes has glycosylated HbA1c levels <8.0%, and very
few patients sustain HbA1c levels <7.0 % [40].
Depression and anxiety were more common among people
with poor glycemic control; however, the underlying mecha-
nisms are not well elucidated, with some studies reporting that
people with poor glycemic control are more likely to become
depressed or anxious [4, 10, 13–15, 19–21], while we found
that only people with very poorly controlled glucose levels, as
measured by MCS, were associated with poor mental health
status. Our study found differences between people with poor
glycemic control and normal glycemic level in overall mental
health functioning but not specifically in mental health or
vitality domains of MCS. The exact explanation for the asso-
ciation we observed is unclear: glycemic control may affect
emotional and social function, persons with better emotional
function may be more likely to be prevented from negative
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and positive effects of poor glycemic control, or glycemic
control may be linked with other confounding variables that
affect mental health function.
Our study shows that for an increase of one category of
symptoms of depression, HbA1c increased, on average, by
only a small amount of 0.10 %. A similar increment was
reported in a longitudinal study of people with T2DM who
showed, over a 4-year period, HbA1c values which were, on
average, 0.13 % higher in people who had depression [12].
Previous studies have come to different conclusions about the
association of depression symptoms and glycemic control;
some reported a significant relationship between poorer gly-
cemic control and depressive symptoms [14, 41] while others
found an insignificant or weak association between glycemic
control and depressive symptoms [18, 38, 42]. However, a
meta-analysis reported a significant association [9], and ran-
domized clinical trials of therapies for depression demonstrat-
ed improvement in depressive symptoms corresponding with
improvements in glycemic control [43, 44], and vice versa
[14].
Table 1 Mental health status of women with T2DM, by means and standard errors of HbA1c, fasting, and random blood glucose levels
Variables HbA1c (N=611) Fasting BG (N=352) Random BG (N=314)
N Mean SE 95 % CI N Mean SE 95 % CI N Mean SE 95 % CI
Depression
No depression 558 8.10 0.08 7.94–8.25 321 8.32 0.16 8.00–8.65 288 9.88 0.18 9.53–10.23
Depression symptoms 53 8.24 0.27 7.70–8.78 31 8.65 0.61 7.40–9.90 26 10.91 0.67 9.53–12.28
Anxiety
No anxiety 558 8.11 0.08 7.95–8.27 321 8.34 0.16 8.01–8.66 289 9.87 0.18 9.53–10.22
Anxiety symptoms 53 8.06 0.25 7.56–8.57 31 8.54 0.60 7.31–9.76 25 11.10 0.71 9.60–12.54
Mental health—MCS
Good MCS 323 7.88 0.10 7.69–8.07 173 8.00 0.20 7.60–8.40 177 9.92 0.22 9.49–10.35
Poor MCS 288 8.35 0.12 8.12–8.59 179 8.70 0.24 8.22–9.17 137 10.04 0.28 9.47–10.59
BG blood glucose, SE standard error, MCS mental composite score
Table 2 The associations between symptoms of depression and HbA1c, anxiety and HbA1c (%), and FBG and RBG (mmol/l)
Variables Depression symptoms Anxiety symptoms Mental health—MCS
No (referent) Yes No (referent) Yes Good MCS
(referent)
Poor MCS
HbA1c in %—(N=611)
Unadjusted
estimate
(95 % CI)
8.10 (7.93, 8.25) 0.15 (−0.38, 0.68) 8.11 (7.95, −8.27) −0.05 (−0.58, 0.49) 7.88 (7.68, 8.10) 0.47 (0.17, 0.77)a
Adjusted estimate
(95 % CI)
8.81 (7.67, 9.94) 0.10 (−0.63, 0.81) 8.81 (7.67,9.94) −0.44 (−1.17, 0.28) 8.39 (7.26, 9.52) 0.46 (0.12, −0.80)
Fasting BG in mmol/l—(N=352)
Unadjusted
estimate
(95 % CI)
8.32 (8.00, 8.65) 0.33 (−0.77, 1.42) 8.34 (8.01, 8.66) 0.20 (−0.90, 1.30) 8.00 (7.56, 8.44) 0.70 (0.10, −1.31)
Adjusted estimate
(95 % CI)
11.82 (9.39, 14.25) −0.10 (−1.53, 1.33) 11.82 (9.39, 14.25) −0.03 (−1.49, 1.44) 11.37 (8.90, 13.86) 0.44 (−0.33, 1.21)
Random BG in mmol/l—(N=314)
Unadjusted
estimate
(95 % CI)
9.88 (9.53, 10.24) 1.02 (−0.20, 2.25) 9.87 (9.52, 10.23) 1.19 (−0.05, 2.44) 9.92 (9.47, 10.38) 0.11 (−0.58, 0.79)
Adjusted estimate
(95 % CI)
10.75 (8.13, 13.37) 0.41 (−1.55, 2.36) 10.75 (8.13, 13.37) 0.13 (−1.86, 2.12) 10.75 (8.19, 13.32) −0.02 (−0.81, 0.77)
Approach used was linear regression. Depression and anxiety symptoms adjusted for depression or anxiety, age, comorbidities, physical activity, BMI,
physical health, and sleep problems
BG blood glucose, MCS mental composite score
a Statistically significant
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Although our data found no significant association be-
tween anxiety and HbA1c, HbA1c values were, on average,
0.44 % lower in those with anxiety symptoms. In contrast to
previous studies which suggest that anxiety disorders are
associated with less favorable glycemic control among adults
with DM [19–21], our data did not show such a relationship.
Interestingly, insignificant correlations of HbA1c with depres-
sion and anxiety symptoms also indicated a weak link be-
tween the two. Contrary to this, a strong inverse correlation
between HbA1c and MCS was found, suggesting that women
who score high on MCS scale appear to have lower HbA1c
level than women who score low on MCS. A 1-unit score
increase in the MCS was associated with 0.47 % (−0.17,
−0.77), 0.70 mmol/l (0.10, −1.31), and 0.11 mmol/l (−0.58,
0.79) for HbA1c, FBG, and RBG levels, respectively. The
adjusted effect of MCS on HbA1c was almost unchanged
(reduced by only 1 %), suggesting no—or very little—con-
founding. Despite strong inverse correlations of MCS with
DSSI and CES-D 10, only MCS reflected significant changes
in glycemic control in this study. MCS might have captured
the distress associated with diabetes and is reflected in the
correlation between MCS and glycemic control.
Table 3 Odds ratio (95 % CI) of poor glycemic control (HbA1c >7 %) according to depression and anxiety symptoms (N=611)
Items Depression symptoms Anxiety symptoms Mental health—MCS
No (referent) Yes No (referent) Yes Good MCS (referent) Poor MCS
HbA1c—binary outcome
Normal level, N (%) (referent) 195 (31.9) 16 (2.6) 193 (31.6) 18 (2.9) 126 (20.6) 85 (13.9)
Poor level, N (%) 363 (59.4) 37 (6.1) 365 (59.7) 35 (5.7) 197 (32.2) 203 (33.2)
Unadjusted odds 1.0 0.81 (0.44–1.48) 1.0 0.97 (0.54–1.76) 1.0 0.65 (0.47–0.92)a
Adjusted odds 1.0 0.82 (0.35–1.95) 1.0 1.36 (0.58–3.21) 1.0 0.71 (0.46–1.05)
HbA1c—quartile-based categories
Good controlled, N (%) (referent) 142 (23.3) 13 (2.1) 140 (23.0) 15 (2.5) 94 (15.4) 61 (10.0)
Moderately controlled, N (%) 141 (23.2) 10 (1.6) 138 (22.7) 13 (2.1) 81 (13.3) 70 (11.5)
Unadjusted odds 1.0 0.77 (0.33–1.82) 1.0 0.90 (0.40–1.92) 1.0 1.33 (0.85–2.10)
Adjusted odds 1.0 0.90 (0.28–2.91) 1.0 0.95 (0.32–2.82) 1.0 1.29 (0.77–2.16)
Poorly controlled, N (%) 135 (22.2) 15 (2.5) 137 (22.5) 13 (2.1) 80 (13.1) 70 (11.5)
Unadjusted odds 1.0 1.21 (0.57–2.64) 1.0 0.89 (0.41–1.93) 1.0 1.35 (0.86–2.12)
Adjusted odds 1.0 1.59 (0.52–4.87) 1.0 0.58 (0.20–1.79) 1.0 1.24 (0.74–2.10)
Very poorly controlled, N (%) 139 (22.8) 14 (2.3) 141 (23.2) 12 (2.0) 68 (11.2) 85 (14.0)
Unadjusted odds 1.0 1.10 (0.50–2.42) 1.0 0.79 (0.36–1.76) 1.0 1.93 (1.22–3.03)a
Adjusted odds 1.0 1.43 (0.45–4.55) 1.0 0.47 (0.15–1.49) 1.0 1.70 (1.01–2.88)a
Odds ratio adjusted for depression or anxiety, age, comorbidities, physical activity, BMI, and physical health. Classificationmethod usedwas logistic and
multinomial regression
a Statistically significant
Table 4 Odds ratio (95 % CI) of fasting glucose level according to depression and anxiety symptoms (n=352)
Items Depression symptoms Anxiety symptoms Mental health—MCS
No (referent) Yes No (referent) Yes Good MCS (referent) Poor MCS
FBG—categories
Normal level, N (%) (referent) 75 (21.3) 5 (1.3) 75 (21.3) 5 (1.3) 43 (12.2) 37 (10.5)
Moderate level, N (%) 52 (14.8) 6 (1.7) 49 (13.9) 9 (2.6) 33 (9.4) 25 (7.1)
Unadjusted odds 1.0 1.73 (0.50–5.97) 1.0 2.75 (0.87–8.71) 1.0 0.88 (0.44–1.74)
Adjusted odds 1.0 0.88 (0.17–4.58) 1.0 3.38 (0.67–17.11) 1.0 0.81 (0.33–1.74)
High level, N (%) 194 (55.1) 18 (5.1) 197 (56.0) 13 (3.7) 97 (27.6) 117 (33.2)
Unadjusted odds 1.0 1.55 (0.56–4.27) 1.0 1.29 (0.46–3.63) 1.0 1.40 (0.84–2.35)
Adjusted odds 1.0 1.47 (0.41–5.26) 1.0 0.92 (0.23–3.61) 1.0 1.18 (0.60–2.34)
Fasting glucose adjusted for depression or anxiety, age, comorbidities, physical activity, BMI, physical health, and sleep problems. Classification method
used was logistic and multinomial regression
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Limitations
Our assessment of depression and anxiety symptoms was
based on self-report of symptoms using validated instruments
and not on the Diagnosis and Statistical Manual (DSM)
criteria based clinical diagnostic interview. A clinical confir-
mation of depression or anxiety could not be done because the
DSM for diagnosis of mental disorders states that the standard
diagnostic criteria are applied “in the presence of a psychiatrist
or trained healthcare professional.” Therefore, two instru-
ments were used to examine depression or anxiety symptoms
as no clinical confirmation was available. Although we ap-
plied systematic sampling, participants who frequently
attended the outpatient clinics were more likely to be sampled
than those who attended less frequently, and therefore were
presumed to have better glycemic control. This might have
introduced selection bias.
Conclusions
This study did not find significant associations between
depression and glycemic control and anxiety and glyce-
mic control in Malaysian women with T2DM. Despite
strong inverse correlations of MCS with DSSI-Anxiety
and CES-D 10, only MCS tended to be associated with
significant changes in glycemic control in this study.
This evidence supports the hypothesis that argues
against the existence of a link between depression and
glycemic control and anxiety and glycemic control.
However, as primary care physicians may fail to recog-
nize a substantial number of patients with depression
and/or anxiety symptoms and as the prevalence of dia-
betes continues to increase, in Malaysia, it is important
for health care professionals managing patients with DM
to be aware of the association between depression,
anxiety symptoms, and glycemic control to prevent fur-
ther complications.
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CHAPTER 11 
General Discussion 
 
11.1. Introduction 
A range of analyses and reviews were rigorously undertaken during this PhD study in 
order to explore the relationships between depression and diabetes, and anxiety and 
diabetes, in both a developed and a developing country. The analyses and reviews 
conducted produced a large number of research papers (12) of which six have been 
published, two accepted for publication, and four have been revised according to 
reviewers’ comments and editorial specifications and resubmitted to journals. The 
published papers and manuscripts are included in the results sections and in Appendices 
1A and 4A to 4D and will be referred to where relevant. An attempt was also made to 
identify any bidirectional relationships using longitudinal data. These associations are likely 
to involve complex interactions including those associated with socio-demographic and 
clinical factors (Mezuk et al., 2008; Smith et al., 2013; Venables et al., 2009). Detailed 
discussion on the possible mechanisms underpinning these associations was included in 
previous chapters particularly in Chapter 1. A considerable literature is available that 
examined the association between depression and diabetes; however, very few 
prospective studies have examined the strength and magnitude of the association 
between anxiety and diabetes, controlling for potential confounders. Conclusions 
presented in previous studies that have examined the associations between depression 
and diabetes, and anxiety and diabetes, were based on cross-sectional data (Smith et al., 
2013) and specific geographic locations (US and European Region). These two issues are 
important limitations because it is not ideal to answer questions about the causal or 
temporal sequence of associations and to extrapolate findings to populations living in other 
regions of the world.  
 
To examine the nature of the association between psychological disorders and diabetes, a 
rigorous methodology was adopted to confirm the association using more than one study 
design. The findings presented in this thesis are based on original data as well as data 
derived from previous studies which have produced meta-analyses and a systematic 
review. Initially, a systematic review was completed using prevalence data obtained from 
previous studies to estimate the burden of comorbid depression and anxiety in people with 
diabetes. Following this, four meta-analyses were conducted, and pooled estimates were 
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generated using longitudinal data from previous studies. Finally, original datasets from a 
developed country (Australia - MUSP – longitudinal data) and a developing country 
(Malaysia – cross-sectional data) were analyzed individually to examine the associations 
from two perspectives. 
 
A series of investigations using data from MUSP, a 27-year follow-up study, examined the 
associations between depression and diabetes, and anxiety and diabetes. It is worth 
mentioning here that MUSP was not primarily designed to investigate these associations, 
but the collection of data over 27 years provided a platform to examine the associations 
between risk factors, to which the participating women were exposed early in life and the 
consequences or adverse outcomes in later life. The MUSP study, including the design, 
execution, data collection and entry was conducted by a team of senior investigators and 
their colleagues between 1981 and 2011. However, the development of the current 
concept, construction of derived variables used in this thesis, and the methodological 
procedures and analyses it presents were the work of the candidate himself under the 
guidance of supervisors. In addition to the MUSP analyses, the candidate developed the 
concept, construction of variables, and the methodological procedures and statistical 
analyses for a case-control study in Malaysia. 
 
This chapter summarizes the findings of systematically reviewed literature and research 
articles completed as part of this thesis and presents conclusions based on the research 
findings. It concludes with a discussion of their implications for policy and decision making. 
In the following section, findings from a systematic review, meta-analyses and original 
research papers are presented and discussed. A detailed description of each set of 
findings, including possible explanations of the associations and relevant limitations, can 
be found in the individual manuscripts in the results section. 
 
11.2. Summary of findings related to the main research questions 
In a stepwise approach, the independent associations between depression and diabetes 
and anxiety and diabetes, in both a developed and a developing country, were examined. 
The research objectives are outlined in Chapter 1 (section 1.6.1) and discussed in the 
following sections. 
 
 
 
159 
 
11.3. Association between depression and diabetes 
11.3.1. Global distribution of comorbid depression in people with diabetes 
The first objective of this thesis was to estimate the global distribution of comorbid 
depression in people with type 1 (T1DM) and type 2 (T2DM) diabetes mellitus, via risk-
adjustment. A review of 71 studies found a higher burden of comorbid depression in 
people living in developing regions (26.32%), in people with T1DM (17.90%), in women 
(15.41%) and when assessed by self-report scales (22.66%). No statistically significant 
differences were seen due to gross heterogeneity across countries.  
 
11.3.2. Summary of findings from meta-analyses (depression and diabetes) 
Three meta-analyses were conducted by the candidate and have been published 
(objective 2), they examined the association between depression and diabetes. The first 
meta-analysis examining depression as risk factor for diabetes revealed greater 
cumulative incidence of diabetes in depressed than in non-depressed groups. Both the 
relative risk (67%) and hazard ratio (45%) showed a significant association between 
depressive symptoms and the risk of incident diabetes. The second meta-analysis 
investigated diabetes as risk factor for depression, and found higher cumulative incidence 
of depression in people with diabetes than in people without diabetes. Similar to the first 
meta-analysis, both the relative risk (27%) and hazard ratio (23%) revealed significant 
associations between diabetes and the risk of incident depression. The evidence obtained 
from these meta-analyses endorses the findings of previous studies, and suggest a 
bidirectional association between depression and diabetes (Mezuk et al., 2008; Routella & 
Mannucci, 2012; Routella & Mannucci, 2013). In the third meta-analysis, the effect sizes 
were re-estimated for the bidirectional association between depression and diabetes using 
the quality-effects model. This re-analysis revealed that the associations were weakened 
and the confidence interval, too, was shifted in the direction of the null.  Nevertheless, 
results remained statistically significant. 
 
11.3.3. Summary of findings from MUSP (depression and diabetes) 
One of the objectives of this thesis was to validate the personal disturbance scale, the 
Delusions-Symptoms-States-Inventory/States of Anxiety and Depression (DSSI/sAD), 
among women with diabetes using the MUSP dataset. The findings of factor analyses and 
concordant validity analysis, conducted during this PhD study, support the validity and 
confirmed the psychometric properties of DSSI/sAD for use among women with diabetes. 
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The results also demonstrate that the DSSI/sAD items have similar relationships to one 
another in both diabetic and non-diabetic groups and therefore suggest that they provide 
similar interpretations.  
 
The next objective was to investigate whether depressive symptoms were independently 
associated with diabetes mellitus; this was measured at 21-years post index pregnancy in 
Australian women and longitudinal data collected as a part of the MUSP study was used to 
examine this association. In the 21-year follow-up study, after excluding diabetes cases 
reported at the start of the MUSP study, 301 women reported diabetes. In prospective 
analyses of this subset, women with a positive history of symptoms of depression and 
women with persistent symptoms, had a 1.97-fold (95% CI: 1.14 – 3.40) to 2.23-fold (95% 
CI: 1.09 – 4.57) greater risk of diabetes. These original research results based on the 
MUSP dataset endorse the findings of the meta-analyses undertaken as a part of this 
thesis. 
 
Lastly, the present study investigated whether the presence of diabetes mellitus was 
independently associated with depressive disorders: this was measured at 27-year post 
index pregnancy in Australian women. In the 27-year follow-up study, women with 
diabetes had a greater lifetime prevalence of any depressive disorder compared with 
women without diabetes. Women with diabetes also had higher prevalence of major 
depressive disorder (MDD) compared with women without diabetes. In prospective 
analyses, diabetes increased the risk of any lifetime depressive disorder (OR 1.37, 95% 
CI: 1.03–1.84) and lifetime MDD (OR 1.36, 95% CI: 1.01–1.85). 
 
11.3.4. Summary of findings from Malaysian Study (depression and diabetes)  
This thesis also examined the association between symptoms of depression and anxiety 
and T2DM, in a developing country. Using cross-sectional data obtained in Malaysia, 
women with diabetes (11.8%) had higher depressive symptoms compared with women 
without diabetes (8.4%). In multivariate regression analysis, the presence of T2DM did not 
increase the odds of depression (OR 0.75, 95% CI: 0.38-1.46). Similarly, the duration of 
T2DM did not increase the odds of depression symptoms significantly.  
 
Cross-sectional analyses suggest that T2DM is not a significant risk factor for depression; 
similarly, neither is depression a significant risk factor for T2DM. Interestingly, the cross-
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sectional analysis using the MUSP 21-year dataset produced similar results; that is, no 
significant cross-sectional association between depression symptoms and diabetes.  
 
11.4. Association between anxiety and diabetes 
11.4.1. Global distribution of comorbid anxiety in people with diabetes 
The global distribution of comorbid anxiety in people with T1DM and T2DM diabetes 
mellitus was estimated, via risk-adjustment. A review of 35 studies found a higher burden 
of comorbid of anxiety in developed regions in people with T2DM (20.15%) and when 
assessed by self-report scales (20.75%). Regarding specific anxiety disorders, the burden 
of GAD was higher in developing regions compared to developed regions (12.10 vs. 
5.41%). No statistically significant differences were seen due to gross heterogeneity 
across countries.  
 
11.4.2. Summary of findings from meta-analysis (anxiety and diabetes) 
A previous meta-analysis found that people with diabetes are at greater risk of developing 
anxiety symptoms or disorders (Smith et al., 2013). However, no meta-analysis has 
investigated the development of diabetes in relation to the presence of anxiety symptoms. 
Therefore the risk of diabetes associated with anxiety was examined, using a rigorous 
methodology of bias-adjusted models for conducting a meta-analysis of longitudinal 
studies. A pooled estimate for incident diabetes with subjects who exhibited anxiety 
(exposure) of 1.65 was found, suggesting a 65% increase in the risk of diabetes; however, 
the relative risk for the negative complement (no-diabetes), was 0.987, suggesting there 
would be a 1.3% increase in diabetes had the unexposed group been exposed to anxiety. 
The pooled risk difference was 0.031 (95% CI: - 0.007 to 0.054) and the number needed to 
be exposed for one additional person to be harmed (NNEH) was 33 (95% CI 19 to 143) at 
2 years post exposure. Based on these findings it is suggested that anxiety could lead to 
an increased risk of developing diabetes.  
 
11.4.3. Summary of findings from MUSP (anxiety and diabetes)  
Similar to the analyses conducted for depression, I also investigated whether anxiety 
symptoms were independently associated with diabetes mellitus: this was measured at the 
21-year follow-up in Australian women. In prospective analyses, no significant association 
of diabetes with negative change (not anxious to anxious at subsequent phase) or with 
positive change in symptoms of anxiety (anxious to not anxious at subsequent phase) was 
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found; however, increasing risk was evident. Women with persistent symptoms of anxiety 
had a 1.85-fold greater risk of developing diabetes (95% CI: 1.18 – 2.90). The finding 
suggests that only persistent anxiety symptoms are associated with a modest increase in 
the risk of diabetes at the 21 years follow-up. 
 
Women with diabetes had a higher lifetime prevalence of any anxiety disorder compared 
with women without diabetes that is about one in two women with diabetes. In a 
multivariate model, diabetes was significantly associated with a 30-day episode of any 
anxiety disorder (95% CI: 1.14–2.25) and lifetime posttraumatic stress disorder (OR 1.42, 
95% CI: 1.01–2.02). The present study therefore, endorses the findings of a previous 
meta-analysis suggesting that people with diabetes are at greater risk of developing 
anxiety symptoms or disorders (Smith et al., 2013). 
 
11.4.4. Summary of findings from Malaysian Study (anxiety and diabetes) 
Women with diabetes reported higher anxiety (8.4%) symptoms compared with women 
without diabetes (6.6%); this was similar to the findings for depression. In cross-sectional 
analyses using data collected in Malaysia, the presence of T2DM did not increase the 
odds of anxiety (OR 0.72, 95% CI: 0.38-1.38) symptoms. Similarly the duration of T2DM 
did not increase the odds of anxiety symptoms significantly.  
 
This was similar to findings from the cross-sectional analysis using the MUSP 21-year 
dataset, where there was no significant association between anxiety symptoms and 
diabetes. On the DSSI scale, the odds that a postmenopausal Malaysian woman with 
diabetes was anxious increased significantly when the MENQOL score on the physical, 
vasomotor, and psychosocial domains increased by one unit. 
 
11.5. Glycemic control and symptoms of depression and anxiety 
The data collected from Malaysia included variables that provided an opportunity to 
determine whether symptoms of depression were associated with glycemic control in 
Malaysian women. It has been reported that poor glycemic control is linked to moderate to 
severe depressive symptoms (Anderson et al., 2002; Lustman et al., 2000), and glycemic 
control as a risk factor is associated with higher anxiety scores (Collins et al., 2009).  
 
Two thirds of the women had HbA1c values greater than 7% and more than a quarter of 
them were above 9% indicating poor glycemic control; however there was no significant 
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association between symptoms of depression and anxiety and poor or very poor glycemic 
control in both unadjusted and adjusted cross-sectional analyses. These findings support 
the hypothesis that argues against the existence of a link between depression and 
glycemic control, and anxiety and glycemic control. 
 
11.6. Strength and limitations of the thesis 
The strength of the research findings reported in this thesis lies in analyses of datasets 
obtained from a developed (Australia) and a developing (Malaysia) country. In Australia 
the longitudinal dataset was obtained from a large, ongoing birth cohort study based on 
recruitment between 1981 and 1983, and 6753 mothers were included as the overall study 
sample. In Malaysia, a case-control study based on recruitment of 1240 women with and 
without T2DM between March 2012 and January 2013 provided a cross-sectional dataset. 
 
There are several advantages of using longitudinal data. Longitudinal data obtained from a 
large study usually produces or generates precise and reliable estimates of effects. The 
MUSP longitudinal dataset provided an opportunity to study the associations between risk 
factors that women are exposed to in their early life or around pregnancy, and later-age 
outcomes. MUSP is one of the longest follow-up studies in Australia (27-year follow-up) 
and its sample size (6753) is sufficient for the investigation of common outcomes such as 
mental health problems and chronic diseases. 
 
The main difference between MUSP and the study conducted in Malaysia is the study 
design; the latter was a case-control study. A similar set of variables to that used in MUSP 
was collected from the case-control study in Malaysia.  This provided an opportunity to 
examine the strength and magnitude of the associations between depression and 
diabetes, and anxiety and diabetes. Unlike MUSP, where diabetes was self-reported, in 
the Malaysian case-control study, diabetes was confirmed by physician diagnosis and 
blood glucose measurements. The Malaysian study also provided additional data on blood 
glucose levels. 
 
The limitations associated with MUSP and the Malaysian studies have been discussed in 
detail in each of the papers, submitted or published (Results section). It is important to 
understand the limitations and to bear these in mind when interpreting the findings. A 
common limitation of population-based cohort studies is the dropt-out or attrition from the 
original sample, and this is demonstrated in Figure 11.1 using data from the MUSP study.  
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Figure 11.1: Proportion of women who were retained in the study at each phase 
 
The original mothers’ cohort comprised 6753 women at the start of the study. However, at 
21-year follow-up, only 55.6 percent of women completed the follow-up. Similarly, at 27-
year follow-up, only 49 percent were administered the CIDI-Auto to assess depressive and 
anxiety disorders. Missing data due to drop-out or item non-response may cause bias in 
the analyses and loss of statistical power (Little & Rubin, 1987). Therefore, to improve the 
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precision of estimates and the statistical power, a multiple imputations technique was 
employed to adjust for missing data. This technique was discussed in detail in Chapter 1 
(section 2.1.8) and in each of the MUSP papers (incorporated in Chapters 6 to 8) with the 
exception of the paper on the validation of the DSSI/sAD (Chapter 5). Although the 
multiple imputations technique has been used to adjust for missing data, it is important that 
the reader exercises caution when generalizing the findings to the broader population of 
women with mental health issues or with diabetes. 
 
Important limitations of MUSP data are self-reported diabetes and the use of self-report 
scales to identify depression and anxiety symptoms. It is possible that women may have 
incorrectly reported the presence or absence of diabetes. However, self-report diabetes is 
considered to be a reliable measure of the presence of diabetes (Kriegsman et al., 1996), 
although not as accurate as direct glucose measurement. An evaluation of self-report of 
chronic conditions in the US National Health Interview Survey found that self-report of 
diabetes showed very high agreement with medical records data (NCHS, 1994). Data from 
Taiwan also showed that self-report of diabetes yielded high agreement when compared 
with physical examination and HbA1c (Goldman et al., 2003).  
 
In the present study, information about depressive and anxiety symptoms, among the 
MUSP cohort, measured at the 5, 14 and 21 year MUSP follow-ups, was derived from a 
self-report scale (DSSI/sAD) possibly leading to information bias and misclassification of 
mental health status, including symptoms of depression and anxiety. However, to improve 
the quality of reporting and findings of this thesis, the DSSI/sAD scale in women with and 
without diabetes was validated, prior to its use for the main analyses.  
 
Unlike MUSP, data obtained from Malaysia was cross-sectional in nature and therefore did 
not provide an opportunity to study long-term associations between risk factors and 
outcomes. Despite this limitation, the Malaysian study did provide information about the 
strength and magnitude of the associations of interest. The findings based on cross-
sectional Malaysian data and cross-sectional analyses of MUSP are similar, endorsing the 
validity of our findings. 
 
For adjustment for confounders, both direct acyclic graphs and priori knowledge were 
used, and were discussed in detail where relevant (Chapters 5 to 10). In both, the MUSP 
and the Malaysian study, it was possible to adjust the statistical models for a wide range of 
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possible confounders; however, in this study I did not examine the effects of drugs used by 
participants for chronic conditions.  
 
MUSP is a prospective study with unequal time intervals between data collection phases. 
For example, the MUSP study did not collect data for long periods between 5 to 14 years 
and 14 to 21 years post birth of the index child, thereby ignoring the influence of other 
factors which may have been present during these intervals, and their influence on the 
associations between depression and diabetes, and anxiety and diabetes. Finally, there is 
a possibility that some covariates that were not measured or included in this study, may 
explain the associations between depression and diabetes, and anxiety and diabetes. 
 
11.7. Are these associations causal? 
The main objectives of this thesis were to investigate the independent association between 
depression and diabetes, and anxiety and diabetes and not to examine causal or temporal 
sequences. However it was felt important to discuss causal pathways and identify links 
between depression and diabetes, and anxiety and diabetes.  
 
Bradford Hill’s criteria provide a framework to investigate the causal pathway or sequence 
of the observed associations under investigation (Hill, 1965), and have typically been used 
in epidemiological studies to examine associations between an exposure variable and an 
outcome (Lucas & McMichael, 2005). Lucas and McMichael suggested that causation is 
an interpretation, not an entity; it is merely an inference based on an observed conjunction 
of exposure and health status in time and space (Lucas & McMichael, 2005).  
 
Generally in uncontrolled studies and to a certain extent in longitudinal studies, the 
measurement of exposure and outcome is of less quality than in controlled clinical trials 
(Lucas & McMichael, 2005). The focus of this thesis was on the bidirectional associations 
between depression and diabetes. Although some evidence of bidirectional associations 
between these variables have been reported in previous studies, as well as the present 
study, establishing the causal sequence has not been straight forward. This is because 
mood disorders such as anxiety and depression usually begin at a young age, well before 
the onset of diabetes, particularly T2DM (Kessler et al., 2005), suggesting that depression 
and anxiety are stronger risk factors for diabetes onset than vice versa. Another issue is 
that anxiety and depression are chronic or recurrent in nature (Anderson et al, 2001; 
Grigsby et al., 2002), and having a recent disorder tends to mean that the respondent has 
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a history of that disorder. Lastly, like most other diseases, the development of diabetes 
involves a multifactorial pathogenesis (Lucas & McMichael, 2005), and it is not simply a 
consequence of depression and anxiety.  Table 11.1 discusses the application of the nine 
criteria to the findings of this current study together with evidence from other published 
sources. 
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Table 11.1: Evidence for a causal association between depression and diabetes, anxiety and diabetes using Bradford Hill’s criteria 
Criteria for causation Application to the findings of the present study 
Strength of Association An effect size of less than two indicates a weak association, while greater than three is a strong association (Holt & 
Peveler, 2006). Most studies estimate that the risk of diabetes (attributable to depression or anxiety) has a stronger 
strength of association than the risk of depression or anxiety attributable to diabetes. The strength of association in 
both directions, however, is not strong, as the effect sizes were less than two in the majority of studies (including 
present study). Under this criterion therefore there is weak evidence for causality. (Smith et al., 2013; Mezuk et al., 
2008). 
Consistency The studies reporting associations in either direction did not report these to be consistently present and a large 
number of studies reported no association for the diabetes outcome or the depression/anxiety outcome (Mezuk et 
al., 2008; Rotella et al., 2012, Rotella & Mannucci, 2013).  
Specificity This criterion does not seem to be true for diabetes or exposure to depression and anxiety; multiple risk factors 
may produce or increase the risk of diabetes, or a single exposure (depression or diabetes) may produce a number 
of outcomes (diabetes and cardiovascular problems). 
Temporal Relationship Establishing a finding of new-onset cases or some new-onset feature of the outcome, can add to the evidence of 
causal or temporal sequence (van Reekum et al., 2001). It could be argued that if the association exists between 
diabetes and depression or anxiety, then patients with T2DM may be at higher risk of depression or anxiety, 
because mood disorders begin at a young age, well before the onset of T2DM (Kessler et al., 2005). 
Biological Gradient Almost all previous prospective studies, as well as the present study, restricted analyses to moderate to severe 
depression and anxiety and excluded mild cases of exposures, the impact of a biological gradient therefore is 
difficult to establish (Mezuk et al., 2008; Rotella et al., 2012, Rotella & Mannucci, 2013). 
Biological Plausibility The association between depression or anxiety and obesity or weight gain resulting in diabetes is well recognized 
and this is one potential mechanism by which depression or anxiety may increase the risk of diabetes (Bjorntorp, 
2001; Bjorntorp et al., 1999; Maes et al., 1991; Gariepy et a., 2010; Chiodini et al., 2007; Ehlert et al., 2001; 
Merswolken et al., 2012; Steudte et al., 2011; Young et al., 2004; Torres & Nowson, 2007). There is limited 
evidence as to whether diabetes causes depression or anxiety disorders. Generally it is perceived that individuals 
experiencing diabetes-related complications and disability experience depression as a consequence of their 
disability (Nouwen et al., 2010; Talbot et al., 1999). 
Coherence of Evidence The present study found that there is a greater likelihood that depression causes diabetes than diabetes causes 
depression based on the magnitude of the effect sizes. The findings of the previous studies are inconsistent, where 
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some studies reported no significant association between depression and diabetes (Mezuk et al., 2008; Routella & 
Mannucci, 2012; Routella & Mannucci, 2013). In the case of anxiety, only one of three longitudinal studies 
suggested increased risk of diabetes as a consequence of anxiety (Engum, 2007; Edwards & Mezuk et al, 2012; 
Atlantis et al., 2012). Similarly only three of seven studies, included in a meta-analysis, suggested increased risk 
anxiety disorders as a consequence of diabetes (Smith et al. 2012). 
Experimental Evidence All of the available evidence comes from prospective and cross-sectional studies. No direct experimental evidence 
is available to support a causal inference.  
Analogous Evidence For depression or anxiety causing diabetes, an analogy showing consistencies with other similar situations could 
be that other lifestyle factors (Venables & Jeukendrup, 2009), medical conditions such as polycystic ovary 
syndrome (Barber & Franks, 2012) or drugs, such as antipsychotics (Holt & Peveler, 2006), that cause weight gain 
or obesity are associated with increased rates of diabetes.  
 
Anxiety and depression are two psychological disorders that are associated with larger weight change and are 
frequently reported by both obese men and women (Brumpton et al., 2013; Bjerkeset et al., 2008; Roberts et al., 
2003; Herva et al., 2006).The present study found that more than two thirds of women in our sample with diabetes 
were obese (almost 83% had BMI > 30 kg/m2) increasing the risk of depression and anxiety symptoms. This 
sequence is endorsed by the recent reviews which support a prospective association of obesity-to-depression 
(Faith et al., 2011; Luppino et al., 2010). 
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11.8. Necessary or component causes  
Since the evidence is not strong that diabetes and anxiety/ depression are necessary 
causes without which the respective outcome will not occur, there remains a question 
about whether they are component causes. Previous investigations have shown that 
lifestyle factors (Venables  et al., 2009; Jacka et al., 2010a; Jacka et al., 2011a; Jacka et 
al., 2010b) represent potential component causes of both mood disorders as well as 
diabetes. In the present work we undertook several multivariate analyses to examine the 
association for each factor when the other variables were controlled. In addition, we took 
into account a wide range of factors that might confound the relationships. However, we 
must conclude that if diabetes or mood disorders are component causes, their strength as 
a cause is necessarily weak. This strength of course depends on the prevalence of other 
causal factors for both of these disorders. In the present study we also estimated the 
absolute estimates in addition to relative estimates in our meta-analyses. The small 
relative and absolute effect sizes found in our meta-analyses suggest that again the 
strength of these factors as component causes is low and may be acting far apart in time.  
The finding of the present study that more than two thirds of women with diabetes were 
obese suggests that obesity or weight gain may be the necessary cause required in 
addition to component causes to create a sufficient cause for the outcome. As discussed 
above, presence of obesity in the population may augment the impact of mood disorders 
on diabetes and vice versa.  
 
11.9. Implications 
The data used in this thesis showed that about 8% of women reported diabetes at the 21-
year follow-up of the MUSP study. The associations between depression and diabetes, 
anxiety and diabetes found in this study were not strong in terms of effect sizes. Despite 
the limitations discussed, if we accept that these are component causes of diabetes, then 
blocking their development prevents the completion of a sufficient cause that can 
contribute to both the prevention and treatment of diabetes by this pathway. 
 
11.9.1. Implications for prevention 
Preventive interventions in the area of diabetes and mood disorders are generally well 
established particularly in the case of diabetes (Cabassa et al., 2010). For instance 
lifestyle modifications (that is, physical activity and dietary changes) have been commonly 
used to decrease the risk of diabetes or improve the condition of people with diabetes 
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(Cabassa et al., 2010; Tuomilehto et al., 2011; Rubin  et al., 2014). However, since these 
are component causes, it is important to pay attention to the broad constellation of factors 
that are implicated simultaneously. This approach was demonstrated by a previous study, 
where none of the high-risk individuals with impaired glucose tolerance (IGT) developed 
diabetes during the initial trial period if they reached at least four out of five predefined 
lifestyle targets (Tuomilehto et al., 2001). This is strong evidence that blocking the action 
of a component cause inhibits the completion of the sufficient cause, thereby preventing 
the disease by that pathway. There are many published studies providing support for this 
concept (Tuomilehto et al., 2011; DPPRG, 2009). T2DM can be delayed or prevented 
among people who have IGT with lifestyle interventions or medication (Tuomilehto et al., 
2011). A randomized clinical trial also indicated that an intensive lifestyle intervention 
decreased the diabetes incidence in high-risk adults by 58% (DPPRG, 2009).  
 
Similar to diabetes, depression and anxiety, two modifiable mental health conditions, can 
be prevented or treated successfully with lifestyle intervention, (Rubin et al., 2014; 
Ruusunen et al., 2012) since diabetes does not seem to be a necessary cause, but rather 
a component cause. Lifestyle interventions, for example exercise, prevent the completion 
of a sufficient cause and thus can prevent the disorder (Cabassa et al., 2010). It therefore 
seems that lifestyle risk factors are component causes for both diabetes and mood 
disorders and thus intervention can prevent the development of both diabetes as well as 
clinically significant symptoms of depression and preserve physical HRQoL in 
overweight/obese patients with type 2 diabetes (Rubin et al., 2014). This intervention 
appears to be successful even in non-diabetic populations. Additionally, a Finnish study of 
522 middle-aged participants, who were overweight or obese, reported that among the 
lifestyle changes, particularly, successful reduction of body weight was associated with the 
greatest reduction of depressive symptoms (Ruusunen et al., 2012). 
 
Observational studies have provided evidence for other component causes, for example 
improved diet quality has been found to decrease the symptoms of depression (Jacka et 
al., 2010a; Jacka et al., 2011a; Jacka et al., 2010b; Jacka et al., 2011b). Jacka and 
colleagues conducted several studies to examine the association between diet quality and 
depression (Jacka et al., 2010a; Jacka et al., 2011a; Jacka et al., 2010b; Jacka et al., 
2011b). In their population based study of 1046 Australian women aged 20–94 years, they 
found that a ‘healthy’ dietary pattern was associated with a reduced likelihood of clinically 
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diagnosed depressive disorders, and a dietary pattern comprising processed and 
‘unhealthy’ foods was associated with an increased likelihood of psychological symptoms 
and depression (aJacka et al., 2010). They replicated the findings in the Hordaland Health 
Study of 5731 adults in Norway where participants with better quality diets were less likely 
to be depressed or anxious (Jacka et al., 2011a). A population based study has also 
demonstrated both a cross sectional and longitudinal relationship between diet quality and 
mental health in approximately 3000 Australian adolescents (Jacka et al., 2011b). 
 
Although the strength of diabetes and mood disorders as a cause is not strong, the 
present prospective study suggests that they may represent component causes and that 
other major causes such as obesity for depression or anxiety predicting diabetes and 
diabetic complications for diabetes predicting mood disorders may be required to create a 
sufficient cause. The present study suggests that women who were overweight or obese 
are at greater risk of developing diabetes as well as reported higher proportions of mood 
disorders, suggesting that obesity may be a stronger component cause that either 
diabetes or the mood disorders. Nevertheless, in regard to prevention of diabetes, the 
findings of the present study suggest that healthcare professionals as well as people at 
risk should be aware that the evidence is in favor of mood disorders as a component 
cause (albeit weak) of diabetes. 
 
11.9.2. Implications for treatment  
The present work provides significant implications for treatment since we find that 
symptoms of depression and anxiety are component causes of diabetes. These findings 
suggest that health care professionals managing people with diabetes or mood disorders 
should consider the possible link between diabetes and mood disorders. This is important 
because medications play a vital role in the treatment of medical illnesses. The role of 
medications is particularly important in cases of chronic illnesses such as diabetes, 
chronic depression or anxiety.  
 
Both depression and anxiety have been linked to poor glycemic control in previous studies 
(Anderson et al., 2002; Lloyd et al., 2000; Lustman et al., 2000; Niemcryk et al., 1990). 
However the present study did not find significant association between glycemic control 
and symptoms of depression and anxiety. There is a substantial evidence that treatment of 
mental health conditions is associated with improved glycemic control (Rubin and Peyrot, 
2001; Lustman et al., 2000; Richardson et al., 2008). In non-diabetic populations, 
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untreated depression and anxiety events may predispose the population to increased risk 
of developing diabetes (Mezuk et al., 2011; Smith et al., 2013).  However, in terms of 
prevention, it has been reported that the use of antidepressants to treat depression does 
not lower the risk of developing diabetes (Pan et al., 2010). 
 
It is assumed and often found, that high income, developed countries have adequate 
resources to make drug treatments available for all patients. However, low or middle 
income, developing countries usually have inadequate resources as well as financial 
instability, and it is near to impossible to provide optimal treatment for the majority of 
patients. The affordability or availability of medications, including medications to treat 
diabetes, is a public health issue in developing countries, such as Malaysia (Babar et al., 
2007). The treatment gap between a developed and a developing country is endorsed by 
the present study which found that the use of drugs to treat diabetes in Malaysia, a 
developing country does not correlate with the use of drugs to treat diabetes in Australia 
(full paper can be found in Appendix 1A). The present study found insulin use in Australia 
was substantially higher than in Malaysia and although there was a small decrease, insulin 
use in Australia increased steadily during the study period. This finding is of concern, as 
many patients in Malaysia may be undiagnosed or inappropriately treated. 
 
While the present study suggests that overall burden of any anxiety disorder in people with 
diabetes was within the range reported for the general population, this is consistent with 
the mood disorders acting as component causes and may interact with other factors (for 
e.g. obesity) to increase the risk of developing diabetes by inhibiting insulin function in a 
variety of ways (Chiodini et al., 2007; Ehlert et al., 2001; Merswolken et al., 2012; Steudte 
et al., 2011; Young et al., 2004). Therefore the treatment of one to reduce onset of the 
other is critical in reducing the burden of disease. 
 
General Conclusions 
This PhD study provides insight into the long term association between diabetes and 
mood disorders. Over the past decade, diabetes has reached epidemic proportions, 
particularly in developing countries (Shaw et al., 2010) and differences in the drug 
treatment of diabetes in a developed and a developing country were identified, contributing 
to the relatively scarce literature from developing countries.  
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Based on standardized estimates, one in five people with diabetes will have depression 
and/ or anxiety. Modest evidence of an association or increased risk of mood disorders as 
a consequence of diabetes was detected in this study. While there are a number of 
component causes associated with the outcomes, the most interesting finding is arguably 
the fact that both represent potential component causes of the other. The study also 
recommends some caution about the strength of these component causes. 
 
The value of this study is that it provides a platform for the development of preventive 
programs; targeting people with diabetes is based as much on reducing the burden of 
component causes, as it is on the treatment and associated medication adherence among 
people with the disorder itself.  
 
The findings of this work raise some fundamental questions about whether decision 
makers have an adequate understanding of the interaction of the depression and anxiety 
issues with diabetes. Although the present study provides insight into these issues, 
knowledge about the long-term health consequences of these comorbid conditions has 
been limited or incomplete.  
 
The findings also raise some caution about the possible strength of these component 
causes. Firstly, although the association is not strong in epidemiological terms, and these 
are not necessary causes, then should people with diabetes be screened for depression 
and anxiety on a regular basis? Secondly is it helpful, to the broader population with 
diabetes or to the individual with diabetes, to treat the symptoms of depression and 
anxiety to reduce the risk of future diabetes? Would such approach produce a reduction 
not only in diabetes prevalence but the adherence problems associated with diabetes? 
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ABSTRACT 
 
 
Background 
Once  a  disease  of  developed  countries,  Type  2  Diabetes 
Mellitus (T2DM) has become widespread around the globe. 
In people with T2DM, achievement of therapeutic outcomes 
demands the rational and quality use of medicine. 
 
Aims 
The primary  aim of  this descriptive  study was  to  examine 
the  prevalence  of  diabetes  and  prescribing  patterns  of 
antidiabetic medications in Australia and Malaysia. 
 
Methods  
The most recent, publicly available, statistical reports (2004‐
2008) on the use of medicines published in Australia and in 
Malaysia were  evaluated. Defined daily doses  (DDDs/1000 
population/day) were derived from the reports and used to 
rank and compare individual drug use. 
 
Results  
There was an increasing trend in the prevalence of diabetes 
in Australia although there is a greater predicted increase in 
prevalence  for  Malaysia.    While  drugs  used  for  the 
treatment  of  diabetes  were  not  the  most  highly  utilised 
drugs  in  Australia,  their  use  increased  during  the  study 
period,  from  42.64  to  48.61  DDD/1000/day.  Antidiabetic 
drugs were the most frequently dispensed class of drugs  in 
Malaysia.  Although  the  total  consumption  of  antidiabetic 
drugs in Malaysia decreased between 2006 and 2007 (from 
40.30 to 39.72); this was followed by a marked  increase to 
46.69  in  2008.    There  was  a  marked  reduction  in  the 
dispensing of insulin in Malaysia from 2004 to 2007 (7.77 to 
3.23).   
 
Conclusion 
The utilisation of drugs to treat diabetes does not reflect the 
patterns  of  utilisation  found  in  Australia.  Effective  drug 
utilisation reviews are required to ensure impartial access in 
middle and low‐income countries. 
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What this study adds: 
1. What is known about this subject?  
There  is  a  changing  trend  in  the  prevalence  of  diabetes 
worldwide with  emerging  focus  on  treatment  of  diabetes 
and associated complications. Dispensing trends reflect the 
use  of  drugs  and  therefore  the  treatment  of  medical 
conditions. 
 
2.  What new information is offered in this study? 
The paper highlights the differences in utilisation of drugs to 
treat  diabetes,  between  Australia  and Malaysia  and  their 
concordance  with  national  and  international  treatment 
guidelines. 
 
3.  What  are  the  implications  for  research,  policy,  or 
practice?  
There  is a need to  include effective drug utilisation reviews 
in diabetes management protocol  in developing  countries, 
and  to  facilitate  the  development  of  educational 
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interventions,  review  of  treatment  guidelines,  and 
education of prescribers and patients. 
 
Background 
Diabetes  mellitus  is  a  chronic,  progressive  disorder  that 
affects  millions  of  people  worldwide.1  Once  a  disease  of 
developed countries, Type 2 Diabetes Mellitus  (T2DM) has 
spread to every country in the world.2 The global estimates 
published  in  2010  by  Shaw  et  al.  reported  the  world 
prevalence as 6.4%, affecting 285 million adults (aged 20–79 
years);  it  is  predicted  to  rise  to  7.7%  and  439 million,  by 
2030.3  The  predicted  increase  in  patients with  diabetes  is 
nearly  twice  the  annual  growth  of  the  total  world  adult 
population.3  
 
Both  the  incidence  and  prevalence  of  diabetes  are 
escalating  particularly  in  developing  and  newly 
industrialized  nations,  and  also  among  disadvantaged 
people  in developed  countries;  these populations  are  said 
to  be  at  highest  risk  of  having  diabetes.3  By  2030,  the 
increase  in  the  number  of  adults  with  diabetes  over  the 
preceding decade  is estimated to be 20%  in developed and 
69%  in  developing  countries  respectively.3  Malaysia, 
situated  in  Southeast  Asia,  is  one  of  the most  prominent 
developing,  middle‐income  countries;4  it  was  also  among 
the top 10 countries for diabetes prevalence in 2010 and is 
predicted  to  remain  so  until  2030.3    Diabetes  prevalence 
among  the  adult  population  in  Malaysia  (>18  years)  has 
increased significantly over the years, from 11.6% (2006),5,6 
to 22.9% (2013).7  
 
Diabetes  is  the  fastest growing chronic disease  in Australia 
and the AusDiab Follow‐up Study (2010) estimated the total 
number of Australians with diabetes and pre‐diabetes at 3.2 
million,8  or  14.3%  of  the  population  at  the  time.  This  is  a 
marked  increase  since 1995, when  self‐report  census data 
indicated  that  2.4%  of  Australians  (430,700  people)  had 
been  diagnosed  with  diabetes  at  some  time  during  their 
lives; the figure increased to 3.6% in 2004‐05,9 and to 3.8% 
(an  estimated  818,200  persons)  in  2007‐08.10  In  2011‐12, 
4.0%  of  the  Australian  population  (875,400  people) 
reported  having  some  type  of  diabetes;  however  the 
prevalence  of  diabetes  remained  stable  between  2007‐08 
and 2011‐12 (both 4.0%).11 Diabetes is expected to become 
the  leading  contributor  to  disease  burden  in  Australia  by 
2023.12   
 
Dispensing trends reflect the use of drugs and therefore the 
treatment of medical conditions.13 The primary aim of  this 
descriptive study was to examine the prevalence of diabetes 
and  prescribing  patterns  of  antidiabetic  medications  in 
Australia  and Malaysia,  to evaluate prescribing  trends  and 
their  concordance  with  national  and  international 
treatment guidelines. This comparison was made between a 
developed country with adequate health  resources and an 
increasing prevalence of diabetes (Australia), and a middle‐
income  developing  country  with  a  high  prevalence  of 
diabetes  (Malaysia).  The  underpinning  research  questions 
were  “How does  the utilisation of drugs  to  treat diabetes, 
differ  between Australia  and Malaysia?”  The  findings may 
serve  as means  of  improving  the  quality  use  of medicine, 
enhancing  therapeutic  outcomes,  and  indicating  over‐  or 
under‐consumption of medicines. 
 
Method 
Assessing  the  prevalence  of  Diabetes  in  Australia  and 
Malaysia 
The prevalence of diabetes  in this paper  is presented using 
estimates  reported  by  Shaw  et  al.,3  where  the  authors 
derived  prevalence  estimates  for  Australia  from  the 
Australian Diabetes, Obesity and  Lifestyle Study,14 and  the 
National Diabetes Service Scheme, Diabetes Australia.15  
 
The prevalence of diabetes  in Malaysia  is based on  figures 
published  in National Health and Morbidity Survey (NHMS) 
reports.5,7  NHMS  is  a  nationwide  survey  of  self‐reported 
data  that  includes  medicine  use,  dietary  habits,  various 
disease states, and demographics, which was first published 
in 1986  and  is now published every  ten  years.5,7 Although 
we focused on both types (type 1 and 2) of diabetes in this 
study, about 90% of all cases of diabetes  in both countries 
are T2DM.3 
 
Assessing Diabetes related Medicines Use 
Publicly  available  Australian  and  Malaysian  reports 
containing  statistics  on  medicine  use  for  each  year  from 
2004  to 2008  (inclusive) were used, and  the  focus  for  this 
paper  were  antidiabetic  drugs.16,17  The  published  reports 
from  both  countries  adopted  the  same  unit  (DDD/1000 
population/day)  to  describe  medicine  usage  which 
facilitated  comparison  between  the  two  countries. 
Dispensing  databases  are  compiled  from  claims  data  and 
essentially  such  data  are  designed  for  administrative 
purposes; however, the  large size of such databases makes 
them suitable  for drug utilisation studies despite  their  lack 
of  clinical  information.    To  facilitate  international 
comparison,  drugs  are  classified  according  to  the  World 
Health  Organization  (WHO)  Anatomical  Therapeutic 
Chemical  (ATC)  classification  system,  and  Defined  Daily 
Doses  (DDDs) can be used  to  rank and  compare  individual 
drugs.18  The  DDD  is  the  international  unit  of  drug  use 
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established  by  the  Nordic  Council  on  Medicines  and  the 
WHO and is assumed to be an average dose of the drug per 
day for adults for its main indication.19,20   
Medicines Use Data, Australia 
The  Australian  Statistics  on Medicines  (ASM)  is  an  annual 
government  publication  produced  by  the  Drug  Utilisation 
Sub‐Committee  (DUSC)  of  the  Pharmaceutical  Benefits 
Advisory Committee,  and was  first published  in 1997. The 
“...comprehensive and valid statistics on the Australian use 
of medicines...” is published in the public domain “...for use 
by  interested parties...”.17  The  reports  contain  analyses  of 
retrospective  data  of  subsided  medicines  prescribed  by 
registered General Practitioners (GP) in community practice 
in  Australia.  For  example,  the  report  published  in  2013 
contained  data  from  2010.  These  reports  provide 
information  about medicines which  are  subsidised  by  the 
Australian  Government  for  its  citizens  under  the 
Pharmaceutical Benefits  Scheme  (PBS)  or  the  Repatriation 
Pharmaceutical  Benefits  Scheme  (RPBS);  the  latter  is 
specifically  for  war  veterans  and  their  dependents.17 
Dispensing  data  are  collected  electronically  from  two 
sources,  namely  Medicare  Australia  records  through  the 
PBS/RPBS and the DUSC survey of community pharmacies;17 
both  sources  are  compiled  from  databases  based  on 
electronic claims data.  
 
Medicines Use Data, Malaysia 
The Ministry  of  Health  in Malaysia  publishes  statistics  on 
medicines  using  retrospective  data  derived  from  the 
Ministry  of  Health  (public  institutions),  as  well  as  from 
private hospitals, university and armed  forces,  (private) GP 
prescribing  and  (private)  pharmacy  dispensing.16  The 
medicines  provided  through  public  hospitals  or  clinics  are 
dispensed  free of charge  to Malaysian citizens and  reports 
are therefore restricted to ‘prescription’ medicines,16  while 
prescription medicines dispensed in community pharmacies 
are  paid  for  in  full  by  the  patient.  The  first  Malaysian 
statistics on medicine  (MSM) report was published  in 2013 
contains  data  from  2008.16  The  major  antidiabetic  drug 
classes included for comparison were insulin and analogues, 
biguanides,  sulfonylureas,  alpha  glucosidase, 
thiazolidinediones,  Dipeptidyl  peptidase  4  inhibitors. 
Descriptive analyses presented  in  the  tables and  figures  in 
the  current  paper were  carried  out  using Microsoft  Excel 
2010. Descriptive statistics were used to analyze frequency, 
percentage and mean. 
 
 
 
 
Results 
Diabetes prevalence  
The  population  characteristics  of  Malaysia  (a  developing 
country) and Australia (a developed country) for the period 
of  this  study  were  similar.21,22    There  was  an  increasing 
trend  in  the  percentage  prevalence  of  diabetes  in  both 
countries;  however,  it  was  1.5  times  higher  in  Malaysia 
(10.9 ) than Australia (7.2).3 
 
Drugs used to treat diabetes 
Although  the  increase  in  the  use  of  drugs  used  to  treat 
diabetes  in  Australia  was  steady,  in  Malaysia  it  declined 
pointedly  in  2005  (35.90  DDDs/1000/day), with  a  smaller 
reduction  in  2007  (from  40.39  in  2006  to  39.72 
DDDs/1000/day  in 2007), which was  followed by a marked 
increase in 2008 to 46.69 DDDs/1000/day (Figure 1). 
 
 
 
In Australia  the overall use of antidiabetic drugs  increased 
between  2004  (42.64  DDDs/1000/day)  and  2008  (48.61 
DDDs/1000/day),  although  the most  frequently  dispensed 
therapeutic drug class during the study period  (2004‐2008) 
included drugs  to  treat hyperlipidaemia and cardiovascular 
diseases.17 The  two most  frequently dispensed  sub‐groups 
to  treat  diabetes  in  Australia  were  sulfonylureas  and 
biguanides  (2004‐2008;  Table  1)  although  there  was  a 
decrease  in  the use of sulfonylureas over  the study period 
(14.35  in  2004,  to  11.55  DDDs/1000/day  in  2008).  The 
biguanide  (metformin) was  the most  frequently  used  oral 
antidiabetic drug  in Australia  from 2004 to 2008 and while 
the  use  of  the  sulfonylurea  (glibenclamide) was  relatively 
low,  the use of glibenclamide as well as gliclazide declined 
between 2004 and 2008.  
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In contrast, the most frequently dispensed drugs in Malaysia 
were  sulfonylureas,  used  for  the  treatment  of  diabetes. 
Nationally,  the drug glibenclamide was  ranked  first among 
the top 40 drugs between 2004 (14.49 DDDs/1000/day) and 
2006  (15.53 DDDs/1000/day). Glibenclamide was  replaced 
in subsequent years by metformin (14.28 DDDs/1000/day in 
2007) and gliclazide (18.80 DDDs/1000/day in 2008) (Figure 
2).  
 
 
 
The  use  of  the  alpha  glucosidase  inhibitor  acarbose 
increased  more  than  two‐fold  In  Malaysia  between  2004 
and 2007 (from 0.38 to 0.83 DDDs/1000/day) followed by a 
decrease  to  0.71  DDDs/1000/day  (2008).  The 
thiazolidinediones  (rosiglitazone  and  pioglitazone)  were 
used less frequently in Malaysia in 2008 (0.21) compared to 
Australia  (2.81  DDDs/1000/day  respectively;  Table  1), 
although  the  use  of  rosiglitazone  in  Malaysia  almost 
doubled  from 2006  to 2007  (0.20  to 0.43 DDDs/1000/day; 
Figure 2). 
 
 
Insulin  use  in  Australia  was  substantially  higher  than  in 
Malaysia; despite a small decrease in insulin use in Australia 
between 2004 and 2008, the overall increase from 13.49 to 
16.66 during the study period (Table 1) was not reflected in 
Malaysia (Figure 3).  Insulin dispensing decreased by 50%  in 
Malaysia from 2004 to 2007 (7.78 to 3.23 DDDs/1000/day), 
followed by a small increase to 3.71 DDDs/1000/day in 2008 
(Figure 4).  The most widely used  insulin  in both  countries 
was  premixed  insulin  and  analogues  (intermediate  +  fast‐
acting).  
 
 
 
Discussion 
There were similar trends of increasing diabetes prevalence 
between  the  two  countries but marked  differences  in  the 
utilisation of antidiabetic drugs.3,16,17 The total consumption 
of  drugs  used  to  treat  diabetes  in  Malaysia  decreased 
between  2004  and  2007  and  was  followed  by  a  marked 
increase  in  2008,  while  in  Australia  their  use  steadily 
increased during the same period (2004‐2008). 
 
Based  on  global  estimates,  the  prevalence  of  diabetes  in 
Malaysia  is  significantly higher  than Australia,  a difference 
that  is  predicted  to  continue  to  widen  by  2030.3  The 
increasing  prevalence  among  adults  aged  ≥  18  years  in 
Malaysia  has  been  reported  elsewhere;5,7,23  we  observed 
that the prevalence was steeper in Malaysia than Australia. 
The situation  in Malaysia  is alarming and as the prevalence 
of diabetes  is expected to  increase, the number of patients 
with  diabetes  ‐  diagnosed  and  undiagnosed,  treated  and 
untreated  ‐  is  expected  to  rise  proportionately.  Previous 
studies  in  Malaysia  using  NHMS  III  data  reported  that 
diabetes was most  prevalent  among Malaysians  of  Indian 
origin (37.9%) and among people aged between 45‐75 years 
of  age  (>  20%);5,7  however,  it  was  comparable  between 
genders  and  geographical  locations.7    The  incidence  of 
diabetes  in  Australia  was  also  reported  to  increase  at 
around  45  years  of  age  and  by  2008, was  highest  among 
patients  aged  75  years  and  over.10  However,  a  few  years 
later (2011‐12), the age group with the highest incidence of 
diabetes had decreased to 65‐74 years.17 Regarding gender, 
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just over half (52%) of all diabetic cases (T1DM and T2DM) 
in Australia occurred among women in 1995,9 while a years 
later  (2011‐12),  more  men  in  Australia  reported  having 
diabetes (4.3%) than women (3.6%).17 
 
Despite the high prevalence of diabetes among people living 
in Malaysia,  the  utilisation  of  drugs  to  treat  diabetes was 
not as high as expected. It has also been reported that  less 
than a quarter of patients achieve  their  target HbA1c  level 
(< 7%),24 which suggests that there may be a  large number 
of people with untreated diabetes  in Malaysia or diabetics 
who  do  not  take  appropriate  medication.5  Perhaps 
surprisingly, while  the 10 most  frequently dispensed drugs 
in Malaysia  included  those  to  treat diabetes,16  in Australia 
the most  frequently  dispensed  drugs were  drugs  to  treat 
cardiovascular conditions.17 Despite the fact that there were 
no  antidiabetic  drugs  included  among  the  10  most 
frequently dispensed drugs in Australia, it is interesting that 
their  use  was  higher  than  in  Malaysia,  at  4.35 
DDD/1000/day, on average.   
 
The two most frequently dispensed drug classes in Malaysia 
were  biguanides  and  sulfonylureas.  In  Australia,  the most 
frequently  used  antidiabetic  drugs  were  biguanides  and 
insulins.    The  increased  use  of  metformin  in  Malaysia 
indicates  (improved)  adherence  to  prescribing  guidelines, 
which  recommend metformin as  first  line oral medication, 
particularly in obese individuals.25,26  The introduction of the 
fixed‐dose combination of metformin and sulfonylurea may 
be associated with improved patient compliance and hence, 
utilisation.16,26 In Australia, metformin use followed a similar 
increasing trend during the study period. Thiazolidinedione 
usage in Malaysia decreased during 2005 and 2006 but then 
increased in 2007, when pioglitazone was introduced,16 and 
the use of rosiglitazone almost doubled in 2007 in Malaysia 
while  its  use  remained  constant  in  Australia.17  With  the 
current  controversy  surrounding  the use of  rosiglitazone,27 
we expect the decreasing trend in Malaysia and Australia to 
continue.  
 
Surprisingly, the use of insulin in Malaysia decreased by 50% 
during  the  study  period,  from  7.78  (2004)  to  3.71 
DDD/1000/day  (2008), although  there was an encouraging 
increase of 0.48 DDD/1000/day between 2007 and 2008; by 
comparison, despite  a  decrease  from 2004 to 2005, insulin 
use  in  Australia  increased  overall    and  was  substantially 
higher than in Malaysia.   
 
Due  to  the progressive  failure of  insulin secretion,  therapy 
has to be increased over time.28,29 Patients with T2DM who 
do  not  achieve  optimal  glycaemic  control  with  oral 
antidiabetic  drugs  (HbA1c  <  7.0%)  may  require  insulin 
therapy, and should start insulin therapy as soon as possible 
if HbA1c  >  9.0%  and  blood  glucose  levels  >15mmol/L.30,31 
The  early  use  of  insulin  in  the  treatment  of  T2DM  is  not 
without  controversy  both  in  terms  of  micro‐vascular  and 
macro‐vascular  complications.32 However,  studies  included 
in the NICE Guidelines suggest that combination treatment 
with  insulin  and metformin,  or  insulin  and  a  sulfonylurea, 
show significantly  lower HbA1ac  levels compared to  insulin 
monotherapy.29  Results  from  clinical  trials  have  led  to 
international  management  guidelines  emphasising  the 
importance  of  blood  glucose  control  to  reduce  vascular 
complications in people with diabetes.33‐35 
 
A number of potential barriers  to and  lower acceptance of 
insulin use among Malaysian patients have been  identified.  
These  include  lack  of  knowledge  (e.g.  fear  of  injections, 
glucose  monitoring,  patient  ignorance,  lack  of  awareness 
about the importance of diabetes treatment),5,16,36 negative 
side  effects  (e.g.  insulin‐related  hypoglycaemia),16,36 
patients’  preference  (e.g.  oral  medication,  alternative 
medicines),16,37,38 and cost of  treatment.36 The affordability 
or availability of drugs may also be a  factor as  it has been 
reported that essential drugs are expensive in Malaysia and 
are not available  in all areas such as the far‐eastern region 
where  the  logistics  of  transporting  medicines  is 
challenging.39 
 
Due  to  the  increasing  burden  of  chronic  diseases  in 
Malaysia,  the  Malaysian  government  has  increased  the 
spending  on  health  related  issues;  however,  under‐
treatment, under‐diagnosis, non‐adherence and  the use of 
traditional  medicines  may  lead  to  sub‐optimal  use  of 
antidiabetic agents. We suggest that a crucial step may have 
been  overlooked;  robust  screening  strategies  should  be 
conducted  in urban and  rural areas,  to  identify patients at 
risk of, and suffering  from, undiagnosed diabetes.  In order 
to  control, delay or prevent  complications associated with 
diabetes effective prescribing through targeted training and 
professional development of health care professionals, and 
patient  education  on  appropriate  treatment,  must  be 
promoted  by  the  authorities  who  are  responsible  for 
coordinating services, resources and facilities.  
 
This  study  had  several  limitations  that  may  affect 
generalisation. The variability in antidiabetic medicine use in 
Malaysia  suggests  that  there may  be  some  problem with 
sampling procedures, response rates and hence the quality 
of the data during the period 2004‐8. Although reports from 
both  countries  presented  the  data  in  the  same  unit 
(DDD/1000  population/day),  the  data  sources  are  very 
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different;  Malaysian  data  are  not  as  comprehensive  as 
Australian  data  although  this  improved  over  the  study 
period.  For  example,  in  Malaysia  there  were  only  32 
participating private pharmacies in 2004 which increased to 
814  in  2008.16  It  is  also  possible  that  only  essential  and 
accessible sources were included in the collection of data. It 
is known that Australian reports may underestimate the use 
of  under‐copayment  medicines  (i.e.  non‐subsidised 
medicines which  are  therefore  not  included  in  the  claims 
databases) by up to 20%.17 Finally, this drug utilisation study 
is based on  reports of dispensing data and  the drugs may 
not necessarily have been consumed.16,17  
 
Conclusion 
Despite  these  limitations  this  comparative  study  does 
highlight differing prescribing  trends. Although  there  is  an 
increasing  trend  in  the prevalence of people with diabetes 
in Malaysia  and Australia,  the  utilisation  of  drugs  to  treat 
diabetes  in  Malaysia  does  not  reflect  the  patterns  of 
antidiabetic  drug  utilisation  in  Australia. Many  patients  in 
Malaysia may  be  undiagnosed  or  inappropriately  treated. 
Insulin  is  considered  to  be  the most  appropriate  form  of 
treatment for certain types or stages of diabetes and more 
research  into the  low use of insulin  in Malaysia  is required. 
It  will  be  necessary  to  lay  a  firm  foundation  for  the 
development  of  educational  interventions,  review  of 
treatment  guidelines,  and  education  of  prescribers  and 
patients  to  increase  the  acceptance  of  insulin  therapy. 
Moreover,  effective  drug  utilisation  review  to  promote 
rational medicine  use  should  be  included  in  the  diabetes 
management protocol in Malaysia. 
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A B S T R A C T
Aims: We estimated the incidence and risk of diabetes associated with depressive symptoms using data
from longitudinal studies.
Materials and methods: Databases were systematically searched for relevant studies. Incidence of
diabetes is presented as cumulative incident proportion (CIP). Pooled effect sizes were calculated using
random-effects model. The data were reconstructed to compute relative risk (RR).
Results: The 16 studies selected for review generated 16 datasets of which 8 studies reporting binary
estimates (RR) and 8 studies reporting time-to-event estimates (hazard ratio (HR)). Both RR and HR were
signiﬁcant at 1.67 (95% CI: 1.30–2.15) and 1.45 (95% CI: 1.12–1.87) for incident diabetes associated with
depressive symptoms.
Conclusion: Our observations revealed greater cumulative incidence of diabetes in depressed than in non
depressed groups. Depression should be included among risk factors that required regular screening for
diabetes.
 2014 Diabetes India. Published by Elsevier Ltd. All rights reserved.
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Depression is responsible for a large proportion of burden
associated with non-fatal health outcomes [1,2]. It is also one of the
most common co-morbid conditions associated with diabetes
mellitus (DM) [3,4]. People with DM are almost twice as likely to
suffer from depression as the general population [4–7]. Sadly, this
depression often remains unrecognized and thus untreated [8],
leading to a higher prevalence of depression among people with
DM [5,8]. Diabetes is also thought to be a consequence of
depression and Thomas Willis, a famous physician from Great
Britain, was the ﬁrst to report that diabetes was caused by ‘‘sadness
or long sorrow and other depressions’’ [9]. This relationship was
then demonstrated in a number of epidemiological studies and the
majority agreed with Willis’ hypothesis [10–14]. However, other
studies have suggested that the relationship between diabetes and* Corresponding author. Tel.: +61 469378163.
E-mail addresses: shahzad.syed@uqconnect.edu.au (S.S. Hasan),
a.clavarino@sph.uq.edu.au (A.M. Clavarino), mamun@sph.uq.edu.au (A.A. Mamun),
t.kairuz@pharmacy.uq.edu.au (T. Kairuz).
http://dx.doi.org/10.1016/j.dsx.2014.04.023
1871-4021/ 2014 Diabetes India. Published by Elsevier Ltd. All rights reserved.depression was modest [15–17], and existed only with cases of
severe depression [11,18–23].
Depression as a risk factor for the development of DM has no
strong physiological basis but this relationship may be a
consequence of decline in health-maintenance behaviors among
depressed persons [15,24], or biochemical changes associated with
depression [25,26], with some studies suggesting that depression
is an independent risk factor for the development of DM [27,28].
The aim of this review was to examine the relationship between
depression and incident diabetes by conducting a meta-analysis of
longitudinal studies using relative risk, and extensive review and
synthesis of the data. Previous meta-analyses have demonstrated
an increased risk of diabetes [25,29,30], they are far from
conclusive because of several deﬁciencies. For example, incidence
measures were not computed because most of the longitudinal
studies neither presented data in a four-fold table form nor
supplied adequate information to calculate cumulative incident
proportion (CIP) (i.e. raw numbers of incident diabetes by risk
category). For studies which did not provide data in a four-fold
table form, we imputed (from four-fold table reconstruction) the
CIP. The CIP was also used to estimate cumulative incidence.
Finally to estimate pooled effect sizes studies have not separated
binary point and time-to-event estimates, which we consider may
Table 1
Incidence proportions of diabetes in people exposed/not exposed to depressive
symptoms.
Authors [Ref] Country
Year
Follow-up
years
CIP Cumulative
incidence (%)
1. Eaton
et al. [11]
USA
1996
13.0 E: 6/76 7.89
UE: 80/1604 4.99
2. Kawakami
et al. [21]
Japan
1999
8.0 E:9/278 3.24
UE:34/2102 1.62
3. Stellato
et al. [14]
USA
2000
9.0 E: 7/90 7.78
UE: 23/910 2.53
4. Carnethon
et al. [18]
USA
2003
15.6 E: 32/534 5.99
UE: 128/5496 2.33
5. Palinkas
et al. [22]
USA
2004
8.0 E: 10/70 14.29
UE: 51/840 6.07
6. Everson-Rose
et al. [12]
USA
2004
3.0 E: 28/578 4.84
UE: 58/1998 2.90
7. V den Akker
et al. [17]
Netherlands
2004
15.0 E: 89/1334 6.67
UE: 3156/66670 4.73
8. Mallon
et al. [16]
Sweden
2005
12.0 E: 3/128 2.34
UE: 29/1010 2.87
9. Carnethon
et al. [19]
USA
2007
8.0 E: 39/936 4.17
UE: 108/3745 2.88
10. Engum
et al. [20]
Norway
2007
10.0 E: 152/8159 1.86
UE: 382/28598 1.34
11. Golden
et al. [15]
USA
2008
3.2 E:60/911 6.59
UE: 215/4290 5.01
12. Campayo
et al. [10]
Spain
2010
5.0 E: 25/214 11.68
UE: 138/1949 7.08
13. Demakakos
et al. [47]
UK
2010
5.0 E: 51/823 6.20
UE: 158/5288 2.99
14. Pan
et al. [13]
USA
2010
10.0 E: 524/7051 7.43
UE: 2320/50829 4.56
15. Chen
et al. [46]
Taiwan
2013
7.0 E: 1156/5847 19.77
UE: 762/5847 13.03
E = exposed group, UE = unexposed group; CIP = cumulative incident proportion.
S.S. Hasan et al. / Diabetes & Metabolic Syndrome: Clinical Research & Reviews 8 (2014) 82–87 83be inappropriate [25,29]. We converted all odds ratios (ORs) to
relative risks (RRs) so that risks are uniform.
2. Methods
2.1. Data sources
The following electronic databases were searched: MEDLINE
(1950–July 2013); EMBASE (1980–July 2013); CINAHL (1982–July
2013); PsycINFO (1880–July 2013). After identifying possible
papers, titles and abstracts were screened to select studies,
relevant to the aim of this review. The full texts of the selected
studies were then examined to determine whether the studies met
our inclusion criteria. To locate additional relevant papers, the list
of references in identiﬁed studies was also examined. When
multiple publications from the same study population were
available, we only included the most recent publication.
2.2. Eligibility criteria
The eligibility criteria were based on study type and population
attributes. Regarding study type, the following were included:
studies that investigated the association, comorbidity and/or
coexisting prevalence of diabetes and depression, and/or depres-
sive symptoms, in adults with diabetes mellitus. In this meta-
analysis we included all studies that longitudinally examined the
relationship between depression and onset of diabetes. Studies
that focused on efﬁcacy of treatment, or comorbidities, or which
included other psychiatric conditions were excluded, as were
studies that only examined gestational diabetes mellitus.
2.3. Data abstraction
Data extracted from the studies included the name of ﬁrst
author; publication year; study design; follow-up time in years;
number of subjects in the analysis; gender and age of subjects;
method of depression assessment; method of diabetes assess-
ment; binary point estimates and time-to-event (survival) analysis
estimates with 95% CI (adjusted for the largest number of
confounders); number of confounders that were adjusted for in
the analyses (see Tables 2 and 3 for details of confounders
considered); method of exclusion of depressive and patients with
diabetes at baseline; and new-onset cases. The method of
assessment of diabetes was either based on self-report or clinically
diagnosed based on blood glucose levels or based on the diagnosis
of diabetes from administrative data (drug consumption/hospital-
ization). Depression was based on a diagnosis by psychiatrist
(using Diagnosis and Statistical Manual (DSM) criteria); the
assessment of depressive symptoms was by a self-administered
questionnaire.
2.4. Data analyses
Four-fold cells (2  2 tables; exposure yes/no vs. outcome yes/
no) were imputed for all binary point estimates using the
reconstruction method proposed by Pietrantonj [31]. Studies
using time-to-event estimates (hazard ratios) were presented
separately, as 2  2 table reconstruction was not possible for
studies using time-to-event estimates. The four-fold cells were
used to compute relative risk (RR), and cumulative incident
proportion (CIP). For studies that presented graded relationships
such as low, medium, or high depressive symptoms, only the
estimate for the highest category was selected. We evaluated
heterogeneity using the Cochran’s Q (Q test) and a related metric,
the I2. A p-value of 0.10 was used as the cut-off point for
heterogeneity; therefore a related metric I2 was also reported(I2 = (Q  df)/Q  100%). Pooled results were calculated via the
random effects (RE) model.
To assess the robustness of this meta-analysis, sensitivity
analyses were performed by modifying our selection criteria and
then examining the effect of the variously modiﬁed selection
criteria on the pooled results. A funnel plot was used to examine
the existence of publication bias through visual inspection for
asymmetry and was considered asymmetrical if the intercept of
Egger’s regression line deviated from zero with p < 0.10. When the
funnel plot was found to be asymmetric, additional analyses for
publication bias were performed using the Duval and Tweedie
non-parametric ‘‘Trim and Fill’’ method of accounting for missing
studies in meta-analysis [32]. All imputations were done assuming
random error only. All analyses were conducted using Microsoft
Excel and MetaXL software version 1.3 [33].
3. Results
Our search yielded 850 unique abstracts from MEDLINE, 180
unique abstracts from EMBASE/CINAHL, and 230 from PsycINFO.
After removal of duplication and applying the eligibility criteria, 96
relevant papers were examined for further consideration. Of these,
80 studies were excluded for reasons such as failing to remove
prevalent cases of diabetes at baseline and insufﬁcient data to
generate pooled effect sizes. Studies that examined the association
of antidepressant use and DM were also excluded [34–36]. A total
of 16 articles were then included in our review; these provided 16
datasets.
Three studies used the same sample [13,23,37]; however, two
of these were retained: the most recent publication by Pan et al.
[13], and Saydah et al. [23] who used a different risk estimates
(hazards ratio), in the 2003 publication, and thus were in different
analyses. However for estimating CIP, these studies were not
Table 2
Summary of ﬁndings of longitudinal studies assessing relationship between depression and incident diabetes using binary point estimates.
Authors
(country – year)
Follow-up
years
%
female
Age (yrs) Assessment of
depression
Assessment of
diabetes
Original effect size Reconstructed RR Adjustment for
confounders
1. Stellato et al.
(USA – 2000)
9.0 0.0 40–70 CES-D Self-report OR: 3.09 (1.34–7.12) 2.94 (1.31–6.60) Testosterone, SHBG,
hypertension, CVS, BMI
2. Everson-Rose et al.
(USA – 2004)
3.0 100 42 CES-D Self-report + FPG OR: 1.66 (1.05–2.61) 1.63 (1.05–2.54) Age, site, race, education,
medication use
3. Palinkas et al.
(USA – 2004)
8.0 57.0 50 BDI OGTT/FPG OR: 2.50 (1.29–4.87) 2.30 (1.23–4.30) Age, sex, physical activity,
BMI
4. Engum et al.
(Norway – 2007)a
10.0 55.0 30 ADI Self-report + FPG OR: 1.40 (1.16–1.69) 1.39 (1.16–1.68) Age, gender,
socioeconomic status,
lifestyle, metabolic
and clinical factors
5. Eaton et al.
(USA – 1996)
13.0 63.0 >18 DIS Self-report RR: 2.23 (0.90–5.55) 2.23 (0.90–5.54) Age, sex, race, BMI
6. Carnethon et al.
(USA – 2003)
15.6 59.0 25 GWBS Self-report + MRD RR: 2.52 (1.73–3.67) 2.52 (1.73–3.67) Age, race, sex
7. Mallon et al.
(Sweden – 2005)a
12.0 53.0 45 Self-report Self-report RR: 0.90 (0.30–2.90) 0.90 (0.29–2.80) Age, not married, living
alone, hypertension,
obesity, smoking, alcohol,
snoring and sleep
duration
8. Pan et al. (USA – 2010) 10.0 100 50–75 MHI-5 Self-report + MR RR: 1.17 (1.05–1.30) 1.17 (1.05–1.30) Age, marital status, family
history, physical activity,
BMI, antidepressant use
a Most adjusted model was not used in previous review.
S.S. Hasan et al. / Diabetes & Metabolic Syndrome: Clinical Research & Reviews 8 (2014) 82–8784included, so there was no over-inﬂation of the sample. There were
two studies published by Golden et al., in 2004 [38], and 2008 [15],
where they used the same sample, and only the most recent was
retained. Among studies assessing depression predicting diabetes,
four-fold cells were reconstructed and used to compute CIP from
ORs (4 studies) or RR (4 studies). The data presented by Kumari
et al. [39] was insufﬁcient to compute a four-fold cell and the study
was excluded. The reconstructed CIP was then used to compute RR
and RD for meta-analysis while original effect sizes (HRs) were
presented separately.
Table 1 presents the country-speciﬁc cumulative incident
proportions and incidences of diabetes onset for depression
(exposed) and non depression (unexposed) groups.
3.1. Depressive symptoms as a risk factor for diabetes
The summary of cohort studies assessing depression as a risk
factor for diabetes (in binary estimates) included in the review is
presented in Table 2. Nine studies reported their ﬁndings in the
form of binary point estimates. However, only eight studies thatDEP to DM - RR
RR
6420
Study 
Mallon et al - Sweden (2005) 
Pan et al - USA (2010) 
Engum et al - Norway (2007) 
Everson-Rose et al - USA (2004) 
Overall 
Q=25.94, p=0.00, I2=73%
Eaton et al - USA (1996) 
Palinkas et al - USA (2004) 
Carnethon et al - USA (2003) 
Stellato et al - USA (2000) 
    RR (95% CI)          % Weight
   0.90  (  0.29,  2.80)      4.10
   1.17  (  1.05,  1.30)     22.93
   1.39  (  1.16,  1.68)     21.18
   1.63  (  1.05,  2.54)     13.79
   1.67  (  1.30,  2.15)    100.00
   2.23  (  0.90,  5.54)      5.82
   2.30  (  1.23,  4.30)      9.67
   2.52  (  1.73,  3.67)     15.61
   2.94  (  1.31,  6.60)      6.91
Fig. 1. Random-effects forest plot showing the risk of diabetes for individual studies
using self-report questionnaires, diagnostic criteria, and all studies combined;
studies using reconstructed relative ratios. Bars and diamonds indicate 95% CIs.
DEP = depression; DM = diabetes mellitus; RR = relative risk.presented complete data to formulate four-fold cell were used to
calculate CIP and RR. Of these eight studies, six studies reported
statistically signiﬁcant associations; where, increasing risk of
incident diabetes as a result of depression was present. A
signiﬁcant heterogeneity was present, with a pooled RR of 1.67
(95% CI: 1.30–2.15) (Fig. 1) for studies examining depression as a
risk factor of diabetes.
For eight studies that presented their ﬁndings in the form of
hazard ratios, there were four studies in which the association was
statistically signiﬁcant where increasing risk was evident (Table 3).
The pooled hazard ratio was 1.45 (95% CI: 1.12–1.87) and there was
an evidence of heterogeneity (Fig. 2).
3.2. Sensitivity analysis and publication bias
Studies with <10 years follow-up (RR: 1.98), those adjusted
for 5 confounders (RR: 2.20), and conducted in the United States
(US) (RR: 1.92) showed signiﬁcantly higher risk of incident
diabetes than studies with 10 years of follow-up (RR: 1.52),
adjusted for >5 confounders (RR: 1.24) and conducted outside the
US (RR: 1.37). The funnel plot revealed gross asymmetry, as most of
the studies reported higher relative risks on one side of the line
representing the most precise relative risk (Fig. 3). The Egger’s test
for publication bias also suggested asymmetry (intercept 0.449;
p = 0.025). Using the Trim and Fill method to impute missing
studies, three dummy studies were added and the revised estimate
was 1.26 (95% CI: 1.02–1.57).
4. Discussion
The current study is the ﬁrst to report cumulative incidences of
diabetes in depressed and non depressed groups, using data from
longitudinal studies. A greater risk of diabetes in people with
depressive symptoms has been reported previously [25,29,30]. In
line with these studies, our observations revealed greater CIPs of
diabetes in depressed than in non depressed groups. Of 15 studies
included in our review, 8 studies were from Northern America, 5
from Europe and 2 from East Asia. We note that a study conducted
in Taiwan [46] documented highest whereas a study from Norway
Table 3
Summary of ﬁndings of longitudinal studies assessing relationship between depression and incident diabetes using time-to-event estimates (HR: hazards ratio).
Authors
(country – year)
Follow-up
years
%
female
Age (yrs) Assessment
of depression
Assessment
of diabetes
Hazards ratio Adjustment for
confounders
1. Kawakami et al.
(Japan – 1999)a
8.0 0.0 18 ZSDS OGTT + FPG 2.31 (1.03–5.20) Age, education,
occupation, work shift,
obesity, physical activity,
smoking, alcohol, chronic
conditions, family history
2. Saydah et al.
(USA – 2003)
9.0 74.0 32–86 CES-D Self-report 1.11 (0.79–1.56) Age, sex, race, BMI,
physical activity, education
3. V den Akker et al.
(Netherlands – 2004)
15.0 58.0 20 ICPC-P76 ICPC-T90 1.04 (0.84–1.28) Age, sex, BMI,
socioeconomic, interaction
with depression
4. Carnethon et al.
(USA – 2007)a
8.0 59.2 65 CES-D Medication + FPG 1.41 (0.91–2.19) Age, race, sex, education,
marital status, physical
activity, smoking, alcohol
intake, BMI, C-reactive
protein level
5. Golden et al.
(USA – 2008)a
3.2 60.1 45–84 CES-D +
antidepressant
use
FPG 1.21 (0.87–1.67) Age, sex, ethnicity,
examination site, BMI,
Lipids, BP, IL-6, C-reactive
protein, SES, daily caloric
intake, smoking status,
alcohol, and physical activity
6. Campayo et al.
(Spain – 2010)
5.0 55.0 55 GMSS + AGECAT Self-report 1.65 (1.02–2.66) Age, sex, family history of DM,
hypertension, functional
disability, smoking, alcohol,
antidepressant/antipsychotics/
statin use
7. Demakakos et al.
(UK – 2010)
5.0 55.7 50 Medication CES-D 1.62 (1.15–2.29) Age, sex, marital status, clinical
factors, education, income, BMI
8. Chen et al.
(Taiwan – 2013)
7.0 46.4 20 Medical records ICD-9-CM 2.02 (1.80–2.27) Age, sex, complications, clinical
factors, geographical area
a Most adjusted model was not used in previous review.
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non depressed groups.
The study found a signiﬁcant association between depression
and incident diabetes and of the 16 studies assessing this
association, 10 suggested increased risk. In our quantitative
analysis using the random-effects model, we found a 1.67-fold
increase in risk or 1.45-fold increase in hazard for diabetes in
adults with depressive symptoms. Similar results were reported in
previous meta-analyses, although they had not separated binary
point estimates from HRs for estimating pooled effect sizes [25,29].
Potential mechanisms involving psychological, socioeconomic
and biological factors are described elsewhere [27,40,41].
Our funnel plot suggested possible publication bias. However,
the variation across different means of assessment was insigniﬁcantDEP to DM - HR
ES
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Study 
V den Akker et al - Netherlands (2004) 
Saydah et al - USA (2003) 
Golden et al - USA (2008) 
Carnethon et al - USA (2007) 
Overall 
Q=39.86, p=0.00, I2=82%
Demakakos et al - UK (2010) 
Campayo et al - Spain (2010) 
Chen et al - Taiwan (2013) 
Kawakami et al - Japan (1999) 
    ES (95% CI)          % Weight
   1.04  (  0.84,  1.28)     15.39
   1.11  (  0.79,  1.56)     13.16
   1.21  (  0.87,  1.67)     13.42
   1.41  (  0.91,  2.19)     11.38
   1.45  (  1.12,  1.87)    100.00
   1.62  (  1.15,  2.29)     13.08
   1.65  (  1.02,  2.66)     10.68
   2.02  (  1.80,  2.27)     16.62
   2.31  (  1.03,  5.20)      6.27
Fig. 2. Random-effects forest plot showing the risk of diabetes for individual studies
using self-report questionnaires, diagnostic criteria, and all studies combined;
studies using HRs. Bars and diamonds indicate 95% CIs. ES = HR (hazard ratios);
DEP = depression; DM = diabetes mellitus.when studies using standard diagnostic criteria were separated from
studies using self-report scales; this suggests that the ﬁnding was
unlikely to be an artiﬁcial result of measurement error. The funnel
plot suggested possible publication bias (Fig. 3). Funnel plot
asymmetry may be due to publication bias, but it may also result
from clinical heterogeneity between studies or methodological
heterogeneity between studies [40]. Two assessment methods are
often used to identify depressive symptoms and DM, self-report and
diagnostic criteria. Most studies used non-standardized self-report
measures of diabetes. The variation across different means of
diabetes assessment was insigniﬁcant when studies using standard
diagnostic criteria were separated from studies using self-report
scales; this suggests that the ﬁnding was unlikely to be an artiﬁcial
result of measurement error. Knol et al. conducted a meta-analysis in
which they separated the studies where DM was assessed by bloodDEP to DM - RR
ln ES
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Fig. 3. Funnel plot with 95% conﬁdence interval relative risk of studies examining
risk of diabetes included in the meta-analysis using reconstructed relative ratios
(RR) (n = 8). ES = RR (relative risk); DEP = depression; DM = diabetes mellitus.
S.S. Hasan et al. / Diabetes & Metabolic Syndrome: Clinical Research & Reviews 8 (2014) 82–8786glucose measures from physician diagnosis or patient self-report,
and their study demonstrated a similar pooled relative risk of
depression [25]. Confounding therefore may have resulted in the
asymmetry seen in our study but has been adjusted for in the pooled
analysis and so has been accounted for. Finally, publication bias may
exist as the published studies may not be representative of
all studies that have been done since positive results tend to be
submitted and published more often than negative results [42]
and we have tried to address what its impact might have been via our
trim and ﬁll analysis.
4.1. Limitations
Limitations of the current review include language bias (only
English-language databases and journals were searched), and
publication bias, as signiﬁcant studies were more likely to be
published and easily indentiﬁed. The majority of the longitu-
dinal studies were published from the USA, Europe and other
developed countries where people of color and Caucasians
experienced similar rates of depression and diabetes risk [43];
studies in developing countries may present different ﬁndings.
Moreover, issues with longitudinal research designs and
confounding bias cannot be entirely ruled out [44,45]. Both
depression and diabetes are multifactorial diseases and is
therefore quite obvious that the impact of a single risk factor
can be modest. In other words, the impact of a single risk factor,
corrected for other confounding variables, on a multifactorial
disease, is usually small, but this is not necessarily linked to a
low impact from a clinical point of view.
5. Conclusions
This study provides evidence using longitudinal data that
cumulative incidence of diabetes is higher in depressed than in non
depressed subjects. We also found a signiﬁcant association
between depression and incident diabetes in terms of relative
measures. Depression should be included among risk factors that
required regular screening for diabetes.
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Abstract This meta-analysis examined depression as a
consequence of diabetes by conducting a meta-analysis,
using data from longitudinal studies. Databases were sys-
tematically searched for relevant studies. Incidence of
depression is presented as cumulative incident proportion
(CIP). Pooled effect sizes were calculated using random-
effects model. The data were reconstructed to compute
relative risk (RR) and CIP. The 16 studies selected for
review generated 16 datasets of which 11 studies reporting
binary estimates (RR) and 5 studies reporting time-to-event
estimates [hazard ratio (HR)]. Both RR and HR were sig-
nificant at 1.27 (95 % CI 1.17–1.38) and 1.23 (95 % CI
1.08–1.40) for incident depression associated with diabetes
mellitus. Our observations also revealed greater cumulative
incidence of depression in diabetes than in non diabetes
groups. Our study shows that diabetes is a significant risk
factor for the onset of depression.
Keywords Depression  Diabetes mellitus 
Longitudinal  Meta-analysis
Introduction
The prevalence of diabetes mellitus is increasing world-
wide. The International Diabetes Federation (IDF) reported
that almost 382 million people suffered from diabetes in
2013, and the number is expected to rise to 592 million by
the year 2035 (IDF 2013). People with diabetes experience
a number of complications in the course of the disease,
including mental health-related illnesses such as depres-
sion. Depression is one of the most common co-morbid
conditions associated with diabetes (Kessler et al. 1995;
WHO 2000), and people with diabetes are almost twice as
likely to suffer from depression as the general population
(Anderson et al. 2001). However this often remains
unrecognized and thus untreated, leading to a higher
prevalence of depression among people with diabetes
(Bouwman et al. 2010; Silva et al. 2012). People with
diabetes are more likely to suffer from depression and to
rate their health as worse when compared with non-diabetic
people (Zhang et al. 2005). Depression and diabetes are
two serious medical conditions and health concerns that
afflict million of people worldwide.
Diabetes is a significant risk factor for depression and
doubles the likelihood of co-morbid depression (Anderson
et al. 2001). The psychosocial burden of a chronic disease
such as diabetes may carry with it a risk for developing
depressive symptoms (Knol et al. 2007). Individuals
experiencing diabetes-related complications and disability
may experience depression as a consequence of their dis-
ability (Palinkas et al. 1991; Talbot et al. 1999; de Jonge
et al. 2006). Perceived disability and awareness of having a
chronic illness may impose higher levels of psychological
burden on people with diabetes, particularly in individuals
with low levels of social support (Talbot and Nouwen
2000). Depression as a consequence of diabetes could be
S. S. Hasan (&)  A. M. Clavarino  T. Kairuz
School of Pharmacy, The University of Queensland,
20 Cornwall Street, Woolloongabba, QLD 4102, Australia
e-mail: shahzad.syed@uqconnect.edu.au
A. M. Clavarino
e-mail: a.clavarino@sph.uq.edu.au
T. Kairuz
e-mail: t.kairuz@pharmacy.uq.edu.au
A. A. Mamun
School of Population Health, The University of Queensland,
Herston Road, Herston, QLD 4006, Australia
e-mail: mamun@sph.uq.edu.au
123
Community Ment Health J (2015) 51:204–210
DOI 10.1007/s10597-014-9744-5
explained by the burden of chronic disease or by bio-
chemical changes that occur as a result of diabetes (Knol
et al. 2007; Kinder et al. 2002). Depression may also be
regarded as a co-morbid condition that results from the
daily burden of having diabetes and/or its complications
(Kinder et al. 2002; Golden et al. 2008; Katon et al. 2004;
Barbour and Blumenthal 2005). There is only a modest
association between diabetes and the incidence of depres-
sion. It may be that competing risks for late-life depression
such as macro-vascular disease, functional or cognitive
decline, mask this relationship. Moreover, depression is
also difficult to diagnose in older adults (Gallo et al. 1994).
The aim of this review was to examine the relationship
between diabetes and incident depression by conducting a
meta-analysis of longitudinal studies using relative risk
(RR), in addition to cumulative incidence, and extensive
review and synthesis of the data. Previous meta-analyses
have demonstrated an increased risk of depression (Knol
et al. 2007; Mezuk et al. 2008; Nouwen et al. 2010; Rotella
and Mannucci 2012; Hasan et al. 2013); they are far from
conclusive because of several deficiencies. For example
incidence measures were not computed because most of the
longitudinal studies available have neither presented data
in a fourfold (2 9 2) table form nor supplied adequate
information to calculate a cumulative incident proportion
(CIP). Moreover to estimate pooled effect sizes studies
have not separated binary point and time-to-event esti-
mates, which we consider may be inappropriate (Mezuk
et al. 2008; Nouwen et al. 2010). For consistency, we have
converted odds ratios (ORs) to RRs and presented hazard
ratio (HR) separately.
Methods
The following electronic databases were searched: MED-
LINE (up to December, 2013); EMBASE (up to December,
2013); CINAHL (up to December 2013); PsycINFO (up to
December 2013). In the final stage Google Scholar was
also carefully scanned to find any missed or additional
studies. The following main keywords: depression disor-
ders and/or symptoms, mental disorders, major depressive
disorder, depressive reactions and/or symptomatology,
diabetes mellitus, diabetes mellitus, type 2, longitudinal,
cohort studies. Studies using longitudinal design and
probable type 2 diabetes containing sufficient data to
generate a risk estimate were included. Studies that only
examined gestational diabetes mellitus and type 1 diabetes
were excluded, but those with mixed samples of type 2
diabetes and type 1 diabetes, were included. There were
some studies that did not specify the type of diabetes, but
were included because the age of the recruited populations
suggested they would be predominantly subjects with type
2 diabetes. We excluded studies that contained cases of
existing depression.
After identifying possible studies, titles and abstracts
were screened to remove studies that were not relevant to
the aim of this review. The full texts of the remaining
studies were then examined to determine whether the
studies met our inclusion criteria. The references cited in
identified, relevant, original research and review articles
were then scanned for any additional articles that would
possibly be relevant to our review; moreover, the reference
lists of previous reviews and their included studies were
also examined. When multiple publications from the same
study population were available, we only included the most
recent publication.
The eligibility criteria were based on study type and
population attributes. Regarding study type, studies that
investigated the association, comorbidity and/or coexisting,
prevalence of diabetes and depression and/or depressive
symptoms or reaction were included. For population attri-
butes, studies that assessed depression and/or depressive
reaction or symptomatology in adults with diabetes were
included. In this meta-analysis we included all studies that
longitudinally examined the relationship between diabetes
and onset of depression. Studies that focused on efficacy of
treatment, or comorbidities, or which included other med-
ical and psychiatric conditions were excluded, as well as
any studies that were not longitudinal in design.
Data extracted from the studies included the name of
first author; publication year; study design; follow-up time
in years; number of subjects in the analysis; gender and age
of subjects; method of depression assessment; method of
diabetes assessment; binary point estimates and time-to-
event (survival) analysis with 95 % CI (adjusted for the
largest number of confounders); number of confounders;
method of exclusion of depressive and diabetes patients at
baseline; and new-onset cases. The method of assessment
of diabetes was either based on self-report or clinically
diagnosed based on blood glucose levels or based on the
diagnosis of diabetes on administrative data (drug con-
sumption/hospitalization). Depression was based on a
diagnosis by psychiatrist [using Diagnosis and Statistical
Manual (DSM) criteria]; the assessment of depressive
symptoms was by a self-administered questionnaire.
Statistical Analysis
Four-fold cells (2 9 2 tables) were imputed for all binary
point estimates using the reconstruction method proposed
by Pietrantonj (2006). Studies using time-to-event esti-
mates (HRs) were presented separately, as 2 9 2 table
reconstruction was not possible for studies using time-to-
event estimates. The four-fold cells were used to compute
RR, and cumulative incidence proportion (CIP). For studies
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that presented graded relationships such as low, medium,
or high depressive symptoms, only the estimate for the
highest category was selected. We evaluated heterogeneity
using the Cochran’s Q heterogeneity test (Q test) and a
related metric, the I2. A p value of 0.10 was used as the cut-
off point for heterogeneity. However, when the number of
studies is small, Cochran’s Q test has low power; therefore
a related metric I2 was also reported as it quantifies the
percentage of variability due to heterogeneity rather than
chance, as variability due to chance depends on study size
(I2 = (Q – df)/Q 9 100 %). Pooled results were calculated
via random effects (RE) model (Mezuk et al. 2008; Rotella
and Mannucci 2012).
To ensure the robustness of our meta-analysis, we per-
formed sensitivity analyses by modifying our selection
criteria and then examining the effect of the modified
selection criteria on the pooled results. We thus examined
selection by self-report versus clinical assessment of
depression and diabetes, by regional differences [United
Studies (US) versus non-US], by number of confounders
that were adjusted for in the analyses and length of follow-
up period. The follow-up period was classified into
B5 years and [5 years for diabetes predicting depression.
We considered the funnel plot to be asymmetrical if the
intercept of Egger’s regression line deviated from zero with
p \ 0.10. Additional analyses for publication bias were
performed when the funnel plot was asymmetric using the
Duval and Tweedie (2000) non-parametric ‘‘Trim and Fill’’
method of accounting for missing studies in meta-analysis.
All analyses were conducted using Microsoft Excel and
MetaXL software version 1.3 (MetaXL 2012).
Results
Our search yielded 846 unique abstracts from MEDLINE,
280 unique abstracts from EMBASE/CINAHL, 260 from
PsycINFO and 50 from Google Scholar. After removal of
duplication and applying the eligibility criteria, 68 rele-
vant papers were examined for further consideration. Of
these, 52 studies were excluded for the following reasons:
failing to remove prevalent cases of depression at base-
line; case–control study design; insufficient data to gen-
erate pooled effect sizes; and presence of specific
depression risk factors. Although it is assumed that anti-
depressant use may mask the longitudinal relationship
between depression and diabetes, studies that examined
the association of antidepressant use and diabetes were
also included (Egberts et al. 1997; Kivimaki et al. 2010;
Knol et al. 2009; Luijendijk et al. 2008). Of these, two
studies (Egberts et al. 1997; Luijendijk et al. 2008) used
the same data, and only the most recent study by
Luijendijk et al. was retained.
Two studies used the same sample (Arroyo et al. 2004;
Pan et al. 2010); and only the most recent publication by
Pan et al. (2010) was retained. Similarly, there were two
studies published by Golden et al. (2004, 2008), where they
used the same sample, and only the most recent was
retained, which examined diabetes predicting depression.
A total of 16 articles were then included in our review;
eleven assessing diabetes and incident depression using
binary point and five studies using time-to-event estimates.
Among the studies (n = 11) assessing diabetes pre-
dicting depression, four-fold cells were reconstructed and
used to compute CIP from ORs (10 studies) or RR (1
study). The reconstructed CIP was then used to compute
RR and CIP for meta-analysis while original effect sizes
(HRs) were used for studies that reported time-to-event
estimates and presented separately. Table 1 presents the
country-specific CIPs and incidences of depression onset
for diabetes (exposed) and non diabetes (unexposed)
groups.
Depression as a Consequence of Diabetes
A total of 16 longitudinal studies assessing depression as a
consequence of diabetes were included in this review; these
provided 16 datasets. Eleven studies that reported their
findings using binary point estimates and provided suffi-
cient data to formulate four-fold cell were used to recon-
struct RR and CIP. In six studies the association was not
statistically significant but increasing risk of incident
depression as a result of diabetes was present in most cases.
For RR, significant heterogeneity was present, with a
pooled RR of 1.27 (95 % CI 1.17–1.38). Only five studies
reported time-to-event (survival) estimates but there was
significant heterogeneity. The five studies generated a
pooled HR of 1.23 (95 % CI 1.08–1.40).
Sensitivity Analysis and Publication Bias
In our sensitivity analysis, non-US studies (RR 1.33, 95 %
CI 1.09–1.64) and studies that adjusted for less than 5
confounders (RR 1.22, 95 % CI 1.05–1.43) produced a
significantly higher RR than studies conducted in the US
(RR 1.24, 95 % CI 1.13–1.37) and studies that adjusted for
5 or more confounders (RR 1.22, 95 % CI 1.05–1.43).
Moreover, studies with B5 years of follow-up produced a
significantly higher relative risk (RR 1.54, 95 % CI
1.16–2.04) than studies with more than 5 years of follow-
up (RR 1.25, 95 % CI 1.17–1.33). The funnel plot was
reasonably asymmetrical and Egger’s test for publication
bias also suggested asymmetry (intercept = 0.243,
p = 0.001) for studies using binary point estimates. How-
ever ‘Trim and Fill’ method used to impute missing studies
did not result in additional dummy studies.
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For studies using time-to-event, the funnel plot revealed
gross asymmetry, as most of the studies reported higher
RRs on one side of the line representing the most precise
RR. It is evident that negative studies are missing in the
funnel plot or that smaller studies were reporting more
extreme effects as a result of systematic biases. The
Egger’s test for publication bias also suggested asymmetry.
The Trim and Fill method resulted in two dummy studies
being added and the revised estimate was 1.14 (95 % CI
1.00–1.30).
Discussion
Patients with diabetes showed greater cumulative incidence
of depression compared to non diabetes patients. Of the 16
studies of diabetes predicting incident depression, only
eight studies suggested increased risk. In our quantitative
analysis using random-effects model, we demonstrated a
1.27-fold increase in risk for depression in adults with
diabetes. These relative estimates are similar to previously
reported figures that were calculated without segregating
binary point and time-to-event estimates by Mezuk et al.
(1.15-fold) and Nouwan et al. (1.24-fold) (Mezuk et al.
2008; Nouwen et al. 2010). Routelle et al., however, pre-
sented their findings as unadjusted odds ratios and adjusted
HRs (Rotella and Mannucci 2012). They found a higher
incidence of depression in diabetes subjects, with unad-
justed and adjusted risk of 1.29-fold and 1.25-fold,
respectively. For five studies using time-to-event estimates,
we generated a pooled HR of 1.23.
Interestingly studies with 5 or less years of follow-up
produced a significantly higher RR compared to studies
with more than 5 years of follow-up. Most studies used
non-standardized self-report measures of depression sug-
gesting that the methods for screening and diagnosis of
depression may not be fully reliable. Similar variations
were noted when studies were separated based on regions
and numbers of confounders adjusted for. However, it is
important to remember that published studies are not rep-
resentative of all studies as positive results tend to be
submitted and published more often than negative findings
(Tsoi et al. 2009).
The association between diabetes and the onset of
depression is often conceptualized as having various pos-
sible indirect mechanisms (Hasan et al. 2013). In our
analysis, with separate pooled effect sizes (RR and HR),
we did found evidence to support the hypothesis that dia-
betes is a ‘‘depressogenic’’ condition. This finding is
alarming because increased risk of depression in people
with diabetes might lead to increased fatal or non fatal
suicidal ideation or behavior (Pompili et al. 2009). Gen-
erally, suicide is associated with psychiatric disorder whereT
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presence of depression is one of the contributing risk factor
(Goldston et al. 1997; Harris and Barraclough 1997).
There are several limitations that may affect its gener-
alizability and acceptability, including language bias (only
English-language databases and journals were searched),
and publication bias (significant studies were more likely to
be published and easily indentified). The majority of the
longitudinal studies included were published from the US,
Europe and other developed countries where people of
color and Caucasians experienced similar rates of depres-
sion and diabetes risk (Wagner et al. 2007). Brayne et al.
(2005) argued that longitudinal research designs, which
examine direction of a relationship, could be murky, as
some of the lifestyle factors and biological substrates, or
other common antecedents of both conditions, may have
been operating for years before diagnosis. Moreover,
confounding bias cannot be entirely ruled out. For instance
the analyses in most of the studies were not adjusted for
smoking, which appears to strengthen the association
between depression and diabetes, and alcohol abuse which
can be very difficult to establish in large-scale studies
(Albers et al. 2011). According to IDF, 80 % of people
with diabetes live in low- and middle-income countries
(IDF 2013). This may also cause significant limitation to
our incidence estimation as all longitudinal studies inclu-
ded in our study were from developed and high income
countries. Based on our sensitivity analysis, we assume that
the association between these two conditions may also
result from clinical heterogeneity between studies or
methodological heterogeneity between studies.
Despite some limitations, our study did provide the
evidence using longitudinal data that incidence of depres-
sion is higher in diabetes than in non diabetes subjects and
there is a significant association between diabetes and
incident depression.
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A B S T R A C T
This meta-analysis examined the reciprocal relationship between depression and diabetes mellitus
type 2 (T2DM) by conducting a bias adjusted meta-analysis of longitudinal studies using relative and
absolute risk estimates. Speciﬁcally, the data were reconstructed to compute relative risk (RR), risk
difference (RD), and the number needed to be exposed for one additional person to be harmed
(NNEH) or beneﬁted (NNEB). The 25 studies selected for review generated 29 datasets of which 15
examined endpoint A (depression as a risk factor for T2DM), and 14 examined endpoint B (T2DM as a
risk factor for depression). For both endpoints, there was a small relative risk increase (for both the
RR and hazard ratio (HR)) though with signiﬁcant heterogeneity between studies. This however
translated to a non-signiﬁcant NNEH of 87 (NNEB 161 to 1 to NNEH 35) and NNEH of 233 (NNEB 28
to 1 to NNEH 23) for studies examining endpoint A and endpoint B respectively. This study suggests
that the magnitude of the relative risk increase for depression as a risk factor or consequence of
T2DM is small without signiﬁcant impact on absolute risk indices. While these risks may be
considered in terms of individual patient management, they are unlikely to have an impact on a
population perspective.
 2013 Elsevier B.V. All rights reserved.
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People with diabetes mellitus type 2 (T2DM) experience a
number of complications in the course of the disease, including
mental health-related illnesses such as depression. The latter is
one of the common co-morbid conditions associated with T2DM
(Kessler et al., 1995; WHO, 2000), and is particularly prevalent
among such patients (Anderson et al., 2001; Ali et al., 2006). The
presence of T2DM doubles the risk for having a diagnosis of
depression compared to those without this condition (Eaton et al.,
1996), and such patients are also more likely to have deﬁcits in
cognitive function (Wandell and Aberg, 1998; Wandell, 1999).
Furthermore, the latter are also almost twice as likely to suffer
from depression as the general population (Anderson et al., 2001;
Egede et al., 2002; Nichols et al., 2007; Bouwman et al., 2010). Once
depression develops, it can represent a barrier to glycemic control
(Silva et al., 2012) and, sadly, often remains unrecognized and thus
untreated (Pouwer, 2009) thus perpetuating the presence of
depression among people with T2DM (Bouwman et al., 2010;
Pouwer, 2009).
Conversely, depression is quite common itself being responsi-
ble for a large proportion of the burden associated with non-fatal
health outcomes (WHO, 2005; Murray and Lopez, 1997) and there
is some suggestion that it could increase the risk of T2DM. Thomas
Willis, a famous physician from Great Britain was the ﬁrst to report
that diabetes was caused by ‘‘sadness or long sorrow and other
depressions’’ (Willis, 1971). This relationship was never convinc-
ingly demonstrated until Eaton et al. (1996) reported an
association that agreed with Willis’ hypothesis (Willis, 1971).
However the general response from researchers was that given the
‘‘modest’’ relationship, it could be ‘‘partially explained by lifestyle’’
(Golden et al., 2008), or might only exist with severe depression
(Eaton et al., 1996; Carnethon et al., 2003; Arroyo et al., 2004;
Brown et al., 2005; Kawakami et al., 1999; Palinkas et al., 2004;
Golden et al., 2004; Saydah et al., 2003).
It is clear therefore that the relationship between depression
and T2DM, while not conclusive (Brown et al., 2006), could be
bidirectional (Golden et al., 2008; Engum, 2007). Biologically both
hypotheses have some support. For example, depression as a
consequence of T2DM could be explained by the burden of chronic
disease or biochemical changes that occur as a result of T2DM
(Kinder et al., 2002; Knol et al., 2007). Depression however may
also be a co-morbid condition that results from the daily burden of
having T2DM and/or its complications. Conversely, depression as a
risk factor for the development of T2DM could be the consequence
of a decline in health-maintenance behaviors among depressed
persons (Golden et al., 2008; Kinder et al., 2002; Katon et al., 2004;
Barbour and Blumenthal, 2005), or biochemical changes associated
with depression (Bjorntorp, 2001; Knol et al., 2006).
While previous meta-analyses exist on this topic which support
somewhat the bidirectional hypotheses (Knol et al., 2006; Mezuk
et al., 2008; Nouwen et al., 2010; Rotella and Mannucci, 2012), they
are far from conclusive because of several deﬁciencies. For
example, absolute risk measures were not computed because
most of the longitudinal studies neither presented data in a four-
fold table form nor supplied adequate information to calculate
cumulative incidence proportions (i.e. raw numbers of incident
diabetes or depression by risk category). They also mainly focused
on relative measures (the binary point estimates relative risk; RRand odds ratio; OR) or the time-to-event estimate (hazard ratio;
HR). Also, there was no examination of bias risks. The aim of this
review was therefore to use more rigorous methodology to
examine the reciprocal relationship between depression and DM
by conducting a meta-analysis of longitudinal studies using bias
adjusted models, and extensive review and synthesis of the data.
The advantage this provides is to reduce the variance of the ﬁnal
estimator thus precluding results that could be unrealistically far
from true estimates. In addition to bias adjustment we also
separated binary point estimates (OR, RR) and time-to-event
estimates (HR), which we think were inappropriately combined in
previous reviews (Knol et al., 2006; Mezuk et al., 2008; Nouwen
et al., 2010). We also converted all odds ratios (ORs) to relative
risks (RRs) (see Section 2) so that risks are uniform. Finally, and
most importantly, we also imputed (from four-fold table
reconstruction) both the Cumulative Incident Proportion (CIP)
and then the absolute effect measure (risk difference) which was
then pooled and compared against the relative pooled estimates,
thus allowing us to judge the impact of any excess risk on the real
world.
2. Methods
2.1. Data sources
Search terms included combinations of the following: incident
diabetes, diabetes mellitus, type 2 diabetes mellitus, direction, co-
morbid, relationship, risk factor, depression, and/or depressive
reaction and/or symptomatology, incident depression. Studies
using longitudinal design and probable type 2 diabetes to generate
a risk estimate were included, whereas we excluded existing cases
of either depression (for diabetes predicting incident depression)
or diabetes (for depression predicting incident diabetes). Various
electronic databases were searched: MEDLINE (1950 to December,
2012); EMBASE (1980 to December, 2012); CINAHL (1982 to
December 2012); PsycINFO (1880 to December 2012). In the ﬁnal
stage Google Scholar was also carefully scanned to ﬁnd any missed
or additional studies.
After possible studies were identiﬁed, titles and abstracts were
screened to remove studies that were clearly irrelevant to the aim
of this review. The full texts of the remaining studies were then
examined to determine whether the studies met our inclusion
criteria. The references cited in identiﬁed relevant original research
and review articles were then scanned for any additional articles
that would possibly be relevant to our review; moreover, the
reference lists of previous reviews and included studies were also
examined. Studies were excluded if the authors did not explicitly
exclude subjects with prevalent diabetes at baseline and if there
were insufﬁcient data to estimate a relative risk, an odds ratio, risk
ratio or hazard ratio. When multiple publications from the same
study population were available, we only included the most recent
publication.
2.2. Eligibility criteria
Only studies relevant to the scope of the review were included.
The eligibility criteria were based on study type and population
attributes. Regarding study type, studies that investigated the
association, unidirectional or bidirectional, comorbidity and/or
S.S. Hasan et al. / Asian Journal of Psychiatry 6 (2013) 460–472462coexisting, prevalence of diabetes and depression and/or depres-
sive symptoms or reaction were included. For population
attributes, studies that assessed depression and/or depressive
reaction or symptomatology in adults with T2DM or in mixed
samples of T2DM and type 1 diabetes mellitus (T1DM), were
included. However, in the latter mixed studies, only data on type 2
diabetes were extracted. Studies that only examined gestational
diabetes mellitus and type 1 diabetes were also excluded. Seven
studies (Bisschop et al., 2004; Polsky et al., 2005; Kim et al., 2006;
de Jonge et al., 2006; Maraldi et al., 2007; Luijendijk et al., 2008;
Mallon et al., 2005) did not specify the type of diabetes, but were
included because the ages of populations recruited suggested they
would be predominantly subjects with T2DM. In this meta-
analysis we only included studies that longitudinally examined the
relationship between depression and onset of diabetes and vice
versa. Studies that focused on efﬁcacy of treatment, or which
included other medical and psychiatric conditions were excluded,
as well as editorials, commentaries, and any studies that were not
longitudinal in design. Studies that examined the association of
antidepressant use and DM were also excluded because we assume
that antidepressant use may mask the longitudinal relationship
between depression and DM.
2.3. Data abstraction and quality assessment
Data extracted from the studies included the name of ﬁrst
author; publication year; study design; follow-up time in years;
number of subjects in the analysis; gender and age of subjects;
method of depression assessment; method of diabetes assess-
ment; binary point estimates and time-to-event (survival)
estimates with 95% CI (the one adjusted for the largest number
of confounders); number of confounders that were adjusted for in
the analyses (see Tables 1–3 for details of confounders consid-
ered); method of exclusion of depressive and patients with
diabetes at baseline; and new-onset cases. The method of
assessment of diabetes was either based on self-report or clinically
diagnosed based on blood glucose levels or based on the diagnosis
of diabetes from administrative data (drug consumption/hospital-
ization). At the baseline this was corrected for undetected diabetes
as well. Depression was determined based on a diagnosis of
depression during a consultation with a psychiatrist (based on
Diagnosis and Statistical Manual (DSM) criteria); the assessment of
depressive symptoms was by a self-administered questionnaire.
The researchers carefully weighed the studies against a quality
checklist to estimate a quality index that would serve to rank
studies in terms of deﬁciencies. Quality was assessed using a
study-speciﬁc modiﬁcation of the quality criteria of observational
studies published by Shamliyan et al. (2010). The ﬁnal checklist
contained 11 items that were scored equally and consisted of
questions related to design speciﬁc protection against bias
(prospective vs retrospective), protection against selection bias
(e.g. refusals, attrition), protection against information bias
(adequate follow-up, accuracy of measurements of diabetes and
depression) and adequate consideration of confounders. We
examined the possible effect of various methodological factors
on the magnitude of the effect size by sub-grouping the studies
into higher and lower risk. Associations of the latter sub-groups
with methodology-related items were then quantiﬁed and used to
weight quality-related items within our quality score.
2.4. Statistical analysis
Four-fold cells (2  2 tables; exposure yes/no vs outcome yes/
no) were imputed for all binary point estimates using the
reconstruction method proposed by Pietrantonj (2006). Studies
using time-to-event estimates (hazard ratios) were presentedseparately, as 2  2 table reconstruction was not possible for
studies using time-to-event estimates. The four-fold cells were
used to compute relative risk (RR), risk difference (RD) and
cumulative incidence proportion (CIP). From pooled RD, the
number needed to be exposed for one additional person to be
harmed (NNEH) was also computed (reciprocal of average RD).
Two separate analyses were conducted: looking at depression as a
risk factor for T2DM, and looking at T2DM as a risk factor for
depression. For studies that presented graded relationships such as
low, medium, or high depressive symptoms, only the estimate for
the highest category was selected.
We evaluated heterogeneity using the Cochran’s Q heteroge-
neity test (Q test) and a related metric, the I2. A smaller p-value of
Cochran’s Q test means signiﬁcant heterogeneity among different
studies. In our review, a usual p-value of 0.10 was used as the cut-
off point for heterogeneity. However, when the number of studies
is small, Cochran’s Q test has low power. Therefore a related metric
I2 was also reported as it quantiﬁes the percentage of variability
due to heterogeneity rather than chance as variability due to
chance depends on study size (I2 = (Q  df)/Q  100%). Pooled
results were calculated via both the quality effects (QE) (Doi et al.,
2011, 2012; Doi, 2010; Doi and Thalib, 2008) and the random
effects (RE) models (Mezuk et al., 2008).
2.5. Sensitivity analysis and publication bias
To assess the robustness of this meta-analysis, sensitivity
analyses were performed by modifying our selection criteria and
then examining the effect of the variously modiﬁed selection
criteria on the pooled results. We thus examined selection by self-
report vs clinical assessment of depression and diabetes, by
regional differences (United States (US) vs non-US), by length of
follow-up period, and by number of confounders adjusted for in
the analyses. The follow-up period was classiﬁed into <10 years
and 10 years for depression predicting diabetes, and 5 years and
>5 years for diabetes predicting depression; different consider-
ations for follow-up were used because the studies following
diabetes had much less follow-up than studies following depres-
sion.
A funnel plot was used to examine the existence of publication
bias through visual inspection for asymmetry. However, it is
difﬁcult to establish the symmetry of the funnel plots through
visual examination alone and we therefore also considered the
funnel plot to be asymmetrical if the intercept of Egger’s regression
line deviated from zero with p < 0.10.
Additional analyses for publication bias were performed when
the funnel plot was asymmetric using the Duval and Tweedie non-
parametric ‘‘Trim and Fill’’ method of accounting for missing
studies in meta-analysis (Duval and Tweedie, 2000). This method
provides an estimate of the number of missing studies (with
imputed estimates). All imputations were done assuming random
error only. The QE meta-analysis was then re-run with quality
scores given to the imputed studies of their corresponding (same
standard error) existing studies to arrive at a pooled estimate that
corrects somewhat for publication bias. No protocol for this review
had been previously submitted or published. All analyses were
conducted using Microsoft Excel and MetaXL software version 1.3
(Meta XL, 2012) and Stata version 11 (Stata Corp, College Station,
USA) was used for the Trim and Fill analysis.
3. Results
Our search (Fig. 1) yielded 2665 unique abstracts from
MEDLINE, 1630 unique abstracts from EMBASE/CINAHL, 560 from
PsycINFO and 550 from Google Scholar. After removal of
duplication and applying the eligibility criteria, 100 relevant
Table 1
Summary of ﬁndings of longitudinal/cohort studies assessing relationship between depression and incident diabetes using binary point estimates.
Authors (country-yr) Follow-up
years
% Female Age
(yrs)
Assessment of
depression
Assessment of
diabetes
Original effect size Reconstructed CIP Reconstructed RR Adjustment for confounders
Studies reported odds ratios
1. Stellato et al.
(USA – 2000)
9.0 0.0 40 CES-D Self-report OR: 3.09 (1.34–7.12) E: 7/90
UE: 23/910
2.94
1.31–6.60
Testosterone, SHBG,
hypertension, CVS, BMI
2. Everson-Rose et al.
(USA – 2004)
3.0 100 42 CES-D Self-report + FPG OR: 1.66 (1.05–2.61) E: 28/578
UE: 58/1998
1.63
1.05–2.54
Age, site, race, education,
medication use
3. Kumari et al.
(UK – 2004)a
10.5 44.0 35 GHQ with
depression
subscale based
on factor
analysis
Self-report +OGTT OR: 1.14 (0.83–1.57) New cases: 361
Total: 10138
Incomplete data Age, length of follow-up, employment
grade, ethnic group, ECG abnormalities,
family history of diabetes, body mass
index, height, systolic blood pressure,
exercise, smoking, and life events
4. Palinkas et al.
(USA – 2004)
8.0 57.0 50 BDI OGTT/FPG OR: 2.50 (1.29–4.87) E: 10/70
UE: 51/840
2.30
1.23–4.30
Age, sex, physical activity,
BMI
5. Engum et al.a
(Norway – 2007)
10.0 55.0 30 ADI Self-report + FPG OR: 1.40 (1.16–1.69) E: 152/8159
UE: 382/28598
1.39
1.16–1.68
Age, gender, socioeconomic status,
lifestyle, metabolic and clinical factors
Studies reported relative risk
6. Eaton et al.
(USA – 1996)
13.0 63.0 >18 DIS Self-report RR: 2.23 (0.90–5.55) E: 5/71
UE: 46/1558
2.23 (0.90–5.54) Age, sex, race, BMI
7. Carnethon et al.
(USA – 2003)
15.6 59.0 25 GWBS Self-report +MRD RR: 2.52 (1.73–3.67) E: 32/534
UE: 128/5496
2.52 (1.73–3.67) Age, race, sex
8. Mallon et al.a
(Sweden – 2005)
12.0 53.0 45 Self-report Self-report RR: 0.90 (0.30–2.90) E: 3/128
UE: 29/1010
0.90 (0.29–2.80) Age, not married, living alone, hypertension,
obesity, smoking, alcohol use, snoring, sleep
duration
9. Pan et al.
(USA – 2010)
10.0 100 50–75 MHI-5 Self-report +medical
records
RR: 1.17 (1.05–1.30) E: 371/6680
UE: 2288/48541
1.17 (1.05–1.30) Age, marital status, family history, physical
activity, BMI, antidepressant use
CIP = cumulative incidence proportion, E =exposed group, UE=unexposed group.
a Most adjusted model was not used in previous review; estimates for Kumari et al. derived from previous review by Mezuk et al. (Everson-Rose et al., 2004; Stellato et al., 2000).
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Table 2
Summary of ﬁndings of longitudinal/cohort studies using time-to-event estimates (HR: hazards ratio).
Authors (country-yr) Follow-up
years
% Female Age
(yrs)
New cases Assessment
of depression
Assessment of
diabetes
HR Adjustment for
confounders
Studies assessing relationship between depression and incident diabetes
1. Kawakami et al.
(Japan – 1999)a
8.0 0.0 18 43/2380 Zung-SDS OGTT + FPG 2.31 (1.03–5.20) Age, education,
occupation, work shift,
obesity, physical
activity, smoking,
alcohol, chronic medical
conditions, family
history
2. Saydah et al.
(USA – 2003)
9.0 74.0 32–86 465/8870 CES-D Self-report 1.11 (0.79–1.56) Age, sex, race, BMI,
physical activity,
education
3. V den Akker et al.
(Netherlands – 2004)
15.0 58.0 20 3245/68004 ICPC-P76 ICPC-T90 1.04 (0.84–1.28) Age, sex, BMI,
socioeconomic,
interaction with
depression
4. Carnethon et al.
(USA – 2007)a
8.0 59.2 65 147/4681 CES-D Medication + FPG 1.41 (0.91–2.19) Age, race, sex, education,
marital status, physical
activity, smoking,
alcohol intake, BMI, C-
reactive protein level,
baseline CES-D score
5. Golden et al.
(USA – 2008)a
3.2 60.1 45–84 275/5201 CES-D +
antidepressant
use
FPG 1.21 (0.87–1.67) Age, sex, race/ethnicity,
examination site, BMI,
lipids, BP, IL-6, C-
reactive protein, SES
factors, daily caloric
intake, smoking status,
alcohol use, and physical
activity
6. Campayo et al.
(Spain–2010)
5.0 55.0 55 163/3521 GMSS + AGECAT Self-report 1.65 (1.02–2.66) Age, sex, family history
of DM, hypertension,
functional disability,
smoking, alcohol,
antidepressant/
antipsychotics/statin
use
Studies assessing relationship between diabetes and incident depression
1. Polsky et al.
(USA – 2005)
6.0 52.0 51–61 571/7909 CES-D Self-report 1.17 (0.98–1.41) Age, sex, race, marital
status, education,
wealth, income, self-
rated health, disability,
baseline CES-D, and
chronic conditions
2. Brown et al.
(Canada – 2006)
12.0 53.0 20 2534/88776 ICD and Rx based Medical records
and ICD
1.04 (0.94–1.15) Age, sex, number of MD
visits, co-morbid
arthritis, cancer,
vascular disease, insulin
use
3. Golden et al.
(USA – 2008)a
3.1 45.5 45–84 60/4847 CES-D +
antidepressant
FPG 1.52 (1.09–2.12) Demographics, BMI,
metabolic &
inﬂammatory factors,
SES & lifestyle factors,
medication,
hypertension
4. Aarts et al.
(Netherlands–2009)
8 51.9 40 122/6140 ICPC-P76 ICPC-T90 1.26 (1.12–1.42) age, practice
identiﬁcation code and
depression preceding
DM
5. Hsu et al.
(Taiwan–2012)
7 48.5 20 258/14048 Medical
records
ICD-9-CM 1.46 (1.24–1.71) Age, sex, occupation,
income, hypertension,
stroke, hyperlipidemia,
CAD.
a Most adjusted model was not used in previous review (Aarts et al., 2009; Campayo et al., 2010; Carnethon et al., 2007; van den Akker et al., 2004; Hsu et al., 2012).
S.S. Hasan et al. / Asian Journal of Psychiatry 6 (2013) 460–472464papers were examined for further consideration. Of these, 75
studies were excluded for the following reasons: failing to remove
prevalent cases of depression or diabetes at baseline; study design;
insufﬁcient data to generate pooled effect sizes; and presence of
speciﬁc diabetes or depression risk factors. Studies that examined
the association of antidepressant use and DM were also excluded
because we assume that antidepressant use may mask the
longitudinal relationship between depression and DM (Egbertset al., 1997; Kivimaki et al., 2010; Knol et al., 2009). A total of 25
articles were then included in our review; these provided 15
datasets assessing depression and incident diabetes and 14 datasets
examining diabetes and incident depression. There were four more
data-sets than studies because four studies (Palinkas et al., 2004;
Engum, 2007; Golden et al., 2008; Pan et al., 2010) examined
both depression predicting diabetes and diabetes predicting
depression and thus these each provided two data-sets for
Table 3
Summary of ﬁndings of longitudinal studies assessing relationship between diabetes and incident depression using binary point estimates.
Authors (country-yr) Follow-up
years
% Female Age (yrs) Assessment of
depression
Assessment of
diabetes
Original effect size Reconstructed CIP Reconstructed RR Adjustment for confounders
Studies reported relative risk
1. Palinkas et al.
(USA – 2004)
8.0 57.0 50 years BDI OGTT OR: 0.73 (0.41–1.30) E: 13/103
UE: 126/729
0.76
0.44–1.30
Age, sex, physical activity,
and BMI
2. de Jonge et al.
(Spain – 2006)a
5.0 58.0 55 GMS-AGECAT Self-report +medical
records
OR: 1.28 (0.91–1.79) E: 40/465
UE: 231/3471
1.26
0.91–1.74
Age, sex, partner, education,
hypertension, smoking, statin
use and cognitive functioning
3. Kim et al.
(Korea – 2006)
2.0 55.0 65 GMS-AGECAT Self-report + FBG OR: 1.0 (0.4–2.5) E: 5/42
UE: 51/423
1.0
0.42–2.36
Unadjusted
4. Bisschop et al.
(USA – 2007)a
6.0 53.3 55–85 CES-D Self-report OR: 0.73 (0.53–0.99) E: 43/78
UE: 796/1065
0.83
0.64–1.06
Physical limitation, age, sex,
education level, and living
with a partner
5. Engum et al.
(Norway – 2007)
10.0 55.0 30 HADS Self-report + FPG OR: 1.24 (0.78–1.98) E: 18/319
UE: 1600/35354
1.23
0.78–1.93
Age, sex, education, and
marital status
6. Maraldi et al.
(USA – 2007)a
5.9 48.0 70–79 CES-D+ self
reported
antidepressant
use
Self-report +medical
records
OR: 1.19 (0.96–1.47) E: 122/475
UE: 340/1585
1.15
0.96–1.39
Age, sex, race, study site,
baseline CES-D score,
education level, smoking,
alcohol intake, physical
activity, hypertension,
cerebro-vascular disease,
ankle-brachial index, obesity,
cystatin-C levels, IL-6 levels,
6-m walking speed, and
cognitive impairment
7. Luijendijk et al.
(Netherlands – 2008)
5.0 58.0 61 DSM-IV
CES-D
MR OR: 2.07 (1.11–3.85) E: 13/378
UE: 42/2498
2.03
1.10–3.75
Age, sex, education, income,
disability, cognitive function,
BMI, and medication
8. O’Connor et al.
(USA – 2009)
6.0 48.1 40 ICD+medical
records
ICD+medical records OR: 1.32 (1.07–1.63) E: 207/13937
UE: 153/13627
1.32
1.07–1.62
Age at index date, sex,
primary care visits in the at-
risk period
Studies reported relative risk
9. Pan et al.
(USA – 2010)
10.0 100 50–75 SF-36/MHI-5 Self-report +medical
records
RR: 1.29 (1.18–1.40) E: 464/2227
UE: 7244/46922
1.29 (1.18–1.41) Age, marital status, family
history, lifestyle factors, BMI,
insulin therapy
CIP= cumulative incidence proportion, E = exposed group, UE=unexposed group.
a Most adjusted model was not used in previous review (O’Connor et al., 2009).
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(n = 75)
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qualitative synthesis  
(n = 25)
Datasets included in 
quantitative synthesis  
(Meta-analysis)
(n = 25) 
15 datasets examining 
depression to DM and 14 
datasets examining DM to 
4 studies had data on both 
directions 
Fig. 1. Study ﬂow diagram – process of including studies.
S.S. Hasan et al. / Asian Journal of Psychiatry 6 (2013) 460–472466analysis. These data-sets are referred to subsequently under results
in terms of their parent studies because data from the same study
appear in different analyses.
Three studies used the same sample (Saydah et al., 2003; Arroyo
et al., 2004; Pan et al., 2010); however, two of these were retained:
the most recent publication by Pan et al. (2010) and Saydah et al.
(2003). These two studies used different risk estimates, (RR vs HR),
and thus were in different analyses (Pan et al. in the binary
estimates analysis and Saydah et al. in the time-to-event analysis),
so there was no over-inﬂation of the sample. There were two
studies published by Golden et al. (2004, 2008), where they used
the same sample, and only the most recent which examined both
depression predicting diabetes and diabetes predicting depression
was retained.
Among studies assessing depression predicting diabetes, four-
fold cells were reconstructed and used to compute CIP from ORs (4
studies) or RR (4 studies). The data presented by Kumari et al.
(2004) was insufﬁcient to compute a four-fold cell and the study
was excluded when the authors did not respond to our request for
additional data. Similarly CIP was reconstructed from 9 studies
examining diabetes predicting depression. The reconstructed CIP
was then used to compute RR and RD for meta-analysis while
original effect sizes (HRs) were used for studies that reported time-
to-event estimates and presented separately.
3.1. Quantitative synthesis
3.1.1. Depression as a risk factor for diabetes mellitus
The summary of cohort studies assessing depression as a risk
factor for diabetes included in the review is presented in Table 1.Nine studies reported their ﬁndings in the form of binary point
estimates. However, only eight studies that presented complete
data to formulate four-fold cell were used to reconstruct CIP, RR
and RD. Of these eight studies, only two studies reported
statistically insigniﬁcant associations; however, increasing risk
of incident diabetes as a result of depression was present. For both
RR and RD, signiﬁcant heterogeneity was present, with a pooled RR
of 1.41 (95% CI: 1.13–1.76) (Fig. 2) and RD of 0.0115 (95% CI:
0.0062 to 0.0292). The NNEH was 87 (NNEB 161 to 1 to NNEH
35) for studies examining depression as a risk factor of diabetes
(Fig. 2).
For six studies that presented their ﬁndings in the form of
hazard ratios, there were four studies in which the association
was not statistically signiﬁcant but increasing risk was
evident (Table 2). However, there was no evidence of
heterogeneity (Fig. 3) and the pooled hazard ratio was 1.24
(95% CI: 1.05–1.47).
3.1.2. Diabetes as a risk factor for depression
Fourteen studies examined depression as a consequence of DM.
The summary of longitudinal studies assessing depression as a
consequence of diabetes that were included in this review is
presented in Table 3. Nine studies that reported their ﬁndings
using binary point estimates and provided sufﬁcient data to
formulate four-fold cell were used to reconstruct CIP, RR and RD.
There were six studies in which the association was not
statistically signiﬁcant but increasing risk of incident depression
as a result of diabetes was present in most cases. For both RR and
RD, signiﬁcant heterogeneity was present, with a pooled RR of 1.23
(95% CI: 1.15–1.31) (Fig. 2) and RD of 0.0043 (95% CI: 0.0358 to
Fig. 2. Quality-effects forest plot showing the risk of diabetes (top) and risk of depression for individual studies using self-report questionnaires, diagnostic criteria, and all
studies combined; studies using reconstructed RR. Bars and diamonds indicate 95% CIs. DM = diabetes mellitus; DEP = depression.
S.S. Hasan et al. / Asian Journal of Psychiatry 6 (2013) 460–472 4670.0444). The NNEH was 233 (NNEB 28 to 1 to NNEH 23) for studies
examining depression as a consequence of diabetes.
Five studies reported time-to-event (survival) estimates but
there was signiﬁcant heterogeneity (Table 2 and Fig. 3). The ﬁve
studies generated a pooled HR of 1.22 (95% CI: 1.05–1.42).
3.2. Sensitivity analysis and publication bias
We conducted a number of sensitivity analyses using recon-
structed RR to examine the robustness of our ﬁndings. Since both
depression and diabetes can have extended prodromal periods
(Mezuk et al., 2008), we also categorized studies based on follow-
up time.3.2.1. Depression as a risk factor for diabetes mellitus
Studies with <10 years follow-up time had a signiﬁcantly
higher relative risk (RR: 2.05) than studies with 10 years (RR:
1.34) of follow-up time. Studies conducted in the US were almost
similar to studies conducted outside the US (RR: 1.32). However,
studies where the outcome was adjusted for less than or equal to
ﬁve confounders showed almost double the risk compared to
studies where more than ﬁve confounders were adjusted in
analysis. The funnel plot to detect publication bias revealed gross
asymmetry, as most of the studies reported higher relative risks on
one side of the line representing the most precise relative risk
(Fig. 4). It is evident that negative studies are missing in the funnel
plot or that smaller studies were reporting more extreme effects as
Fig. 3. Quality-effects forest plot showing the risk of diabetes and depression for individual studies using self-report questionnaires, diagnostic criteria, and all studies
combined; studies using time-to-event estimates. Bars and diamonds indicate 95% CIs. ES: effect size. HR = hazards ratio.
S.S. Hasan et al. / Asian Journal of Psychiatry 6 (2013) 460–472468a result of systematic biases. The latter is more likely given that the
QE model ‘down-weighted’ the majority of these studies. The
Egger’s test for publication bias also suggested asymmetry
(intercept 0.449; p = 0.025). Under the assumption of missing
studies, the Trim and Fill method was used to impute missing
studies, and this resulted in three dummy studies being added and
the revised QE estimate (assuming the same quality and standard
error as the corresponding study) was 1.26 (95% CI: 1.02–1.57). The
revised RD was 0.0108 (95% CI: 0.0040 to 0.0255) with an
adjusted NNEH of 93 (NNEB 250 to 1 to NNEH 40).ln ES
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Fig. 4. Funnel plot with 95% conﬁdence interval relative risk of studies examining
risk of diabetes included in the meta-analysis using reconstructed RR (n = 8).3.2.2. Diabetes mellitus as a risk factor for depression
Studies with 5 years following time (RR: 1.40), non-US studies
(RR: 1.36) and studies that used standard criteria (RR: 1.24)
produced signiﬁcantly higher relative risk than studies with >5
years of follow-up time (RR: 1.18), US studies (RR: 1.17) and
studies that used self-report scales (RR: 1.20). Only non-US studies
suggested diabetes as a signiﬁcant predictor of depression.
However, studies where more than 5 confounders were adjusted
in analysis were similar to studies where outcome was adjusted for
less than or equal to 5 confounders. The funnel plot was reasonably
symmetrical and Egger’s regression concurred (intercept = 0.655,
p = 0.107).
4. Discussion
4.1. Depression as a risk factor for diabetes mellitus
We found a modest relationship between depression and
incident T2DM and of the 15 studies examining this relationship,
eight suggested increased risk. In our quantitative analysis using
the quality-effects model, we demonstrate a 1.41 fold increase in
risk or 1.24 fold increase in hazard for T2DM in adults with
depression. This concurs with the 1.37 fold risk increase reported
previously (Knol et al., 2006).
Although our results on a relative scale concur with previous
reports, the risk difference, which is a measure of absolute risk (not
reported in previous reviews), shows a very small difference in risk
of T2DM between depressed and non-depressed persons. Our
S.S. Hasan et al. / Asian Journal of Psychiatry 6 (2013) 460–472 469ﬁndings also suggest that if we increase the length of follow-up
time, based on what we found in our sensitivity analysis, we may
end up with an insigniﬁcant association, negligible risk difference,
and large NNEH of 87. It may be pointed out that the NNEH
describes the disease burden associated with exposure or risk
factor(s) and is a useful measure especially if the exposure is
modiﬁable (such as diabetes and depression) (Bender and Blettner,
2002). In order to understand the impact of the NNEH, we could
take an example of Australia where the prevalence of depression in
the adult population was 4% (859,942) in 2007–08 (ABS, 2007,
2008, 2009). It can therefore be estimated that 9885 (859942/
NNEH) depressed persons may develop diabetes over approxi-
mately 10 years that would not have done so otherwise. These are
very small numbers compared to the population prevalence
suggesting that from a population perspective, the impact is small.
This is especially so given the non-signiﬁcance of the pooled
average risk differences.
4.2. Diabetes mellitus as a risk factor for depression
We also found a modest relationship between DM and incident
depression. Of 12 studies reporting DM predicting incident
depression, only four studies suggested increased risk. In our
analysis using the quality-effects model, there was a 1.2 fold
increase in both the risk and the hazard of incident depression after
diabetes onset. The reported prevalence of T2DM in Australia in the
adult population was about 3.3% (709,452) in 2007–08 (ABS, 2007,
2008, 2009). Therefore, again, absolute risks were small and it can
be estimated that an additional 3045 (709452/NNEH) people with
diabetes will develop depression as a consequence of diabetes over
approximately 5 years.
A previous meta-analysis (Mezuk et al., 2008) provided similar
evidence for a bidirectional relationship but reported a weaker
relationship for people with T2DM developing depression (in-
crease of 15%) as opposed to depressed persons developing
diabetes (increase of 60%). We found a similar trend but a follow-
up meta-analysis of 11 studies conducted by Nouwen et al. (2010)
found a lesser increase (24%) in the risk of T2DM.
4.3. Risk mechanisms
The evidence suggests that depression is ‘‘diabetogenic’’ but we
must be wary of detection bias; people with depression are more
likely to seek a physician’s care, resulting in a greater likelihood of
medical conditions, such as T2DM, being diagnosed (Nouwen et al.,
2010). Depression is associated with increased activity of the HPA-
axis and the sympathetic nervous system (Bjorntorp, 2001),
resulting in increased cortisol release and increased release of
the catecholamines (epinephrine and nor-epinephrine). Cortisol is
a stress hormone, which stimulates glucose production, increases
lipolysis and circulating free fatty acids, decreases insulin secretion
from beta cells and decreases sensitivity to insulin (Bjorntorp,
2001; Ramasubbu, 2002). It is postulated that a chronically high
cortisol level, which is a feature of about 50% of depressed patients,
results in obesity, insulin resistance and T2DM (Bjorntorp, 2001;
Bjorntorp et al., 1999).
Epinephrine generates responses in glucose and fat metabolism
similar to those of cortisol (148), possibly resulting in insulin
resistance and T2DM. The credibility of this hypothesis is further
strengthened by ﬁndings on other medical problems that are
accompanied by hypercortisolemia such as Cushing’s syndrome,
sleeping disorders, work stress and schizophrenia (Buckley and
Schatzberg, 2005; Lundberg, 2005; Ryan et al., 2003), which
appeared to be associated with an increased level of cortisol and an
increased risk of T2DM and insulin resistance (Ryan et al., 2003;
Kawakami et al., 1999). A dys-regulation of the immune systemalso plays a role in the association between depression and
elevated risk of T2DM; both depression and T2DM are found to be
associated with increased C-reactive protein, TNF-a and pro-
inﬂammatory cytokines, including IL-6 (Dentino et al., 1999;
Kiecolt-Glaser and Glaser, 2002; Maes et al., 1997; Pradhan et al.,
2001; Schmidt et al., 1999).
The role of inﬂammatory mediators in the development of
diabetes was supported by two population-based studies (Schmidt
et al., 1999; Ford, 2002). It is suggested that inﬂammation may be
associated with oxidative damage and the release of free radicals
(Paolisso et al., 1993) that damage pancreatic b cells (Rabinovitch
et al., 1992), thus limiting the release of insulin. The inﬂammatory
process also may inhibit insulin uptake (Paolisso et al., 1993), a
critical process in glucose regulation. Moreover, in cross-sectional
studies, inﬂammatory markers including the cytokines interleu-
kin-1b, and tumor necrosis factor-a (Appels et al., 2000) and C-
reactive protein (Dotevall et al., 2001) were also found to be
elevated in depressed persons. However, there is disagreement
between this assumption and the previous assumption that
cortisol inhibits inﬂammation and the immune response; whereas
depression is correlated with both elevated cortisol and increased
inﬂammatory markers. This contradiction could be explained with
the help of a recent ﬁnding that melancholic depressed patients
had increased HPA axis activity and no signs of inﬂammation,
whereas non-melancholic depressed patients did show signs of
inﬂammation and normal HPA axis activity (Kaestner et al., 2005).
Conversely, the association between T2DM and the onset of
depression is weaker and often conceptualized as having various
possible indirect mechanisms. For example, the psychosocial
burden of a chronic disease such as T2DM may carry with it a risk
for developing depressive symptoms (Knol et al., 2007); the
authors implicate the psychosocial burden of chronic disease,
rather than the disturbed glucose regulation speciﬁc to diabetes, as
a risk factor for depression. Cognition related to diabetes, such as
perceived disability and awareness of having a chronic illness, may
impose higher levels of psychological burden on people with
diabetes, particularly in individuals with low levels of social
support (Talbot and Nouwen, 2000). It has also been hypothesized
that an increased risk of depression in DM might be due to an
increased awareness of depression among patients with DM,
yielding more diagnoses of depression in this population (Nouwen
et al., 2010). Finally, individuals experiencing diabetes-related
complications and disability may experience depression as a
consequence of their disability (de Jonge et al., 2006; Palinkas et al.,
1991; Talbot et al., 1999). There is little evidence for biochemical
changes associated with diabetes which then lead to depression
although there is some suggestion that activation of the HPA axis
could account for an increased risk of depression in individuals
with diabetes compared to those without the condition (Knol et al.,
2007; Kinder et al., 2002).
4.4. Problems in interpretation of the data
The funnel plot suggested possible publication bias (Fig. 4).
From our analysis, we can see that a funnel plot is not a very
reliable method of investigating publication bias, although it does
give us some idea of whether our study results are scattered
symmetrically around a central, more precise effect. Although
depression was a stronger risk factor for diabetes, the funnel plot
was asymmetrical and this may be due to publication bias,
however, it may also result from clinical heterogeneity between
studies or methodological heterogeneity between studies. We
therefore ran a sensitivity analysis and noted that adjustment for
fewer confounders was associated with larger risk estimates. The
variation across different means of diabetes assessment was not
really large although there was a trend for higher estimates of risk
S.S. Hasan et al. / Asian Journal of Psychiatry 6 (2013) 460–472470with self reports. Knol et al. (2006) conducted a meta-analysis in
which they separated the studies where DM was assessed by blood
glucose measures from physician diagnosis or patient self-report,
and their study too demonstrated a small impact on the relative
risk of depression. Confounding therefore may have resulted in
the asymmetry seen in our study but has been adjusted for in the
pooled analysis and so has been accounted for. Finally, publication
bias may exist as the published studies may not be representative
of all studies that have been done since positive results tend to be
submitted and published more often than negative results (Tsoi
et al., 2009) and we have tried to address what its impact might
have been via our trim and ﬁll analysis.
4.5. Strengths and limitations
There are some strengths and limitations of this review. The
strengths include comprehensive literature search and a more
precise outcome deﬁnition and method of research synthesis. A
meta-analysis based on the RE model is considered as conservative
and results in wider CIs around the point estimate; it is commonly
used when heterogeneity between studies exists (Fleiss and Gross,
1991). The problem with the RE model is that it introduces other
errors (Knol et al., 2006). In particular, the methodology in the RE
model is, in the authors’ opinion, grossly ﬂawed to the extent that,
even in standard meta-analyses, there is a lack of interpretation of
a RE summary (Alkhalaf et al., 2011). Peto referred to the use of RE
model in meta-analysis as ‘‘wrong’’ because it answers a question
that is ‘‘abstruse and uninteresting’’ (Peto, 1987). However, the
considerations of Peto on RE may not be appropriate, because they
are speciﬁcally referred to clinical trials, and not to observational
studies. Moreover, use of the RE model requires strong assump-
tions that are unlikely to be valid in practice. Most notably, the RE
analysis is based on ‘‘the peculiar premise that the trials done are
representative of some hypothetical population of trials, and that
the heterogeneity can be represented by a single variance’’ (Senn,
2007). We take the approach in this paper that when heterogeneity
has been detected, there is a strong case for investigating its
possible origin, and redistributing the weights based on such a
determination. Weight redistribution based on the common
between study variance will not be helpful in such cases since it
is doubtful that any useful question can be formulated that a RE
model analysis could answer. The advantage of the QE model is the
adjustment for bias in observational studies and also the absence
of the conceptual problems that abound with the RE model
(Alkhalaf et al., 2011).
This review had several limitations that may affect its
generalizability and acceptability. Limitations of the current
review include language bias (only English-language databases
and journals were searched), and publication bias (signiﬁcant/
positive studies were more likely to be published and easily
indentiﬁed). The majority of the longitudinal studies were
published from USA, Europe and other developed countries where
non-Caucasians and Caucasians experience similar rates of
depression and diabetes risk (Wagner et al., 2007). Brayne et al.
(2005) has also argued that longitudinal research designs,
examining direction of the relationship could be murky, as some
of the lifestyle factors and biological substrates, or other common
antecedents of both conditions, may have been operating years
before diagnosis. Moreover, confounding bias cannot be entirely
ruled out. For instance the analyses in most of the studies were not
adjusted for smoking, which appears to strengthen the association
or alcohol abuse which can be very difﬁcult to establish in large-
scale studies (Albers et al., 2011). Finally, the limitation of methods
for detecting depression in large epidemiological studies should
also be considered since the methods for screening and diagnosis
of depression may not be fully reliable.5. Conclusions
This study provides evidence that depression results in a small
increase in relative risk for the development of T2DM and at the
same time, T2DM also results in a small relative risk increase for
depression. However, average (pooled) risk differences are
insigniﬁcant suggesting that the relative risk increase is too small
to have a signiﬁcant impact on absolute risk at the population
level for individuals with either depression or diabetes. Based on
small relative and absolute effect sizes, we assume that the causal
direction (not association) between these two conditions (both
directions) may share common causes or risk factors. Further
studies are needed to draw deﬁnitive conclusions.
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Is anxiety a risk factor for the onset of type 2 diabetes mellitus in adults? 
Application of biased-adjusted method 
 
Abstract 
 
Objective 
 
This study investigated the association 
between anxiety and diabetes onset 
using data from four longitudinal studies.  
Methods 
 
The risk difference (RD), and the number 
needed to be exposed for one additional 
person to be harmed (NNEH) at two 
years follow-up, were computed. We 
compared relative risk (RR) for a positive 
outcome (diabetes) with the RR for its 
negative complement (no diabetes) for 
each study.  
Results 
 
The pooled estimate for incident diabetes 
with subjects who exhibited anxiety 
(exposure) was 1.65, suggesting a 65% 
increase in the risk of diabetes. The RR 
for the negative complement (no-
diabetes), was 0.987, suggesting there 
would be a 1.3% increase in diabetes had 
the unexposed group been exposed to 
anxiety. The pooled RD was 0.031 (95% 
CI: - 0.007 to 0.054) and the NNEH was 
33 (95% CI 19 to 143) at 2 years post 
exposure.  
Conclusion 
 
Despite some limitations this study 
showed that anxiety could lead to an 
increased risk of developing diabetes. 
The findings suggest that by selecting the 
RR as the effect size as well as the 
outcome with the higher baseline risk (in 
this case no-diabetes), we can avoid the 
artificial magnification of the effect size. 
Keywords 
 
Anxiety, diabetes, longitudinal, adults 
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Introduction 
 
Anxiety is one of the most common 
problems experienced by individuals 
suffering from type 2 diabetes and the 
prevalence is considerably higher than 
that of the normal population [1], or even 
among patients with mental illness [2]. It 
is estimated that in the general population 
the prevalence of anxiety ranges between 
12% and 21% [3- 6], while among 
patients with type 2 diabetes, 42% have 
symptoms of anxiety [7]. The results from 
available longitudinal studies examining 
the association between type 2 diabetes 
and anxiety are inconsistent [8-10]. There 
is evidence regarding anxiety disorders 
and increased type 2 diabetes burden 
[11], increased complications [12], poor 
glycemic control [13], and reduced quality 
of life [14]; however, there has been little 
focus on the possibility of anxiety as a 
risk factor for later onset of type 2 
diabetes.  
 
The findings of a meta-analysis by Smith 
et al., suggests that people with diabetes 
are more likely to have anxiety disorders 
or elevated anxiety symptoms compared 
to people who do not have diabetes [15]. 
However, there are no meta-analyses 
investigating the development of diabetes 
in relation to anxiety symptoms. This 
study investigated the association 
between anxiety and the risk of diabetes 
in two steps. In the first step, the diabetes 
outcome was assessed to obtain pooled 
estimates [16]. In the second step, we 
also compared the pooled relative risk 
(RR) for the negative complement (no 
diabetes) as suggested previously [17]. 
These approaches were used in the 
current study to more clearly determine 
the magnitude of any excess risk (e.g. 
anxiety) on diabetes incidence. 
 
Methods 
Two electronic databases were searched: 
MEDLINE/PubMed, and PsycINFO using 
the following main keywords: anxiety 
disorders and/or symptoms, mental 
disorders, generalized anxiety disorder, 
GAD, OCD, panic disorder and/or attack, 
phobias (e.g. agoraphobia, and social 
phobia), claustrophobia, post-traumatic 
stress disorder (PTSD), diabetes mellitus, 
diabetes insipidus, diabetes mellitus, type 
2, longitudinal, cohort studies.  Inclusion 
criteria were studies of a longitudinal 
design which had no type 2 diabetes 
among subjects at baseline, while studies 
that examined existing cases of diabetes 
were excluded.  After possible studies 
were identified, titles and abstracts were 
screened to remove studies that were 
clearly irrelevant to this study. The full 
texts of the remaining studies, which 
included narrative reviews, were then 
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examined to determine whether the 
studies met our inclusion criteria. 
References cited in the reference list of 
each identified relevant original research 
or review article were scanned to identify 
any additional articles that would possibly 
be relevant to our review; these were 
then also subsequently scanned for 
reviews and studies which may have 
been relevant.  
 
Eligibility criteria were based on study 
type and population attributes. Studies 
that only examined gestational diabetes 
mellitus and type 1 diabetes were 
excluded. For population attributes, 
studies that assessed anxiety and/or 
anxiety reaction or symptomatology in 
adults with type 2 diabetes or in mixed 
samples of type 2 diabetes and type 1 
diabetes, were included. Two studies did 
not specify the type of diabetes [10,18],  
but were included because the age of the 
recruited populations suggested they 
would be predominantly subjects with 
type 2 diabetes. In this meta-analysis we 
only included studies that examined the 
relationship between anxiety and the 
onset of diabetes longitudinally. Studies 
that focused on other medical and 
psychiatric conditions were excluded. 
Editorials, commentaries, and any studies 
that were not longitudinal in design were 
also excluded. 
Data extraction and quality assessment 
Data extracted from the studies included 
the name of first author; publication year; 
study design; follow-up time in years; 
number of subjects in the analysis; 
gender and age of subjects; method of 
anxiety assessment; method of diabetes 
assessment; binary point estimates and 
time-to-event (survival) estimates with 
95% CI (adjusted for the largest number 
of confounders); number of confounders 
that were adjusted for in the analyses 
(see Table 1 for details of confounders 
considered); method of exclusion of 
patients with diabetes at baseline; and 
new-onset cases. The method of 
assessment of diabetes was either based 
on self-report or clinically diagnosed 
based on blood glucose levels or based 
on the diagnosis of diabetes from 
administrative data (drug consumption or 
hospitalization). The condition of anxiety 
was based on a diagnosis by a 
psychiatrist (based on Diagnosis and 
Statistical Manual (DSM) criteria for 
anxiety); the assessment of anxiety 
symptoms was by a self-administered 
questionnaire.  
   
Quality was assessed using a study-
specific modification of the quality criteria 
of observational studies published by 
Shamliyan et al [19]. The researchers 
carefully weighted the studies against a 
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quality checklist to estimate a quality 
index that would serve to rank studies in 
terms of deficiencies. The final checklist 
contained 11 items that were scored 
equally and consisted of questions 
related to design specific protection 
against bias (prospective versus 
retrospective), protection against 
selection bias (e.g. refusals, attrition), 
protection against information bias 
(adequate follow-up, accuracy of 
measurements of diabetes and anxiety) 
and adequate consideration of 
confounders. For studies that presented 
graded relationships such as low, 
medium, or high anxiety symptoms, only 
the estimate for the highest category was 
selected.  
 
Negative complement analysis 
The relative risk (RR) is affected by both 
the magnitudes of the RD as well as the 
baseline risks and for any given RD is 
magnified when baseline risks are small. 
Thus the RR for a positive outcome 
(diabetes) may differ substantially from 
the RR for its negative complement (no 
diabetes) [17]. It has been suggested that 
the outcome with higher baseline risk is 
the correct outcome to report because 
such magnification only occurs at the 
lower spectrum of baseline risks. In this 
study the risk of diabetes in the 
exposed/unexposed groups represents 
the smaller baseline risk and thus we 
chose to compare its complement, “no-
diabetes”, with the diabetes outcome. In 
addition, RRs are subject to this anomaly 
at only the lower end of the risk spectrum 
but with ORs the anomaly occurs at both 
ends of the risk spectrum [17]. Hence our 
choice of converting effects back to RR’s. 
 
Statistical analysis 
Four-fold cells (2 X 2 tables; exposure 
yes/no vs outcome yes/no) were imputed 
for all ORs using the reconstruction 
method proposed by Pietrantonj [20]. 
Studies using time-to-event estimates 
(hazard ratios) were presented 
separately, as 2 x 2 table reconstruction 
was not possible for studies using time-
to-event estimates. The four-fold cells 
were used to compute relative risk (RR) 
and cumulative incidence proportion 
(CIP). Finally, and most importantly, we 
also examined whether RR for the 
positive outcome (diabetes) differs 
substantially from the RR for its negative 
complement, that is, no-diabetes and how 
this would impact on different baseline 
levels of risk. 
 
The risk difference (RD) at two years 
follow-up was computed by estimating the 
events based on the yearly incidence rate 
of the complementary outcome in each 
study. For studies which had duration 
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more than two years, the yearly incidence 
rate (IR) was estimated as IR = - [ln(1 – 
CIt/t] where CIt is the cumulative 
incidence proportion of events at the end 
of the study and t is the duration of follow-
up [21]. The two year cumulative 
incidence was then computed as (2)1 IRe
. From pooled RD, the number needed to 
be exposed for one additional person to 
be harmed (NNEH) at two years was also 
computed (reciprocal of pooled RD). 
 
Pooled results were calculated via both 
the quality effects (QE) [22-24], and the 
conventional random effects model. We 
considered the funnel plot to be 
asymmetric if the intercept on Egger’s 
regression deviated from zero with p < 
0.10. Additional analyses for publication 
bias were performed when the funnel plot 
was asymmetric using the Duval and 
Tweedie non-parametric “Trim and Fill” 
method of accounting for missing studies 
in meta-analysis [25]. This method 
provides an estimate of the number of 
missing studies (with imputed estimates). 
All imputations were done assuming 
random error only. The QE meta-analysis 
was then re-run with quality scores given 
to the imputed studies of their 
corresponding (same standard error) 
existing studies to arrive at a pooled 
estimate that corrects somewhat for 
publication bias. This method used in 
sensitivity analysis is novel; no protocol 
has been published. All analyses were 
conducted using Microsoft Excel and 
MetaXL software version 1.4 [26] and 
Stata version 12 (Stata Corp, College 
Station, USA) was used for the Trim and 
Fill analysis. 
 
Results 
Diabetes outcome 
Only four longitudinal studies were 
available; these provided four longitudinal 
datasets assessing anxiety and incident 
diabetes. The cumulative incidence of 
diabetes by exposure groups and 
summary of cohort studies are given in 
Table 1. All four studies reported their 
findings in the form of odds ratios, and 
only two studies reported statistically 
significant associations.  
 
The pooled QE estimate for diabetes after 
exposure to anxiety was a RR of 1.65, 
suggesting a 65% increase in the risk of 
diabetes. The Egger’s test for publication 
bias did not suggest asymmetry (intercept 
0.379; p = 0.280).  
 
Negative complement analysis 
The RR for the negative complement, no-
diabetes was 0.987, suggesting there 
would be a 1.3% decrease in non-
diabetics had the unexposed group been 
exposed to anxiety. Both analyses 
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resulted in statistically significant results; 
however, the magnitude of the effect 
seems exaggerated when the risk of 
diabetes was directly computed (RR 1.65, 
95% CI: 1.15 – 2.36) versus its negative 
complement (no-diabetes) (RR 0.987, 
95% CI 0.978 – 0.995) (Figure 1).  
 
Comparison to the RD at 2 years 
We computed the RR that would result if 
our RD data at 2 years was to be used to 
compute it in conjunction with baseline 
risk. The results are given in Figure 2 and 
Table 2. Minor variations in the 
magnitude of the RD and baseline risks 
result in large variation in RR-Y but not in 
RR Not-Y. Thus the RR-Y does not seem 
generalizable to different baseline risks. 
 
Discussion 
We found a significant relationship 
between anxiety and incident diabetes in 
our quantitative analysis with a 65% 
increase in the risk of diabetes in adults 
with anxiety. This is higher than the 25% 
increase in odds reported previously by 
Smith et al. for the converse outcome of 
anxiety in diabetes [15]. However, the 
negative complement outcome (no-
diabetes) reveals a low relative risk of 
diabetes mellitus with anxiety when 
compared to reports that use the outcome 
of incident diabetes. Specifically, the RR 
estimate for no-onset of diabetes was 
0.987. This suggests only a 1.3% 
increase in the risk of new diabetes onset 
if patients who are unexposed to anxiety 
were to be exposed; this differs 
substantially from the magnitude of effect 
when risk of diabetes was the outcome. 
 
The question is which RR represents the 
underlying risk correctly. We show that 
RR for diabetes is grossly affected by 
minor variations in RD and baseline risk 
(Figure 1 & Table 2). Thus to generalize 
from RR back to RD for varying levels of 
CER requires the RR with larger baseline 
risks. The RR with smaller baseline risk 
does not seem generalizable.  
 
Numerous studies have suggested that 
anxiety is associated with an up-
regulation or dysregulation of the 
Hypothalamo-Pituitary-Adrenal (HPA) 
axis resulting in elevated cortisol levels, 
which is also seen in depression, and that 
can inhibit insulin function in a variety of 
ways [27-29]. Obesity has been shown to 
be associated with anxiety disorders in 
various general population studies; it is 
possible for anxiety disorders to lead to 
weight gain [30]. Psychiatric conditions 
are often comorbid and some psychiatric 
problems have been found to lead to 
weight gain, including mood disorders 
[31,32], and personality disorders [32]. 
Anxiety disorders tend to co-morbid with 
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depression [33], and it is possible that the 
comorbidity between depression and 
anxiety is the most important factor. 
 
Limitations 
This review had several limitations that 
may affect its generalizability and 
acceptability. Limitations of the current 
review include language bias (only 
English-language databases and journals 
were searched), and publication bias 
(significant/ positive studies were more 
likely to be published and easily 
identified) and the limited number of 
longitudinal studies. Brayne et al. (2005) 
has argued that longitudinal research 
designs which examine the direction of a 
relationship could be “murky”, as some of 
the lifestyle and biological factors, or 
other common antecedents of both 
conditions may have been present years 
before diagnosis [34]. The methods used 
to ascertain the presence of anxiety were 
not uniform and included studies that 
measured anxiety after diagnosis and 
studies that used self-report scales; both 
types were used to obtain pooled 
estimate. This may have important 
implications, as different types of anxiety 
disorders have been associated with 
diabetes, such as panic disorder and 
generalised anxiety disorder (GAD) which 
are common in people with diabetes [35]. 
Finally, distinguishing between type 1 and 
type 2 diabetes in large epidemiological 
studies, is not always possible since the 
exact timing of diabetes onset and 
diagnosis may not be fully reliable. 
 
Conclusions 
Despite these limitations, this study did 
support the assumption that anxiety could 
lead to an increased risk of developing 
diabetes. It is clear that reclassification of 
the event as the outcome with higher 
baseline risk (no-onset of diabetes) puts 
the RR into perspective and thus avoids 
the mathematical exaggeration of the RR 
that occurs with the use of lower baseline 
risks [17]. There is still a documented risk 
but it is small. Further research is 
warranted to confirm this finding so that 
patients at risk can be correctly identified 
and the development of diabetes can be 
prevented.  
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Figure 1: Quality-effects forest plot showing the risk of diabetes for individual studies using 
self-report questionnaires, diagnostic criteria, and all studies combined; studies using 
reconstructed RR, top (anxiety to diabetes) and below (anxiety to no diabetes). Bars and 
diamonds indicate 95% CIs.  
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Figure 2: Quality-effects forest plot showing the risk of diabetes for individual studies using 
self-report questionnaires, diagnostic criteria, and all studies combined with outcome at 2 yrs; 
studies using RD. Bars and diamonds indicate 95% CIs.
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 246 
 
Table 1: Summary of findings of longitudinal studies assessing relationship between anxiety and incident diabetes 
Authors  
(country-yr) 
Follow-up 
years 
Age 
yrs 
Depression 
assessment 
Diabetes 
assessment 
Adjustment for 
confounders 
Original 
OR 
Imputed 
RR 
EER at 2 yrs 
% 
1. Engum et al  
(Norway - 2007) 
10.0 ≥ 30 ADI Self-report 
+ FPG 
Age, gender, 
SES, lifestyle 
factors, clinical 
factors 
1.40 
(1.16-1.63) 
1.56 
(1.33-1.84) 
E: 0.51 
UE: 0.32 
2. Edwards & Mezuk 
(USA - 2012) 
11.0 ≥ 42 DIS Self-report 
 
Demographics, 
health 
behaviours, 
comorbidity 
1.00 
(0.53-1.89) 
1.00 
(0.66-1.50) 
E:1.48 
UE:1.49 
3. Atlantis et al 
(Netherlands – 2012) 
2.0 18--65 CIDI Self-report 
+ FPG 
Age & lifestyle 
cumulative risk 
score 
10.5 
(1.4-78.7) 
6.28 
(0.74-53.59)
E: 1.10 
UE: 0.18 
4. Hasan et al  
(Australia - 2014) 
7.0 > 18 DSSI Self-report Age, BMI, 
depression, 
education, 
marital status 
2.30 
(1.38-3.84) 
2.10 
(1.49-2.95) 
E: 4.51 
UE: 2.09 
OR = odds ratio; RR = relative risk; EER = Exposed Events Rate 
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Table 2: Summary of negative component analysis and comparison to the risk difference at 2 years 
Study Baseline Risk 
at 2 yrs 
RD at 2 yrs RR Not Ya RR Yb 
Engum et al - 2007 0.00322 0.001833 0.998 1.6 
Edwards & Mezuk et al - 2012 0.01485 -8.3E-06 1.000 1.0 
Atlantis et al - 2012 0.00175 0.00922 0.991 6.3 
Hasan et al - 2013 0.02088 0.024216 0.975 2.2 
a RR (outcome not Y) = (RD/(CER-1))+1 b RR (outcome Y) = (RD/CER)+1 
RR = Relative Risk 
RD = Risk Difference 
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MR Number: 
 
 
 
 
Date questionnaire completed:  ________ / _________ / __________ 
 
Year of diagnosis of diabetes mellitus:  _________________ 
 
 
 
 
 
 
 
 
 
QUESTIONNAIRE 
 
 
THE QUESTIONS ARE ABOUT YOURSELF AND THERE ARE NO RIGHT OR WRONG ANSWERS 
OR TRICK QUESTIONS.  ALL ANSWERS ARE STRICTLY CONFIDENTIAL. ANSWERING EACH 
QUESTION IS VOLUNTARY.  
 
 
 
If you feel the need to discuss any issues that might arise as a result of your participation in this study, 
please see the contact list provided in the participant information sheet if you require further clarification. 
 
 
 
Thank you very much for agreeing to participate in this study. 
 
 
 
Please turn the page to begin 
 
 
 
 
 
 
 
F     
STUDY OF MENTAL HEALTH AND RELATED FACTORS AMONG 
WOMEN WITH AND WITHOUT DIABETES 
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Your Background 
For the questions regarding your background, please answer or circle the item that describes you most 
appropriately. 
 
1. What is your age in years?  
 
 
2. With which ONE of the following ethnic groups do you identify? 
 a. Malay  1 
 b. Chinese  2 
 c. Indian  3 
 d. Iban  4 
 e. Bidayu  5 
 f. Melanau  6 
 g. Kadazan  7 
 f. Other (specify) _______________  8 
 
 
3. What is (or was) your main occupation? (circle one that best suits you) 
 a. Government employee  1 
 b. Non‐government employee  2 
 c. Self employed  3 
 d. Non paid/volunteer  4 
 e. Student  5 
 f. Homemaker (carrying out household tasks without being paid)  6 
 g. Retired/pensioner  7 
 h. Unemployed (able to work)  8 
 i. Unemployed (unable to work)  9 
 j. Never had a paid job  10 
 k. Other (please specify) ___________________________________  11 
 
 
4. How many hours do you normally work in all your PAID jobs each week? 
 a. No paid job  1 
 b. 1‐15 hours  2 
 c. 16‐24 hours  3 
 d. 25‐34 hours  4 
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 e. 35‐40 hours  5 
 f. 41 hours or more  6 
 
5. What is your current marital status? (circle one that best describes you) 
 a. Single (not married)  1 
 b. Living together  2 
 c. Married  3 
 d. Separated  4 
 f. Divorced  5 
 g. Widowed  6 
 h. Other (specify) ____________  7 
 
 
6. How many children do you have?  
 
 
7. What is the highest level of education you have completed? (circle one 
that best describes you) 
 
 a. No formal education  0 
 b. Pre‐school  1 
 c. Primary school  2 
 d. LCE/PMR/SRP (awarded after completing 9 years of schooling)  3 
 e. SPM/MCE/O’Level (lower secondary)  4 
 f.  STPM/HSC/A‐Level (upper secondary)  5 
 g. Diploma  6 
 h. Bachelor degree  7 
 i. Post Graduate degree  8 
 
 
8. From the list below, please circle the number closest to your household average monthly and annual 
income. 
Gross income is your income before tax and other deductions are taken out. This includes wages, pensions, 
government payments and  income  from other  sources  such as  investments.  If unsure,  circle  the number 
closest to the amount you think may be correct. 
 
 Monthly income  Annual income 
 a. No income    1 
 b. Less than RM1650  Less than RM20,000  2 
 c. RM1650‐RM2499  RM20,000‐RM29,999  3 
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 d. RM2500‐RM3499  RM30,000‐RM39,999  4 
 e. RM3500‐RM4299  RM40,000‐RM49,999  5 
 f. RM4300‐RM4999  RM50,000‐RM59,999  6 
 g. RM5000‐RM5899  RM60,000‐RM69,999  7 
 h. RM5900‐RM6999  RM70,000‐RM79,999  8 
 i. RM7000‐RM7599  RM80,000‐RM89,999  9 
 j. RM7500‐RM8499  RM90,000‐RM99,999  10 
 k. RM8500‐RM10499  RM100,000‐RM124,999  11 
 l. RM10500‐RM12499  RM125,000‐RM149,000  12 
 m. RM12500 or more  RM150,000 or more  13 
 
 
9. In what type of area do you live? 
Urban areas are built‐up, non agricultural areas whereas rural areas are mainly agricultural lands 
 
 a. Urban 
 
     Name of area: ____________________ 
1 
 b. Rural 
 
     Name of area: ____________________ 
 
2 
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Your medical and pregnancy history 
In this section we would like to ask about your health and social life. 
 
1. The next few questions are about health 
problems you might have had at any time in 
your life. Have you ever been diagnosed with 
any of the following? (circle one response for 
each item) 
No  Yes  How old were 
you when first 
diagnosed? 
(enter you age 
in years) 
Did you receive any 
treatment? 
No  Yes 
 a. Early onset diabetes (high blood sugar)    
     Type‐I 
1  2    1  2 
 b. Late onset diabetes Type‐II  1  2    1  2 
 c. Heart attack (myocardial infarction)  1  2    1  2 
 d. Hypertension (high blood pressure)  1  2    1  2 
 e. Heart failure  1  2    1  2 
 f. Cardiac arrhythmias (irregular heart beat)  1  2    1  2 
 g. Stroke  1  2    1  2 
 h. Lung disease (Asthma, COPD)  1  2    1  2 
 i. Kidney disease  1  2    1  2 
 j. Others (specify) _____________________  1  2    1  2 
 
 
 
2. How many times have you?  
Please identify the total number of pregnancies, your 
age at each pregnancy,  and the outcome 
Number of times 
(if never, write 0) 
Age (s) 
(write age you were at 
each pregnancy or the 
year) 
 a. Been pregnant     
 b. Pregnancies from assisted reproduction (IVF)    
 c. Had a miscarriage     
 d. Had stillbirth     
 e. Had a termination or abortion (s)     
 f. Given birth to a live child     
 
 
3. Have you EVER had ANY of the following complications during 
pregnancy? 
No  Yes 
 a. Gestational diabetes (high sugar during pregnancy)  1  2 
 b. High blood pressure  1  2 
 c. Pre‐eclampsia (e.g. high blood pressure, protein in urine)  1  2 
d.  Depression (feeling sad or depressed)  1  2 
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3. Have you EVER had ANY of the following complications during 
pregnancy? 
No  Yes 
e.  Anxiety (feeling anxious)  1  2 
f.  Sleep disturbances  1  2 
 
 
 
4. The next few questions are about health 
problems your CHILDREN might have had at any 
time in life. Have your children ever had any of 
the following: 
No  Yes  How many 
children have 
this condition? 
How many 
children are 
receiving 
treatment? 
 
 
 a. Early onset diabetes (high blood sugar) ‐ Type‐I  1  2     
 b. Late onset diabetes ‐ Type‐II  1  2     
 c. Heart attack (myocardial infarction)  1  2     
d.  Hypertension (high blood pressure)  1  2     
 e. Heart failure  1  2     
 f. Cardiac arrhythmias (irregular heart beat)  1  2     
 g. Stroke  1  2     
 h. Lung disease (e.g. Asthma, COPD)  1  2     
 i. Kidney disease  1  2     
 j. Others (specify) _________________________  1  2     
 
 
5. How often do you or your carer measure your blood glucose level? 
 
 
6. Have you received any advice on diabetes management from the 
following health care professional (s)? (circle either 1 or 2 for each person) 
NO  YES 
 a. Consultant/specialist (endocrinologist)  1  2 
 b. General practitioner  1  2 
 c. Pharmacist  1  2 
 d. Nurse  1  2 
 a. My blood glucose is not measured regularly  1 
 b. Everyday  2 
 b. Once a week  3 
 c. Once a month   4 
 d. Every 6 months  5 
 e. Every 12 months  6 
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6. Have you received any advice on diabetes management from the 
following health care professional (s)? (circle either 1 or 2 for each person) 
NO  YES 
 e. Dietitian/Nutritionist   1  2 
 f. Dentist  1  2 
 g. Physiotherapist  1  2 
 h. Other (specify) ________________________________  1  2 
 
 
7. How useful did you find this 
information? (circle one of the 
numbers from 0 to 5 for each 
healthcare professional) 
Did not see 
this person 
Not useful 
at all 
      Extremely 
useful 
 a. Consultant/specialist (e.g.      
endocrinologist) 
0  1  2  3  4  5 
 b. General practitioner  0  1  2  3  4  5 
 c. Pharmacist  0  1  2  3  4  5 
 d. Nurse  0  1  2  3  4  5 
 e. Dietitian/Nutritionist  0  1  2  3  4  5 
 f. Dentist  0  1  2  3  4  5 
 g. Physiotherapist  0  1  2  3  4  5 
 h. Other (specify) __________  0  1  2  3  4  5 
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Your lifestyle 
 The next questions are concerned with your average physical activity over the LAST 6 MONTHS.  
 
1. On average, how many times a week do you exercise vigorously for a period of at  least 20 minutes? 
(Vigorously means exercise which makes you breathe harder or puff and pant, and includes activities such as 
swimming, athletics) 
 a. Not at all  1 
 b. 1 to 2 times a week  2 
 c. 3 or more times a week  3 
 
2. On average, how many times a week do you walk for recreation or exercise? 
 a. Not at all  1 
 b. 1 to 2 times a week  2 
 c. 3 or more times a week  3 
 
 
3. Have you used any of these methods to lose weight or to control your 
weight in the LAST 12 MONTHS? (circle either 1 or 2 for each of the 
statements) 
NO  YES 
 a. Commercial weight loss programs  1  2 
 b. Meal replacements or slimming products  1  2 
 c. Exercise  1  2 
 d. Cut down on the size of meals or between meal snacks  1  2 
 e. Cut down on fats of sugar  1  2 
 f. Low glycemic index (GI) diet  1  2 
 g. Diet book diets  1  2 
 h. Laxatives, diuretics or diet pills  1  2 
 i. Vegetarian diet  1  2 
 j. Fasting   1  2 
 k. Smoking  1  2 
 l. Surgery  1  2 
 m. Other (please specify) __________________________________  1  2 
 
 
4. How would you describe yourself now? (Circle the number that best describes you) 
 a. Very underweight  1 
 b. Moderately underweight  2 
 c.  Average  3 
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 d.  Moderately overweight  4 
 e. Very overweight  5 
 f. Obese  6 
 
 
5. Excluding pregnancy, how many times EVER in your 
adult life have you? (circle one response for each 
question) 
Never  1‐2 times  3‐4 times  5 or more 
times 
 a. Lost 5 kg or more on purpose  1  2  3  4 
 b. Lost 5 kg or more for any other reason  1  2  3  4 
 c. Gained 5 kg or more which you had previously lost 
on purpose 
1  2  3  4 
 
 
6. Which of the following best describes your smoking status now? (circle one that best 
describes you) 
 
 a. I have never smoked  1  If 1, go to Q9 
 b. I used to smoke  2 
 c. I now smoke occasionally   3 
 d. I now smoke regularly  4 
 
 
7. In the LAST WEEK how many cigarettes did you usually smoke PER DAY? (circle one that best describes you) 
 a. Did not smoke at all  1 
 b. 1‐9 per day  2 
 c. 10‐19 per day  3 
 d. 20‐29 per day  4 
 e. 30‐49 per day  5 
 f.  50 or more per day  6 
 
8. How many times have you tried to quit smoking? 
 (Write ‘0’ if never tried) 
 Number of times   
 
9. Have you ever consumed a drink that contains alcohol such as beer, wine, spirits, fermented cider, sake, 
samsu, tuak or others? 
         Yes   No     if No, go to Q1 in the next section. 
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10. Over the last 12 months, on days when you were drinking, how many glasses of alcohol or equivalent 
did you usually drink? (total number per day) 
 a. 1 glass  1 
 b. 2 glasses  2 
 c. 3 glasses  3 
 d. 4 glasses  4 
 e. 5 or more glasses  5 
 
11. How many times have you tried to quit drinking alcohol? 
 (Write ‘0’ if never tried) 
 Number of times   
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Your Reproductive Health 
1. For each of the following statements, please circle Yes or No to indicate whether you have experienced the problem in the PAST MONTH. If YES, please rate 
how much the problem has bothered you using the scale from 1 (Not at all bothered) to 7 ( Extremely bothered) 
  No  Yes  Not at all bothered        Extremely bothered 
 a. Hot flushes or flashes  No  Yes  1  2  3  4  5  6  7 
 b. Night sweats  No  Yes  1  2  3  4  5  6  7 
 c. Sweating  No  Yes  1  2  3  4  5  6  7 
 d. Being dissatisfied with my personal life  No  Yes  1  2  3  4  5  6  7 
 e. Feeling anxious or nervous  No  Yes  1  2  3  4  5  6  7 
 f. Experiencing poor memory  No  Yes  1  2  3  4  5  6  7 
 g. Accomplishing less than I used to  No  Yes  1  2  3  4  5  6  7 
 h. Feeling depressed, down or blue  No  Yes  1  2  3  4  5  6  7 
 i. Being impatient with other people  No  Yes  1  2  3  4  5  6  7 
 j. Feelings of wanting to be alone  No  Yes  1  2  3  4  5  6  7 
 k. Flatulence (wind) or gas pains  No  Yes  1  2  3  4  5  6  7 
 l. Aching in muscles and joints  No  Yes  1  2  3  4  5  6  7 
 m. Feeling tired or worn out  No  Yes  1  2  3  4  5  6  7 
 n. Difficulty sleeping  No  Yes  1  2  3  4  5  6  7 
 o. Aches in back of neck or head  No  Yes  1  2  3  4  5  6  7 
 p. Decrease in physical strength   No  Yes  1  2  3  4  5  6  7 
 q. Decrease in stamina  No  Yes  1  2  3  4  5  6  7 
 r. Feeling a lack of energy  No  Yes  1  2  3  4  5  6  7 
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  No  Yes  Not at all bothered        Extremely bothered 
 s. Drying skin  No  Yes  1  2  3  4  5  6  7 
 t. Weight gain  No  Yes  1  2  3  4  5  6  7 
 u. Increased facial hair  No  Yes  1  2  3  4  5  6  7 
 v. Changes in appearance, texture or tone of 
your skin 
No  Yes  1  2  3  4  5  6  7 
 w. Feeling bloated  No  Yes  1  2  3  4  5  6  7 
 x. Low backache  No  Yes  1  2  3  4  5  6  7 
 y. Frequent urination  No  Yes  1  2  3  4  5  6  7 
 z. Involuntary urination when laughing or 
coughing 
No  Yes  1  2  3  4  5  6  7 
 aa. Change in your sexual desire  No  Yes  1  2  3  4  5  6  7 
 bb. Vaginal dryness during intercourse  No  Yes  1  2  3  4  5  6  7 
 cc. Avoiding intimacy  No  Yes  1  2  3  4  5  6  7 
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2. Have your periods stopped? 
 a.  No  1  If Yes, go to Q5 
 b.  Yes  2   
 
3. If No, do you have irregular periods (heavy/light or shorter/longer periods)? 
 
If Yes or Don’t know, go to Q5 
 
 
4. If No, when did you have your last period? 
 a.  In the last month  1 
 b.  In the last 3 months  2 
 c.  Between 3 and 11 months ago  3 
 d. 12 months ago or more  4 
 
 
5. Are you currently taking:  No  Yes 
 a. Oral contraceptives (OC) e.g. “the pill”  1  2 
 b. Hormone replacement therapy (HRT)  1  2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 a. No  1 
 b. Yes  2 
 c.  Don’t know  3 
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Your Mental Health 
The next questions are about your mental health.  
 
1. Have you ever been diagnosed with the following conditions by a doctor?  No  Yes 
a. Depression   1  2 
b. Anxiety  1  2 
c. Sleep problem  1  2 
 
2. If YES, at what age were you first diagnosed with the following conditions?    Age (years) 
a. Depression    
b. Anxiety   
c. Sleep problem   
 
3. Since diagnosis, how many episodes have you 
had, lasting 2 weeks or more? 
None  1 episode  2 episodes  3 or more 
a. Depression  1  2  3  4 
b. Anxiety  1  2  3  4 
c. Sleep problems  1  2  3  4 
 
4. Below is a list of ways you might have felt or 
behaved. Please circle the response that is closest to 
how you have been feeling in the LAST TWO WEEKS. 
All the 
time 
Most of 
the time
Some of 
the time 
Rarely  Never 
a. I have worried about every little thing  1  2  3  4  5 
b. I have been so miserable that I have had difficulty 
sleeping 
1  2  3  4  5 
c. I have been breathless or had a pounding heart  1  2  3  4  5 
d. I have been so worked up that I couldn’t sit still  1  2  3  4  5 
e. I have been depressed without knowing why  1  2  3  4  5 
f. I have gone to bed not caring if I ever woke up  1  2  3  4  5 
g. For no good reason I have had feelings of panic  1  2  3  4  5 
h. I have been so low in spirit that I have sat up for 
ages doing absolutely nothing 
1  2  3  4  5 
i. I have had a pain or tense feeling in my neck or 
head 
1  2  3  4  5 
j. The future seems hopeless  1  2  3  4  5 
k. Worrying has kept me awake at night  1  2  3  4  5 
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4. Below is a list of ways you might have felt or 
behaved. Please circle the response that is closest to 
how you have been feeling in the LAST TWO WEEKS. 
All the 
time 
Most of 
the time
Some of 
the time 
Rarely  Never 
l.  I have lost interest in just about everything   1  2  3  4  5 
m. I have been so anxious that I couldn’t make up my 
mind about the simplest thing  
1  2  3  4  5 
n. I have been  so depressed that I have thought of 
doing away with myself 
1  2  3  4  5 
 
5. Below is a list of ways you might have felt or 
behaved. Please indicate how often you have felt 
these DURING THE PAST WEEK. 
Rarely or 
none of the 
time (less 
than 1 day) 
Some or little
of the 
time (1‐2 
days) 
Occasionally 
or a moderate 
amount of 
time (3‐4 
days) 
Most or all of
the time (5‐6 
days) 
a. I was bothered by things that don’t usually 
bother me 
1  2  3  4 
b. I had trouble keeping my mind on what I was 
doing 
1  2  3  4 
c. I felt depressed  1  2  3  4 
d. I felt everything I did was an effort  1  2  3  4 
e. I felt hopeful about the future  1  2  3  4 
f. I felt fearful  1  2  3  4 
g. My sleep was restless  1  2  3  4 
h. I was happy  1  2  3  4 
i. I felt lonely  1  2  3  4 
j. I could not “get going”  1  2  3  4 
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 Your Sleep 
The next questions are about your quality of sleep.  
 
1. During the PAST MONTH, when have you usually gone to bed at night?   
 
             USUAL BED TIME 
 
 
 
2. During the PAST MONTH, how long (in minutes) has it usually taken you to fall asleep each night?   
 
            NUMBER OF MINUTES 
 
 
3. During the PAST MONTH, when have you usually gotten up in the morning?   
 
            USUAL GETTING UP TIME 
 
 
 
 
 
4. During the PAST MONTH, how many hours of actual sleep did you get at night?   
    (This may be different from the number of hours you spend in bed) 
 
            HOURS OF SLEEP PER NIGHT 
 
 
For each of the following questions, check one best response. Please answer all questions 
5. During the PAST MONTH, how often have you had 
trouble sleeping because you:  
Not during 
the past 
month 
Less than 
once a 
week 
Once or 
twice a week 
Three or 
more times a 
week 
a. Cannot get to sleep within 30 minutes  1  2  3  4 
b. Wake up in the middle of the night or early morning 1  2  3  4 
c. Have to get up to use the bathroom  1  2  3  4 
d. Cannot breathe comfortably   1  2  3  4 
e. Cough or snore loudly  1  2  3  4 
f. Feel too cold  1  2  3  4 
g. Feel too hot  1  2  3  4 
h. Had bad dreams  1  2  3  4 
i. Have pain  1  2  3  4 
j. Other reasons please specify  1  2  3  4 
AM  PM 
   
    
AM  PM 
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5. During the PAST MONTH, how often have you had 
trouble sleeping because you:  
Not during 
the past 
month 
Less than 
once a 
week 
Once or 
twice a week 
Three or 
more times a 
week 
___________________________________ 
 
6. During the PAST MONTH, how would you rate your overall sleep quality? 
 a. Very good  1 
 b. Fairly good  2 
 c. Fairly bad  3 
 d. Very bad  4 
 
7. During the PAST MONTH, how often have you taken medicine (prescribed or “over the counter”) to 
help you sleep? 
 a. Not during the past month  1 
 b. Less than once a week  2 
 c. Once or twice a week  3 
 d. Three or more times a week  4 
 
 
8. During the PAST MONTH, how often have you had trouble staying awake while driving, eating meals, 
or engaging in social activity? 
 a. Not during the past month  1 
 b. Less than once a week  2 
 c. Once a twice a week  3 
 d. Three or more times a week  4 
 
9. During the PAST MONTH, how much of a problem has it been for you to keep up enough enthusiasm 
to get things done? 
 a. No problem at all  1 
 b. Only a very slight problem  2 
 c. Somewhat of a problem  3 
 d. A very big problem  4 
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Your Well Being 
The next questions are about your quality of life over the LAST TWO WEEKS.  
 
1. In general, would you say that your health is: 
 a. Excellent  1 
 b. Very good  2 
 c. Good  3 
 d. Fair  4 
 e. Poor  5 
 
 
2. The following two questions are about activities you might 
do during a typical day. Does YOUR HEALTH NOW LIMIT YOU 
in these activities? If so, how much? 
Yes, limited a 
lot 
Yes, limited a 
little 
No, not limited 
at all 
a. MODERATE ACTIVITIES, such as moving a table, pushing a 
vacuum cleaner, bowling, or playing golf 
1  2  3 
b. Climbing SEVERAL flights of stairs  1  2  3 
 
 
3. During the PAST 4 WEEKS have you had any of the following problems with 
your work or other regular activities AS A RESULT OF YOUR PHYSICAL HEALTH?
Yes  No 
a. ACCOMPLISHED LESS than you would like  1  2 
b. Were limited in the KIND of work or other activities  1  2 
 
 
4. During  the PAST 4 WEEKS, were you  limited  in  the kind of work you do or 
other  regular activities, AS A RESULT OF ANY EMOTIONAL PROBLEMS  (such as
feeling depressed or anxious)? 
Yes  No 
a. ACCOMPLISHED LESS than you would like  1  2 
b. Didn’t do work or other activities as CAREFULLY as usual  1  2 
 
 
5. During the PAST 4 WEEKS, how much did PAIN interfere with your normal work (including both work 
outside the home and housework)? 
 a. Not at all  1 
 b. A little bit  2 
 c. Moderately   3 
 d. Quite a bit  4 
 e. Extremely  5 
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The next three questions are about how you feel and how things have been DURING THE PAST WEEKS. 
For each question, please give the one answer that comes closest to the way you have been feeling. How 
much of the time during the PAST WEEKS – 
6. Think back over the LAST 
TWO WEEKS 
All of the 
time 
Most of the 
time 
A good bit 
of the time
Some of the 
time 
A little of 
the time 
None of the 
time 
a. Have you felt calm and 
peaceful? 
1  2  3  4  5  6 
b. Did you have a lot of energy?  1  2  3  4  5  6 
c. Have you felt downhearted 
and blue? 
1  2  3  4  5  6 
 
 
7.  During  the  PAST  4  WEEKS,  how  much  of  the  time  has  your  PHYSICAL  HEALTH  OR  EMOTIONAL 
PROBLEMS interfered with your social activities (like visiting with friends, relatives, etc.)? 
 
 a. All of the time  1 
 b. Most of the time  2 
 c. A good bit of the time  3 
 d. Some of the time  4 
 e. A little of the time  5 
 f.  None of the time  6 
 
 
8. How true or false are each of the following 
statements for you? 
Definitely 
true 
Mostly 
true 
Don’t 
know 
Mostly 
false 
Definitely 
false 
a. I seem to get sick a little easier than other 
people 
1  2  3  4  5 
b. I am as healthy as anybody I know  1  2  3  4  5 
 
 
9. How satisfied are you with your life as a whole these days? Would you say you are: 
 a. Very satisfied  1 
 b. Satisfied  2 
 c. Dissatisfied  3 
 d. Very dissatisfied  4 
 
10. How would you say you feel these days? Would you say you are: 
 a. Very happy  1 
 b. Fairly happy  2 
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 c. Not too happy  3 
 d. Very unhappy  4 
 
                                                    Hooray you are finished!!!!! 
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To be completed by researcher 
PATIENT ASSESSMENT SHEET – DIABETIC PATIENTS 
 
 
CODE NUMBER:   
 
1. Physical Measurements 
 
a. Height    _________    cm 
b. Weight    _________    kg 
c. Waist circumference    _________    cm 
2. Last five readings of participant’s blood pressure (BP) 
Date of measurement 
(DD/MM/YY) 
Systolic BP  Diastolic BP 
1.     
2.     
3.     
4.     
5.     
 
3. Last five readings of participant’s glucose level  
Date of measurement 
(DD/MM/YY) 
Random glucose level  HbA1c 
1.     
2.     
3.     
4.     
5.     
 
 
 
 
 
 
 
 
F         
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4. Please provide the following details for each current prescribed antidiabetic medicine taken 
Name of medications  No  Yes  Dose taken 
How often per 
day 
How much 
Insulin  1  2     
Metformin  1  2     
Glibenclamide 
 
1  2     
Glimepride 
 
1  2     
Gliclazide 
 
1  2     
Glipizide  1  2     
Acarbose  1  2     
Rosiglitazone  1  2     
Pioglitazone   1  2     
Repaglinide  1  2     
Others, ________________  1  2     
 
5. Diabetes complications chart 
Complications  No  Yes  Comments 
Retinopathy  1  2   
Nephropathy  1  2   
Neuropathy  1  2   
Cardiovascular disease  1  2   
Hyperlipidemia  1  2   
Diabetic foot ulcer (amputation)  1  2   
Others, ____________________  1  2   
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APPENDIX 6A: Estimation of sample size  
 
Sample size was calculated using formula below: 
 
SS = (Z)2 * (p) * q   
           (c)2 
Where: 
Z = Z value (e.g. 1.96 for 95% confidence level)  
p = percentage prevalence, expressed as decimal  
q = 1 – p  
c = margin of error, expressed as decimal (2.5%, 0.025) 
 
Prevalence estimation: 
For sample size estimation, we need prevalence (p). Since data was collected in 2012, so 
prevalence of diabetes in 2012 was used. 
  
Increase in expected prevalence of diabetes/year = 0.11 
  
Estimated prevalence in 2012 = 0.11 X 2012 - 2010 = 0.22 
                                                = 0.22 + 11.6 
                                                = 11.82%  
Sample size estimation: 
Based on the formula above, the estimated sample size was: 
ss = (1.96 * 1.96)2 x (0.1182) x (1-0.1182) 
                (0.025 * 0.025) 
 
ss = 640  
Note: 640 was the required sample size for cases, to match the frequency of cases, 640 controls 
were selected. 
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